


(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
15 June 2006 (15.06.2006)

PCT

(10) International Publication Number
WO 2006/062716 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2005/041664(22) International Filing Date:
18 November 2005 (18.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/629,363 18 November 2004 (18.11.2004) US
60/649,179 2 February 2005 (02.02.2005) US
60/672,546 18 April 2005 (18.04.2005) US(71) Applicant (for all designated States except US): YALE
UNIVERSITY [US/US]; Two Whitney Avenue, New
Haven, CT 06511 (US).

(72) Inventor: and

(75) Inventor/Applicant (for US only): HOH, Josephine
[US/US]; Apartment 506, 152 Temple Street, New Haven,
CT 06510 (US).(74) Agent: GRANAHAH, Patricia; Fish & Neave IP Group,
Roxus & Gray LLP, One International Place, Boston, MA
02110-2624 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BI, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

----- without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guide-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

(57) Abstract: The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD.

WO 2006/062716 A2

METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

FUNDING

This invention was made with United States government support under grants NIH-K25HG000060 and NIH-R01EY015771, awarded by the National Institutes of Health.

- 5 The United States government has certain rights in the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

- This application claims the benefit of U.S. Provisional Application No. 60/629,363, filed November 18, 2004; U.S. Provisional Application No. 60/649,479, filed February 2, 2005; and U.S. Provisional Application No. 60/672,346, filed April 18, 2005. The teachings of each of these referenced provisional applications are incorporated by reference
10 herein in their entirety.

BACKGROUND OF THE INVENTION

- Age-related macular degeneration (AMD) is the leading cause of age-related blindness in the developed world. Its incidence is increasing as lifespan lengthens and the elderly population expands (D.S. Friedman et al., Arch Ophthalmol 122, 564 (2004)). It is a chronic disease characterized by progressive destruction of the retina's central region (macula), causing central field visual loss (J. Tuo, C. M. Bojanowski, C. C. Chan, Prog Retin Eye Res 23, 229 (2004)). One key characteristic of AMD is the formation of extracellular deposits called drusen that are concentrated in and around the macula behind
15 the retina between the retina pigment epithelium (RPE) and choroid. To date, no therapy for this disease has proven to be broadly effective, especially in more advanced forms. Several risk factors have been linked to AMD, including age, smoking, and family history (AREDS Research Group, Ophthalmology 107, 2224 (2000)). Candidate gene association studies and genome-wide linkage scans have been performed to identify genetic risk
20 factors for AMD. A variety of candidate genes have been proposed based on their association with other retinal diseases or their known function. While some rare variants of some of these genes are associated with disease phenotype, no genetic differences have been observed that can account for a large proportion of the overall prevalence (J. Tuo, C.

M. Bojanowski, C. C. Chan, *Prog Retin Eye Res* 23, 229 (2004)). Additional information about genetic determinants of AMD is badly needed.

SUMMARY OF THE INVENTION

The present invention relates to identification of variations in a human gene
5 correlated with a predisposition to AMD, which is useful in identifying or aiding in
identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in
the diagnosis of AMD. It also relates to methods for identifying or aiding in identifying
individuals at risk for developing AMD, methods for diagnosing or aiding in the diagnosis
10 of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits
containing probes or primers, methods of treating an individual at risk for or suffering from
AMD and compositions useful for treating an individual at risk for or suffering from AMD.

In one embodiment, the present invention provides polynucleotides useful for the
detection or aiding in the detection of a CFH gene that is correlated with the occurrence of
AMD in humans and, in specific embodiments, variations in the CFH gene that are
15 correlated with AMD in humans. In another embodiment, the present invention provides
methods and compositions useful for identifying or aiding in identifying individuals at risk
for developing AMD. In a further embodiment, the methods and compositions of the
invention may be used for the treatment of an individual suffering from AMD or at risk for
developing AMD. The disclosure also provides diagnostic kits for detecting a variant CFH
20 gene in a sample from an individual. Such kits are useful in identifying or aiding in
identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in
the diagnosis of AMD in an individual.

In one embodiment, the invention provides an isolated polynucleotide for the
detection of a variant CFH gene; the isolated polynucleotide comprises a nucleic acid
25 molecule that specifically detects a variation in the CFH gene that is correlated with the
occurrence of AMD in humans. Isolated polynucleotides are useful for detecting, in a
sample from an individual, a variant CFH gene that is correlated with AMD in humans.
The polynucleotides of the invention may further be used in allele-specific assays (e.g.,
allele-specific hybridization, primer extension, or ligation assays known in the art) to detect
30 a variation in the CFH gene that is correlated with the occurrence of AMD. Allele-specific
probes and primers are able to specifically hybridize to one or more alleles of a gene and

will not hybridize to other alleles of the same gene. For example, an allele-specific polynucleotide probe of the invention may hybridize to a variant CFH gene but will not hybridize to a wildtype CFH gene. In certain embodiments, the isolated polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In particular embodiments, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising all or a portion of a CFH gene, or allelic variants thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans. In other embodiments, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising at least 10 contiguous nucleotides of a CFH gene, or allelic variants thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans. In further embodiments, the isolated polynucleotide is a primer that hybridizes, under stringent conditions, adjacent, upstream, or downstream to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In certain embodiments, an isolated polynucleotide primer of the invention is at least 10 nucleotides long and hybridizes to one side or another of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The subject polynucleotides may contain alterations, such as one or more nucleotide substitutions, additions or deletions, provided they hybridize to their target variant CFH gene with the same degree of specificity. As used herein, the term "isolated" when used in relation to a nucleic acid, refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. By contrast, non-isolated nucleic acids are nucleic acids such as DNA and RNA found in the state they exist in nature.

The polynucleotides described herein (e.g., a polynucleotide probe or a polynucleotide primer) may be DNA or RNA. The subject polynucleotide may be single-stranded or double-stranded. Polynucleotide probes and primers of the invention may be from about 5 nucleotides to about 3000 nucleotides. In some embodiments, the polynucleotide probes and primers of the invention are from about 8 nucleotides to about 500 nucleotides. In other embodiments, the polynucleotide probes and primers of the invention are from about 10 nucleotides to about 250 nucleotides. In certain embodiments, the subject polynucleotide probes and primers are about 20 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). In other embodiments, the

subject polynucleotide probes and primers are from about 50 to about 100 nucleotides (e.g., 45, 50, 55, 60, 65, 75, 85, or 100 nucleotides). The subject polynucleotides may comprise one or more non-natural or modified nucleotides. Non-natural or modified nucleotides include, without limitation, radioactively, fluorescently, or chemically labeled nucleotides.

5 In certain embodiments, the polynucleotide primer of the invention hybridizes upstream or downstream from a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In one embodiment, the polynucleotide hybridizes vicinal to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. For example, hybridization may occur in such a manner that fewer than 10 nucleotides
10 separate the variation and the end of the hybridized primer proximal to the variation. In another embodiment, hybridization occurs in such a manner that 1-3 nucleotides separate the variation and the end of the hybridized primer proximal to the variation. In certain other embodiments, the polynucleotide primer hybridizes immediately adjacent to the variation. In another embodiment, the polynucleotide primer of the invention hybridizes a
15 distance (e.g., at least 10 nucleotides) from a variation in the CFH gene that is correlated with the occurrence of AMD in humans. For example, hybridization may occur in such a manner that the end of the hybridized primer proximal to the variation is 10, 25, 50, 100, 250, 1000, 5000, or up to 10,000 nucleotides from the variation in the CFH gene. The invention described herein also relates to a pair of polynucleotide primers that specifically
20 detect a variation in the CFH gene that is correlated with the occurrence of AMD in humans, wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation. A pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD in humans may hybridize to the
25 region in such a manner that the ends of the hybridized primers proximal to the variation are from about 20 to about 10,000 nucleotides apart. Alternatively, the pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD in humans may hybridize to the region in such a manner that the ends of the hybridized primers proximal to the variation
30 are from about 100 to about 7,500 nucleotides apart, or from about 200 to about 5,000 nucleotides apart.

In another embodiment, the invention described herein provides three or more polynucleotide primers useful for distinguishing between two alleles of the CFH gene (for example, a wildtype allele and an allele that is correlated with the occurrence of AMD in humans). The first primer hybridizes to a nucleotide sequence that is common to both alleles, such as a non-allelic nucleotide sequence that is upstream or downstream of the variation in the CFH gene that is correlated with the occurrence of AMD. A second primer specifically hybridizes to a sequence that is unique to a first allele (e.g., a variation in the CFH gene that is correlated with the occurrence of AMD in humans). A third primer specifically hybridizes to a nucleotide sequence that is unique to the second allele (e.g., a wildtype CFH gene). The set of three primers result in the amplification of a region of DNA that is dependent on which CFH allele is present in the sample. For instance, one region of DNA is amplified if the CFH gene has a variation in the CFH gene that is correlated with the occurrence of AMD, and another region is amplified if a wildtype CFH gene is present in the sample. Alternatively, two primers out of the set may hybridize to a nucleotide sequence that is common to two alleles of the CFH gene, such as non-allelic nucleotide sequences that are upstream and downstream of a variation in the CFH gene that is correlated with the occurrence of AMD in humans, and a third primer specifically hybridizes to one of the two alleles of the CFH gene (such as a wildtype allele or an allele that is correlated with the occurrence of AMD in humans).

A variety of variations in the CFH gene that predispose an individual to AMD may be detected by the methods and compositions described herein. In a particular embodiment, the variation encodes an amino acid other than histidine at position 402 of the CFH protein. In a specific embodiment, the variation encodes tyrosine at position 402 of the CFH protein. In another embodiment, the variation encodes an amino acid other than valine at position 62 of the CFH protein. In a specific embodiment, the variation encodes isoleucine at position 62 of the CFH protein. In other embodiments, the methods and compositions described herein may be used to detect variations in the CFH gene that predispose an individual to AMD, such as those listed in Tables 4, 5 and 7. For example, other variant genes, such as those in which the variation is in a coding region (e.g., variations that encode: an amino acid other than serine, such as alanine, at position 58 of the CFH protein; an amino acid other than arginine, such as histidine, at position 127 of the CFH protein; an amino acid other than glutamine, such as lysine, at position 400 of the CFH protein; an amino acid other than valine, such as isoleucine, at position 609 of the

CFH protein; an amino acid other than serine, such as isoleucine, at position 890 of the CFH protein; an amino acid other than glutamic acid, such as aspartic acid, at position 936 of the CFH protein; an amino acid other than valine, such as leucine, at position 1007 of the CFH protein; an amino acid other than asparagine, such as tyrosine, at position 1050 of the CFH protein; an amino acid other than proline, such as glutamine, at position 1166 of the CFH protein; or an amino acid other than arginine, such as cysteine, at position 1210 of the CFH protein. See Tables 4, 5 and 7) can be detected using the methods and compositions described herein. Alternatively, variant genes in which the variation is in a noncoding region, such as those listed in Tables 4, 5 and 7, may be detected using the methods and compositions described herein. As used herein, the term "variant CFH gene" refers to DNA that includes a variation in the CFH gene that is correlated with the occurrence of AMD. As used herein, the terms "wildtype CFH DNA" and "wildtype CFH gene" refer to DNA that does not include a variation in the CFH gene that is correlated with AMD.

The present invention also relates to a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans. Such a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with AMD in humans, but not to a wildtype CFH gene (wildtype CFH DNA is the term used above); and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that a variant CFH gene that is correlated with age related macular degeneration is present in the sample. Samples used in the methods described herein may comprise cells from the eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract, urine, muscle, cartilage, skin, or any other tissue or bodily fluid from which sufficient DNA or RNA can be obtained. Samples may be collected by a variety of means for collecting cells, such as for example, a buccal swab. The sample is processed, if necessary, to render the DNA or RNA that is present available for assaying in the methods described herein. For example, samples may be processed such that DNA from the sample is available for amplification or for hybridization to another polynucleotide. The processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material, or may be purified to isolate available DNA or RNA. Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods described herein. Methods for

processing samples include, but are not limited to, mechanical, chemical, or molecular means of lysing and/or purifying cells and cell lysates. Processing methods may include, for example, chromatographic methods such as ion exchange (e.g., cation and anion), size exclusion, gel filtration, affinity, and hydrophobic interaction chromatography, or
5 ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide.

In other embodiments, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising: (a) combining the sample
10 (referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization
15 in the combination but not in the control indicates that a variant CFH gene that correlates with AMD is present in the sample. In a further embodiment, the extent of hybridization is determined when comparing hybridization that occurs in the combination with hybridization in a control. The control is the same as the test sample and is treated the same as the test sample except that the polynucleotide probe is one that does not bind to a
20 variation in the CFH gene that is correlated with the occurrence of AMD in humans. Alternatively, the polynucleotide probe is one that binds only to a wildtype CFH gene. The control can be assayed serially or simultaneously with the combination described above. Alternatively, results from a control may be established in a reference assay previously or subsequent to the combination described above. The sample used in the control is typically
25 the same type of sample as the test sample and is treated the same as the test sample except that it is combined with a polynucleotide that does not hybridize to a variant CFH gene that is correlated with the occurrence of AMD in humans.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of
30 AMD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans; (b) combining a second

portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFH gene; and (c) determining whether hybridization occurs. The occurrence of hybridization in the first portion, but not in the second portion, indicates that a variant CFH gene that is correlated with AMD is present in the sample.

5 In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding amino acid 402 of the CFH protein and the second polynucleotide primer hybridizes to the
10 other side of DNA encoding amino acid 402 of the CFH protein; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 402 of the CFH protein. The presence of the variation indicates that a variant CFH gene that is correlated with the occurrence of AMD in humans is detected in
15 the sample.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding
20 amino acid 62 of the CFH protein and the second polynucleotide primer hybridizes to the other side of DNA encoding amino acid 62 of the CFH protein; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 62 of the CFH protein. The presence of the variation indicates that a
25 variant CFH gene that is correlated with the occurrence of AMD in humans is detected in the sample.

Any method known in the art for amplifying nucleic acids may be used for the methods described herein. For example, DNA in a sample may be amplified using polymerase chain reaction (PCR), RT-PCR, quantitative PCR, real time PCR, Rapid
30 Amplified Polymorphic DNA Analysis, Rapid Amplification of cDNA Ends (RACE), or rolling circle amplification.

In other embodiments, the invention provides methods of identifying or aiding in identifying an individual at risk for developing AMD. In one specific embodiment, such a method comprises assaying a sample obtained from the individual for the presence of a variant CFH gene that is correlated with the occurrence of AMD in humans. The presence
5 of a variant CFH gene indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with AMD in humans, but does not hybridize
10 to a wildtype CFH gene; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD, comprises: (a) obtaining DNA from an individual; (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid
15 402 of the CFH protein; and (c) determining whether a variation that encodes an amino acid other than histidine at position 402 of the CFH protein is present in the DNA. The presence of the variation indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD, comprises: (a) obtaining DNA from an individual;
20 (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 62 of the CFH protein; and (c) determining whether a variation that encodes an amino acid other than valine at position 62 of the CFH protein is present in the DNA. The presence of the variation indicates that the individual is at risk for developing AMD.

In another embodiment, the invention provides a method of detecting, in a sample
25 obtained from an individual, a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans. Such a method comprises: (a) combining the sample with an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) determining whether binding occurs. The occurrence of binding indicates that a variant
30 CFH polypeptide that is correlated with the occurrence of age related macular degeneration is present in the sample.

In another embodiment, the invention provides diagnostic kits useful for detecting a variant CFH gene in a sample from an individual. A diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFH gene in a sample.

In another embodiment, a diagnostic kit useful for detecting a variant CFH gene in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFH in a sample. Optionally, the diagnostic kit additionally comprises a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.

The present invention also relates to compositions for treating a subject suffering from AMD. In a particular embodiment, a composition for treating a subject suffering from AMD comprises an effective amount of an isolated or recombinantly produced CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier. In a particular embodiment, the CFH polypeptide, or the fragment thereof, inhibits the activation of C3. In another embodiment, the invention provides a method of treating a subject suffering from AMD, comprising administering to the subject an effective amount of an isolated or recombinantly produced CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from AMD, comprising an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier. As used herein, the term "effective amount" refers to the amount of an isolated or recombinantly produced CFH nucleic acid or polypeptide, or a composition comprising a CFH nucleic acid or polypeptide, that is in sufficient quantities to treat a subject or to treat the disorder itself. For example, an effective amount is sufficient to delay, slow, or prevent the onset or progression of AMD or related symptoms.

In other embodiments, the invention provides a method of treating a subject suffering from AMD, comprising administering to the subject an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier.

- 5 In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments,
- 10 hybridization of the antisense sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene. In certain other embodiments, hybridization of the antisense sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA. A nucleic acid molecule comprising an antisense sequence that hybridizes to a
- 15 variant CFH gene or mRNA may comprise one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a nucleic acid
- 20 molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans, and a pharmaceutically acceptable carrier.

- In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that
- 25 hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, hybridization of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof to the variant CFH gene reduces the amount of
- 30 RNA transcribed from the variant CFH gene. In other embodiments, hybridization of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof to the variant CFH mRNA reduces the amount of protein translated from the variant CFH

mRNA, and/or alters the splicing of the variant CFH mRNA. A nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA may comprise one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier, wherein binding of the aptamer to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, binding of the small molecule to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In another embodiment, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) an antibody

that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, binding of the antibody to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In another embodiment, the invention also provides a
5 method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

The methods and compositions described herein for treating a subject suffering
10 from AMD may be used for the prophylactic treatment of individuals who have been diagnosed or predicted to be at risk for developing AMD. For instance, the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of AMD or related symptoms. Alternatively, the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from AMD. For
15 example, the composition is administered in an amount and dose that is sufficient to delay or slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition.

As described herein for CFH, variations in CFH-like genes in humans (e.g., CFHL1, CFHL3, and CFHL4) are also useful for identifying or aiding in identifying
20 individuals at risk for developing AMD. Variations in CFHL1, CFHL3, and CFHL4 may also be useful for diagnosing or aiding in the diagnosis of AMD, identifying or aiding in identifying individuals at risk for developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or
25 suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD. Examples of variations in CFHL1, CFHL3, and CFHL4 that may be correlated with the occurrence of AMD are found in Tables 8-10. Such variations, which can be in a coding or noncoding region of a CFHL gene (e.g., CFHL1, CFHL3, and CFHL4) can be useful in the methods and compositions described herein.

30 In one embodiment, the present invention provides polynucleotides useful for the detection or aiding in the detection of a CFHL gene (e.g., CFHL1, CFHL3, or CFHL4) that is correlated with the occurrence of AMD in humans and, in specific embodiments,

variations in a CFHL gene that are correlated with AMD in humans. The disclosure also provides diagnostic kits for detecting a variant CFHL gene in a sample from an individual. Such kits are useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD in an individual.

5 In another embodiment, the invention provides an isolated polynucleotide for the detection of a variant CFHL gene, such as CFHL1, CFHL3, or CFHL4, in a sample from an individual, comprising a nucleic acid molecule that specifically detects a variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans.

10 In another embodiment, the invention provides a polynucleotide primer that hybridizes, under stringent conditions, adjacent to a variation in a CFHL gene that is correlated with the occurrence of age related macular degeneration in humans. In certain embodiments, the invention provides a pair of polynucleotide primers that specifically detect a variation in a CFHL gene that is correlated with the occurrence of age related
15 macular degeneration in humans, wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation. The pair of polynucleotide primers may hybridize to a region of a CFHL gene in such a manner that the ends of the hybridized primers proximal to the variation are from about 100 to about 10,000 nucleotides apart.

20 The present invention also relates to a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of AMD in humans. Such a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with AMD in humans, but not to a wildtype CFHL gene; and (b) determining
25 whether hybridization occurs. The occurrence of hybridization indicates that a variant CFHL gene that is correlated with age related macular degeneration is present in the sample. A used herein, the term "wildtype CFHL gene" refers to a CFHL gene, such as CFHL1, CFHL3, or CFHL4, that is not correlated with the occurrence of AMD.

30 In other embodiments, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of age related macular degeneration in humans, comprising: (a) combining the sample

(referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization in the combination but not in the control indicates that a variant CFHL gene that correlates with AMD is present in the sample. In a further embodiment, the extent of hybridization is determined when comparing hybridization that occurs in the combination with hybridization in a control. The control is the same as the test sample and is treated the same as the test sample except that the polynucleotide probe is one that does not bind to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans. Alternatively, the polynucleotide probe is one that binds only to a wildtype CFHL gene.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans; (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFHL gene; and (c) determining whether hybridization occurs. The occurrence of hybridization in the first portion, but not in the second portion, indicates that a variant CFHL gene that is correlated with AMD is present in the sample.

In other embodiments, the invention provides methods of identifying or aiding in identifying an individual at risk for developing AMD. In one specific embodiment, such a method comprises assaying DNA obtained from the individual for the presence of a variant CFHL gene that is correlated with the occurrence of AMD in humans. The presence of a variant CFHL gene indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with AMD in humans, but does not hybridize to a wildtype CFHL gene; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing AMD.

In another embodiment, the invention provides diagnostic kits useful for detecting a variant CFHL gene in a sample from an individual. A diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFHL gene in a sample.

In another embodiment, a diagnostic kit useful for detecting a variant CFHL gene in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFHL in a sample. Optionally, the diagnostic kit additionally comprises a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans.

The embodiments and practices of the present invention, other embodiments, and their features and characteristics, will be apparent from the description, figures and claims that follow, with all of the claims hereby being incorporated by this reference into this Summary.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-1B are graphs showing statistical data of a genome-wide association study of genes associated with AMD. Figure 1A shows p-values of the genome-wide association scan. $-\log_{10}(p)$ is plotted for each SNP in chromosomal order. The spacing between SNPs on the plot is uniform and does not reflect distances between SNPs on the chromosomes. The dotted horizontal line shows the cutoff for $p=0.05$ after Bonferroni correction. The vertical lines show chromosomal boundaries. Figure 1B shows variations in genotype frequencies between cases and controls.

Figures 2A-2D show data on SNPs that are associated with AMD. Figure 2A shows linkage disequilibrium (LD) across the CFH region, plotted as pairwise D' values. Figure 2B shows a schematic of the region in strong LD with the two associated SNPs in

the data. The vertical bars represent the approximate location of the SNPs available in the data set. The shaded region is the haplotype block found in the HapMap data. Figure 2C shows haplotype blocks in the HapMap CEU data cross the region. Darker shades indicate higher values of D' . Lighter shades indicate high D' with a low LOD score. The dark lines show the boundaries of haplotype blocks. Figure 2D shows a maximum parsimony cladogram derived from haplotypes across the 6-SNP region. The number by each line indicates which of the six SNPs varies along the branch. SNP 4 is rs380390 and SNP 6 is rs1329428, which are the two SNPs initially identified as associated with AMD.

Figures 3A-3C show immunofluorescent localization of CFH protein in human retina. Figure 3A shows human retina sections stained with anti-human CFH antibody. Figure 3B shows human retina sections stained with anti-human CFH antibody pre-incubated with CFH protein as negative control. The nuclei are identified by DAPI staining. The magnified view of the boxed area in Figure 3A is shown in Figure 3C. The fluorescent and DIC channels are collected from each image and presented as the left and right pictures, respectively, in each panel. The fluorescent pictures in Figure 3A and Figure 3B are merged images from CFH labeling and DAPI stained nuclei. The DIC picture in Figure 3C is a merged image of CFH labeling and the DIC channel. The black spots in DIC images correspond to melanin granules in RPE and choroids. The anti-CFH antibody primarily stains the choroids (Figure 3A), especially strong in the wall of vessels lumen and in area close to RPE (Figure 3C), and the immunoreactivity can be competed away with purified human CFH protein (Figure 3B). The fluorescent signal from RPE arises from the autofluorescence of lipofuscin which cannot be competed away by human factor H protein. GC: ganglion cells layer, INL: inner nuclear layer, ONL: outer nuclear layer, RPE: retinal pigment epithelium. Scale bar: 40 μ m in Figures 3A and 3B, 20 μ m in Figure 3C.

Figure 4A-4E show immunohistochemistry for activated complement C5b-9. Tissues from three patients are illustrated. Figures 4A and 4B show post-mortem fundus images from patients 1 and 2, respectively. The site illustrated histologically is indicated with an asterisk. Figure 4C shows tissue from patient 1 who is immunopositive for C5b-9 throughout Bruch's membrane and in intercapillary pillars (thin black arrows). Overlying retinal pigment epithelium is hypertrophic, and associated retina demonstrated marked photoreceptor loss. Complement deposition is also present within the elastica of a

choroidal artery (double headed black arrow), as well as within the walls of a choroidal vein (white arrow). Figure 4D shows C5b-9 deposition in Bruch's membrane, intercapillary pillars (arrows) and drusen (asterisk) in patient 2. The internal aspect of a choroidal vein is also immunopositive (white arrow). Figure 4E shows tissue from patient 3, an 86-year old with histologic evidence of early AMD. Activated complement deposition is noted throughout Bruch's membrane, in drusen (asterisks) and in the internal wall of a choroidal vein (white arrow). Scale bar: 20 μ m in Figures 4C and 4D), 15 μ m in Figure 4E.

Figure 5 shows the polypeptide sequence for human Complement Factor H (GenBank Accession CAA68704).

DETAILED DESCRIPTION OF THE INVENTION

To provide an overall understanding of the invention, certain illustrative embodiments will now be described, including compositions and methods for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. However, it will be understood by one of ordinary skill in the art that the compositions and methods described herein may be adapted and modified as is appropriate for the application being addressed and that the compositions and methods described herein may be employed in other suitable applications, and that such other additions and modifications will not depart from the scope hereof.

1. Overview

The discovery that variations in the CFH gene are associated with AMD is useful for the early diagnosis and treatment of individuals predisposed to AMD. The determination of the genetic constitution of the CFH gene in an individual is useful in treating AMD at earlier stages, or even before an individual displays any symptoms of AMD. Furthermore, diagnostic tests to genotype CFH may allow individuals to alter their behavior to minimize environmental risks to AMD (e.g., smoking). Accordingly, the present invention relates to the identification of a variant CFH gene correlated with a predisposition to AMD, which is useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. It also relates to methods for identifying or aiding in identifying individuals at risk for

developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD.

5 In accordance with the present invention, a common variation in the CFH gene has been shown to be strongly associated with AMD. The present invention relates to methods and compositions for detecting such variations that predispose a human to AMD. A CFH gene can either be the cDNA or the genomic form of the gene, which may include upstream and downstream regulatory sequences. The CFH polypeptide can be encoded by
10 a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, etc.) of the full-length or fragment are retained. Examples of CFH nucleotide sequences include human nucleotide sequences (SEQ ID NOs: 1 or 2), a mouse nucleotide sequence (SEQ ID NO: 3), and a rat nucleotide sequence (SEQ ID NO: 4). Polynucleotide
15 probes and primers of the invention may hybridize to any contiguous portion of a CFH gene, such as those shown in SEQ ID NOs 1-4. Examples of CFH polypeptide sequences include human polypeptide sequences (SEQ ID NOs: 5 or 6 and Figure 5), a mouse polypeptide sequence (SEQ ID NO: 7), and a rat polypeptide sequence (SEQ ID NO: 8). The CFH gene may further include sequences located adjacent to the coding region on both
20 the 5' and 3' ends for a distance of about 1-2 kb on either end such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences.

25 The CFH gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains of 60 amino acids each. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation (Rodriguez de Cordoba et al., *Mol Immunol.* 41:355-67 (2004)). The complement system protects against infection and attacks diseased
30 and dysplastic cells and normally spares healthy cells. Cells involved in immune surveillance and response to disease are recruited to augment the lytic action of activated complement components. When C3 convertase is activated, it leads to the production of

- C3a and C3b and then to the terminal C5b-9 complex. CFH on cells and in circulation regulates complement activity by inhibiting the activation of C3 to C3a and C3b, and by inactivating existing C3b. Variations in the CFH gene have previously been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy.
- 5 Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

2. CFH polynucleotide probes and primers

- In certain embodiments, the invention provides isolated and/or recombinant polynucleotides that specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. Polynucleotide probes of the invention hybridize to a variation (referred to as a variation of interest) in such a CFH gene, and the flanking sequence, in a specific manner and thus typically have a sequence which is fully or partially complementary to the sequence of the variation and the flanking region. Polynucleotide probes of the invention may hybridize to a segment of target DNA such that the variation aligns with a central position of the probe, or the variation may align with a terminal position of the probe. In one embodiment, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising a variant CFH gene, or a portion or allelic variant thereof, that is correlated with the occurrence of AMD in humans. In another embodiment, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising at least 10 contiguous nucleotides of a CFH gene, or an allelic variant thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans.
- 10
15
20

- In certain embodiments, a polynucleotide probe of the invention is an allele-specific probe. The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., *Nature* 324:163-166 (1986); Dattagupta, EP 235726; and Saiki WO 89/11548. Allele-specific probes can be designed to hybridize to a segment of a target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms or variations in the respective segments from the two individuals. Hybridization conditions should be
- 25
30

sufficiently stringent such that there is a significant difference in hybridization intensity between alleles. In some embodiments, a probe hybridizes to only one of the alleles.

A variety of variations in the CFH gene that predispose an individual to AMD may be detected by the methods and polymucleotides described herein. For example, any nucleotide polymorphism of a coding region, exon, exon-intron boundary, signal peptide, 5-prime untranslated region, promoter region, enhancer sequence, 3-prime untranslated region or intron that is associated with AMD can be detected. These polymorphisms include, but are not limited to, changes that: alter the amino acid sequence of the proteins encoded by the CFH gene, produce alternative splice products, create truncated products, introduce a premature stop codon, introduce a cryptic exon, alter the degree or expression to a greater or lesser extent, alter tissue specificity of CFH expression, introduce changes in the tertiary structure of the proteins encoded by CFH, introduce changes in the binding affinity or specificity of the proteins expressed by CFH or alter the function of the proteins encoded by CFH. In a specific embodiment, the variation in the CFH gene encodes an amino acid other than histidine (e.g., tyrosine) at position 402 of the CFH protein. In another specific embodiment, the variation in the CFH gene encodes an amino acid other than valine (e.g., isoleucine) at position 62 of the CFH protein. Other examples of variations in the CFH gene that may predispose an individual to AMD are found in Tables 4 and 5. For example, other variant genes, such as those in which the variation is in a coding region (e.g., variations that encode: an amino acid other than serine, such as alanine, at position 58 of the CFH protein; an amino acid other than arginine, such as histidine, at position 127 of the CFH protein; an amino acid other than glutamine, such as lysine, at position 400 of the CFH protein; an amino acid other than valine, such as isoleucine, at position 609 of the CFH protein; an amino acid other than serine, such as isoleucine, at position 890 of the CFH protein; an amino acid other than glutamic acid, such as aspartic acid, at position 936 of the CFH protein; an amino acid other than valine, such as leucine, at position 1007 of the CFH protein; an amino acid other than asparagine, such as tyrosine, at position 1050 of the CFH protein; an amino acid other than proline, such as glutamine, at position 1166 of the CFH protein; or an amino acid other than arginine, such as cysteine, at position 1210 of the CFH protein. See Tables 4 and 5) can be detected using the methods and compositions described herein for other variants. Alternatively, variant genes in which the variation is in a noncoding region, such as those listed in Tables 4 and 5, may be detected using the methods and compositions described

herein. The subject polynucleotides are further understood to include polynucleotides that are variants of the polynucleotides described herein, provided that the variant polynucleotides maintain their ability to specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. Variant polynucleotides may include, for
5 example, sequences that differ by one or more nucleotide substitutions, additions or deletions.

In certain embodiments, the isolated polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. As used herein, the term "hybridization" is used in
10 reference to the pairing of complementary nucleic acids. The term "probe" refers to a polynucleotide that is capable of hybridizing to another nucleic acid of interest. The polynucleotide may be naturally occurring, as in a purified restriction digest, or it may be produced synthetically, recombinantly or by nucleic acid amplification (e.g., PCR amplification).

15 It is well known in the art how to perform hybridization experiments with nucleic acid molecules. The skilled artisan is familiar with the hybridization conditions required in the present invention and understands readily that appropriate stringency conditions which promote DNA hybridization can be varied. Such hybridization conditions are referred to in standard text books, such as *Molecular Cloning: A Laboratory Manual*, Cold Spring
20 Harbor Laboratory (2001); and *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons (1992). Particularly useful in methods of the present invention are polynucleotides which are capable of hybridizing to a variant CFH gene, or a region of a variant CFH gene, under stringent conditions. Under stringent conditions, a polynucleotide that hybridizes to a variant CFH gene does not hybridize to a wildtype CFH gene.

25 Nucleic acid hybridization is affected by such conditions as salt concentration, temperature, organic solvents, base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will readily be appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30°C, or may be in excess of 37°C or 45°C.
30 Stringency increases with temperature. For example, temperatures greater than 45°C are highly stringent conditions. Stringent salt conditions will ordinarily be less than 1000 mM, or may be less than 500 mM or 200 mM. For example, one could perform the

hybridization at 6.0x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0x SSC at 50 °C to a high stringency of about 0.2x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. Particularly useful in methods of the present invention are polynucleotides which are capable of hybridizing to a variant CFH gene, or a region of a variant CFH gene, under stringent conditions. It is understood, however, that the appropriate stringency conditions may be varied in the present invention to promote DNA hybridization. In certain embodiments, polynucleotides of the present invention hybridize to a variant CFH gene, or a region of a variant CFH gene, under highly stringent conditions. Under stringent conditions, a polynucleotide that hybridizes to a variation in the CFH gene does not hybridize to a wildtype CFH gene. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6.0x SSC at room temperature followed by a wash at 2.0x SSC at room temperature. The combination of parameters, however, is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson, 1968. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art. One method for obtaining DNA encoding the biosynthetic constructs disclosed herein is by assembly of synthetic oligonucleotides produced in a conventional, automated, oligonucleotide synthesizer.

A polynucleotide probe or primer of the present invention may be labeled so that it is detectable in a variety of detection systems, including, but not limited, to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, chemical, and luminescent systems. A polynucleotide probe or primer of the present invention may further include a quencher moiety that, when placed in proximity to a label (e.g., a fluorescent label), causes there to be little or no signal from the label. Detection of the label may be performed by direct or indirect means (e.g., via a biotin/avidin or a biotin/streptavidin linkage). It is not intended that the present invention be limited to any particular detection system or label.

In another embodiment, the isolated polynucleotide of the invention is a primer that hybridizes, under stringent conditions, adjacent, upstream, or downstream to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The isolated polynucleotide may hybridize, under stringent conditions, to a nucleic acid molecule comprising all or a portion of a variant CFH gene that is correlated with the occurrence of AMD in humans. Alternatively, the isolated polynucleotide primer may hybridize, under stringent conditions, to a nucleic acid molecule comprising at least 50 contiguous nucleotides of a variant CFH gene that is correlated with the occurrence of AMD in humans. For example, a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to the region of the CFH gene that encodes amino acid 402 of the CFH protein. Alternatively, a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to the region of the CFH gene that encodes amino acid 62 of the CFH protein.

As used herein, the term "primer" refers to a polynucleotide that is capable of acting as a point of initiation of nucleic acid synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid strand occurs (for example, in the presence of nucleotides, an inducing agent such as DNA polymerase, and suitable temperature, pH, and electrolyte concentration). Alternatively, the primer may be capable of ligating to a proximal nucleic acid when placed under conditions in which ligation of two unlinked nucleic acids occurs (for example, in the presence of a proximal nucleic acid, an inducing agent such as DNA ligase, and suitable temperature, pH, and electrolyte concentration). A polynucleotide primer of the invention may be naturally occurring, as in a purified restriction digest, or may be produced synthetically. The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used. Preferably, the primer is an oligodeoxyribonucleotide. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method. In certain embodiments, the polynucleotide primer of the invention is at least 10 nucleotides long and hybridizes to one side or another of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The subject polynucleotides may contain alterations, such as one or more nucleotide substitutions, additions or deletions, provided they hybridize to their target variant CFH gene with the same degree of specificity.

In one embodiment, the invention provides a pair of primers that specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. In such a case, the first primer hybridizes upstream from the variation and a second primer hybridizes downstream from the variation. It is understood that one of the primers hybridizes to one strand of a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD, and the second primer hybridizes to the complementary strand of a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD. As used herein, the term "region of DNA" refers to a sub-chromosomal length of DNA.

In another embodiment, the invention provides an allele-specific primer that hybridizes to a site on target DNA that overlaps a variation in the CFH gene that is correlated with the occurrence of AMD in humans. An allele-specific primer of the invention only primes amplification of an allelic form to which the primer exhibits perfect complementarity. This primer may be used, for example, in conjunction with a second primer which hybridizes at a distal site. Amplification can thus proceed from the two primers, resulting in a detectable product that indicates the presence of a variant CFH gene that is correlated with the occurrence of AMD in humans.

3. Detection assays

In certain embodiments, the invention relates to polynucleotides useful for detecting a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration. Preferably, these polynucleotides are capable of hybridizing under stringent hybridization conditions to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration.

The polynucleotides of the invention may be used in any assay that permits detection of a variation in the CFH gene that is correlated with the occurrence of AMD. Such methods may encompass, for example, DNA sequencing, hybridization, ligation, or primer extension methods. Furthermore, any combination of these methods may be utilized in the invention.

In one embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by DNA sequencing. DNA sequence determination may be performed by standard methods such as dideoxy chain

termination technology and gel-electrophoresis, or by other methods such as by pyrosequencing (Biotage AB, Uppsala, Sweden). For example, DNA sequencing by dideoxy chain termination may be performed using unlabeled primers and labeled (e.g., fluorescent or radioactive) terminators. Alternatively, sequencing may be performed using
5 labeled primers and unlabeled terminators. The nucleic acid sequence of the DNA in the sample can be compared to the nucleic acid sequence of wildtype DNA to identify whether a variation in the CFH gene that is correlated with the occurrence of AMD is present.

In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by hybridization. In
10 one embodiment, a polynucleotide probe hybridizes to a variation in the CFH gene, and flanking nucleotides, that is correlated with AMD, but not to a wildtype CFH gene. The polynucleotide probe may comprise nucleotides that are fluorescently, radioactively, or chemically labeled to facilitate detection of hybridization. Hybridization may be performed and detected by standard methods known in the art, such as by Northern
15 blotting, Southern blotting, fluorescent in situ hybridization (FISH), or by hybridization to polynucleotides immobilized on a solid support, such as a DNA array or microarray. As used herein, the term "DNA array," and "microarray" refers to an ordered arrangement of hybridizable array elements. The array elements are arranged so that there are preferably at least one or more different array elements immobilized on a substrate surface. The
20 hybridization signal from each of the array elements is individually distinguishable. In a preferred embodiment, the array elements comprise polynucleotides, although the present invention could also be used with cDNA or other types of nucleic acid array elements.

In a specific embodiment, the polynucleotide probe is used to hybridize genomic DNA by FISH. FISH can be used, for example, in metaphase cells, to detect a deletion in
25 genomic DNA. Genomic DNA is denatured to separate the complementary strands within the DNA double helix structure. The polynucleotide probe of the invention is then added to the denatured genomic DNA. If a variation in the CFH gene that is correlated with the occurrence of AMD is present, the probe will hybridize to the genomic DNA. The probe signal (e.g., fluorescence) can then be detected through a fluorescent microscope for the
30 presence of absence of signal. The absence of signal, therefore, indicates the absence of a variation in the CFH gene that is correlated with the occurrence of AMD. In another specific embodiment, a labeled polynucleotide probe is applied to immobilized

polynucleotides on a DNA array. Hybridization may be detected, for example, by measuring the intensity of the labeled probe remaining on the DNA array after washing. The polynucleotides of the invention may also be used in commercial assays, such as the Taqman assay (Applied Biosystems, Foster City, CA).

5 In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by primer extension with DNA polymerase. In one embodiment, a polynucleotide primer of the invention hybridizes immediately adjacent to the variation. A single base sequencing reaction using labeled dideoxynucleotide terminators may be used to detect the variation. The presence of
10 a variation will result in the incorporation of the labeled terminator, whereas the absence of a variation will not result in the incorporation of the terminator. In another embodiment, a polynucleotide primer of the invention hybridizes to a variation in the CFH gene that is correlated with the occurrence of AMD. The primer, or a portion thereof, will not hybridize to a wildtype CFH gene. The presence of a variation will result in primer
15 extension, whereas the absence of a variation will not result in primer extension. The primers and/or nucleotides may further include fluorescent, radioactive, or chemical probes. A primer labeled by primer extension may be detected by measuring the intensity of the extension product, such as by gel electrophoresis, mass spectrometry, or any other method for detecting fluorescent, radioactive, or chemical labels.

20 In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by ligation. In one embodiment, a polynucleotide primer of the invention hybridizes to a variation in the CFH gene that is correlated with the occurrence of AMD. The primer, or a portion thereof will not hybridize to a wildtype CFH gene. A second polynucleotide that hybridizes to a region
25 of the CFH gene immediately adjacent to the first primer is also provided. One, or both, of the polynucleotide primers may be fluorescently, radioactively, or chemically labeled. Ligation of the two polynucleotide primers will occur in the presence of DNA ligase if a variation in the CFH gene that is correlated with the occurrence of AMD is present. Ligation may be detected by gel electrophoresis, mass spectrometry, or by measuring the
30 intensity of fluorescent, radioactive, or chemical labels.

In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by single-base extension (SBE). For example, a fluorescently-labeled primer that is coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer may be used. Typically, the method, such as that described by Chen et al., (PNAS 94:10756-61 (1997), incorporated herein by reference) uses a locus-specific polynucleotide primer labeled on the 5' terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3' end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently labeled dideoxynucleotides (ddNTPs) in dye-terminator sequencing fashion, except that no deoxyribonucleotides are present. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

Methods of detecting a variation in the CFH gene that is correlated with the occurrence of AMD may include amplification of a region of DNA that comprises the variation. Any method of amplification may be used. In one specific embodiment, a region of DNA comprising the variation is amplified by using polymerase chain reaction (PCR). PCR was initially described by Mullis (See e.g., U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,965,188, herein incorporated by reference), which describes a method for increasing the concentration of a region of DNA, in a mixture of genomic DNA, without cloning or purification. Other PCR methods may also be used to nucleic acid amplification, including but not limited to RT-PCR, quantitative PCR, real time PCR, Rapid Amplified Polymorphic DNA Analysis, Rapid Amplification of cDNA Ends (RACE), or rolling circle amplification. For example, the polynucleotide primers of the invention are combined with a DNA mixture (or any polynucleotide sequence that can be amplified with the polynucleotide primers of the invention), wherein the DNA comprises the CFH gene. The mixture also includes the necessary amplification reagents (e.g., deoxyribonucleotide triphosphates, buffer, etc.) necessary for the thermal cycling reaction. According to standard PCR methods, the mixture undergoes a series of denaturation, primer annealing, and polymerase extension steps to amplify the region of DNA that comprises the variation in the CFH gene. The length of the amplified region of DNA is determined by the relative positions of the primers with respect to each other, and

therefore, this length is a controllable parameter. For example, hybridization of the primers may occur such that the ends of the primers proximal to the variation are separated by 1 to 10,000 base pairs (e.g., 10 base pairs (bp) 50 bp, 200 bp, 500 bp, 1,000 bp, 2,500 bp, 5,000 bp, or 10,000 bp).

5 Standard instrumentation known to those skilled in the art are used for the amplification and detection of amplified DNA. For example, a wide variety of instrumentation has been developed for carrying out nucleic acid amplifications, particularly PCR, e.g. Johnson et al, U.S. Pat. No. 5,038,852 (computer-controlled thermal
10 cycler); Wittwer et al, Nucleic Acids Research, 17: 4353-4357 (1989)(capillary tube PCR); Hallsby, U.S. Pat. No. 5,187,084 (air-based temperature control); Garner et al, Biotechniques, 14: 112-115 (1993)(high-throughput PCR in 864-well plates); Wilding et
15 al, International application No. PCT/US93/04039 (PCR in micro-machined structures); Schnipelsky et al, European patent application No. 90301061.9 (publ. No. 0381501 A2)(disposable, single use PCR device), and the like. In certain embodiments, the invention described herein utilizes real-time PCR or other methods known in the art such as the Taqman assay.

 In certain embodiments, a variant CFH gene that is correlated with the occurrence of AMD in humans may be detected using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of
20 single stranded PCR products, as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770 (1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification
25 products can be related to base-sequence differences between alleles of target sequences.

 In one embodiment, the amplified DNA is analyzed in conjunction with one of the detection methods described herein, such as by DNA sequencing. The amplified DNA may alternatively be analyzed by hybridization with a labeled probe, hybridization to a DNA array or microarray, by incorporation of biotinylated primers followed by avidin-
30 enzyme conjugate detection, or by incorporation of ³²P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment. In a specific

embodiment, the amplified DNA is analyzed by determining the length of the amplified DNA by electrophoresis or chromatography. For example, the amplified DNA is analyzed by gel electrophoresis. Methods of gel electrophoresis are well known in the art. See for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 5 1992. The amplified DNA can be visualized, for example, by fluorescent or radioactive means, or with other dyes or markers that intercalate DNA. The DNA may also be transferred to a solid support such as a nitrocellulose membrane and subjected to Southern Blotting following gel electrophoresis. In one embodiment, the DNA is exposed to ethidium bromide and visualized under ultra-violet light.

10 4. Therapeutic Nucleic Acids Encoding CFH Polypeptides

In certain embodiments, the invention provides isolated and/or recombinant nucleic acids encoding a CFH polypeptide, including functional variants, disclosed herein. For example, SEQ ID NOs: 1 or 2 are nucleic acid sequences that encode CFH and SEQ ID NOs: 5 or 6 and Figure 5 encode CFH polypeptides. The subject nucleic acids may be 15 single-stranded or double stranded. Such nucleic acids may be DNA or RNA molecules. These nucleic acids may be used, for example, in methods for making CFH polypeptides or as direct therapeutic agents (e.g., in a gene therapy approach).

The subject nucleic acids encoding CFH polypeptides are further understood to include nucleic acids that are variants of SEQ ID NOs: 1 or 2. Variant nucleotide 20 sequences include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants; and will, therefore, include coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 1 or 2. Coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 1 or 2 may be tested for their ability to inhibit the activation of 25 C3 to C3a and C3b, and by inactivating existing C3.

In certain embodiments, the invention provides isolated or recombinant nucleic acid sequences that are at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 1 or 2. One of ordinary skill in the art will appreciate that nucleic acid sequences complementary to SEQ ID NO: 1 or 2, and variants of SEQ ID NO: 1 or 2 are 30 also within the scope of this invention. In further embodiments, the nucleic acid sequences

of the invention can be isolated, recombinant, and/or fused with a heterologous nucleotide sequence, or in a DNA library.

In other embodiments, nucleic acids of the invention also include nucleic acids that hybridize under stringent conditions to the nucleotide sequence designated in SEQ ID NO: 1 or 2, complement sequence of SEQ ID NO: 1 or 2, or fragments thereof. As discussed above, one of ordinary skill in the art will understand readily that appropriate stringency conditions which promote DNA hybridization can be varied. For example, one could perform the hybridization at 6.0 x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0 x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50 °C to a high stringency of about 0.2 x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6 x SSC at room temperature followed by a wash at 2 x SSC at room temperature.

Isolated nucleic acids which differ from the nucleic acids as set forth in SEQ ID NO: 1 or 2 due to degeneracy in the genetic code are also within the scope of the invention. For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" variations which do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the subject proteins will exist among mammalian cells. One skilled in the art will appreciate that these variations in one or more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding a particular protein may exist among individuals of a given species due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymorphisms are within the scope of this invention.

The nucleic acids and polypeptides of the invention may be produced using standard recombinant methods. For example, the recombinant nucleic acids of the invention may be operably linked to one or more regulatory nucleotide sequences in an

expression construct. Regulatory nucleotide sequences will generally be appropriate to the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the invention. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. The expression vector may also contain a selectable marker gene to allow the selection of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

In certain embodiments of the invention, the subject nucleic acid is provided in an expression vector comprising a nucleotide sequence encoding a CFH polypeptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the CFH polypeptide. Accordingly, the term regulatory sequence includes promoters, enhancers, termination sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred protein processing sequences, preferred signal sequences for protein secretion, and other expression control elements. Examples of regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, CA (1990). For instance, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding a CFH polypeptide. Such useful expression control sequences, include, for example, the early and late promoters of SV40, tet promoter, adenovirus or cytomegalovirus immediate early promoter, RSV promoters, the *lac* system, the *trp* system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast α -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses,

and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other
5 protein encoded by the vector, such as antibiotic markers, should also be considered.

A recombinant nucleic acid of the invention can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of recombinant CFH polypeptides include plasmids and other vectors. For
10 instance, suitable vectors include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

Some mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription
15 units that are expressed in eukaryotic cells. The pcDNA1/amp, pcDNA1/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both
20 prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (PHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene therapy delivery systems. The various methods employed in the preparation of the
25 plasmids and in transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (2001). In some instances, it may be desirable to express the recombinant polypeptide by the use of a baculovirus expression system. Examples of such
30 baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

In one embodiment, a vector will be designed for production of a subject CFH polypeptide in CHO cells, such as a Pcmv-Script vector (Stratagene, La Jolla, Calif.), pcDNA4 vectors (Invitrogen, Carlsbad, Calif) and pCI-neo vectors (Promega, Madison, Wisc.). In other embodiments, the vector is designed for production of a subject CFH polypeptide in prokaryotic host cells (e.g., *E. coli* and *B. subtilis*), eukaryotic host cells such as, for example, yeast cells, insect cells, myeloma cells, fibroblast 3T3 cells, monkey kidney or COS cells, mink-lung epithelial cells, human foreskin fibroblast cells, human glioblastoma cells, and teratocarcinoma cells. Alternatively, the genes may be expressed in a cell-free system such as the rabbit reticulocyte lysate system.

As will be apparent, the subject gene constructs can be used to express the subject CFH polypeptide in cells propagated in culture, e.g., to produce proteins, including fusion proteins or variant proteins, for purification.

This invention also pertains to a host cell transfected with a recombinant gene including a coding sequence (e.g., SEQ ID NO: 1 or 2) for one or more of the subject CFH polypeptides. The host cell may be any prokaryotic or eukaryotic cell. For example, a CFH polypeptide of the invention may be expressed in bacterial cells such as *E. coli*, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

Accordingly, the present invention further pertains to methods of producing the subject CFH polypeptides. For example, a host cell transfected with an expression vector encoding a CFH polypeptide can be cultured under appropriate conditions to allow expression of the CFH polypeptide to occur. CFH polypeptides may be secreted and isolated from a mixture of cells and medium containing the CFH polypeptides. Alternatively, the polypeptide may be retained cytoplasmically or in a membrane fraction and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide. In a particular embodiment, the CFH polypeptide is a fusion protein containing a domain which facilitates the purification of the CFH polypeptide.

In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N-terminus of the desired portion of the recombinant CFH polypeptide, can allow purification of the expressed fusion protein by affinity chromatography using a Ni^{2+} metal resin. The purification leader
5 sequence can then be subsequently removed by treatment with enterokinase to provide the purified polypeptide (e.g., see Hochuli et al., (1987) *J. Chromatography* 411:177; and Janknecht et al., *PNAS USA* 88:8972).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in
10 accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR
15 amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 1992).

5. Other therapeutic modalities

20 *Antisense polynucleotides*

In certain embodiments, the invention provides polynucleotides that comprise an antisense sequence that acts through an antisense mechanism for inhibiting expression of a variant CFH gene. Antisense technologies have been widely utilized to regulate gene expression (Buskirk et al., *Chem Biol* 11, 1157-63 (2004); and Weiss et al., *Cell Mol Life*
25 *Sci* 55, 334-58 (1999)). As used herein, "antisense" technology refers to administration or in situ generation of molecules or their derivatives which specifically hybridize (e.g., bind) under cellular conditions, with the target nucleic acid of interest (mRNA and/or genomic DNA) encoding one or more of the target proteins so as to inhibit expression of that protein, e.g., by inhibiting transcription and/or translation, such as by steric hinderance,
30 altering splicing, or inducing cleavage or other enzymatic inactivation of the transcript. The binding may be by conventional base pair complementarity, or, for example, in the

case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, "antisense" technology refers to the range of techniques generally employed in the art, and includes any therapy that relies on specific binding to nucleic acid sequences.

5 A polynucleotide that comprises an antisense sequence of the present invention can be delivered, for example, as a component of an expression plasmid which, when transcribed in the cell, produces a nucleic acid sequence that is complementary to at least a unique portion of the target nucleic acid. Alternatively, the polynucleotide that comprises
10 an antisense sequence can be generated outside of the target cell, and which, when introduced into the target cell causes inhibition of expression by hybridizing with the target nucleic acid. Polynucleotides of the invention may be modified so that they are resistant to endogenous nucleases, e.g. exonucleases and/or endonucleases, and are therefore stable in vivo. Examples of nucleic acid molecules for use in polynucleotides of the invention are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S.
15 Pat. Nos. 5,176,996; 5,264,564; and 5,256,775). General approaches to constructing polynucleotides useful in antisense technology have been reviewed, for example, by van der krol et al. (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48:2659-2668.

Antisense approaches involve the design of polynucleotides (either DNA or RNA)
20 that are complementary to a target nucleic acid encoding a variant CFH gene. The antisense polynucleotide may bind to an mRNA transcript and prevent translation of a protein of interest. Absolute complementarity, although preferred, is not required. In the case of double-stranded antisense polynucleotides, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend
25 on both the degree of complementarity and the length of the antisense sequence. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a target nucleic acid it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

30 Antisense polynucleotides that are complementary to the 5' end of an mRNA target, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation of the mRNA. However, sequences

complementary to the 3' untranslated sequences of mRNAs have recently been shown to be effective at inhibiting translation of mRNAs as well (Wagner, R. 1994. *Nature* 372:333). Therefore, antisense polynucleotides complementary to either the 5' or 3' untranslated, non-coding regions of a variant CFH gene could be used in an antisense approach to inhibit translation of a variant CFH mRNA. Antisense polynucleotides complementary to the 5' untranslated region of an mRNA should include the complement of the AUG start codon. Antisense polynucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could also be used in accordance with the invention. Whether designed to hybridize to the 5', 3', or coding region of mRNA, antisense polynucleotides should be at least six nucleotides in length, and are preferably less than about 100 and more preferably less than about 50, 25, 17 or 10 nucleotides in length.

Regardless of the choice of target sequence, it is preferred that in vitro studies are first performed to quantitate the ability of the antisense polynucleotide to inhibit expression of a variant CFH gene. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of antisense polynucleotide. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense polynucleotide are compared with those obtained using a control antisense polynucleotide. It is preferred that the control antisense polynucleotide is of approximately the same length as the test antisense polynucleotide and that the nucleotide sequence of the control antisense polynucleotide differs from the antisense sequence of interest no more than is necessary to prevent specific hybridization to the target sequence.

Polynucleotides of the invention, including antisense polynucleotides, can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. Polynucleotides of the invention can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. Polynucleotides of the invention may include other appended groups such as peptides (e.g., for targeting host cell receptors), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, *Proc Natl Acad Sci. USA*

86:6553-6556; Lemaitre et al., 1987, *Proc Natl Acad Sci. USA* 84:648-652; PCT Publication No. W088/09810, published Dec. 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134, published Apr. 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, e.g., Zon, *Pharm. Res.* 5:539-549 (1988)). To this end, a polynucleotide of the invention may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

Polynucleotides of the invention, including antisense polynucleotides, may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxytriethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxymethyl-2-thiouracil; beta-D-mannosylqueosine, 5-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

Polynucleotides of the invention may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

A polynucleotide of the invention can also contain a neutral peptide-like backbone. Such molecules are termed peptide nucleic acid (PNA)-oligomers and are described, e.g., in Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:14670 and in Eglon et al. (1993) *Nature* 365:566. One advantage of PNA oligomers is their capability to bind to complementary DNA essentially independently from the ionic strength of the medium due to the neutral backbone of the DNA. In yet another embodiment, a polynucleotide of the invention comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a

phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In a further embodiment, polynucleotides of the invention, including antisense polynucleotides are -anomeric oligonucleotides. An -anomeric oligonucleotide forms
5 specific double-stranded hybrids with complementary RNA in which, contrary to the usual -units, the strands run parallel to each other (Gautier et al., 1987, *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, *Nucl. Acids Res.* 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, *FEBS Lett.* 215:327-330).

Polynucleotides of the invention, including antisense polynucleotides, may be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of
15 Stein et al. *Nucl. Acids Res.* 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., *Proc. Natl. Acad. Sci. USA* 85:7448-7451 (1988)), etc.

While antisense sequences complementary to the coding region of an mRNA sequence can be used, those complementary to the transcribed untranslated region and to the region comprising the initiating methionine are most preferred.

Antisense polynucleotides can be delivered to cells that express target genes in vivo. A number of methods have been developed for delivering nucleic acids into cells; e.g., they can be injected directly into the tissue site, or modified nucleic acids, designed to target the desired cells (e.g., antisense polynucleotides linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be
25 administered systematically.

However, it may be difficult to achieve intracellular concentrations of the antisense polynucleotides sufficient to attenuate the activity of a variant CFH gene or mRNA in certain instances. Therefore, another approach utilizes a recombinant DNA construct in which the antisense polynucleotide is placed under the control of a strong pol III or pol II
30 promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of antisense polynucleotides that will form

complementary base pairs with the variant CFH gene or mRNA and thereby attenuate the activity of CFH protein. For example, a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an antisense polynucleotide that targets a variant CFH gene or mRNA. Such a vector can remain episomal or become
5 chromosomally integrated, as long as it can be transcribed to produce the desired antisense polynucleotide. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. A promoter may be operably linked to the sequence encoding the antisense polynucleotide. Expression of the sequence encoding
10 the antisense polynucleotide can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Berni and Chambon, *Nature* 290:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797 (1980)), the herpes thymidine kinase
15 promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA* 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature* 296:3942 (1982)), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct that can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue, in which case administration may be
20 accomplished by another route (e.g., systemically).

RNAi constructs - siRNAs and miRNAs

RNA interference (RNAi) is a phenomenon describing double-stranded (ds)RNA-dependent gene specific posttranscriptional silencing. Initial attempts to harness this phenomenon for experimental manipulation of mammalian cells were foiled by a robust
25 and nonspecific antiviral defense mechanism activated in response to long dsRNA molecules. Gil et al. *Apoptosis* 2000, 5:107-114. The field was significantly advanced upon the demonstration that synthetic duplexes of 21 nucleotide RNAs could mediate gene specific RNAi in mammalian cells, without invoking generic antiviral defense mechanisms. Elbashir et al. *Nature* 2001, 411:494-498; Caplen et al. *Proc Natl Acad Sci*
30 2001, 98:9742-9747. As a result, small-interfering RNAs (siRNAs) and micro RNAs (miRNAs) have become powerful tools to dissect gene function. The chemical synthesis of small RNAs is one avenue that has produced promising results. Numerous groups have

also sought the development of DNA-based vectors capable of generating such siRNA within cells. Several groups have recently attained this goal and published similar strategies that, in general, involve transcription of short hairpin (sh)RNAs that are efficiently processed to form siRNAs within cells. Paddison et al. PNAS 2002, 99:1443-1448; Paddison et al. Genes & Dev 2002, 16:948-958; Sui et al. PNAS 2002, 8:5515-5520; and Brummelkamp et al. Science 2002, 296:550-553. These reports describe methods to generate siRNAs capable of specifically targeting numerous endogenously and exogenously expressed genes.

Accordingly, the present invention provides a polynucleotide comprising an RNAi sequence that acts through an RNAi or miRNA mechanism to attenuate expression of a variant CFH gene. For instance, a polynucleotide of the invention may comprise a miRNA or siRNA sequence that attenuates or inhibits expression of a variant CFH gene. In one embodiment, the miRNA or siRNA sequence is between about 19 nucleotides and about 75 nucleotides in length, or preferably, between about 25 base pairs and about 35 base pairs in length. In certain embodiments, the polynucleotide is a hairpin loop or stem-loop that may be processed by RNase enzymes (e.g., Drosha and Dicer).

An RNAi construct contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the mRNA transcript for a variant CFH gene. The double-stranded RNA need only be sufficiently similar to natural RNA that it has the ability to mediate RNAi. The number of tolerated nucleotide mismatches between the target sequence and the RNAi construct sequence is no more than 1 in 5 basepairs, or 1 in 10 basepairs, or 1 in 20 basepairs, or 1 in 50 basepairs. It is primarily important that the RNAi construct is able to specifically target a variant CFH gene. Mismatches in the center of the siRNA duplex are most critical and may essentially abolish cleavage of the target RNA. In contrast, nucleotides at the 3' end of the siRNA strand that is complementary to the target RNA do not significantly contribute to specificity of the target recognition.

Sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters (e.g., University

of Wisconsin Genetic Computing Group). Greater than 90% sequence identity, or even 100% sequence identity, between the inhibitory RNA and the portion of the target gene is preferred. Alternatively, the duplex region of the RNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a portion of the target gene transcript (e.g., 400 mM NaCl, 40mM PIPES pH 6.4, 1 mM EDTA, 50 °C or 70 °C hybridization for 12-16 hours; followed by washing).

Production of polynucleotides comprising RNAi sequences can be carried out by any of the methods for producing polynucleotides described herein. For example, polynucleotides comprising RNAi sequences can be produced by chemical synthetic methods or by recombinant nucleic acid techniques. Endogenous RNA polymerase of the treated cell may mediate transcription in vivo, or cloned RNA polymerase can be used for transcription in vitro. Polynucleotides of the invention, including wildtype or antisense polynucleotides, or those that modulate target gene activity by RNAi mechanisms, may include modifications to either the phosphate-sugar backbone or the nucleoside, e.g., to reduce susceptibility to cellular nucleases, improve bioavailability, improve formulation characteristics, and/or change other pharmacokinetic properties. For example, the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. Modifications in RNA structure may be tailored to allow specific genetic inhibition while avoiding a general response to dsRNA. Likewise, bases may be modified to block the activity of adenosine deaminase. Polynucleotides of the invention may be produced enzymatically or by partial/total organic synthesis, any modified ribonucleotide can be introduced by in vitro enzymatic or organic synthesis.

Methods of chemically modifying RNA molecules can be adapted for modifying RNAi constructs (see, for example, Heidenreich et al. (1997) *Nucleic Acids Res*, 25:776-780; Wilson et al. (1994) *J Mol Recog* 7:89-98; Chen et al. (1995) *Nucleic Acids Res* 23:2661-2668; Hirschbein et al. (1997) *Antisense Nucleic Acid Drug Dev* 7:55-61). Merely to illustrate, the backbone of an RNAi construct can be modified with phosphorothioates, phosphoramidate, phosphodithioates, chimeric methylphosphonate-phosphodiester, peptide nucleic acids, 5-propynyl-pyrimidine containing oligomers or sugar modifications (e.g., 2'-substituted ribonucleosides, a-configuration).

The double-stranded structure may be formed by a single self-complementary RNA strand or two complementary RNA strands. RNA duplex formation may be initiated either

inside or outside the cell. The RNA may be introduced in an amount which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of double-stranded material may yield more effective inhibition, while lower doses may also be useful for specific applications. Inhibition is sequence-specific in that nucleotide sequences corresponding to the duplex region of the RNA are targeted for genetic inhibition.

In certain embodiments, the subject RNAi constructs are "siRNAs." These nucleic acids are between about 19-35 nucleotides in length, and even more preferably 21-23 nucleotides in length, e.g., corresponding in length to the fragments generated by nuclease "dicing" of longer double-stranded RNAs. The siRNAs are understood to recruit nuclease complexes and guide the complexes to the target mRNA by pairing to the specific sequences. As a result, the target mRNA is degraded by the nucleases in the protein complex or translation is inhibited. In a particular embodiment, the 21-23 nucleotides siRNA molecules comprise a 3' hydroxyl group.

In other embodiments, the subject RNAi constructs are "miRNAs." microRNAs (miRNAs) are small non-coding RNAs that direct post transcriptional regulation of gene expression through interaction with homologous mRNAs. miRNAs control the expression of genes by binding to complementary sites in target mRNAs from protein coding genes. miRNAs are similar to siRNAs. miRNAs are processed by nucleolytic cleavage from larger double-stranded precursor molecules. These precursor molecules are often hairpin structures of about 70 nucleotides in length, with 25 or more nucleotides that are base-paired in the hairpin. The RNase III-like enzymes Drosha and Dicer (which may also be used in siRNA processing) cleave the miRNA precursor to produce an miRNA. The processed miRNA is single-stranded and incorporates into a protein complex, termed RISC or miRNP. This RNA-protein complex targets a complementary mRNA. miRNAs inhibit translation or direct cleavage of target mRNAs. (Brennecke et al., *Genome Biology* 4:228 (2003); Kim et al., *Mol. Cells* 19:1-15 (2005).

In certain embodiments, miRNA and siRNA constructs can be generated by processing of longer double-stranded RNAs, for example, in the presence of the enzymes Dicer or Drosha. Dicer and Drosha are RNase III-like nucleases that specifically cleave dsRNA. Dicer has a distinctive structure which includes a helicase domain and dual RNase III motifs. Dicer also contains a region of homology to the

RDE1/QDE2/ARGONAUTE family, which have been genetically linked to RNAi in lower eukaryotes. Indeed, activation of, or overexpression of Dicer may be sufficient in many cases to permit RNA interference in otherwise non-receptive cells, such as cultured eukaryotic cells, or mammalian (non-oocyte) cells in culture or in whole organisms.

- 5 Methods and compositions employing Dicer, as well as other RNAi enzymes, are described in U.S. Pat. App. Publication No. 2004/0086884.

In one embodiment, the *Drosophila* *in vitro* system is used. In this embodiment, a polynucleotide comprising an RNAi sequence or an RNAi precursor is combined with a soluble extract derived from *Drosophila* embryo, thereby producing a combination. The
10 combination is maintained under conditions in which the dsRNA is processed to RNA molecules of about 21 to about 23 nucleotides.

The miRNA and siRNA molecules can be purified using a number of techniques known to those of skill in the art. For example, gel electrophoresis can be used to purify such molecules. Alternatively, non-denaturing methods, such as non-denaturing column
15 chromatography, can be used to purify the siRNA and miRNA molecules. In addition, chromatography (e.g., size exclusion chromatography), glycerol gradient centrifugation, affinity purification with antibody can be used to purify siRNAs and miRNAs.

In certain embodiments, at least one strand of the siRNA sequence of an effector domain has a 3' overhang from about 1 to about 6 nucleotides in length, or from 2 to 4
20 nucleotides in length. In other embodiments, the 3' overhangs are 1-3 nucleotides in length. In certain embodiments, one strand has a 3' overhang and the other strand is either blunt-ended or also has an overhang. The length of the overhangs may be the same or different for each strand. In order to further enhance the stability of the siRNA sequence, the 3' overhangs can be stabilized against degradation. In one embodiment, the RNA is
25 stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine nucleotide 3' overhangs by 2'-deoxythymidine is tolerated and does not affect the efficiency of RNAi. The absence of a 2' hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium and may be beneficial *in vivo*.

30 In certain embodiments, a polynucleotide of the invention that comprises an RNAi sequence or an RNAi precursor is in the form of a hairpin structure (named as hairpin RNA). The hairpin RNAs can be synthesized exogenously or can be formed by

transcribing from RNA polymerase III promoters in vivo. Examples of making and using such hairpin RNAs for gene silencing in mammalian cells are described in, for example, Paddison et al., *Genes Dev*, 2002, 16:948-58; McCaffrey et al., *Nature*, 2002, 418:38-9; McManus et al., *RNA* 2002, 8:842-50; Yu et al., *Proc Natl Acad Sci USA*, 2002, 99:6047-52). Preferably, such hairpin RNAs are engineered in cells or in an animal to ensure continuous and stable suppression of a desired gene. It is known in the art that miRNAs and siRNAs can be produced by processing a hairpin RNA in the cell.

In yet other embodiments, a plasmid is used to deliver the double-stranded RNA, e.g., as a transcriptional product. After the coding sequence is transcribed, the complementary RNA transcripts base-pair to form the double-stranded RNA.

Aptamers and small molecules

The present invention also provides therapeutic aptamers that specifically bind to variant CFH polypeptides that are associated with AMD, thereby modulating activity of the variant CFH polypeptide. An "aptamer" may be a nucleic acid molecule, such as RNA or DNA that is capable of binding to a specific molecule with high affinity and specificity (Ellington et al., *Nature* 346, 818-22 (1990); and Tuerk et al., *Science* 249, 505-10 (1990)). An aptamer will most typically have been obtained by in vitro selection for binding of a target molecule. For example, an aptamer that specifically binds a variant CFH polypeptide can be obtained by in vitro selection for binding to a variant CFH polypeptide from a pool of polynucleotides. However, in vivo selection of an aptamer is also possible. Aptamers have specific binding regions which are capable of forming complexes with an intended target molecule in an environment wherein other substances in the same environment are not complexed to the nucleic acid. The specificity of the binding is defined in terms of the comparative dissociation constants (K_d) of the aptamer for its ligand (e.g., a variant CFH polypeptide) as compared to the dissociation constant of the aptamer for other materials in the environment or unrelated molecules in general. A ligand (e.g., a variant CFH polypeptide) is one which binds to the aptamer with greater affinity than to unrelated material. Typically, the K_d for the aptamer with respect to its ligand will be at least about 10-fold less than the K_d for the aptamer with unrelated material or accompanying material in the environment. Even more preferably, the K_d will be at least about 50-fold less, more preferably at least about 100-fold less, and most preferably at least about 200-fold less. An aptamer will typically be between about 10 and about 300

nucleotides in length. More commonly, an aptamer will be between about 30 and about 100 nucleotides in length.

Methods for selecting aptamers specific for a target of interest are known in the art. For example, organic molecules, nucleotides, amino acids, polypeptides, target features on cell surfaces, ions, metals, salts, saccharides, have all been shown to be suitable for isolating aptamers that can specifically bind to the respective ligand. For instance, organic dyes such as Hoechst 33258 have been successfully used as target ligands for in vitro aptamer selections (Werstuck and Green, *Science* 282:296-298 (1998)). Other small organic molecules like dopamine, theophylline, sulforhodamine B, and cellobiose have also been used as ligands in the isolation of aptamers. Aptamers have also been isolated for antibiotics such as kanamycin A, lividomycin, tobramycin, neomycin B, viomycin, chloramphenicol and streptomycin. For a review of aptamers that recognize small molecules, see Famulok, *Science* 9:324-9 (1999).

An aptamer of the invention can be comprised entirely of RNA. In other embodiments of the invention, however, the aptamer can instead be comprised entirely of DNA, or partially of DNA, or partially of other nucleotide analogs. To specifically inhibit translation in vivo, RNA aptamers are preferred. Such RNA aptamers are preferably introduced into a cell as DNA that is transcribed into the RNA aptamer. Alternatively, an RNA aptamer itself can be introduced into a cell.

Aptamers are typically developed to bind particular ligands by employing known in vivo or in vitro (most typically, in vitro) selection techniques known as SELEX (Ellington et al., *Nature* 346, 818-22 (1990); and Tuerk et al., *Science* 249, 505-10 (1990)). Methods of making aptamers are also described in, for example, U.S. Pat. No. 5,582,981, PCT Publication No. WO 00/20040, U.S. Pat. No. 5,270,163, Lorsch and Szostak, *Biochemistry*, 33:973 (1994), Mannironi et al., *Biochemistry* 36:9726 (1997), Blind, Proc. Nat'l. Acad. Sci. USA 96:3606-3610 (1999), Huizenga and Szostak, *Biochemistry*, 34:656-665 (1995), PCT Publication Nos. WO 99/54506, WO 99/27133, WO 97/42317 and U.S. Pat. No. 5,756,291.

Generally, in their most basic form, in vitro selection techniques for identifying aptamers involve first preparing a large pool of DNA molecules of the desired length that contain at least some region that is randomized or mutagenized. For instance, a common oligonucleotide pool for aptamer selection might contain a region of 20-100 randomized

nucleotides flanked on both ends by an about 15-25 nucleotide long region of defined sequence useful for the binding of PCR primers. The oligonucleotide pool is amplified using standard PCR techniques, although any means that will allow faithful, efficient amplification of selected nucleic acid sequences can be employed. The DNA pool is then
5 in vitro transcribed to produce RNA transcripts. The RNA transcripts may then be subjected to affinity chromatography, although any protocol which will allow selection of nucleic acids based on their ability to bind specifically to another molecule (e.g., a protein or any target molecule) may be used. In the case of affinity chromatography, the transcripts are most typically passed through a column or contacted with magnetic beads or
10 the like on which the target ligand has been immobilized. RNA molecules in the pool which bind to the ligand are retained on the column or bead, while nonbinding sequences are washed away. The RNA molecules which bind the ligand are then reverse transcribed and amplified again by PCR (usually after elution). The selected pool sequences are then put through another round of the same type of selection. Typically, the pool sequences are
15 put through a total of about three to ten iterative rounds of the selection procedure. The cDNA is then amplified, cloned, and sequenced using standard procedures to identify the sequence of the RNA molecules which are capable of acting as aptamers for the target ligand. Once an aptamer sequence has been successfully identified, the aptamer may be further optimized by performing additional rounds of selection starting from a pool of
20 oligonucleotides comprising the mutagenized aptamer sequence. For use in the present invention, the aptamer is preferably selected for ligand binding in the presence of salt concentrations and temperatures which mimic normal physiological conditions.

The unique nature of the in vitro selection process allows for the isolation of a suitable aptamer that binds a desired ligand despite a complete dearth of prior knowledge
25 as to what type of structure might bind the desired ligand.

The association constant for the aptamer and associated ligand is preferably such that the ligand functions to bind to the aptamer and have the desired effect at the concentration of ligand obtained upon administration of the ligand. For in vivo use, for example, the association constant should be such that binding occurs well below the
30 concentration of ligand that can be achieved in the serum or other tissue. Preferably, the required ligand concentration for in vivo use is also below that which could have undesired effects on the organism.

The present invention also provides small molecules and antibodies that specifically bind to a variant CFH polypeptide that is associated with AMD, thereby inhibiting the activity of a variant CFH polypeptide. Examples of small molecules include, without limitation, drugs, metabolites, intermediates, cofactors, transition state analogs, ions, metals, toxins and natural and synthetic polymers (e.g., proteins, peptides, nucleic acids, polysaccharides, glycoproteins, hormones, receptors and cell surfaces such as cell walls and cell membranes).

Antibodies

Another aspect of the invention pertains to antibodies. In one embodiment, an antibody that is specifically reactive with a variant CFH polypeptide may be used to detect the presence of a variant CFH polypeptide or to inhibit activity of a variant CFH polypeptide. For example, by using immunogens derived from a variant CFH peptide, anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (see, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the variant CFH peptide, an antigenic fragment which is capable of eliciting an antibody response, or a fusion protein. In a particular embodiment, the inoculated mouse does not express endogenous CFH, thus facilitating the isolation of antibodies that would otherwise be eliminated as anti-self antibodies. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of a variant CFH peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.

Following immunization of an animal with an antigenic preparation of a variant CFH polypeptide, antisera can be obtained and, if desired, polyclonal antibodies can be isolated from the serum. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Such techniques are well known in the art, and include, for example, the hybridoma

technique (originally developed by Kohler and Milstein, (1975) *Nature*, 256: 495-497), the human B cell hybridoma technique (Kozbar et al., (1983) *Immunology Today*, 4: 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. pp. 77-96).

- 5 Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with a variant CFH polypeptide and monoclonal antibodies isolated from a culture comprising such hybridoma cells.

The term "antibody" as used herein is intended to include fragments thereof which are also specifically reactive with a variant CFH polypeptide. Antibodies can be
10 fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab)₂ fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody of the present invention is further intended to include bispecific, single-chain, and chimeric and
15 humanized molecules having affinity for a variant CFH polypeptide conferred by at least one CDR region of the antibody. In preferred embodiments, the antibody further comprises a label attached thereto and able to be detected (e.g., the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor).

In certain embodiments, an antibody of the invention is a monoclonal antibody, and
20 in certain embodiments, the invention makes available methods for generating novel antibodies that bind specifically to variant CFH polypeptides. For example, a method for generating a monoclonal antibody that binds specifically to a variant CFH polypeptide may comprise administering to a mouse an amount of an immunogenic composition comprising the CFH polypeptide effective to stimulate a detectable immune response, obtaining
25 antibody-producing cells (e.g., cells from the spleen) from the mouse and fusing the antibody-producing cells with myeloma cells to obtain antibody-producing hybridomas, and testing the antibody-producing hybridomas to identify a hybridoma that produces a monoclonal antibody that binds specifically to the variant CFH polypeptide. Once
obtained, a hybridoma can be propagated in a cell culture, optionally in culture conditions
30 where the hybridoma-derived cells produce the monoclonal antibody that binds specifically to the CFH polypeptide. The monoclonal antibody may be purified from the cell culture.

The term "specifically reactive with" as used in reference to an antibody is intended to mean, as is generally understood in the art, that the antibody is sufficiently selective between the antigen of interest (e.g., a variant CFH polypeptide) and other antigens that are not of interest that the antibody is useful for, at minimum, detecting the presence of the antigen of interest in a particular type of biological sample. In certain methods employing the antibody, such as therapeutic applications, a higher degree of specificity in binding may be desirable. Monoclonal antibodies generally have a greater tendency (as compared to polyclonal antibodies) to discriminate effectively between the desired antigens and cross-reacting polypeptides. One characteristic that influences the specificity of an antibody:antigen interaction is the affinity of the antibody for the antigen. Although the desired specificity may be reached with a range of different affinities, generally preferred antibodies will have an affinity (a dissociation constant) of about 10^{-6} , 10^{-7} , 10^{-8} , 10^{-9} or less.

In addition, the techniques used to screen antibodies in order to identify a desirable antibody may influence the properties of the antibody obtained. For example, if an antibody is to be used for binding an antigen in solution, it may be desirable to test solution binding. A variety of different techniques are available for testing interaction between antibodies and antigens to identify particularly desirable antibodies. Such techniques include ELISAs, surface plasmon resonance binding assays (e.g., the Biacore binding assay, Bia-core AB, Uppsala, Sweden), sandwich assays (e.g., the paramagnetic bead system of IGEN International, Inc., Gaithersburg, Maryland), western blots, immunoprecipitation assays, and immunohistochemistry.

6. Screening Assays

In certain aspects, the present invention relates to the use of CFH polypeptides to identify compounds (agents) which are agonist or antagonists of CFH polypeptides. Compounds identified through this screening can be tested in cells of the eye, (e.g., epithelial and endothelial cells) as well as other tissues (e.g., muscle and/or neurons) to assess their ability to modulate CFH activity in vivo or in vitro. In certain aspects, compounds identified through this screening modulate the formation of drusen deposits. Optionally, these compounds can further be tested in animal models to assess their ability to modulate CFH activity in vivo.

There are numerous approaches to screening for therapeutic agents that target CFH polypeptides. In certain embodiments, high-throughput screening of compounds can be carried out to identify agents that affect activity of CFH polypeptides. A variety of assay formats will suffice and, in light of the present disclosure, those not expressly described
5 herein will nevertheless be comprehended by one of ordinary skill in the art. As described herein, the test compounds (agents) of the invention may be created by any combinatorial chemical method. Alternatively, the subject compounds may be naturally occurring biomolecules synthesized in vivo or in vitro. Compounds (agents) to be tested for their ability to act as modulators of CFH activity can be produced, for example, by bacteria,
10 yeast, plants or other organisms (e.g., natural products), produced chemically (e.g., small molecules, including peptidomimetics), or produced recombinantly. Test compounds contemplated by the present invention include non-peptidyl organic molecules, peptides, polypeptides, peptidomimetics, sugars, hormones, and nucleic acid molecules.

The test compounds of the invention can be provided as single, discrete entities, or
15 provided in libraries of greater complexity, such as made by combinatorial chemistry. These libraries can comprise, for example, alcohols, alkyl halides, amines, amides, esters, aldehydes, ethers and other classes of organic compounds. Presentation of test compounds to the test system can be in either an isolated form or as mixtures of compounds, especially in initial screening steps. Optionally, the compounds may be optionally derivatized with
20 other compounds and have derivatizing groups that facilitate isolation of the compounds. Non-limiting examples of derivatizing groups include biotin, fluorescein, digoxigenin, green fluorescent protein, isotopes, polyhistidine, magnetic beads, glutathione S transferase (GST), photoactivatable crosslinkers or any combinations thereof.

In many drug screening programs which test libraries of compounds and natural
25 extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test
30 compound. Moreover, the effects of cellular toxicity or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of the drug on the molecular target.

In certain embodiments, the subject compounds are identified by their ability to interact with a CFH polypeptide of the invention. The interaction between the compound and the CFH polypeptide may be covalent or non-covalent. For example, such interaction can be identified at the protein level using in vitro biochemical methods, including photo-crosslinking, radiolabeled ligand binding, and affinity chromatography (Jakoby WB et al., 1974, *Methods in Enzymology* 46:1). In certain cases, the compounds may be screened in a mechanism based assay, such as an assay to detect compounds which bind to a CFH polypeptide. This may include a solid phase or fluid phase binding event. Alternatively, the gene encoding a CFH polypeptide can be transfected with a reporter system (e.g., β -galactosidase, luciferase, or green fluorescent protein) into a cell and screened against the library preferably by a high throughput screening or with individual members of the library. Other mechanism based binding assays may be used, for example, binding assays which detect changes in free energy. Binding assays can be performed with the target fixed to a well, bead or chip or captured by an immobilized antibody or resolved by capillary electrophoresis. The bound compounds may be detected usually using colorimetric or fluorescence or surface plasmon resonance.

7. Pharmaceutical Compositions

The methods and compositions described herein for treating a subject suffering from AMD may be used for the prophylactic treatment of individuals who have been diagnosed or predicted to be at risk for developing AMD. In this case, the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of AMD or related symptoms. Alternatively, the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from AMD. In this case, the composition is administered in an amount and dose that is sufficient to delay or slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition to the point of eliminating the disorder. It is understood that an effective amount of a composition for treating a subject who has been diagnosed or predicted to be at risk for developing AMD is a dose or amount that is in sufficient quantities to treat a subject or to treat the disorder itself.

In certain embodiments, compounds of the present invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide) are formulated with a pharmaceutically

acceptable carrier. For example, a CFH polypeptide or a nucleic acid molecule coding for a CFH polypeptide can be administered alone or as a component of a pharmaceutical formulation (therapeutic composition). The subject compounds may be formulated for administration in any convenient way for use in human medicine.

5 In certain embodiments, the therapeutic methods of the invention include administering the composition topically, systemically, or locally. For example, therapeutic compositions of the invention may be formulated for administration by, for example, injection (e.g., intravenously, subcutaneously, or intramuscularly), inhalation or
10 insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal, nasal, or parenteral administration. The compositions described herein may be formulated as part of an implant or device. When administered, the therapeutic composition for use in this invention is in a pyrogen-free, physiologically acceptable form. Further, the composition may be encapsulated or injected in a viscous form for delivery to the site where the target cells are present, such as to the cells of the eye. Techniques and
15 formulations generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. In addition to CFH polypeptides or nucleic acid molecules coding for CFH polypeptides, therapeutically useful agents may optionally be included in any of the compositions as described above. Furthermore, therapeutically useful agents may, alternatively or additionally, be administered simultaneously or sequentially with
20 CFH polypeptides or nucleic acid molecules coding for CFH polypeptides according to the methods of the invention.

In certain embodiments, compositions of the invention can be administered orally, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an
25 aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of an agent as an active ingredient. An agent may also be administered as a bolus, electuary or paste.

30 In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, and the like), one or more therapeutic compounds of the present invention may be mixed with one or more pharmaceutically acceptable carriers, such as

sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-
5 agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols,
10 sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

15 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
20 propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

25 Suspensions, in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

30 Certain compositions disclosed herein may be administered topically, either to skin or to mucosal membranes. The topical formulations may further include one or more of the wide variety of agents known to be effective as skin or stratum corneum penetration enhancers. Examples of these are 2-pyrrolidone, N-methyl-2-pyrrolidone,

dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azone. Additional agents may further be included to make the formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes, fragrances, preservatives, stabilizers, and surface active agents. Keratolytic agents such as those known in the art may also be included. Examples are salicylic acid and sulfur.

Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The ointments, pastes, creams and gels may contain, in addition to a subject compound of the invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide), excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a subject compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

It is understood that the dosage regimen will be determined for an individual, taking into consideration, for example, various factors which modify the action of the subject compounds of the invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide), the severity or stage of AMD, route of administration, and characteristics unique to the individual, such as age, weight, and size. A person of ordinary skill in the art is able to determine the required dosage to treat the subject. In one embodiment, the dosage can range from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. Based upon the composition, the dose can be delivered continuously, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a particular composition can be determined without undue experimentation by one skilled in the art. For example, the compound may be delivered

hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery.

In certain embodiments, pharmaceutical compositions suitable for parenteral administration may comprise a CFH polypeptide or a nucleic acid molecule coding for a CFH polypeptide in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The compositions of the invention may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.

In certain embodiments, the present invention also provides gene therapy for the *in vivo* production of CFH polypeptides. Such therapy would achieve its therapeutic effect by introduction of CFH polynucleotide sequences into cells or tissues that are deficient for normal CFH function. Delivery of CFH polynucleotide sequences can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Targeted liposomes may also be used for the therapeutic delivery of CFH polynucleotide sequences.

- Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or an RNA virus such as a retrovirus. A retroviral vector may be a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. Retroviral vectors can be made target-specific by attaching, for example, a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody. Those of skill in the art will recognize that specific polynucleotide sequences can be inserted into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the CFH polynucleotide. In one preferred embodiment, the vector is targeted to cells or tissues of the eye.
- Alternatively, tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.
- Another targeted delivery system for CFH polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (see e.g., Fraley, et al., Trends Biochem. Sci., 6:77, 1981). Methods for efficient gene transfer using a liposome vehicle, are known in the art, see e.g., Mannino, et al., Biotechniques, 6:682, 1988. The composition of the liposome is usually a combination of phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine. The targeting of liposomes is also possible based on, for example, organ-specificity, cell-specificity, and organelle-specificity and is known in the art.

Moreover, the pharmaceutical preparation can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g. retroviral packages, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system. In the case of the latter, methods of introducing the viral packaging cells may be provided by, for example, rechargeable or biodegradable devices. Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals, and can be adapted for release of viral particles through the manipulation of the polymer composition and form. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of the viral particles by cells implanted at a particular target site. Such embodiments of the present invention can be used for the delivery of an exogenously purified virus, which has been incorporated in the polymeric device, or for the delivery of viral particles produced by a cell encapsulated in the polymeric device.

A person of ordinary skill in the art is able to determine the required amount to treat the subject. It is understood that the dosage regimen will be determined for an individual, taking into consideration, for example, various factors which modify the action of the subject compounds of the invention, the severity or stage of AMD, route of administration, and characteristics unique to the individual, such as age, weight, and size. A person of ordinary skill in the art is able to determine the required dosage to treat the subject. In one embodiment, the dosage can range from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. The dose can be delivered continuously, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a

particular composition can be determined without undue experimentation by one skilled in the art. For example, the compound may be delivered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery. As used herein, the term "subject" means any individual animal capable of becoming afflicted with AMD. The
5 subjects include, but are not limited to, human beings, primates, horses, birds, cows, pigs, dogs, cats, mice, rats, guinea pigs, ferrets, and rabbits. In the preferred embodiment, the subject is a human being.

Samples used in the methods described herein may comprise cells from the eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract,
10 urine, muscle, cartilage, skin, or any other tissue or bodily fluid from which sufficient DNA or RNA can be obtained.

The sample should be sufficiently processed to render the DNA or RNA that is present available for assaying in the methods described herein. For example, samples may be processed such that DNA from the sample is available for amplification or for
15 hybridization to another polynucleotide. The processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material. Alternatively, samples may be processed to isolate the available DNA or RNA from one or more contaminants that are present in its natural source. Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods
20 described herein. Methods for processing samples may include, without limitation, mechanical, chemical, or molecular means of lysing and/or purifying cells and cell lysates. Processing methods may include, for example, ion-exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and
25 immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide

8. Kits

Also provided herein are kits, e.g., kits for therapeutic purposes or kits for detecting a variant CFH gene in a sample from an individual. In one embodiment, a kit comprises at
30 least one container means having disposed therein a premeasured dose of a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In another embodiment, a kit

comprises at least one container means having disposed therein a premeasured dose of a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In a further embodiment, a second polynucleotide primer that hybridizes, under stringent
5 conditions, to the other side of a variation in the CFH gene that is correlated with the occurrence of AMD in humans is provided in a premeasured dose. Kits further comprise a label and/or instructions for the use of the therapeutic or diagnostic kit in the detection of CFH in a sample. Kits may also include packaging material such as, but not limited to, ice, dry ice, styrofoam, foam, plastic, cellophane, shrink wrap, bubble wrap, paper, cardboard,
10 starch peanuts, twist ties, metal clips, metal cans, drierite, glass, and rubber (see products available from www.papermart.com for examples of packaging material).

The practice of the present methods will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of
15 the art. Such techniques are explained fully in the literature. See, for example, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory (2001); *DNA Cloning*, Volumes I and II (D. N. Glover ed., 1985); *Oligonucleotide Synthesis* (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No: 4,683,195; *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Transcription And Translation* (B. D. Hames & S. J. Higgins
20 eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); *Immobilized Cells And Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); the treatise, *Methods In Enzymology* (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu
25 et al. eds.), *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

EXAMPLES

30 The following examples are for illustrative purposes and are not intended to be limiting in any way.

EXAMPLE 1: Whole genome SNP association for genes correlated with AMD.

Described herein is a whole-genome case-control association study for genes involved in AMD. Two crucial factors were used in designing this experiment; clearly defined phenotypes were chosen for cases and controls. The definition of a case was based on both a quantitative photographic assessment of the presence of at least some large drusen combined with photographic evidence of sight-threatening AMD (geographic atrophy or neovascular AMD). The definition of a control was based on the study participant having either no drusen or only a few small drusen. Data was analyzed using a statistically conservative approach to correct for the large number of SNPs tested, thereby guaranteeing that the actual probability of a false positive is no greater than the reported p-values.

A subset of individuals who participated in the Age-Related Eye Disease Study (AREDS) (AREDS Research Group, Arch Ophthalmol 119, 1417, (2001)) were used in the association study. From the AREDS sample, 96 case subjects were identified who, at their most recent study visit, had either uniocular choroidal neovascularization (50 cases) or geographic atrophy either central or non-central to the macula (46 cases). The fellow eye of these case subjects was required to have at least one large drusen ($>125 \mu\text{m}$ in diameter), and total drusen area equivalent to a circle of at least $1061 \mu\text{m}$ in diameter. The group of study participants who had both large drusen and sight-threatening AMD was selected because there can be many precursors to the development of either choroidal neovascularization or geographic atrophy. Controls were 50 individuals from the AREDS sample who had few or no drusen ($<63 \mu\text{m}$ in diameter in each eye) for the duration of their participation in AREDS. All individuals identified themselves as "White, not of Hispanic origin." To the extent possible, the proportions of gender and smoking status were kept the same in cases and controls. Controls were purposely chosen to be older than the cases to increase the probability that they will remain without AMD (Table 1).

Table 1. Summary of sample phenotypes.

	Cases (n=96)	Controls (n=50)
Males (%)	44	54
Never smoked (%)	36	52
Formerly smoked (%)	58	48

Currently smoke (%)	5	0
Mean age (\pm s.d.) (years)	79 \pm 5.2	82 \pm 2.2
Age range (years)	65-89	78-87
One eye with neovascular AMD, other eye with at least one large drusen (%)	52	0
One eye with geographic atrophy AMD, other eye with at least one large drusen (%)	48	0
Both eyes with few or no drusen (%)	0	100

EXAMPLE 2: Genotyping and SNP identification of individuals in study population

- Each individual was genotyped using the Affymetrix GeneChip Mapping 100K Set of microarrays (H. Matsuzaki et al., Nat Methods 1, 109 (2004)). This mapping assay consists of two chips (XbaI and HindIII) with approximately 50,000 SNPs each that are used for each individual. About 250 ng of genomic DNA was digested with two restriction enzymes XbaI and HindIII and processed according to the Affymetrix protocol (H. Matsuzaki et al., Nat Methods 1, 109 (2004)). The images were analyzed using GDAS software (Affymetrix). For the data obtained from each chip, two internal quality control measures were used: the call rate always exceeded 95% and heterozygosity on the X chromosome correctly identified the gender of the individual. Thirty-one identical SNPs were placed on both chips and checked that they yielded the same genotype for the same individual to ensure that no samples were confused.
- Three experiments were performed to test the reproducibility of this system. First, 4 samples were processed twice with the Xba chips. Next, 2 replicates of a reference DNA positive control provided by Affymetrix were run on Xba chips alongside the samples. Finally, results for 3 individuals were compared with genotyping using the Affymetrix 10K SNP platform to test the accuracy of this assay (H. Matsuzaki et al., Genome Res 14, 414 (2004)).

- An assessment of the percentage of the individuals producing a genotype call for each SNP was made in order to examine the genotyping quality for each individual SNP. A SNP with a call rate of 100% means every individual is successfully assigned a genotype for this SNP and there is no missing data. Call rates were required to be at least 85% to remove SNPs for which genotyping was consistently problematic. SNPs which are

monomorphic in the data were also removed, since these SNPs are uninformative. SNPs in which genotype frequencies deviated from the Hardy-Weinberg equilibrium expectation (HWD $\chi^2 > 25$, $P = 0.05$, 1 df, after Bonferroni correction) were removed as being likely to contain genotyping errors rather than real disequilibrium. SNPs for which no homozygotes
5 were observed in the entire sample were also likely due to errors and removed. Altogether, of the 116,204 SNPs genotyped, 105,980 SNPs with a call rate of at least 85%, both alleles observed, at least one homozygote observed, and a HWD $\chi^2 \leq 25$ were found and considered. Of these, the 103,611 SNPs that lie on the 22 autosomal chromosomes were analyzed. A summary of genotyping quality can be found in Table 2.

Table 2. Genotyping quality control and informativeness.

Per-chip data quality	
Median call rate per chip	99.1%
Minimum call rate per chip	95.6%
Chips for which gender matches	292 (100%)
Per-individual data quality	
Median call rate per individual	99.1%
Minimum call rate per individual	96.7%
Average number of matches for common SNPs between two chips	30.7/31
Minimum number of matches for common SNPs between two chips*	28/31
Reproducibility	
Xba Repeat concordance (4 replicates)	99.886%
Xba Positive control concordance (2 replicates)	99.870%
10K concordance (3 replicates)	99.767%
Call rate (per-SNP)	
Total number of SNPs	116204
SNPs with 100% call rate	81456
SNPs with call rate between 85% and 100%	33262
SNPs with call rate less than 85%	1486
Locus Polymorphism	
Number of SNPs with no polymorphism observed	8538
Number of SNPs with minor allele frequency < 0.01	3604
Number of SNPs with only heterozygotes observed	19
Number of polymorphic SNPs with no heterozygotes observed	71
Hardy-Weinberg Equilibrium	
Number of SNPs significantly out of equilibrium	231

*For the most part, when SNPs do not match it is due to one of the SNPs not being called. In only 3 out of 4485 comparisons is a mismatch observed, which is equivalent to 99.93% concordance.

EXAMPLE 3: Statistical analysis of SNP association with disease status

Allelic association with disease status was tested for each SNP. A 2x2 contingency table of allele frequencies was constructed. The Pearson χ^2 value and a P-value were calculated, based on the central χ^2 distribution under the null hypothesis of no association with 1 degree of freedom. This nominal P-value was corrected for multiple testing by applying the Bonferroni correction, in which only SNPs with a p-value less than 0.05/103,611 = 4.8×10^{-7} were considered. This produced a Bonferroni-corrected P-value. This correction is known to be conservative and thus may "overcorrect" the raw p-values (L. M. McIntyre, E. R. Martin, K. L. Simonsen, N. L. Kaplan, *Genet Epidemiol* 19, 18 (2000)). While this technique may overlook real associations, it adjusts for the large number of multiple comparisons and yields p-values that do not underestimate the false positive rate.

Two methods of genomic control were used to look for population stratification, GC and GCF (B. Devlin, S. A. Bacanu, K. Roeder, *Nat Genet* 36, 1129 (2004)). In the first method, the median χ^2 value was taken for allelic association with a number of SNPs assumed to be unassociated with the disease (null SNPs). The test statistic $\chi^2_{(1)}$ values were divided by this median, and tested for significance using the χ^2 distribution. Alternatively, for the GCF method, the mean rather than the median of the null χ^2 statistics was used; significance of the quotient was tested using the $F(1,L)$ distribution, where L is the number of null SNPs used (B. Devlin, S. A. Bacanu, K. Roeder, *Nat Genet* 36, 1129 (2004)). Two different sets of unassociated SNPs were used: all the SNPs successfully genotyped except the two significant (see below) ones, and the set of 31 SNPs that are in common between the two chips used in the assay (see Example 2 above).

The candidate region was defined by looking for adjacent SNPs in which all four gametes were observed (R. R. Hudson, N. L. Kaplan, *Genetics* 111, 147 (1985)) and bounding the region there. To look at linkage disequilibrium between SNPs in the candidate region, haplotype frequencies in the region were inferred using PHASE version 2.1 (M. Stephens, P. Donnelly, *Am J Hum Genet* 73, 1162 (2003); M. Stephens, N. J. Smith, P. Donnelly, *Am J Hum Genet* 68, 978 (2001)). Based on the inferred haplotype frequencies across the entire region, pairwise linkage disequilibrium was calculated by first computing the two-locus haplotype frequencies implied by the overall haplotype

frequencies. The measure of linkage disequilibrium, D' , was then calculated using standard equations (D. L. Hartl, A. G. Clark, *Principles of Population Genetics* (Sinauer Associates, Sunderland, MA, ed. Third, 1997)) and plotted using the program GOLD (G. R. Abecasis, W. O. Cookson, *Bioinformatics* 16, 182 (2000)).

- 5 To define the smaller haplotype blocks within the 4-gamete region, the HapMap data website was used (<http://www.hapmap.org>). Genotypes for SNPs in the region between SNPs rs10494744 and rs10484502 were downloaded. Genotypes for the CEU population (CEPH Utah population of northern and western European ancestry) were downloaded and visualized using Haploview version 3.0. Haplotype blocks were then
- 10 defined using the method and parameters of Gabriel et al (S. B. Gabriel et al., *Science* 296, 2225 (2002)).

- Haplotypes across the narrower region defined by the HapMap block were also inferred using PHASE version 2.1. Haplotypes with an estimated frequency of at least 1% were considered for further analysis. Phylogenetic trees were built using the maximum
- 15 parsimony of PHYLIP 3.62 ("dnaps" program). The odds ratio in a nested clastic framework was calculated for the haplotypes (P. Armitage, G. Berry, *Statistical Methods in Medical Research* (Blackwell Scientific Publications, Oxford, ed. Second, 1987); A. R. Templeton, E. Boerwinkle, C. F. Sing, *Genetics* 117, 343 (1987)).

- Odds ratios, confidence intervals, and population attributable risk were calculated
- 20 as described in P. Armitage, G. Berry, *Statistical Methods in Medical Research* (Blackwell Scientific Publications, Oxford, ed. Second, 1987). The population frequency of the alleles of interest (see Example 4 below) is relatively high, 23% for and 41% for homozygous rs380390 and rs1329428, respectively. Therefore, the odds ratios necessarily calculated from the case control design study used here will over-estimate (without changing the
- 25 significance levels) the equivalent relative risk estimate needed to calculate lifetime risk. A prospective cohort study design will provide valid estimates of lifetime risk in persons who have and have not inherited the alleles.

EXAMPLE 4: Polymorphisms in the Complement Factor H gene are associated with AMD

Of the autosomal SNPs, only two, rs380390 and rs10272438, are significantly associated with disease status (Bonferroni corrected $p=0.0043$ and $p=0.0080$, respectively; Figure 1A). One criticism of case-control association studies such as this one is that population stratification can result in false positive results. If the cases and controls are drawn from populations of different ancestry, with different allele frequencies, it is possible to detect these population differences instead of loci associated with the disease. All individuals in this study self-identify their ethnicity as non-Hispanic white and all of the case and control individuals are drawn from the same AREDS population. There was some differential recruiting of cases from office practices and recruiting of controls from radio and newspaper advertising (AREDS Research Group, Ophthalmology 107, 2224 (2000)). Finding two SNPs out of $>100,000$ implied no genetic stratification, but genomic control methods were used to control for this possibility (B. Devlin, S. A. Bacanu, K. Roeder, Nat Genet 36, 1129 (2004)). It was consistently found that the significance of the tests was not inflated and that, therefore, these two SNPs are significantly associated with disease.

SNP rs380390 was successfully genotyped in all individuals. In 21 individuals, no genotype was determined for SNP rs10272438, and it appears to be excessively out of Hardy-Weinberg equilibrium ($HWE\chi^2=36$), indicating possible genotyping errors. Missing genotypes were determined by resequencing. After including these additional genotypes, the association was no longer significant after Bonferroni correction. Furthermore, the SNP with the third lowest p -value, rs1329428 (Bonferroni corrected $p=0.14$), is located 1.8 kb away from rs380390 on the same chromosome. The genotype frequencies at these two neighboring loci clearly vary between the case and control populations (Figure 1B). Homozygotes for the C allele of rs380390 and the C allele at rs1329428 clearly have an increased risk of developing AMD (Table 1). The risk conferred by these genotypes accounts for approximately 45% (rs380390) to 61% (rs1329428) of the cases observed in the population (Table 3). Therefore, we decided to focus on these two SNPs as marking our most promising locus.

Table 3. Risk ratios and population attributable risks for various genotypes and haplotypes.

	rs380390 (C/G)	rs1329428 (C/T)
Risk allele	C	C
Allelic Association χ^2 nominal p-value	4.1e-08	1.4e-06
Odds ratio (dominant) (95% CI)	4.6 (2.0-11)	4.7 (1.0-22)
PAR (95% CI)	70% (42%-84%)	80% (0%-96%)
Frequency in HapMap CEU	0.70	0.82
Odds ratio (recessive) (95% CI)	7.4 (2.9-19)	6.2 (2.9-13)
PAR (95% CI)	46% (31%-57%)	61% (43%-73%)
Frequency in HapMap CEU	0.23	0.41

Dominant and recessive refer to the risk factor consisting of having at least one copy (dominant) or two copies (recessive) of the risk allele. PAR is the population attributable risk. The dominant odds ratio and PAR compare likelihood of AMD in individuals with one copy of the risk allele versus individuals with no copy of the risk allele. The recessive odds ratio and PAR compare likelihood of AMD in individuals with two copies of the risk allele versus individuals with no more than one copy of the risk allele. The population frequencies for the risk genotypes are taken from the CEU HapMap population (CEPH collection of Utah residents of northern and western European ancestry).

rs380390 and rs1329428 lie in an intron of the gene for complement factor H (CFH). As both of these SNPs are noncoding and neither appears to alter a conserved sequence, these two SNPs may be in linkage disequilibrium with a corresponding functional mutation. To circumscribe the region in which the functional mutation may lie, the linkage disequilibrium throughout this region was analyzed (Figure 2A). The two associated SNPs lie in a region of high linkage disequilibrium that is around 500 kb long. As this region is longer than other typically observed blocks of high linkage disequilibrium (S. B Gabriel et al., Science 296, 2225 (2002)) and there are long stretches in this region where there are no SNPs in our dataset (Figure 2B), other data sources with denser SNP coverage were used to narrow down the region.

Data from the International HapMap project was used to analyze patterns of linkage disequilibrium in a population of residents of Utah with ancestry from northern and western Europe (the CEPH sample) (The International HapMap Consortium, Nature 426, 789 (2003)). In the 500 kb region of interest, there are 152 SNPs in the HapMap data set. Using a standard definition of linkage disequilibrium blocks (S. B Gabriel et al., Science

296, 2225 (2002)), it was found that the two associated SNPs lie in a block that is 41 kb long and entirely contained within the CFH gene (Figure 2C).

There are six SNPs from the present study's data set in this 41 kb region. These SNPs form four predominant haplotypes with a frequency greater than 1% (Table 4).

- 5 Combined, these four haplotypes represent 99% of the chromosomes in this study. Reconstructing inferred haplotypes and building a phylogenetic tree allowed assessment of the evolutionary relationship between haplotypes (Figure 2D). Using inferred haplotypes for each individual, the odds ratio of disease in a nested clastic framework under both dominant and recessive models were computed (A. R. Templeton, E. Boerwinkle, C. F. Sing, Genetics 117, 343 (1987)). The highest risk is conferred by haplotype N1, which is the only haplotype containing the risk allele at SNP rs380390.

Table 4. Haplotypes in the haplotype block that harbors the putative disease variant.

Name	rs2019727	rs10489456	rs3753396	rs380390	rs2284664	rs1329428	Frequency
N1	A	C	T	C	C	G	0.59
N1	A	C	T	G	C	G	0.0068
N3	A	C	T	G	T	A	0.12
N4	A	T	C	G	C	G	0.15
N5	T	C	T	G	C	A	0.12
N6	T	C	T	G	C	G	0.0071

- 15 Haplotype frequencies are estimated using the program PHASE (M. Stephens, P. Donnelly, Am J Hum Genet 73, 1162 (2003); M. Stephens, N. J. Smith, P. Donnelly, Am J Hum Genet 68, 978 (2001)). The SNPs used to construct the haplotypes are the SNPs from the mapping microarrays found in the 41 kb haplotype block defined by the HapMap data. Frequencies are the estimated frequency of each haplotype in the combined case and control population. The two SNPs that show association in the initial analysis are indicated in boldface.

- 20 Having at least one copy of this haplotype increases the risk for AMD 4.6-fold (95% CI 2.0-11). Having two copies of this haplotype increases the risk for AMD 7.4-fold (95% CI 3.0-19). Therefore, functionally relevant mutation should be found in the context of haplotype N1. This mutation will occur somewhere in the CFH gene, as the 41kb haplotype block is entirely within CFH.

EXAMPLE 5: Resequencing confirms that variations in CFH are correlated with AMD

- To identify the functional mutation underlying susceptibility to AMD, 96 individuals (66 cases and 30 controls) were chosen for exonic resequencing, including the exon/intron junctions. Most of these individuals were selected either because SNP rs380390 was homozygous (representing opposite risk groups) or SNP rs10272438 was not successfully genotyped (the same plates were used to re-sequence this SNP for genotyping). Three additional individuals were randomly selected to get a total of 96 for a full plate. Primer design, PCR amplification, bi-directional sequencing of PCR products, and mutation analyses were performed by Geniaissance (New Haven, CT).
- All CFH exons were sequenced, including those outside of the 41kb block, as well as the region of SNP rs380390 as a control. Priority was given to sequencing homozygotes at SNP rs380390 to make it easier to determine haplotypes. SNP rs380390 was successfully resequenced in 93 individuals; the genotype derived from resequencing matched the original genotype in all cases. A total of 50 polymorphisms were identified; 17 of these have a minor allele frequency of at least 5% (Table 5). Of these 17, three represent non-synonymous mutations. If these SNPs are ranked based on the allelic association χ^2 measure, SNP rs1061170 is the most associated among the non-synonymous SNPs. This SNP represents a mutation between tyrosine and histidine. This SNP is located in exon 9 of CFH, only 2 kb upstream of the 41 kb haplotype block. Adding this SNP to the haplotype analysis reveals that 97% of the chromosomes with the highest-risk haplotype (N1) also have the risk allele (His).

Table 5. New polymorphisms identified through resequencing.

Region	Position	Change	Type	MAF	AA Change	rs Number
promoter	120992	A/G	noncoding	0.005263		
promoter	120865	A/G	noncoding	0.010526		
promoter	120546	C/T	noncoding	0.242105		rs3753394
promoter	120410	T/C	noncoding	0.005263		
promoter	120294	A/G	noncoding	0.005263		
intron 1	99391	C/T	noncoding	0.117021		rs511397
exon 2	99242	T/G	nonsynonymous	0.005319	Ser 58 Ala	
exon 2	99230	G/A	nonsynonymous	0.117021	Val 62 Ile	rs800292
intron 2	99114	G/A	noncoding	0.005319		
intron 3	98283	T/C	noncoding	0.005263		

intron 3	98188	T/G	noncoding	0.005263		
exon 4	96315	G/A	nonsynonymous	0.005263	Arg 127 His	
exon 7	87139	A/C	synonymous	0.415789		rs1061147
intron 7	83059	T/C	noncoding	0.005263		
intron 7	82966	G/T	noncoding	0.410526		rs482934
intron 7	82957	A/G	noncoding	0.005263		
exon 9	82232	C/A	nonsynonymous	0.005208	Gln 400 Lys	
exon 9	82226	C/T	nonsynonymous	0.414894	His 402 Tyr	rs1061170
intron 9	58652	T/C	noncoding	0.005319		
exon 10	58516	G/A	synonymous	0.22043		rs2274700
intron 10	58319	A/G	noncoding	0.005319		rs203678
intron 10	58260	C/G	noncoding	0.005319		
intron 10	56838	G/T	noncoding	0.367021		rs203674
exon 12	47084	G/A	nonsynonymous	0.005263	Val 609 Ile	
intron 12	46992	T/G	noncoding	0.005208		
exon 13	45721	A/G	synonymous	0.143617		rs3753396
exon 15	43875	A/G	synonymous	0.005376		
intron 15	40549	A/G	noncoding	0.215054		rs7514261
intron 15	40445	C/T	noncoding	0.021277		
intron 15	40412	G/C	noncoding	0.365591		rs380390
intron 15	40333	G/C	noncoding	0.005319		rs380060
intron 15	40179	C/T	noncoding	0.215054		rs7540032
intron 15	35577	T/G	noncoding	0.005208		rs435628
intron 15	35537	C/A	noncoding	0.357895		rs375046
intron 16	35263	C/T	noncoding	0.005263		rs428060
exon 17	34821	C/T	synonymous	0.026316		
exon 17	34786	G/T	nonsynonymous	0.005263	Ser 890 Ile	rs515299
intron 17	31825	A/C	noncoding	0.005319		
exon 18	31689	G/T	nonsynonymous	0.154255	Glu 936 Asp	rs1065489
intron 18	30673	T/G	noncoding	0.005556		rs385892
intron 18	30547	T/C	noncoding	0.111702		rs16840522
intron 18	30546	A/G	noncoding	0.005319		rs385543
exon 19	30396	G/T	nonsynonymous	0.005319	Val 1007 Leu	rs534399
intron 19	28886	T/C	noncoding	0.154255		rs513699
exon 20	28877	C/T	synonymous	0.154255		rs513729
exon 20	28867	A/T	nonsynonymous	0.015957	Asn 1050 Tyr	
intron 20	28592	A/G	noncoding	0.012987		

intron 20	26589	G/C	noncoding	0.005618		
exon 22	25219	C/A	nonsynonymous	0.005556	Pro 1166 Gln	
exon 22	25088	C/T	nonsynonymous	0.005618	Arg 1210 Cys	

Location of each polymorphism refers to the position on GenBank accession AL049744.8 (SEQ ID NO: 9), or the complementary DNA strand of GenBank accession AL049744.8. MAF is minor allele frequency.

Other data support the finding that mutations in CFH are correlated with AMD.

The gene for CFH is located on chromosome 1q31, a region that had been previously identified by six independent linkage scans to be involved in AMD (J. Majewski et al., Am J Hum Genet 73, 540 (2003); J. M. Seddon, S. L. Santangelo, K. Book, S. Chong, J. Cote, Am J Hum Genet 73, 780 (2003); D. E. Weeks et al., Am J Hum Genet 75, 174 (2004); G. R. Abecasis et al., Am J Hum Genet 74, 482 (2004); S. K. Iyengar et al., Am J Hum Genet 74, 20 (2004); and D. W. Schultz et al., Hum Mol Genet 12, 3315 (2003)). In one of these linkage studies, using a single large pedigree the authors concluded that mutations in a different gene in this region (HEMICENTIN-1), was responsible for AMD (D. W. Schultz et al., Hum Mol Genet 12, 3315 (2003)). This conclusion was based on the observation that of all the polymorphisms tested, only the HEMICENTIN-1 mutation perfectly cosegregated with disease status. Mutations in HEMICENTIN-1, however, have not been found to be generally associated with AMD in three separate, independent population-based association studies (G. R. Abecasis et al., Am J Hum Genet 74, 482 (2004); M. Hayashi et al., Ophthalmic Genet 25, 111 (2004); and G. J. McKay et al., Mol Vis 10, 682 (2004)). Mutations in CFH, as disclosed herein, are therefore more likely to be the cause of linkage signals observed at chromosome 1q31.

Example 6: Immunolocalization of C5b-9 complex in the eyes of patients suffering from AMD

Various components of the complement cascade, including the terminal C5b-9 complex, have been identified as components of drusen in the eyes of patients with AMD (L. V. Johnson, W. P. Leitner, M. K. Staples, D. H. Anderson, Exp Eye Res 73, 887 (2001); R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, FASEB J 14, 835 (2000)). The eyes of four patients with AMD were examined to look for the presence of C5b-9 (Figure 4). Post-mortem retinas from four donors were examined. Three were obtained through the Foundation Fighting Blindness (FFB) eye donor program. All of these had a clinical diagnosis of dry AMD. One pair of eyes embedded in paraffin was

obtained from an 86 year old Caucasian female through the autopsy service of the Yale School of Medicine. No clinical history was available. Histologically, these retinas have multiple large or coalescing drusen with minimal RPE and photoreceptor loss consistent with a diagnosis of early AMD. Approval for research on human post mortem donor eyes
5 was obtained from the Yale School of Medicine.

Upon enucleation, eyes were fixed in 4% paraformaldehyde, 0.5% glutaraldehyde in 0.1 M phosphate buffer for several days. The fixed eyes were transferred to 2% paraformaldehyde for storage. Six 0.5 cm circular punches were taken from each of the AMD donor eyes. Three of these were selected from the central retina at the junction of
10 atrophic and more normal retina, and the remaining three from peripheral retina. Retinal plugs were embedded in paraffin and sections cut at 5µm.

Following deparaffinization and rehydration, antigen retrieval was performed by boiling sections in a microwave oven for 10 minutes in 10 mM sodium citrate (pH 6.0). Sections were allowed to cool for 20 minutes, prior to a 5-minute endogenous peroxidase block in 5% H₂O₂. Immunohistochemistry was performed using a mouse monoclonal
15 antibody against human activated complement C5b-9 (Quidel Corporation, San Diego, CA, catalogue #A239). Primary antibody was applied at a concentration of 1:250 in 1X PBS. Biotinylated goat anti-mouse (cat # BA9200) secondary antibody (Vector, Burlingame, CA) was used at a concentration of 1:200. Nickel enhanced diaminobenzidine (DAB; cat
20 # SK4100; Vector) was used to visualize bound antibody. Negative controls were obtained by omission of the primary antibody. Images were obtained with a Zeiss Axioplan microscope equipped with differential interference contrast lenses and a Zeiss Axiocam digital camera.

Immunofluorescence Microscopy for CFH

25 Donor eyes were embedded in optimal cutting temperature compound (OCT; Miles Laboratory, Elkhart, IN), snap frozen, and stored at -70°C. Frozen retina sections were cut at 8 to 10 µm and placed on slides (Superfrost/Plus; Fisher Scientific, Fair Lawn, NJ). All human eyes were obtained with the informed consent of the donors, and the research with human eyes was performed in accordance with the tenets of the Declaration of Helsinki
30 and the Institutional Review Board (IRB).

For immunofluorescence labeling, frozen sections of human retina were fixed in 4% paraformaldehyde in phosphate buffer saline (PBS) for 10 minutes. The tissue sections were blocked for 30 minutes with 5% normal donkey serum (Jackson ImmunoResearch, West Grove, PA), diluted in IC buffer (PBS, containing 0.2% Tween-20, 0.1% sodium azide), and incubated for 1 hour at room temperature with a goat anti-human Factor H antibody (Quidel, Santa Clara, CA) diluted 1:200 in staining buffer (IC buffer plus 1% normal donkey serum). Sections were washed repeatedly in IC buffer and incubated for 1 hour with the nuclear dye 4',6'-diamino-2 phenylindole (DAPI; 1 µg/mL) and Alexa-488 Donkey anti-goat antibodies (Molecular Probes, Eugene, OR) diluted 1:250 in staining buffer. After repeated washing with IC buffer, sections were covered in mounting medium (Gel Mount; Biomoda, Foster City, CA) and coverslipped. For the control, the same concentration of anti-human factor H antibody was preincubated for 1 hour with purified human factor H protein (Calbiochem, La Jolla, CA) at the ratio of 3 µg for 1 µl of antibodies. The pretreated antibodies were then used to stain tissue sections as just described. Specimens were analyzed on a laser scanning confocal microscope (model SP2; Leica Microsystems, Exton, PA) equipped with Nomarski optics. Immunolabeled and negative control sections were imaged under identical scanning conditions. Images were processed with Photoshop (Adobe Systems, San Jose, CA).

In all patients, deposition of activated complement C5b-9 was noted in Bruch's membrane. Immunostaining frequently extended to include the intercapillary pillars, and was strongly present within drusen. Staining was rarely noted in the stroma vasculature. However, when it was present, it was invariably located in the inner (toward the retina) walls of choroidal veins, and in severe cases, arteries. No immunostaining for C5b-9 was noted in the retina or elsewhere in sections. The negative control failed to exhibit any staining. These and other biochemical analyses of the composition of drusen may indicate that AMD results from an aberrant inflammatory process in which inappropriate complement activation plays a role (G. S. Hageman et al., *Prog Retin Eye Res* 20, 705 (2001)). This is supported by a mouse model of AMD in which complement components are found in the drusen (J. Ambati et al., *Nat Med* 9, 1390 (2003)).

Moreover, both age and smoking, two significant risk factors for AMD, influence plasma levels of complement factor H (J. Esparza-Gordillo et al., *Immunogenetics* 56, 77 (2004)). CFH sequences have also been observed in an EST library derived from human

RPE and choroid (G. Wistow et al., *Mol Vis* 8, 205 (2002)). Immunofluorescence experiments confirm that CFH is present in this region of the eye (Figure 3). The fluorescent images and their corresponding DIC images obtained from two different areas of human retina sections show strong staining in choroid vessels and area close to RPE (likely to be underneath the Bruch's membrane) (Figure 3). This finding is consistent with the observation that the RPE and choroid produce mRNA for several complement components found in drusen (R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, *FASEB J* 14, 835 (2000)). Drusen of similar composition to that found in AMD are found in the eyes of patients with membranoproliferative glomerulonephritis type II (MPGNII), a kidney disease (R. F. Mullins, N. Aptsiauri, G. S. Hageman, *Eye* 15, 390 (2001)); factor H deficiency can cause MPGNII (S. R. D Cordoba, J. Esparza-Gordillo, E. G. d. Jorge, M. Lopez-Trascasa, P. Sanchez-Corral, *Mol Immunol* 41, 355 (2004)). Our immunostaining experiments (Figures 3 and 4) suggest a pathogenesis of AMD in which loss, impairment, or deficiency of factor H results in complement deposition in choroidal capillaries (more severe) and choroidal vessels (less severe) with subsequent leakage of plasma proteins in to Bruch's membrane. Finally, nutritional supplementation with zinc at 80 mg/day decreases the risk of AMD; biochemical studies have shown that factor H function is sensitive to zinc concentration (AREDS Research Group, *Arch Ophthalmol* 119, 1417, (2001); A. M. Blom, L. Kask, B. Ramesh, A. Hillarp, *Arch Biochem Biophys* 418, 108 (2003)).

The present invention provides among other things polynucleotides useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Also incorporated by reference in their entirety are any polynucleotide and polypeptide sequences which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) (www.tigr.org) and/or the National Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov).

5

Table 6. Primer sequences used in resequencing.

Region	Forward primer sequence	Reverse primer sequence
promoter	AGAAATCGTGGTCTCTGTGTGTGG	AGCAGCTGGTGATATCCTCTGG
promoter	TCAAATGAGAGTGAAGCCAGTTGC	CTGTPCACAACTCCAGTCTCTCC
exon 1	GTGGGAGTGCAGTGAGAATTGG	AACTCAACAAATGCAAAAGCC
exon 2	GATAGACCTGTGACTGTCTAAGC	GGCAATAGTGATATAATTTCAGGC
exon 3	AOCTCAGCCTCCCAAGTGC	TGCATACTGTTTTCCCACTCTCC
exon 4	AAGGAGGAGGAGAAGGACGAAGG	CAGGCTGCATTGTTTTTTGG
exon 5	CCACTCCCATAGAAAAGAATCAGG	ACTTCTTTGCACCACTCTCTTCC
exon 6	GATAAATCATTTATTAAGCGG	GAACCTTGAACACAGAAAATGC
exon 7	GGATGACTTTGGAGAAGAAGG	TATGAGTTTCGGCAACTTCG
exon 8	TCATCTTCATTAACAAAGACC	AGATCTATTTTGGTCACITTTGC
exon 9	CTTTGTTAGTAACTTTAGTTCG	TTATACACAGTTGAAAAACC
exon 10	GGCAACTCTGAGCTTATTTTCC	AGAGTAGGAAAAGCCTGAATGG
exon 11	CATAAGTATTTTTGTACGG	CAAAACTCCCTCTTTTCCC
exon 12	ATCTGATGCCCTCTGTATGACC	ATTCACTACTCAATACATGTCC
exon 13	CACCATCTGTGATTGTTAAGG	GAATCTCCATAGTAATAAGG
exon 14	CAATGTGTGATGGAGAGTGG	ATTGAATTATAAGCAATATGC
exon 15	CATTTACGCGACAGAATACAGG	GTGTGTGTGTGTGTGTGTGC
intron 15	AAGGCAGGAAAAGTGTCTTATGC	GTCAAACTACTGAAAAATCACC
exon 16	AACGTGTACACAGCTGAAAAG	GTGGTGATTGATTAATGTGC
exon 17	GGTGGAGGAATATATCTTTGC	ATAGAATAGATTCAATCATGC
exon 18	CGATAGACAGACAGACACCAGAAGG	CAGCTATAATTTCCACAGCAGTCC
exon 19	GTGTAATCTCAATTGCTACGGCTACC	CAAGTAGCTGGGACTTCAGATGC
exon 20	TAGTTTCATGCTTTTCCTC	GAATTTAAGCAACCATCAGTC
exon 21	CCAGGACTCATTTCTTTCACC	CTTCTGACAGAAATATTTGG
exon 22	TGATGTTTCTACATAGTTGG	GGAGTAAAACAATACATAAAAAATG

exon 15	5375	92	1	0	0	AG Gln 783 Gly	CTACATATAGTACAGATGTAGAGG [AG Gln 783 Gly] AAGAAGGATGATACACAAATCT
intron 15	49549	60	26	7	-0.9218916	G/A	AATCAGAAATATCTCTCCAGAT [GA] TTCTCTCAGAAATTCAGATAT
intron 15	49445	90	4	0	0	C/T	CTGTGGAAATCCATTTATGTGTA [CT] GATGAGTCTTCATGGCTTTTC
intron 15	49412	54	10	29	43.60994	G/C	TTTTCATGGCTTTTCAATACCTTCG [CG] GCTATACAGTCTTGA-AAATTCAT
intron 15	49315	93	1	0	0	G/C	TCATTAACATATATGATTCCTTT [GC] AGATCTGGGTGGTGGTTCTGAT
intron 15	49375	60	26	7	-0.9218916	C/T	CCATGCGATATCACTCTGGAT [CT] TAAGCTATCTCCTTTATTAAT
intron 15	49377	93	1	0	0	T/G	GATCAAAATATTTTCATCAAAAG [GG] TCTAAATTTAAATTTTAAATTT
intron 15	49537	55	12	28	-17.286741	C/A	TTTTATTTTATTTTATTTATTA [CA] ATATATATATTTTAAATTTT
intron 16	35263	94	1	0	0	C/T	ATTAAGTATATTTCTCTGCTCT [CT] GTGTAAACAGAGCAATCTTTC
exon 17	34821	90	5	0	0	CTT His 878 His	GTTCACACACCTCAGATAGAKA [CTT His 878 His] GGAACCAATATCAACAGATTT
exon 17	34786	94	1	0	0	Q/T Ser 980 Ile	AATCTATCAGCTCTTCAAGAAA [GT Ser 980 Ile] TATGCACTATGGGACTAAATGAGT
intron 17	31923	53	1	0	0	A/C	ATTGTGTACTCTCTGTGATTC [AG] TAGTAGCTCTGTGATTTGTTATTT
intron 18	31889	70	19	5	-1.4115003	Q/T Gln 936 Asp	GGCTCTGTGTAAATCTCACTGAA [GT Gln 936 Asp] ATTCTCATGTGTGTGTAGTCTCAA
intron 18	30673	89	1	0	0	T/G	CTCTAGCTCTACAAATTTCTCAG [GG] CTCTAAATCATCTCAATCTGTA
intron 18	30547	78	11	3	-2.5060694	T/C	TTGTGTAGATTAATGATGATTTCTA [TGA] ATATATGATTTATGATTCATTA
intron 19	30396	93	1	0	0	A/G	TTGTGTACATATTCATCTATCTCT [AG] TATGCTATTATAGATTCATAGA
intron 20	28856	65	29	0	0.9359118	G/T Val 1007 Leu	CALACCAATGGAGAGAGAAGAGAT [GT Val 1007 Leu] TGTATAAGCCGCTGGACAACTGAC
exon 20	28877	63	29	0	0.9359118	T/C	GUTGGAACCACTCTTTTCTTCTCA [TC] TCAAGACACTCTGTGTGATATGCG
exon 20	28867	91	3	0	0	Q/T Thr 1046 Thr	ACTCTTTTCTTCTATCAGAC [CT Thr 1046 Thr] TCTGTGTGATATCCCAACAGTAC
intron 20	28927	91	3	0	0	A/T Asn 1050 Tyr	TTTCTATCAGACACCTCTCTGTGTG [AT Asn 1050 Tyr] ATCCGCCCACTGACAAATGCTTA
intron 20	28932	75	2	0	0	A/G	AATAGATTTTCAAAATCCAAATMAA [AG] TGACTGATGTGCTTAAATTCAT
intron 20	26889	88	1	0	0	G/C	GTATATATACAGCTGTGTTT [GG] TCTTCCCTTAATTCAGCTTGAT
exon 22	25219	89	1	0	0	C/A Pro 1166 Gln	GTTACTGTTTATTTATTTACAGATC [CA Pro 1166 Gln] GTGTGTATATATCTGGAGAAATATATG
exon 22	25586	88	1	0	0	Q/T Arg 1219 Cys	TAAACGGGATATGCTGCTTCTACCA [CT Arg 1219 Cys] GTTCTCACATTCGGAACAGCATG

Table 8. Variations in CFHL1 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank Accession AL049741.7, or the complementary DNA strand of GenBank Accession AL049741.7.

RefSeq Position	Common/Uncommon	Common/Uncommon	Common/Uncommon	Change	Sequence Context
promoter 24624	49	9	22	-10,7769145	AAGTACCAATCTGTAAGAGTCCTACATGAGACAAATATTTTGGAGGTAAAT
promoter 24629	37	24	2	0	ACGATCTCAAGAGTCCATGACATGAGAGATATTTATTTATTTATTTGTAAGTAAATTTGT
promoter 24630	50	9	24	-11,2118554	TTC
promoter 24607	49	8	22	-11,3772888	TTC
promoter 24558	74	2	0	0	GT
promoter 24545	40	6	20	-11,82719892	-A/C/0
promoter 24482	68	19	5	-11,37873106	C/T
promoter 24455	74	19	0	0.229044145	G/A
promoter 24426	68	20	5	-1,229945884	G/T
promoter 24412	74	19	0	0.229044145	C/T
promoter 24305	80	14	0	-0.303372133	C/T
promoter 24182	74	19	1	0	T/C
promoter 24141	92	1	0	0	C/T
exon 1 23873	92	1	0	0	C/G
exon 1 23857	91	1	0	0	C/A
intron 1 23822	77	12	5	-2,697405836	C/G
intron 1 23813	78	13	0	0	A/G
intron 1 18234	71	0	20	-20,66756969	-T/T/0
intron 1 18264	73	0	19	-20,2008135	C/T
intron 2 17916	74	10	7	-4,394231059	G/A
intron 2 16939	65	17	8	-2,896651253	C/T
intron 2 16814	60	11	20	-10,13791403	A/G
intron 2 16837	89	1	0	0	T/C
intron 3 18399	60	11	19	-9,794247488	T/C
intron 3 16843	59	11	20	-10,05311275	T/A
exon 5 13128	85	5	0	0	T/C
exon 5 13092	66	17	7	-2,409781559	G/A
exon 6 11741	39	11	20	-10,05311275	GT Arg 302 Arg
exon 6 11703	19	11	60	-20,90247488	T/A Arg 314 Arg
exon 6 11593	19	11	60	-5,794247488	A/C

Table 9. Variations in CFHL3 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank Accession AL049741.8, or the complementary DNA strand of GenBank Accession AL049741.8.

Region	Position	Consensus	Common	Rare	Rare/Comm	HW P-value	Change	Sequence Context
promoter	3759	86	2	0	0	A/G		ATTTTCACATTGTGGGGGGGGGAGT AAAAAGACTTTCAGTGC CAACAGC
promoter	4374	63	17	9	-1.220461572	T/G		AATCCACAGATGATGTGGGAACCC ATG AACTGGATATATGAAAGCTATTTC
promoter	4465	64	17	9	-2.26153442	A/C		TACTGTAGTGGACTTAATTCACGA TAC CCAAGCTGTGAACCTTAATTAATGAAA
promoter	4502	64	17	16	-3.69998612	C/A		AACATAATATGAAGAATTCACAA CC [CA] CAACACAGGGGAACCTGAACATTTGGT
exon 1	4607	88	1	0	0	G/C Gln 18 Asn		ACCTGTGGGTTCTCTGTGCTAATG GCG Gln 18 Asn ACAAGTGAAGTTAAAGAGAGATCTAA
intron 2	5382	79	2	1	-1.435387193	T/C		ATGTTTATGCGATCTTATTAATAATAT TC [G] GTTAACAATATATTTTAATTAATTTT
intron 4	1971.0	56	15	8	-2.93563472	-T/T.1		TCCGCACATATAAAGATTTT TTTT -T/T.1 CAGATCTCTCAAGAAAGTGTGGCC
exon 5	19820	56	14	10	-4.079188573	C/T Pro 241 Ser		TTTCAAGATCTGGATCAACATCCCA G [CT Pro 241 Ser] CCTACTATAGTCAAGGGTCTTAA
exon 5	19835	58	14	8	-3.249405761	A/T Pro 262 Pro		GTATAATGGAAGTGTGCGAACCA CC [AT Pro 262 Pro] AGATGGCTAAAGTAAAGTCTTAAAG
intron 5	19917	58	14	8	-3.249405761	T/A		ATACGTAACTCTTAAATTTAGATTA A [TA] CCTGAGAAATATGAGTAATTAAGTT
intron 5	19928	79	0	1	0	T/C		CTTAAAGTCTTAAATCTGAGAAATA T [C] CAGAGTAATTAAGTTTATTAATTTCT
intron 5	20057	78	0	1	-2.193896652	G/A		CAGATCTTAAATATAGGTATATAA [G/A] CTTGGAAATTAATTCATTAATCAATG
intron 5	22021	69	1	0	0	G/T		TATTTTAACTAAAGTACTCACTAG [G/T] ATGCATTTTATTTGCTCTATGAAAGA
exon 6	23027	69	1	0	0	TAA-7289.7		GAAGAAACAATGATATAAATAACA TAA-7289.7 AAGTTTAAAGGAAGAAGTACAGAA
exon 6	23203	66	3	1	-1.147786072	G/A		ATAAGGCAAGATTTTACCTTAAT [G/A] TATGTCCAACTCCACTTTTCCACT
exon 6	23222	68	0	3	-5.25860221	A/G		AAGAAATAATATATATAGTTTCA [A/G] TTTCCACTTAATATATCTCAAAA

Table 10. Variations in CFHL4 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence in Chromosome 7:32512024-33512123.

Region	Position	Consensus	Common	Rare	Rare/Comm	HW P-value	Change	Sequence Context
promoter	7013	93	1	0	0	C/T		GTTTATTTCAAGTGTGATCAACA [C/T] GGCTCTCTATCTCAATTTTCTTC
promoter	7369	91	4	0	0	C/G		AATAGTGTGACAGAGCCTTCATTC C [C/G] TGTATTAAGACTCTTCTACTTAA
promoter	7377	91	5	0	0	C/A		CTGAACTTTGTAATTTACTTAAGTGA [C/A] CTTAAAGCCCTAGCTTTGTGGTAGT
promoter	7385	95	1	0	0	C/G		TGATATTTACTTAAGTGAACCTTAAG [C/G] CCTAGCTTTGTGGTATGTGCACTTAA
exon 2	22144	94	2	0	0	T/C Asp 76 Asn		TGGGATATACA TTTACTGCACACAGA T [C Asp 76 Asn] GGGTGGTTGCCACACTGCCATGCC
exon 3	22436	94	1	0	0	T/C Ile 132 Ile		CAGATGGAAATATCTTCAGGTTCAT T [C Ile 132 Ile] ACATGTTGCCAAATGTGATGTCAG
intron 5	27640	88	4	2	-2.226371993	T/G		CTCAAAAGTCAGTATGTAGCACA AAT [T/G] AATCACTATTAACTTAATTTGGATAT
intron 5	27701	69	18	6	-1.93321388	C/A		TAHTTATCTCAAACTACATTAAG [G/A] ATGCATTTTATTTCTCTCAAGAAAG
exon 6	27884	74	19	2	-0.208237586	T/A Gln 306 Gln		ACCAATGATATTTATGTAAATTTGG [G/A Gln 306 Gln] ATATATATGGAATACATCACTTCA

ClaimsWe claim:

1. An isolated polynucleotide for the detection of a variant CFH gene, in a sample from an individual, comprising a nucleic acid molecule that specifically detects a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
2. The polynucleotide of claim 1, wherein the polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
3. The probe of claim 2, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.
4. The probe of claim 3, wherein the variation encodes tyrosine at position 402 of the CFH protein.
5. The probe of claim 2, wherein the probe is a DNA probe.
6. The probe of claim 5, wherein the probe is from about 8 nucleotides to about 500 nucleotides.
7. The probe of claim 5, wherein the probe is from about 10 nucleotides to about 250 nucleotides.
8. The probe of claim 5, wherein the probe comprises one or more non-natural or modified nucleotides.
9. The probe of claim 8, wherein the one or more non-natural or modified nucleotides are radioactive, fluorescently, or chemically labeled nucleotides.
10. A polynucleotide primer that hybridizes, under stringent conditions, adjacent to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
11. The polynucleotide primer of claim 10, which hybridizes immediately adjacent to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
12. A pair of polynucleotide primers that specifically detect a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans,

wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation.

13. A pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, wherein the polynucleotide primers hybridize to the region in such a manner that the ends of the hybridized primers proximal to the variation are from about 20 to about 10,000 nucleotides apart.

14. The pair of polynucleotide primers of claim 12, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.

15. The pair of polynucleotide primers of claim 14, wherein the variation encodes tyrosine at position 402 of the CFH protein.

16. The pair of polynucleotide primers of claim 12, wherein the primers are DNA primers.

17. The pair of polynucleotide primers of claim 16, wherein the primers are each from about 8 nucleotides to about 500 nucleotides.

18. The pair of polynucleotide primers of claim 16, wherein the primers are each from about 10 nucleotides to about 250 nucleotides.

19. The pair of polynucleotide primers of claim 16, wherein the primers comprise one or more non-natural or modified nucleotides.

20. The pair of polynucleotide primers of claim 19, wherein the one or more non-natural or modified nucleotides are radioactive or fluorescently labeled nucleotides.

21. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising:

- (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, but not to a wildtype CFH gene; and
- (b) determining whether hybridization occurs,
- wherein the occurrence of hybridization indicates that a variant CFH gene

that is correlated with the occurrence of age related macular degeneration is present in the sample.

22. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans,

5 comprising:

(a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, thereby producing a combination;

10 (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and

(c) comparing hybridization that occurs in the combination with hybridization in a control, wherein the control is a polynucleotide probe that does not bind to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans or binds only to a wildtype CFH gene, and the sample is the same type of sample as in (a) and is treated the same as the sample in (a), and wherein the occurrence of hybridization in the combination but not in the control indicates that a variant CFH gene that correlates with age related macular degeneration is present in the sample.

23. The method of claim 22, wherein the extent of hybridization is determined in step (c).

24. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans,

25 comprising:

(a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans;

30 (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFH gene; and

(c) determining whether hybridization occurs, wherein the occurrence of hybridization in the first portion but not in the second portion indicates that a variant CFH gene that is correlated with the occurrence of age related macular degeneration is present in the sample.

5 25. The method of claim 21, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.

26. The method of claim 25, wherein the variation encodes tyrosine at position 402 of the CFH protein.

10 27. The method of claim 21, wherein the sample comprises cells obtained from the eye, ear, nose, tooth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract, urine, muscle, cartilage, skin, or any other tissue or bodily fluid.

28. The method of claim 21, wherein the polynucleotide probe is a DNA probe.

29. The method of claim 21, wherein the polynucleotide probe is from about 8 nucleotides to about 500 nucleotides.

15 30. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising:

20 (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding amino acid 402 of the CFH protein and the second polynucleotide primer hybridizes to the other side of DNA encoding amino acid 402 of the CFH protein;

(b) amplifying DNA in the sample, thereby producing amplified DNA;

(c) sequencing amplified DNA; and

25 (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 402 of the CFH protein, wherein the presence of the variation indicates that a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans is detected in the sample.

31. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising assaying a sample obtained from the individual for the presence of a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, wherein the presence of a variant CFH
5 gene indicates that the individual is at risk for developing age related macular degeneration.

32. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising:

- 10 (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, but does not hybridize to a wildtype CFH gene; and
- 15 (b) determining whether hybridization occurs, wherein the occurrence of hybridization indicates that the individual is at risk for developing age related macular degeneration.

33. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising:

- 20 (a) obtaining DNA from an individual;
- (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 402 of the CFH protein; and
- (c) determining whether a variation that encodes an amino acid other than histidine at position 402 of the CFH protein is present in the DNA, wherein the presence of the variation indicates that the individual is at risk
25 for developing age related macular degeneration.

34. A diagnostic kit for detecting a variant CFH gene in a sample from an individual, comprising:

- 30 (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and

(b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFH gene in a sample.

35. A diagnostic kit for detecting a variant CFH gene in a sample from an individual, comprising:

- 5 (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and
- 10 (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFH in a sample.

36. The diagnostic kit of claim 35, additionally comprising a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.

15 37. A composition for treating a subject suffering from age related macular degeneration, comprising:

- (a) an effective amount of an isolated or recombinantly produced wildtype CFH polypeptide, or a fragment thereof; and
- (b) a pharmaceutically acceptable carrier.

20 38. The composition of claim 37, wherein the CFH polypeptide or the fragment thereof inhibits the activation of C3.

39. A method of treating a subject suffering from age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 37.

25 40. A composition for treating a subject suffering from age related macular degeneration, comprising:

- (a) an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof; and
- (b) a pharmaceutically acceptable carrier.

41. A method of treating a subject suffering from age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 40,

- 5 42. A method of detecting, in a sample obtained from an individual, a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans, comprising:

(a) combining the sample with an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and

- 10 (b) determining whether binding occurs,
wherein the occurrence of binding indicates that a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration is present in the sample.

43. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 15 (a) a nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and
(b) a pharmaceutically acceptable carrier.

- 20 44. The composition of claim 43, wherein hybridization of the antisense sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene.

45. The composition of claim 43, wherein hybridization of the antisense sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA.

- 25 46. The composition of claim 43, wherein said nucleic acid molecule includes one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA.

47. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the
30 composition of claim 43.

48. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- (a) a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier.

49. The composition of claim 48, wherein hybridization of the siRNA or miRNA sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene.

50. The composition of claim 48, wherein hybridization of the siRNA or miRNA sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA.

51. The composition of claim 48, wherein said nucleic acid molecule includes one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA.

52. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 48.

53. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- (a) an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,

wherein binding of the aptamer to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

54. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 53.

55. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- (a) a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,

wherein binding of the small molecule to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

56. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 55.

57. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- (a) an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,

wherein binding of the antibody to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

58. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 57.




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D





FIG. 3A





FIG. 3B



FIG. 3C

FIG. 4



Poly peptide Sequence for Homo sapiens Complement Factor H (GenBank Accession CAA68704)

1	mrllekli	nlwaicvaed	cnelprrmt	eiltgswsdq	typestqaiy	karpyrslg
61	nvlmvrkge	wvalnplrkc	gkxpcghpgd	tpfgftltg	gnvfeygka	vytcnsgyql
121	lgeinyreod	tdgwtndipi	cevvkclpvt	apengkiwss	anepdreyhf	gqavrfvns
181	gykiegdeem	hcsddgfwsk	ekpkcveisc	kspdvingsp	isckliyken	erfqvkcung
241	yeysergdav	ctesgwrplp	sceekscdnp	yipngdyspl	rikhrtgdei	tyqctngfyp
301	atrgntakot	stgwipaprc	tlkpcdyxdi	khggyihem	ripyfpwavg	kyysvycdeh
361	fetpsgsywd	hihtqdqws	pavpcirky	fpylengyng	nhgrkfvggk	sidvachpgy
421	alpkadtvtc	cmengwsptp	rcilrvktcsk	ssidengfi	sesqtrvalk	ekakyqckig
481	yvtadgtsq	sircgkdgws	aqptclksed	ipvfmmark	ndftwflnd	tldeyechdg
541	esntgsetts	ivogynqwsd	lpicyerece	lpkiadvhlp	drkkdykvq	evlktfackpg
601	ftivpnsvq	cyhfglspdl	pickeqgqsc	gpppellingn	vkektkeeyg	hseavveycn
661	prflmkpnmk	iqcvdggewt	lpvciveest	cgdipalehg	waglsppvy	ygdsvfeinc
721	esftmighrs	itcimgwbtq	lpqcvaiddk	kkkasnlil	leehlknkke	fdhnsniryr
781	crqkgewiht	vcingrwdpe	vnscmagigl	cpvpqgipns	hmtttlnyr	dgaqsvlog
841	enylleqgee	itckdgrvqs	iplvekipc	sppdqeglp	inasrsaqea	yahgcklsey
901	ceggrtrisee	nettcymgkw	akclgekwsh	spacittdcl	vvahmsdsyq	ygeevtykcf
961	egfgldgpai	acclgekwsh	ppacittdcl	slpsfensap	mgekkdvvka	geqvtyrcat
1021	yykmdgasny	tcinsrwtgr	ptcrdtscvn	pptvgnavip	srqmskypsg	ervrtyqcrsp
1081	yemfgdeevm	clngnwtpp	qckdstgkcg	pppiddngdi	tsfpisvyp	aseveyqoon
1141	lyqlqgnkri	tcnrgwseep	pkcllhpvcis	reimenynia	lrwtakqkly	srtgesvefv
1201	ckrgyrlssr	shrtittcwo	gkleyptcak	x		

FIG. 5

1/64

SEQUENCE LISTING

<110> Yale University
Hoh, Josephine

<120> METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

<130> YU-PWO-038

<150> US 60/629,363

<151> 2004-11-16

<150> US 60/649,479

<151> 2005-02-02

<150> US 60/672,346

<151> 2005-04-16

<160> 59

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 4004

<212> DNA

<213> Homo sapiens

<400> 1

```

ccttttgcag caagttcttt cctgcactaa tccaattctt tggaaaggga gaactggagc 60
ttgtgaacac agttagctgg taastgtcct cttaaaagat ccaaaaaaat agactcttag 120
caaagattat ttgctctatg ttatgggcta ttgtgttagc agaagattgc aatgaacttc 180
ctccaagaag aaatacagaa attctgcacg gtctctggto tgaccaaaac tatccagaag 240
gcaccacaggc tatctataaa tgcgcgcctg gatataagtc tcttggaaat gtaataatgg 300
tatgcaggaa gggagaatgg gttgctctta atccattaaq gaaatgtcag aaaagggcct 360
gtggacatcc tggagatact ccttttggtt ccttiacct tacaggagga aatgtgtttg 420
aatattggtt aaagctgtg tatcatatga atgagggtta tcaattgtca ggtgagatta 480
attaccgtga atgtgacaca gatggatgga ccaatgatat tctatattgt gaagtgttga 540
agtgcttacc agtgacagca ccagagaatg gaaaatttgt cagtagtgtc atggaaccag 600
atcgggaata ccatlittga caagcagtag ggtttgtatg tsactcaggc tacaagattg 660
aaggagatga agaaatgcac tgttcagacg atgggttttg gagtaaaagag aaaaaaagt 720
gtgtggaaat ttcatgcaaa tcccagatg ttacaantgg atctctata tctcagaaga 780
ttatttataa ggagaatgaa cgatttcaat ataaatgtaa catgggttat gaatcacagt 840
aaagaggaga tgcgttatgc actgaatctg gatgggtctc gttgccttca tgtgaagaaa 900
aatcatgtga taactcttat attccaaatg gtgactaotc acctttaagy altaaacaca 960
gaactggaga tgaastcacg taccagtgtt aaaaaggttt ttatcctgcc accoggggaa 1020
atacagcaaa agtcacaagt actgggttga taactgtctc gagatgtacc tggaaacctt 1080
gtgattatcc agacattaaa catggaggto tatatcatga gaatatctgt agaccatact 1140
ttccagtagc tttaggaaaa tattactcct attactgtga tgaacatttt gagactccgt 1200
caggaaatga cgtggatcac attcaattga cacaagatgg atggtcgcca gcagtaccat 1260
gctccagaaa atgtttattt ccttatttgg aaaaatgtata taatcaaaat catggaagaa 1320
agttttatca tggtaaatct atagacgttg cctgccatcc tggctacgct gaactctcag 1380
cgccagccac agttacatgt atggagaatg gctggtctcc tactcccaga tgcattccgt 1440
tcaaaaactc tcccaatca agratagata ttgagaatgg gtttatttct gaactctcag 1500
atacatatgc cttaaaagaa aaagcgaat atcaatgcaa actaggatat tgaacagcag 1560
atgttgaact atcaggatga attacatgtg ggaagaatgg atggtcagct caaccacagt 1620
gcattaaatc ttgtgatatc ccagtatlla tgaatgcagc aactaaaaat gacttccatc 1680
ggtttaagct gaatgacaca ttggactatg aatgcacatg tggttatgaa agcaatattg 1740
gaagaccacc tggttccata gtgtgtgggt caaatgggtg gtctgatata cccatatgtt 1800
atgaagagaa atgcgaactt cctaaaaatg atgtacactt agtctctagt cgcagaagaa 1860
accagatga aattggagag gtgtgaaat tctctgcaa accaggattt acaatagttg 1920

```



```

gacctaatto  cgttcagtcg  taccactttg  gatgtgtccc  tgacctccca  atatgtaaag  1980
agcaagtaca  atcatgtggt  ccacctctcg  aactctctca  tgggaatggt  aaggaaaaaa  2040
cgaaagagaa  atatggacac  agtgaagtgg  tgggaatatta  ttgcaatctc  agatttcttaa  2100
tgaaggggacc  taataaaatt  caatgtgttg  atggagagig  gacaaacttta  ccagtggtga  2160
ttgttgaggga  gagtacctgt  ggagatatca  ctgaacttga  acatggctgg  gccacagcttt  2220
cttccccctcc  ttattacctac  ggagattcac  tggaaaltcaa  ttgtctcagaa  tcattttacaa  2280
tgatttgacca  cagatcaaat  acgtgtattc  atggagtatg  gaccccaact  cccacagtggt  2340
tggcaataga  taacttblaag  aagtgcgaat  catcaaattt  aattatactt  gaggaacact  2400
taaaaaacaa  gaaggaaatc  gatcataatt  ctacaatnaa  gtacagatgt  agaggaaaaa  2460
aaggatggat  acacacagtc  tgcataaalt  gaagatggga  tccagaagtg  aactgctcaa  2520
tgggcacaa  acattattgc  ccacctccac  ctacagattcc  caattctcac  aatatgacaa  2580
ccacactgaa  ttatcgggat  ggagaaaaag  tatctgttct  ttgccaagaa  aattatctta  2640
ttcagggaagg  agaagaattt  acatgcacaa  atggagaagt  gcagtcacaa  ccactctgtg  2700
ttgaaaaaat  tccattgtca  caaccacctc  agatagaaca  cggaaaccatt  aartcatcca  2760
ggtcttcaca  agaagttat  gcaatggga  ctcaatttga  ttatacttgt  gaggggtgggt  2820
tcaggatatc  tgaagaaat  gaaacaacat  gctacatggg  aaaatggagt  totccacctc  2880
agtggtgaagg  cctctcttgt  aaatctccac  ctgagatttc  tcatgtgtgt  tagtctcaca  2940
tgcagacatc  ttatcagat  ggagaaagaa  taactgtaca  argtllltga  ggttttggaa  3000
ttgatggggc  tgcatttcca  aaatgcttag  gagaaaaatg  gtctccacct  ccactcatga  3060
taaaaaacaa  taattgaaca  ttactagct  ttgaaaatgc  cataccactg  ggagagaaga  3120
aggatgtgta  taaggogggt  gagcaagtga  ctacactctg  tgcacacat  taaaaaatgg  3180
atggagacct  ttgtgaatcg  cccacagtac  agagtacgtt  atcaatgtag  gagcccttat  3240
acacactctg  atctgtgtag  agtgtacgt  tkaaatggaa  actggacgga  accocctcaa  3300
gggatgaaag  agtgaactgt  cctccacctc  agtaccagt  agcaactgt  agaacagatga  3360
ctacaggaaa  atgtggggcc  cctcagttg  tcatcagttg  atcaatgtag  gagcccttat  3420
tgtcagtata  tgtccacgt  cctcagttg  tcatcagttg  atcaatgtag  gagcccttat  3480
aggggtacaaa  gcaataaaca  tgtcgaatgt  tcatcagttg  atcaatgtag  gagcccttat  3540
atctcctttc  aaatccctga  gaaattatgg  aaatataaa  attttgtgtg  aaagggggat  3600
ccaaacacaa  gottttatcg  agaaacaggt  aatcagttga  attttgtgtg  aaagggggat  3660
atcctctttc  atcaggttcl  cacacacatg  cataaagtgc  acactgttat  aaactggagc  3720
atccaaacttg  tgcacaaaga  tagaatcaat  tatgttatgt  ttactcttat  ttactcttat  3780
agttatcaat  cagttctcaa  ttcaattttt  tatgttatgt  ttactcttat  ttactcttat  3840
cgtaaaaatt  tggattaaat  tgtgaaaatg  taactataag  ctgagaccgg  tggctctctc  3900
cttaaaagca  ccatattaaa  tctctgaaaa  ctcaaaaaaa  aaaa  4004

```

<210> 2

<211> 1702

<212> DNA

<213> Homo sapiens

<400> 2

```

ccttttgcag  caagttcttt  cctgcactaa  tcacaatttc  tggaaagagga  gaactggagc  60
ttgtgtacac  agttgactgg  taaatgtctc  cttaaaagat  ccaaaaaaatg  agacttctag  120
caaaagattg  tgcctctatg  ttatggcgta  ttbtgtatgc  agaagattgc  aatgaacttc  180
ctccaagaag  aaatcacagaa  attctgcacg  gttcctgggtc  tgaccaacaa  tatccagaaag  240
gcacccaggc  tatctataaa  tgcgccctgt  gatatagato  ccttggaatt  gtaataatgg  300
tatgcaggaa  gggagaatgg  gttgtcttta  atccattaaag  gaaatgtcag  aaaaggccct  360
gtggacatcc  tggagatact  ccttttggtt  ctcttaccct  tacaggagga  aatgtgtttg  420
aatatgggtg  aaaaagctgt  tatcatatga  atgaggggta  tcaatttgct  ggtgagatta  480
attaccctga  atgtgcacaa  gatgtatgga  ccaatgatat  tcttatatgt  gtaagattga  540
agtgttttaa  agtgacagca  ccagagaagt  gaaaatgtgt  cagtatgtca  atggacaacc  600
atggggaata  ccaattttga  caagcagtac  gtttgtatgt  taactcagcc  tacaagattg  660
aaggatgtga  agaaatgcat  tgttcaagac  atgggttttg  gactaaagag  aaaccaaagt  720
gtgtggaaat  tbcattcaaa  tccccagat  tatataatgg  ctctcaata  tctcagaaga  780
ttatttataa  ggagaatgaa  cgaattcaat  ataaatgtac  catgggttca  gaaatcagtg  840
aaaggaggaa  tgcgtatgac  actgaaatct  gatggctacc  acctttaagg  attaaacaca  900
aacatgtgta  taactcttat  taccagtgta  gaattgggtt  taactgtctc  ttatcctgca  960
gaactggaga  atgcacagac  actggctgga  taactgtctc  gagatgtacc  ttgaaactct  1020
gtgatattcc  agacattaaa  catggaggtc  tatatcatga  gaatttgggt  agacactact  1140
tccagatgac  tgtaggaaaa  tattactctc  attactgtga  tgaacattct  ggaactctgt  1200

```

3/54

caggaagtta	ctgggacac	attcaatgca	cacaagatgg	atgggtcgcca	gcagttaccat	1260
gcctccagaaa	atgttatttt	ccttatttgg	aaaatggata	taataaaaaat	catggagagaa	1320
agtttggcttt	gggttaaatct	atagacgttg	cctgccatcc	tggttcangct	cttccaaaag	1380
cgacagacac	agtttaccatg	atggagaatg	gctggtctcc	tactccacaga	tgcatccgtg	1440
tcagctttac	cctctgaact	tctgatcgaa	ggctcatecct	ctccagctact	agtgagatcaa	1500
agatgcacaag	ggccaatgga	accaaagttt	agctcttgcca	gttcaactctg	tggtgtctcga	1560
gatgtggtag	tagtatctgt	tttgttatgt	gtgtattat	ccagccagaa	tgggaaatgc	1620
taattacagct	cctccagag	gcccaatggg	gctggtggct	ttgagattat	taaacctctt	1680
ctctgctgca	aaaaaaaaa	aa				1702

<210> 3

<211> 4252

<212> DNA

<213> Mus musculus

<400> 3

aagttctttcc	ctgctgtgac	cacagttcat	agcagagagg	aactggatgg	tacagcacag	60
attttctcttg	gagtcaggtg	gtcccagaaa	gatccaaatt	atgagactgt	cagcaagaat	120
tattttggctt	ataattatgga	ctgtttgtgc	agcagaagat	tgttaaaggct	ctccctccaa	180
agaaaaattca	gaattattctc	caggctcgtg	gcacagacaa	ctatatccag	aaggacacca	240
ggctacccac	aaatgcgccgc	ctggataccg	aaacacttggc	actattgttaa	aagtatgcga	300
gaattggnaaa	tgggtggcgt	ctaaccatc	caggatatgt	cggcaaaaagc	ctgttgggca	360
tcctcggagac	acaccccttg	gttctcttag	gctggcagtt	ggatctcaat	ttgagtttgg	420
tgcaaaagggt	gtttatacct	gtgatgatgg	glatcaacta	ttaggtgaaa	ttgattaccg	480
tgaattgggt	cgagatggct	ggatcaatga	tattccacta	tgtgaagttg	tgaagtgctc	540
acctgtgaca	gaactcgaga	atgggaagaa	tggagatggt	gcagcagaaa	cagaccsgga	600
atactatttt	ggacaggtgg	tgcggtttga	atgcacttca	ggctccaaga	tgaagagaca	660
taaggaaatt	catgtgctcg	aaaaatggcct	tgggagcaat	gaaagccac	gagttgttga	720
aattctctcgc	accccccgcg	gagtggaana	ttctcagctt	ataaatgtga	aaccagttta	780
caaggagaaat	gaaagatacc	actataagtg	taagcatggt	tatgtgcaca	aaagagaggg	840
ggatgacctc	tgcacagcct	ctggatggag	tctccagctt	ctgagaccca	aaagagagag	900
ctcacctctct	tatatcttaa	atgggtatcta	cacacctcac	aggattatca	acagaaagtg	960
tgatgaaatc	agatatgaa	gtaaattatg	cttctatctc	gttaactggat	caactgtttc	1020
aaagtgtaca	cccatctggc	ggatccctgt	tccaagatgc	accttgaaac	catgtgaatt	1080
tccacaatttc	aaatctggac	gtctgtatta	tgaagagagc	ctgagaccca	acttcccagt	1140
atctatagga	aataagtaca	gctataagtg	tgcacacggg	tttccaccac	cttctgggta	1200
tctctgggac	tacctctggt	gcacagacaa	aggggtggag	octgaaatcc	catcgctcag	1260
gaaattctggt	tctccattatg	tggagaatgg	agactctgca	lactgggaaa	aagtatattgt	1320
gcagggtctag	tctcttaaaag	tccagtgtta	caatggctat	agcttcaaaa	tgcttcaaga	1380
cacaaatgaca	tgtcacagaga	atggctggctc	ccctccctccc	aaatgcattcc	gtatcaagac	1440
atgttccagca	tcagatatac	acattgacaa	tggattttct	tctgaattct	cttctatata	1500
tgctctaaat	agagaaaact	ccctatagatg	taagcagggga	tatgtgacaa	atactgggga	1560
aaatctcagga	tcaataactt	gccttcaaaa	tggatgtgtc	cttcaaacct	catgatctaa	1620
gtctctgtgat	atgcctgtat	ttgagaatttc	tataacttaag	aatactatgga	catgggttaa	1680
gctcaatgac	aaattagact	atgaatgtct	cggttggatt	gaaaatgaa	ctgaactatc	1740
caagggctct	atacaactga	cttatttatgg	atgggtctgat	acacctcat	gttatgaag	1800
agnatgcaat	gttcccactc	tacagacgaaa	actagtgctt	tccccacgac	agaaaaata	1860
cagtgattgga	gatttctgtg	aattctctctg	ccatttcagga	ccacagagttg	ggccagattc	1920
agtgccaatgc	taccatctgtg	gatgggtctcc	tgggtttccct	acatgtaaaag	ctcaagttgc	1980
atcatgtgca	ccacctcttg	aaattcttaa	tggggaaaatt	atgtggagcaa	aaaaagttga	2040
atacagccat	ggtgaagtgc	tgaatatatga	ttgcacacct	agattctcat	tgaaggagacc	2100
cacaaaaatc	cagtggtgtg	atgggaaattg	gacaaacctg	cctgtattgta	ttgaggagaca	2160
gagacaaatc	ggagatccag	tggaagtctat	acatggctct	gccaatgtgt	gttctctccc	2220
ctaccacact	tcttcgcatc	gtggaaaatg	ttgtgaagaa	aacttcccaa	tgatttgaca	2280
tgaggtcagtt	aagtgtagag	gtctgaagtc	gaccacgctt	ctcaaatgtg	ttgcaacaga	2340
ccaaactggag	acgcataact	ccaccatgga	actcggcatg	gaagcaataa	aaccaaaatt	2400
acgtcataatc	tgtatacaat	gaaaaatggga	ttacacatgt	agagacacag	agggatcgca	2460
ctgcctcctct	ccaccgcaga	ttcccaatcac	tcttgaaacca	aactgtcaca	gcaaaactct	2520
ggatggagaaa	aaatttggca	ttcttttgcca	ccaaagtgtt	gaaaccacgg	tgaataactt	2580
aattggtgtgc	aanagatgaa	ggtggcagtc	agacaattga	ctcaactcagg	actcagagga	2640
tctccagccc	ctccacatag	acaatggatc	attacctcgc	tgcattgaaa	aaatttccat	2700
				ccagatctct	cagaagaaag	2760

gagagattcc	attgagtcga	gcagtcgatga	acatggaact	acattcagct	atgtctgtga	2820
tgatggttcc	aggataacctg	aagaaaaatag	gataacctgc	tacatgggaa	aatggagcac	2880
tcacactcgc	tgtgttgagc	ttccttctggtg	acctccacct	tcacttccctc	ttggctatgt	2940
ttctcttgag	ctagagaggtt	accaacatgg	ggaagaggtt	acataccatt	gtctacaggt	3000
ctttgggaatt	gatggacag	catlilatlat	atgcgaagga	ggaaagtgtgt	ctgacccaac	3060
aaaaatgcata	aaaaatgagtt	gtgacgtttt	acccacagtt	aaaaatgccca	taataagagg	3120
aaagagcaaa	aaatcatata	ggacaggaga	acaaagtaca	ttcagatgtct	aatctcctta	3180
tcaaatgaat	ggctcagaca	ctgtgacatg	tgttaatagt	cgggtggatgt	gacacagagt	3240
atgcaaaagt	aattctctgtg	tggatccacc	acatgttgcca	aatgctacta	tagtaaccaag	3300
gaccaagaat	aaatatctac	atgggtgacag	agttacgttat	gaatgtaata	aacctttggga	3360
actattttggg	caagtgggaag	tgatgtgtga	aaatgggata	tgggacagaaa	aaccaaagctg	3420
cggagactaca	acagggaagt	gtgggcctcc	tcacactatt	gacaaatggag	acatcactcc	3480
cttgtcattc	ccagtatatg	aacctattatc	atcagttgaa	tatcaatgcc	agaagtatta	3540
tctccttaag	gggaagaaga	caataacatg	tacaaatgga	aagtgggtctg	agccaccaac	3600
atgctttacat	gcctgtgttaa	taccagaaaa	cattatggaa	tcacacaata	taattctcaa	3660
atggagacac	actgaaaaaga	tttattccca	ttcaggggag	gatattgaa	ttggagtgaa	3720
atctggatatt	tataaagcaa	gagattccac	gocatttctg	acaaagtgcg	ttaatggcac	3780
catcatcttat	ccactctgtg	tataaataca	taatacattt	attagtttgt	ttatgtgttt	3840
agaaagggcac	atgcattgtga	ctaatatact	ttcaattltgc	attggaagtat	tgttttaactc	3900
atgtctctctc	tataactata	acatttttgt	tatatgtgtg	ttaaacttgaa	actttaaaaa	3960
cttatgtccan	aatgcaaaag	cagtaattca	aaactcctaa	tctaaatgat	gatattgtcca	4020
agggacaaact	atttcaatc	agaaagtaga	tgaagtctct	tcacacatctg	ttcttatctca	4080
gaactttctc	agattttctc	ggataccttt	tgatgttaag	tcctgattta	caggggataa	4140
aggtatattat	gactgattct	tcaaatattat	atgatttccc	aaagcatgta	aaacccaaac	4200
tatcatatatt	tattgacta	atgcatacaa	tataattacta	tataatactt	tc	4252

<210> 4

<211> 4250

<212> DNA

<213> *Rattus norvegicus*

<400> 4

acagcacata	cttctctctog	agtcacactgc	tcacagatag	atccaagaca	tgagactgtc	60
agcaagaatt	atttggccta	tattatggac	tgttttgtga	gcagagagatt	gtaaaggtgc	120
tcctccaaga	gaaaactcag	aaattctctc	aggttcgtgg	ttcgaacac	tatatccaga	180
agggactcag	gcaacctaca	aatgcgcgcc	tggataccga	acactltgta	ctatttgttaa	240
agtatggac	aatggagaal	ggtlactctc	taacccaatca	aggatatctc	ggaaaaagcc	300
atgtggcgat	cccgagagaca	caacctttgg	gtccttttag	ctggcagctgt	gatctgaaat	360
tgaattttgt	gcaaaagttg	tttatacatg	tgatgaaagg	tcaccaactt	taggtgaaat	420
tgattatcogt	caatgtgagt	cagatgggtg	gaccaatgat	attccaatat	gtgaagtgtg	480
gaagtgctgt	gagtgacag	aactggagaa	tggaaagaat	gtgagtgtgtg	cagcgcaaac	540
agacacggaa	tatttatttg	gacaggtgtg	acgtlittgaa	tgcacactccg	gcttcagaat	600
ttgaagggacg	aaaggaatgc	actgtctcaga	aaatggcctc	tggagcaaatg	aaaagccaca	660
gtgtgtggaa	atttcttgcc	tgcaccacag	agttgaaaaa	ggagatggta	tatatctgaa	720
accaggtttac	aaggagaatg	aaagattcca	atataaaatg	aagcaagggtt	gaatttaaca	780
agaaagaggg	gatgtgtgtc	gcacgggttc	tggatggaa	cctcagcctt	cctgtgaaag	840
atgacacagt	ttgactccat	atattccaaa	tggatctcac	acacctcaca	gaatttaaca	900
cagaattgtat	gatgaatcca	gatattgaatg	taaaatggc	ttctatctctg	caacccogact	960
acctgtttcca	aagtgttaca	ttactggctg	gatccctgct	ccagatgta	gcttgaaccc	1020
tttgtgatttt	ccacaattcca	aaactggagc	ctgttattat	gaagaaagcc	ggagacccca	1080
cttccccagta	cttataggaa	agggatcacg	ctattactgt	gacacgggtg	ttacaagccc	1140
ttccacagca	taactggact	actctcgttg	cacagtaaat	gggtgggagc	ctgaagtctcc	1200
atgctccagg	caatgtattt	tcactattgt	ggaaatgta	gaatcttlat	actggcaaac	1260
aagatataata	aggggtcagt	ctgcacagaaa	aggtgtgtcc	gtggctcata	atgtctccaa	1320
tgtctcaagt	acatatattat	cagatataga	aaattgaaaat	cccttcccca	actgctcccg	1380
tatcaagact	tgttcagtat	gaaaacacag	gtatagatgt	aaacagggat	ctgaattctga	1440
tattacacat	gctcttaata	taattacttg	tcttcaagat	gaatgggtcac	atgtataacca	1500
taccggagaa	atctcaggaa	tgcctgtatt	tgagaatgtc	atgacataga	ataataaac	1560
atgcatttag	ctctgtgtata	aattagacta	tgaatgtcac	attggatgat	aaatgataa	1620
tggatttaaa	ctcaatgaca	taacatgtac	ttatgttgga	tgtgtctagta	caacctctcg	1680
ttaaacatacc	aaaggtctca	ttccccctgt	acaccaagac	ttagtgtgtt	ttccccagaga	1740
ttatgaagaa	gaatgcagca					1800

5/64

```

agtaaaatac aaagtgtgag attcgttgag ttctctttgc cgttcaggac acagagattgg 1660
agcagattta gtgcaatgct accactttgg atgtgtccct aatttcccaa cgtgtgaaagg 1920
ccaaagtataa tcatgtgacc aacctcttga aatccgaat ggggaaataa aggggaacaaa 1980
aaaagtgtgaa taccgcatgt gtgacgtgggt ggaatatgat tgc aaaccta aggttctact 2040
gaagggccccc aataaaaatcc agtgtgttga cgggaagtgg acaaccttgc cgtatttgcgt 2100
tgagtattgag agaacatgtg gagaccttcc tgcacttgag catggtctgt tccagtattc 2160
gtgtccctccc taaccaccag gagatttcagt ggaattcact tgtgcagaaa ccttcacaaat 2220
gatttcaggc ctagtagttt tctgcattag tggaaagttgg acogagattg ctaaatgtgt 2280
tgcaacagat caactggaga agtgtaaagc cccgaagtca actggcatag atgcaattca 2340
tccaaaataag aatgaattta atcataactt tagtgtgagt tacagatgta gaca aaagca 2400
ggagattgaaa caatcaatct gcatcaatgg aagatgggat cctgaacc aa actgtacaag 2460
aaatgagaaa agattctgcc ctctctcccc acagat tcca aatgccaa tga ttgaac 2520
cacagtga aa tanttgag kg gagagaaagt atctgttct ttgccaaagt gttacctaac 2580
tcaggggccc gaagaanaatgg tgtgtaaa ca tggaaagttgg cagtctgtac cactgtgcac 2640
ggaaaanaatt coattgtccc agccccctas aattgaacat ggaatctatta agtcgcccag 2700
gtctccagaa gagagagatt taattgagtc cagcagttat gaacacggaa ctacattcag 2760
ctatgtctgt gatgatggat tcaggatatt tgaagaaat agggtaacct gcaacattggg 2820
aaaaattggag ttctgtccct gttgtgttgg aataccttgt ggacccccac cttaattcc 2880
ctttgttatt gtctctcgt aactagaaag ttaccaatatt tgaaggaggat ttacatacaa 2940
ttgtcttgaaa ggtcttggaa ttgatggacc agcatttatt aaattgttag gaggacagtg 3000
gtctgcagcca cccaaatgca ta aaacttga ttgtgacaac ttgcccatcat ttgaatttgc 3060
caaacccgca gaagaagaaa aaaaatcata caggtcagga gaacaagatg catcagatg 3120
tccacctccg tatgaaagg atggctctga cattgtcaca ttgtttaaa cgaagtggat 3180
tggaacagccg gtatgcaaa ataatctctg ttgtaatcca ccacatgtgc caaatgtca 3240
tatactaa caaagacaga ctaaatatoc abctgttgac aaagtacgtt atgactgtaa 3300
taaaactttt gaattatttt ggggaagtgg aatgatgtgc caaaacggga ttgcagcaga 3360
accacccgaaa tgc aaagatt ccacagggaa atgtgggctt cctccaccta ttgacaatgg 3420
agacatcacc tcttctgcat taaccagata tgcacacatta hgtagaatg gaaagtgggt 3540
ccagaaactat tatctacta agggaaataa gatcacgaa gattacttcc caattatttg 3600
tcagccacca acctgttllac atgcatgtgt gattatttcc caatcagggg agaataatga 3660
tatagttctc agatggaggg aaaaatgc aaaatgc aaaatgc aaaatgc 3720
attcatgtgt aaacctggat atagaaaatt atccacatgg tgtataaaat tctaatagat 3780
cattgtgggt cacatcaatt atccacatgg tgtataaaat tctaatagat 3840
acctattgaa tgaacctttg tttgaaatg cacatgtata atataaaact ttcttatattg 3900
tacatttgg atattgttta gctcattttc ccaataaagt agaacattgc attcaaaact 3960
gtgggttaac agtaacttta cagactgttg aaactatgtc taagcaagaa aataaatgtt 4020
cctaactcaa aatatgatat gtccaaggac ttttcagatt ttcttgagaa ccttttgggt 4080
agttcttcaa ttacgttctt attccagtg agtggaaagc acactgact ttgacttcaa ttgatttaac 4140
ttaggttcaa attccagtg agtggaaagc atatcacaaa tgcatacagc taatttctgt 4200
gtccatcctt ttatcaata aagaattcta agaaagttct tgcattatgaa 4250

```

<210> 5
 <211> 1231
 <212> PRT
 <213> Homo sapiens

<400> 5
 Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
 1 5 10 15
 Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
 20 25 30
 Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
 35 40 45
 Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
 50 55 60
 Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
 65 70 75 80
 Gln Lys Arg Pro Gly Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
 85 90 95
 Thr Leu Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
 100 105 110

6/64

Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu
 115 120 125
 Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser
 145 150 155 160
 Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe
 165 170 175
 Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys
 180 185 190
 Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile
 195 200 205
 Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys
 210 215 220
 Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly
 225 230 235 240
 Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp
 245 250 255
 Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile
 260 265 270
 Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp
 275 280 285
 Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly
 290 295 300
 Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys
 305 310 315 320
 Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr
 325 330 335
 His Glu Asn Met Arg Arg Pro Tyr Phe Pro Val Ala Val Gly Lys Tyr
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr
 355 360 365
 Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro
 370 375 380
 Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln
 385 390 395 400
 Asn His Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys
 405 410 415
 His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met
 420 425 430
 Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Lys Thr Cys
 435 440 445
 Ser Lys Ser Ser Ile Asp Ile Glu Asn Gly Phe Ile Ser Glu Ser Gln
 450 455 460
 Tyr Thr Tyr Ala Leu Lys Glu Lys Ala Lys Tyr Gln Cys Lys Leu Gly
 465 470 475 480
 Tyr Val Thr Ala Asp Gly Glu Thr Ser Gly Ser Ile Thr Cys Gly Lys
 485 490 495
 Asp Gly Trp Ser Ala Gln Pro Thr Cys Ile Lys Ser Cys Asp Ile Pro
 500 505 510
 Val Phe Met Asn Ala Arg Thr Lys Asn Asp Phe Thr Trp Phe Lys Leu
 515 520 525
 Asn Asp Thr Leu Asp Tyr Glu Cys His Asp Gly Tyr Glu Ser Asn Thr
 530 535 540
 Gly Ser Thr Thr Gly Ser Ile Val Cys Gly Tyr Asn Gly Trp Ser Asp
 545 550 555 560
 Leu Pro Ile Cys Tyr Glu Arg Glu Cys Glu Leu Pro Lys Ile Asp Val
 555 560 565 570 575
 His Leu Val Pro Asp Arg Lys Lys Asp Gln Tyr Lys Val Gly Glu Val
 580 585 590
 Leu Lys Phe Ser Cys Lys Pro Gly Phe Thr Ile Val Gly Pro Asn Ser
 595 600 605

7/64

Val Gln Cys Tyr His Phe Gly Leu Ser Pro Asp Leu Pro Ile Cys Lys
 610 615 620
 Glu Gln Val Gln Ser Cys Gly Pro Pro Pro Glu Leu Leu Asn Gly Asn
 625 630 635 640
 Val Lys Glu Lys Thr Lys Glu Glu Tyr Gly His Ser Glu Val Val Glu
 645 650 655
 Tyr Tyr Cys Asn Pro Arg Phe Leu Met Lys Gly Pro Asn Lys Ile Gln
 660 665 670
 Cys Val Asp Gly Glu Trp Thr Thr Leu Pro Val Cys Ile Val Glu Glu
 675 680 685
 Ser Thr Cys Gly Asp Ile Pro Glu Leu Glu His Gly Trp Ala Gln Leu
 690 695 700
 Ser Ser Pro Pro Tyr Tyr Tyr Gly Asp Ser Val Glu Phe Asn Cys Ser
 705 710 715 720
 Glu Ser Phe Thr Met Ile Gly His Arg Ser Ile Thr Cys Ile His Gly
 725 730 735
 Val Trp Thr Gln Leu Pro Gln Cys Val Ala Ile Asp Lys Leu Lys Lys
 740 745 750
 Cys Lys Ser Ser Asn Leu Ile Ile Leu Glu Glu His Leu Lys Asn Lys
 755 760 765
 Lys Glu Phe Asp His Asn Ser Asn Ile Arg Tyr Arg Cys Arg Gly Lys
 770 775 780
 Glu Gly Trp Ile His Thr Val Cys Ile Asn Gly Arg Trp Asp Pro Glu
 785 790 795 800
 Val Asn Cys Ser Met Ala Gln Ile Gln Leu Cys Pro Pro Pro Pro Gln
 805 810 815
 Ile Pro Asn Ser His Asn Met Thr Thr Thr Leu Asn Tyr Arg Asp Gly
 820 825 830
 Glu Lys Val Ser Val Leu Cys Gln Glu Asn Tyr Leu Ile Gln Glu Gly
 835 840 845
 Glu Glu Ile Thr Cys Lys Asp Gly Arg Trp Gln Ser Ile Pro Leu Cys
 850 855 860
 Val Glu Lys Ile Pro Cys Ser Gln Pro Pro Gln Ile Glu His Gly Thr
 865 870 875 880
 Ile Asn Ser Ser Arg Ser Ser Gln Glu Ser Tyr Ala His Gly Thr Lys
 885 890 895 900
 Leu Ser Tyr Thr Cys Glu Gly Gly Phe Arg Ile Ser Glu Glu Asn Glu
 905 910 915
 Thr Thr Cys Tyr Met Gly Lys Trp Ser Ser Pro Pro Gln Cys Glu Gly
 920 925 930
 Leu Pro Cys Lys Ser Pro Pro Glu Ile Ser His Gly Val Val Ala His
 935 940 945
 Met Ser Asp Ser Tyr Gln Tyr Gly Glu Glu Val Thr Tyr Lys Cys Phe
 950 955 960
 Glu Gly Phe Gly Ile Asp Gly Pro Ala Ile Ala Lys Cys Leu Gly Glu
 965 970 975
 Lys Trp Ser His Pro Pro Ser Cys Ile Lys Thr Asp Cys Leu Ser Leu
 980 985 990
 Pro Ser Phe Glu Asn Ala Ile Pro Met Gly Glu Lys Lys Asp Val Tyr
 995 1000 1005
 Lys Ala Gly Glu Gln Val Thr Tyr Thr Cys Ala Thr Tyr Tyr Lys Met
 1010 1015 1020
 Asp Gly Ala Ser Asn Val Thr Cys Ile Asn Ser Arg Trp Thr Gly Arg
 1025 1030 1035 1040
 Pro Thr Cys Arg Asp Thr Ser Cys Val Asn Pro Pro Thr Val Gln Asn
 1045 1050 1055
 Ala Tyr Ile Val Ser Arg Gln Met Ser Lys Tyr Pro Ser Gly Glu Arg
 1060 1065 1070
 Val Arg Tyr Gln Cys Arg Ser Pro Tyr Glu Met Phe Gly Asp Glu Glu
 1075 1080 1085
 Val Met Cys Leu Asn Gly Asn Trp Thr Glu Pro Pro Gln Cys Lys Asp
 1090 1095 1100

8/64

```

Ser Thr Gly Lys Cys Gly Pro Pro Pro Ile Asp Asn Gly Asp Ile
1105          1110          1115          1120
Thr Ser Phe Pro Leu Ser Val Tyr Ala Pro Ala Ser Ser Val Glu Tyr
          1125          1130          1135
Gln Cys Gln Asn Leu Tyr Gln Leu Glu Gly Asn Lys Arg Ile Thr Cys
          1140          1145          1150
Arg Asn Gly Gln Trp Ser Glu Pro Pro Lys Cys Leu His Pro Cys Val
          1155          1160          1165
Ile Ser Arg Glu Ile Met Glu Asn Tyr Asn Ile Ala Leu Arg Trp Thr
          1170          1175          1180
Ala Lys Gln Lys Leu Tyr Ser Arg Thr Gly Glu Ser Val Glu Phe Val
1185          1190          1195          1200
Cys Lys Arg Gly Tyr Arg Leu Ser Ser Arg Ser His Thr Leu Arg Thr
          1205          1210          1215
Thr Cys Trp Asp Gly Lys Leu Glu Tyr Pro Thr Cys Ala Lys Arg
          1220          1225          1230

```

<210> 6

<211> 449

<212> PRT

<213> Homo sapiens

<400> 6

```

Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
1          5          10          15
Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
          20          25          30
Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
          35          40          45
Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
          50          55          60
Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
          65          70          75
Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
          85          90          95
Thr Leu Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
          100          105          110
Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu
          115          120          125
Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
          130          135          140
Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser
          145          150          155
Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe
          165          170          175
Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys
          180          185          190
Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile
          195          200          205
Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys
          210          215          220
Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly
          225          230          235
Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp
          245          250          255
Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile
          260          265          270
Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp
          275          280          285
Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly
          290          295          300

```

9/64

Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys
 305 310 315 320
 Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr
 325 330 335
 His Glu Asn Met Arg Arg Pro Tyr Phe Pro Val Ala Val Gly Lys Tyr
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr
 355 360 365
 Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro
 370 375 380
 Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln
 385 390 395 400
 Asn His Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys
 405 410 415
 His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met
 420 425 430
 Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Ser Phe Thr
 435 440 445
 Leu

<210> 7
 <211> 1234
 <212> PRT
 <213> Mus musculus

<400> 7
 Met Arg Leu Ser Ala Arg Ile Ile Trp Leu Ile Leu Trp Thr Val Cys
 1 5 10 15
 Ala Ala Glu Asp Cys Lys Gly Pro Pro Pro Arg Glu Asn Ser Glu Ile
 20 25 30
 Leu Ser Gly Ser Trp Ser Glu Gln Leu Tyr Pro Glu Gly Thr Gln Ala
 35 40 45
 Thr Tyr Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys
 50 55 60
 Val Cys Lys Asn Gly Lys Trp Val Ala Ser Asn Pro Ser Arg Ile Cys
 65 70 75 80
 Arg Lys Lys Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe
 85 90 95
 Arg Leu Ala Val Gly Ser Gln Phe Glu Phe Gly Ala Lys Val Val Tyr
 100 105 110
 Thr Cys Asp Asp Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu
 115 120 125
 Cys Gly Ala Asp Gly Trp Ile Asn Asp Ile Pro Leu Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly
 145 150 155 160
 Ala Ala Glu Thr Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe
 165 170 175
 Glu Cys Asn Ser Gly Phe Lys Ile Glu Gly His Lys Glu Ile His Cys
 180 185 190
 Ser Glu Asn Gly Leu Trp Ser Asn Glu Lys Pro Arg Cys Val Glu Ile
 195 200 205
 Leu Cys Thr Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Asn Val Lys
 210 215 220
 Pro Val Tyr Lys Glu Asn Glu Arg Tyr His Tyr Lys Cys Lys His Gly
 225 230 235 240
 Tyr Val Pro Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp
 245 250 255
 Ser Ser Gln Pro Phe Cys Glu Glu Lys Arg Cys Ser Pro Tyr Ile
 260 265 270

10/64

Leu Asn Gly Ile Tyr Thr Pro His Arg Ile Ile His Arg Ser Asp Asp
 275 280 285
 Glu Ile Arg Tyr Glu Cys Asn Tyr Gly Phe Tyr Pro Val Thr Gly Ser
 290 295 300
 Thr Val Ser Lys Cys Thr Pro Thr Gly Trp Ile Pro Val Pro Arg Cys
 305 310 315 320
 Thr Leu Lys Pro Cys Glu Phe Pro Gln Phe Lys Tyr Gly Arg Leu Tyr
 325 330 335
 Tyr Glu Glu Ser Leu Arg Pro Asn Phe Pro Val Ser Ile Gly Asn Lys
 340 345 350
 Tyr Ser Tyr Lys Cys Asp Asn Gly Phe Ser Pro Pro Ser Gly Tyr Ser
 355 360 365
 Trp Asp Tyr Leu Arg Cys Thr Ala Gln Gly Trp Glu Pro Glu Val Pro
 370 375 380
 Cys Val Arg Lys Cys Val Phe His Tyr Val Glu Asn Gly Asp Ser Ala
 385 390 395 400
 Tyr Trp Glu Lys Val Tyr Val Gln Gly Gln Ser Leu Lys Val Gln Cys
 405 410 415
 Tyr Asn Gly Tyr Ser Leu Gln Asn Gly Gln Asp Thr Met Thr Cys Thr
 420 425 430
 Glu Asn Gly Trp Ser Pro Pro Pro Lys Cys Ile Arg Ile Lys Thr Cys
 435 440 445
 Ser Ala Ser Asp Ile His Ile Asp Asn Gly Phe Leu Ser Glu Ser Ser
 450 455 460
 Ser Ile Tyr Ala Leu Asn Arg Glu Thr Ser Tyr Arg Cys Lys Gln Gly
 465 470 475 480
 Tyr Val Thr Asn Thr Gly Glu Ile Ser Gly Ser Ile Thr Cys Leu Gln
 485 490 495
 Asn Gly Trp Ser Pro Gln Pro Ser Cys Ile Lys Ser Cys Asp Met Pro
 500 505 510
 Val Phe Glu Asn Ser Ile Thr Lys Asn Thr Arg Thr Trp Phe Lys Leu
 515 520 525
 Asn Asp Lys Leu Asp Tyr Glu Cys Leu Val Gly Phe Glu Asn Glu Tyr
 530 535 540
 Lys His Thr Lys Gly Ser Ile Thr Cys Thr Tyr Tyr Gly Trp Ser Asp
 545 550 555 560
 Thr Pro Ser Cys Tyr Glu Arg Glu Cys Ser Val Pro Thr Leu Asp Arg
 565 570 575
 Lys Leu Val Val Ser Pro Arg Lys Glu Lys Tyr Arg Val Gly Asp Leu
 580 585 590
 Leu Glu Phe Ser Cys His Ser Gly His Arg Val Gly Pro Asp Ser Val
 595 600 605
 Gln Cys Tyr His Phe Gly Trp Ser Pro Gly Phe Pro Thr Cys Lys Gly
 610 615 620
 Gln Val Ala Ser Cys Ala Pro Pro Leu Glu Ile Leu Asn Gly Glu Ile
 625 630 635 640
 Asn Gly Ala Lys Lys Val Glu Tyr Ser His Gly Glu Val Val Lys Tyr
 645 650 655
 Asp Cys Lys Pro Arg Phe Leu Leu Lys Gly Pro Asn Lys Ile Gln Cys
 660 665 670
 Val Asp Gly Asn Trp Thr Thr Leu Pro Val Cys Ile Glu Glu Glu Arg
 675 680 685
 Thr Cys Gly Asp Ile Pro Glu Leu Glu His Gly Ser Ala Lys Cys Ser
 690 695 700
 Val Pro Pro Tyr His His Gly Asp Ser Val Glu Phe Ile Cys Glu Glu
 705 710 715 720
 Asn Phe Thr Met Ile Gly His Gly Ser Val Ser Cys Ile Ser Gly Lys
 725 730 735
 Trp Thr Gln Leu Pro Lys Cys Val Ala Thr Asp Gln Leu Glu Lys Cys
 740 745 750
 Arg Val Leu Lys Ser Thr Gly Ile Glu Ala Ile Lys Pro Lys Leu Thr
 755 760 765

11/64

Glu Phe Thr His Asn Ser Thr Met Asp Tyr Lys Cys Arg Asp Lys Gln
 776 775 780
 Glu Tyr Glu Arg Ser Ile Cys Ile Asn Gly Lys Trp Asp Pro Glu Pro
 785 790 795 800
 Asn Cys Thr Ser Lys Thr Ser Cys Pro Pro Pro Gln Ile Pro Asn
 805 810 815
 Thr Gln Val Ile Glu Thr Thr Val Lys Tyr Leu Asp Gly Glu Lys Leu
 820 825 830
 Ser Val Leu Cys Gln Asp Asn Tyr Leu Thr Gln Asp Ser Glu Glu Met
 835 840 845
 Val Cys Lys Asp Gly Arg Trp Gln Ser Leu Pro Arg Cys Ile Glu Lys
 850 855 860
 Ile Pro Cys Ser Gln Pro Pro Thr Ile Glu His Gly Ser Ile Asn Leu
 865 870 875 880
 Pro Arg Ser Ser Glu Glu Arg Arg Asp Ser Ile Glu Ser Ser Ser His
 885 890 895
 Glu His Gly Thr Thr Phe Ser Tyr Val Cys Asp Asp Gly Phe Arg Ile
 900 905 910
 Pro Glu Glu Asn Arg Ile Thr Cys Tyr Met Gly Lys Trp Ser Thr Pro
 915 920 925
 Pro Arg Cys Val Gly Leu Pro Cys Gly Pro Pro Pro Ser Ile Pro Leu
 930 935 940
 Gly Thr Val Ser Leu Glu Leu Glu Ser Tyr Gln His Gly Glu Glu Val
 945 950 955 960
 Thr Tyr His Cys Ser Thr Gly Phe Gly Ile Asp Gly Pro Ala Phe Ile
 965 970 975
 Ile Cys Glu Gly Gly Lys Trp Ser Asp Pro Pro Lys Cys Ile Lys Thr
 980 985 990
 Asp Cys Asp Val Leu Pro Thr Val Lys Asn Ala Ile Ile Arg Gly Lys
 995 1000 1005
 Ser Lys Lys Ser Tyr Arg Thr Gly Glu Gln Val Thr Phe Arg Cys Gln
 1010 1015 1020
 Ser Pro Tyr Gln Met Asn Gly Ser Asp Thr Val Thr Cys Val Asn Ser
 1025 1030 1035 1040
 Arg Trp Ile Gly Gln Pro Val Cys Lys Asp Asn Ser Cys Val Asp Pro
 1045 1050 1055
 Pro His Val Pro Asn Ala Thr Ile Val Thr Arg Thr Lys Asn Lys Tyr
 1060 1065 1070
 Leu His Gly Asp Arg Val Arg Tyr Glu Cys Asn Lys Pro Leu Glu Leu
 1075 1080 1085
 Phe Gly Gln Val Glu Val Met Cys Glu Asn Gly Ile Trp Thr Glu Lys
 1090 1095 1100
 Pro Lys Cys Arg Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro Ile
 1105 1110 1115 1120
 Asp Asn Gly Asp Ile Thr Ser Leu Ser Leu Pro Val Tyr Glu Pro Leu
 1125 1130 1135
 Ser Ser Val Glu Tyr Gln Cys Gln Lys Tyr Tyr Leu Leu Lys Gly Lys
 1140 1145 1150
 Lys Thr Ile Thr Cys Thr Asn Gly Lys Trp Ser Glu Pro Pro Thr Cys
 1155 1160 1165
 Leu His Ala Cys Val Ile Pro Glu Asn Ile Met Glu Ser His Asn Ile
 1170 1175 1180
 Ile Leu Lys Trp Arg His Thr Glu Lys Ile Tyr Ser His Ser Gly Glu
 1185 1190 1195 1200
 Asp Ile Glu Phe Gly Cys Lys Tyr Gly Tyr Tyr Lys Ala Arg Asp Ser
 1205 1210 1215
 Pro Pro Phe Arg Thr Lys Cys Ile Asn Gly Thr Ile Asn Tyr Pro Thr
 1220 1225 1230
 Cys Val

12/64

<210> 8
 <211> 1235
 <212> PRT
 <213> Rattus norvegicus

<400> 8
 Met Arg Leu Ser Ala Arg Ile Ile Trp Leu Ile Leu Trp Thr Val Cys
 1 5 10 15
 Val Ala Glu Asp Cys Lys Gly Pro Pro Arg Glu Asn Ser Glu Ile
 20 25 30
 Leu Ser Gly Ser Trp Ser Glu Gln Leu Tyr Ser Glu Gly Thr Gln Ala
 35 40 45
 Thr Tyr Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys
 50 55 60
 Val Cys Lys Asn Gly Glu Trp Val Pro Ser Asn Pro Ser Arg Ile Cys
 65 70 75 80
 Arg Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe
 85 90 95
 Arg Leu Ala Val Gly Ser Glu Phe Glu Phe Gly Ala Lys Val Val Tyr
 100 105 110
 Thr Cys Asp Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu
 115 120 125
 Cys Asp Ala Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly
 145 150 155 160
 Ala Ala Glu Pro Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe
 165 170 175
 Glu Cys Asn Ser Gly Phe Lys Ile Glu Gly Gln Lys Glu Met His Cys
 180 185 190
 Ser Glu Asn Gly Leu Trp Ser Asn Glu Lys Pro Gln Cys Val Glu Ile
 195 200 205
 Ser Cys Leu Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Tyr Leu Lys
 210 215 220
 Pro Val Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Lys Gln Gly
 225 230 235 240
 Phe Val Tyr Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp
 245 250 255
 Asn Pro Gln Pro Ser Cys Glu Glu Met Thr Cys Leu Thr Pro Tyr Ile
 260 265 270 275
 Pro Asn Gly Ile Tyr Thr Pro His Arg Ile Lys His Arg Ile Asp Asp
 280 285 290
 Glu Ile Arg Tyr Glu Cys Lys Asn Gly Phe Tyr Pro Ala Thr Arg Ser
 295 300 305
 Pro Val Ser Lys Cys Thr Ile Thr Gly Trp Ile Pro Ala Pro Arg Cys
 310 315 320
 Ser Leu Lys Pro Cys Asp Phe Pro Gln Phe Lys His Gly Arg Leu Tyr
 325 330 335
 Tyr Glu Glu Ser Arg Arg Pro Tyr Phe Pro Val Pro Ile Gly Lys Glu
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Asn Gly Phe Thr Thr Pro Ser Gln Ser Tyr
 355 360 365
 Trp Asp Tyr Leu Arg Cys Thr Val Asn Gly Trp Glu Pro Glu Val Pro
 370 375 380
 Cys Leu Arg Gln Cys Ile Phe His Tyr Val Glu Tyr Gly Glu Ser Leu
 385 390 395 400
 Tyr Trp Gln Arg Arg Tyr Ile Glu Gly Gln Ser Ala Lys Val Gln Cys
 405 410 415
 His Ser Gly Tyr Ser Leu Pro Asn Gly Gln Asp Thr Ile Leu Cys Thr
 420 425 430
 Glu Asn Gly Trp Ser Pro Pro Lys Cys Val Arg Ile Lys Thr Cys
 435 440 445

13/64

Ser Val Ser Asp Ile Glu Ile Glu Asn Gly Phe Phe Ser Glu Ser Asp
 450 455 460
 Tyr Thr Tyr Ala Leu Asn Arg Lys Thr Arg Tyr Arg Cys Lys Gln Gly
 465 470 480
 Tyr Val Thr Asn Thr Gly Glu Ile Ser Gly Ile Ile Thr Cys Leu Gln
 485 495
 Asp Gly Trp Ser Pro Arg Pro Ser Cys Ile Lys Ser Cys Asp Met Pro
 500 505 510
 Val Phe Glu Asn Ala Met Thr Lys Asn Asn Asn Thr Trp Phe Lys Leu
 515 520 525
 Asn Asp Lys Leu Asp Tyr Glu Cys His Ile Gly Tyr Glu Asn Glu Tyr
 530 535 540
 Lys His Thr Lys Gly Ser Ile Thr Cys Thr Tyr Asp Gly Trp Ser Ser
 545 550 555 560
 Thr Pro Ser Cys Tyr Glu Arg Glu Cys Ser Ile Pro Leu Leu His Gln
 565 570 575
 Asp Leu Val Val Phe Pro Arg Glu Val Lys Tyr Lys Val Gly Asp Ser
 580 585 590
 Leu Ser Phe Ser Cys Arg Ser Gly His Arg Val Gly Ala Asp Leu Val
 595 600 605
 Gln Cys Tyr His Phe Gly Trp Ser Pro Asn Phe Pro Thr Cys Glu Gly
 610 615 620
 Gln Val Lys Ser Cys Asp Gln Pro Leu Glu Ile Pro Asn Gly Glu Ile
 625 630 635 640
 Lys Gly Thr Lys Lys Val Glu Tyr Ser His Gly Asp Val Val Glu Tyr
 645 650 655
 Asp Cys Lys Pro Arg Phe Leu Leu Lys Gly Pro Asn Lys Ile Gln Cys
 660 665 670
 Val Asp Gly Lys Trp Thr Thr Leu Pro Ile Cys Val Glu Tyr Glu Arg
 675 680 685
 Thr Cys Gly Asp Leu Pro Ala Leu Glu His Gly Ser Val Gln Leu Ser
 690 695 700
 Val Pro Pro Tyr His His Gly Asp Ser Val Glu Phe Thr Cys Ala Glu
 705 710 715 720
 Thr Phe Thr Met Ile Gly His Ala Val Val Phe Cys Ile Ser Gly Arg
 725 730 735
 Trp Thr Glu Leu Pro Gln Cys Val Ala Thr Asp Gln Leu Glu Lys Cys
 740 745 750
 Lys Ala Pro Lys Ser Thr Gly Ile Asp Ala Ile His Pro Asn Lys Asn
 755 760 765
 Glu Phe Asn His Asn Phe Ser Val Ser Tyr Arg Cys Arg Gln Lys Gln
 770 775 780
 Glu Tyr Glu His Ser Ile Cys Ile Asn Gly Arg Trp Asp Pro Glu Pro
 785 790 795 800
 Asn Cys Thr Arg Asn Glu Lys Arg Phe Cys Pro Pro Pro Gln Ile
 805 810 815
 Pro Asn Ala Gln Val Ile Glu Thr Thr Val Lys Tyr Leu Asp Gly Glu
 820 825 830
 Lys Val Ser Val Leu Cys Gln Asp Gly Tyr Leu Thr Gln Gly Pro Glu
 835 840 845
 Glu Met Val Cys Lys His Gly Arg Trp Gln Ser Leu Pro Arg Cys Thr
 850 855 860
 Glu Lys Ile Pro Cys Ser Gln Pro Pro Lys Ile Glu His Gly Ser Ile
 865 870 875 880
 Lys Ser Pro Arg Ser Ser Glu Glu Arg Asp Leu Ile Glu Ser Ser Ser
 885 890 895
 Tyr Glu His Gly Thr Thr Phe Ser Tyr Val Cys Asp Asp Gly Phe Arg
 900 905 910
 Ile Ser Glu Glu Asn Arg Val Thr Cys Asn Met Gly Lys Trp Ser Ser
 915 920 925
 Leu Pro Arg Cys Val Gly Ile Pro Cys Gly Pro Pro Pro Ser Ile Pro
 930 935 940

14/54

Leu Gly Ile Val Ser His Glu Leu Glu Ser Tyr Gln Tyr Gly Glu Glu
 945 950 955 960
 Val Thr Tyr Asn Cys Ser Glu Gly Phe Gly Ile Asp Gly Pro Ala Phe
 965 970 975
 Ile Lys Cys Val Gly Gly Gln Trp Ser Glu Pro Pro Lys Cys Ile Lys
 980 985 990
 Thr Asp Cys Asp Asn Leu Pro Thr Phe Glu Ile Ala Lys Pro Thr Glu
 995 1000 1005
 Lys Lys Lys Lys Ser Tyr Arg Ser Gly Glu Gln Val Thr Phe Arg Cys
 1010 1015 1020
 Pro Pro Pro Tyr Arg Met Asp Gly Ser Asp Ile Val Thr Cys Val Asn
 1025 1030 1035
 Thr Lys Trp Ile Gly Gln Pro Val Cys Lys Asp Asn Ser Cys Val Asn
 1045 1050 1055
 Pro Pro His Val Pro Asn Ala Thr Ile Leu Thr Arg His Lys Thr Lys
 1060 1065 1070
 Tyr Pro Ser Gly Asp Lys Val Arg Tyr Asp Cys Asn Lys Pro Phe Glu
 1075 1080 1085
 Leu Phe Gly Glu Val Glu Val Met Cys Gln Asn Gly Ile Trp Thr Glu
 1090 1095 1100
 Pro Pro Lys Cys Lys Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro
 1105 1110 1115 1120
 Ile Asp Asn Gly Asp Ile Thr Ser Leu Ser Leu Pro Val Tyr Ala Pro
 1125 1130 1135
 Leu Ser Ser Val Glu Tyr Gln Cys Gln Asn Tyr Tyr Leu Leu Lys Gly
 1140 1145 1150
 Asn Lys Ile Val Thr Cys Arg Asn Gly Lys Trp Ser Gln Pro Pro Thr
 1155 1160 1165
 Cys Leu His Ala Cys Val Ile Pro Glu Asp Ile Met Glu Lys His Asn
 1170 1175 1180
 Ile Val Leu Arg Trp Arg Glu Asn Ala Lys Ile Tyr Ser Gln Ser Gly
 1185 1190 1195 1200
 Glu Asn Ile Glu Phe Met Cys Lys Pro Gly Tyr Arg Lys Phe Arg Gly
 1205 1210 1215
 Ser Pro Pro Phe Arg Thr Lys Cys Ile Glu Gly His Ile Asn Tyr Pro
 1220 1225 1230
 Thr Cys Val
 1235

<210> 9

<211> 150626

<212> DNA

<213> Homo sapiens

<400> 9

gatcataatg gtatacaaca attaacatca gaatsaaact tggaaacttt acaaacactt 60
 ggaataatga caacatgtac atttaaaacc aatggctcaa tgaaggaaact aaaaaaatt 120
 tggaaagtgt ttgagacaaa tgacaatgga agcacagcat actataatag atgagataga 180
 gcaaaaccag ttcttagagg aaattttata acaataaatg ccttatcaaa agaataaat 240
 tctcaaatga aacaacaaa cattgcacot taaggagcta aaaaatttaag aacaacatta 300
 ctaaaaacaa gtgcgaaaag aaatsataaa gatcagagca gaaacaacaa acgcagagac 360
 taatgttaga tatgacaaaa aasagatttia aaaaatttg acaaacattt 420
 tcttagacta agaaaaataa ccttgcaact taaggagcta ccaataaat aaatcagag aggaaaagg 480
 agacattaca tctgttctta cctggaaaga aaggatcata ttttgagac atacaacata 600
 ttggccaata aattgtgtata aatgagaatc taacagagaa ataatagagt aagttgatta 660
 ccaagattga attaggaata catcaaaaaa gcccaaaacc tgttatcgc actgtgtaat 720
 aatcagattat aaatttcacc catcaaaaaa gggcaaaacc tctcaacta tgcctgaatg 780
 tctaccaaatt attaaaaaaa aaaaacttca gaggtaattt cctgcctctg aacacaaac 840
 aaagaaaatg gaatttttcc aacttattgt agcatgccc gtcctctgtg acacagaggtg 900
 caaacaagga aacaacacaa aaagaaaact acaggtctgt gtcctctgtg acacagaggtg 960
 ttaaaattct taataaaata cacaaaaaag tgaatttctg ttccttggtt tgttggtttt

tgagaagagg	tctctctctg	tcagcccggt	tggaaacgag	gggtgcacac	ctggctggct	1020
ctatccctga	cctcttgggc	tcagccaatc	ctttcaacct	atccctccaga	gtagctggga	1080
ctataggcct	ggggcaaac	accagctaa	ctcaaaagt	aectgcaglt	ttttaaasta	1140
gagttcaatt	aaacaagg	ttgatgtac	aattgtgna	catacaactt	aaaccgtaga	1200
gggctcagaa	gagatcaact	ctctaacccc	acccccgcac	ataggggcaat	accgctatag	1260
gtccacacttt	tagaaaaatc	cttgacctct	gattcgatgt	tggaataatc	tgttacctgc	1320
ttccactgac	gtgacagtc	tcactcaaaag	ctaaccttact	ccccctcata	aatgttttga	1380
aatatctcga	gacagatctt	ataatgobat	aaactctatc	ttttgcatgt	ttcttatgtc	1440
ataatttctt	taactcttca	actactcata	tattctcttc	tatgccatga	tagttggaaa	1500
ccaatcattt	taaaaagtg	taggctaagt	acggatattt	attacagaca	tgatatttgg	1560
tgggcaaac	acacagttga	gagtagcttt	ttgacactga	aaaacatcat	ttcctcatga	1620
agcctgaaag	agatagatgt	tcctctcagt	accaccattg	tcattataata	ttaggggttat	1680
taatgaaat	cttcattttc	ctccacttaa	tttactttta	aaagctaaata	caaatgttgt	1740
ttccactaag	taaatctgcc	ascaaaaaaa	taaaaatctc	tttttgactt	gaatgcotca	1800
tgaatgatgt	atctgtcttc	aacagataaa	taaaaaagac	tttttttttt	ttttgagaca	1860
gaatcttgct	cagttgccca	ggctggagtg	cagtgactgc	atctcogctc	acgcgaagct	1920
ctgcctctct	gattccagca	ataatcccg	ctcagctctc	cagtagctgt	ggagctacaga	1980
cgccctcgac	cagcggccga	taattttttt	tgatattttt	tttagtagaga	cggggtttcg	2040
ccctgttagc	cagtagtggt	ttgatctctc	gaactctgtc	tcggccctcc	tcggccctcc	2100
aaagtgcgtg	gattcaagtg	gtgagccact	gtgcccggcc	asaaagacat	ttttgaaagca	2160
agttaaaatt	taattaaaa	acatgttgct	gatttctttt	gctttgaaga	ttagtttctc	2220
tgaagtaaat	gggtatagtg	aatattcttt	gaatgtatat	gtgaatttca	gtatagcat	2280
aggttttgtct	taattagctat	tttcgctgag	tcagctataa	aaaatttcca	tgactctatt	2340
gttcataata	tagtaataat	tgacagaaaca	ttttttgggg	gaatttcatg	tcacatcttc	2400
tcattaccgc	ttccaataat	aaactgaact	ctgcaatctg	gggtgttccc	ttcactcaat	2460
tttttttgtc	caaaaggaac	aaacaacacg	gcgcacaaaa	accctggcaa	aaactcttga	2520
taaacatcgt	ctctcaacca	ttttcttctg	agattgcgcg	aatcataact	agttttctga	2580
ttctgacctc	tcacttttgt	ctctctattc	ctgtgtgata	aattaatgac	ctttcactgt	2640
gtcgttttat	ttctccactt	aaaaacttta	atggatctca	agtcagctaa	caggacaaga	2700
acctatctac	actttctctc	ctctctactaa	catagatgg	ttctctcagc	aatcttcagg	2760
gtttttatcg	catttaattta	aactgagctt	atctcagaa	ataccaagtt	aaagctcaag	2820
tgcaggttca	ggggcgacgc	attagccatg	atgttttttt	ggaaaagaga	gacacgaagt	2880
atgacattga	cataaaaaat	ctgatattga	gcaatttttc	tcagagataa	aaaactcttg	2940
tttagttttg	tggcattttg	tttgtatgct	atggcatgca	ttcttaccat	agtttagaatt	3000
catgtgtcag	ataagatata	ttattgcat	aaaaaatga	ggcatagacg	aatgtacaaa	3060
tatgtataata	ttcttacctt	ctataggtat	gtataacctat	agaatgttga	acaacatcac	3120
aaatttaata	gcatactatt	tatgtttact	ctataattat	ggasacaagt	atagaaaaata	3180
tattttacat	tcatttttgt	atgaaaactt	aagaatataa	ttcaataaaa	gtttaagttt	3240
aatcatcata	aaccagagag	aactagaaga	acgctatgtg	cacaacgcgt	ttagttgtgga	3300
gtagagaaga	ctagcttcag	agaagtgaac	tccttacttt	gggggaagcg	tttgtatgtt	3360
acagaactcg	atccagagcg	ttgttgggcg	acgcgatgca	cotctctctg	cccgctccct	3420
caagcatgga	tgcacagttt	ctctgctgag	gtctctccgc	tatttgaaaa	tcgaamaact	3480
ggggccctct	gttaacctct	gagatactct	tacattttct	tttgtattgca	ggatattttg	3540
tcaggagtag	aaaggggaat	aaactaaaag	aaatcattta	aatcttctct	ttttttctca	3600
tttttatttt	tatttttaat	agtcttgctc	tgtctccaaa	ctgagatgco	agtggcacta	3660
tattggctca	cgtcaaacct	tgtctccggg	gttcaagtga	ttctctctgc	tcagttctct	3720
gtgaagcttg	aattacagct	gtgtgcgcgc	acatccagct	atttttttta	acttttagta	3780
ggagacagat	ttcatcatgt	tggccaactc	ctggcctcaa	gtgatctg	cgcttgggc	3840
ctcgaaagtg	ctgggattaa	tgtgtgagcc	atcctgtctc	gccaaaaatt	atttttctta	3900
ctcnaacgta	acttcaagcc	tgaagttagt	ttttcatggt	ttaggtttgt	ttctaaaaat	3960
cgcttctccc	acttaaaagc	actggaattt	catagagaaa	tattgaaac	ttagtctgta	4020
gtaggaaaa	tcagaaagag	tatgggtctc	tatgttatgt	caaaagctaa	tgggggcaca	4080
tgaatatatc	acagaaagca	ttctcttgat	gagatgtgaa	acaaattcca	gcataccaaa	4140
gaagtacaat	gggaataaac	tgtaatgcat	ttgggtactgt	aatgatcagt	ttaaaagggg	4200
tttaaaagca	accctgtctc	acaaatgtta	ttgtcaactt	tgacactttg	ttgtggcaac	4260
ttctatagat	gaatataaaa	tttatacaat	ctgtaaaagg	tatttcataat	taaaaataat	4320
gttatttgca	acctattttt	aaataagtat	aaataactta	tgacttgtag	gagaanaata	4380
tggaacatgc	aaattcaatg	aaactattaa	taggttacaa	ttcacaatttt	ttgtccaagt	4440
ttgtctttca	aatagggtag	tttccaaaag	aatgtgtgtg	attagcataa	tgctcagaac	4500
tgaatatatc	actaacattc	aaaaaatttt	attagattta	ctagattctg	aatatagatg	4560
ttccattaatg	atatgaaaaa	tctttcttag	aaacagacaa	aaatcagcag	gaaaatacac	4620
aatcacagta	tatacacaca	taagattctc				4680

ccaagatgta	attaccaaat	tctgatgaat	agcctctaaa	atctgtgtgg	tggctacata	7470
tacatacata	tattcttggag	taaaaagtaa	aaaattatttt	ttagttatta	atgtctcttt	7480
aaataaattgt	gtaaatatcaa	tgggtatccat	ctgtctagagc	taccataaca	aagtaaccatt	7490
gattctcattg	aaatttatttt	tctcacagtt	ctggaggcta	atagatttgg	atagagctgtg	7500
caacaggattt	ggatrrrrctt	gagacctctt	cttttgcctt	gtaaaatggtt	gtattctcttc	7510
tatgcctctgc	tggtatctttc	tctatatggt	gtgtctcttat	tgtctcttcc	tatatagaca	7520
ccagttatata	tggagtagga	ccacactgaa	ctatgtgacct	ttaactttaat	tacattctta	7530
agtgactcctt	ctccaaatgc	agtcacattc	tcaggatttg	ggaaatttgc	ctttaacaaa	7540
tgaatttttgg	cggtgatgcaa	tggagccaat	gctactgaat	acacaaagat	gtttctctct	7550
accacagact	tgaagaagtaa	cccaatgagt	tactttctcc	tltgagaaat	atagggtgga	7560
cccaaatctta	caagacatttt	tgtccaagtt	tactcttaca	aagagtttcat	tggaggagac	7570
aagtttttcaa	ctgggaatctc	agataaggaa	gaatttggca	tcattctttt	ctatagttgt	7580
tttaagaagag	taagtagaaga	agtatagtgc	atatgttttt	ctaattccag	ctctttcaga	7590
atggttactac	ttttctctctt	tccattctac	tttaacttat	ttaactcttta	tttgaaaaaa	7600
atgtacctgt	atcagttcag	ttaacaaagg	aaataacagg	agaattttct	tttttttcca	7610
tttttagcaca	gatccaagttt	gatttttgcac	acaaaaataa	actagcaaat	catgtgatag	7620
ataactactgt	aaaaactaaa	gctctttacc	tagaatacaa	taaaagtggca	tagcttttag	7630
aagagaggct	tggtggaagag	atactctcat	aaattgataa	ttggattttc	atctatcccc	7640
tccactacat	tgttggaaat	attatgaagt	tttgyataat	tacaaaaatt	gtattcttca	7650
tttaatggcca	gagggaaaaag	attgtccagt	acatttggac	catgttggtc	cactggtaat	7660
gttagcagat	agttctttaa	tatgcaaggc	ctgcattcca	aaaggtagtt	aatatagaaa	7670
atattatgact	gttgaggaga	aaacaaatcn	gtgaaacaata	acataaagct	ataaaaataa	7680
tattttatgta	agttgaagcat	acatttggcta	gtgagctcag	aaatgcacaaa	tttactgtca	7690
ttlaaaagta	agttgaagcat	atagctctact	tttggattat	attcagttcg	tgtatttaca	7700
gtttgtgattt	acatgttggc	aatcttggttg	aaattattaag	ttcatatttaa	tgttaattbca	7710
tttttagcagc	ttttcttaagg	tattatagaa	ataaaagaaa	ttcagagatt	taaaagtgtat	7720
tattttgattt	tttggatataa	gaactctataa	aaaaatcaca	ctctgtaaat	tatgaaaaata	7730
tcagtcactct	cccttgcattt	acaaaataaga	aactcttgaa	catltttaagg	ttagaattctg	7740
tctagtgcaca	tgtttctctac	ttaaagtttc	atgagatgat	tcacatattct	ccaatatcaa	7750
tattaaatgt	cttttctacat	gtagaactta	taaaacaaag	aaactatttat	tcacttgtta	7760
agtttaaaatg	agataataatt	tcataaaaatt	aatcttctct	atagctcttca	aaaatatgct	7770
atttctacta	ctacatgtgaa	taaatctctct	ttgttctcata	aaaaatttga	gacatgggga	7780
catagaggaga	tagcatattac	atgaagttac	atttaagatg	ggagctcagat	tgttagactct	7790
ctttcacttt	acctctgtcca	ttagcatagg	aaacccacaa	gggtagaatg	acatttaatta	7800
gtaacaacat	gttagatattt	ctcagtagta	tagtaatgca	aaagtttcag	tgtactgttt	7810
tggtagtttga	aatctttctat	tattagttac	caaggttgat	tcogaatttg	aggaacctac	7820
cacgaacatc	ggcctttaag	gtcactttagt	aaatatcaaa	gttcagagag	ttttgcaaaa	7830
tgccttcaata	attccagttta	gtggtttctac	aaacctctgt	ggaatttgatt	ccctgtaactg	7840
tactctgaata	atattatttta	gggscagtag	tggactgaal	ccaaaagata	tataaataat	7850
taattttattt	tatctctctat	ttttttgagta	aagagagtat	caataaaggg	aacgaaaaagg	7860
ttctctcaact	actgggagaaa	ctgaggggaa	aaaggttcaat	aargcttcaat	ccagaaaaatt	7870
ccgaagtttca	gggaattcttag	tgatgccccca	ctaatttatcc	tttacttactg	agtggtactgt	7880
cttttaggaaa	actctccagaa	gcaaggaaaag	ctactgttgg	tgtactccagc	tgttagctgcg	7890
agctctctacc	agataaattg	tgtccttttca	cttgttccaa	gtttttcttta	ggtacatcttc	7900
atgggggaaat	ctaaaggagaa	agcaagcttaa	aatacaaaata	cagctacaaa	tcaaaaatca	7910
agatcgtatt	aaaatagctt	gtaaaataca	aatcaaattt	aaaaataaaa	ttcctataac	7920
tcaagtataaa	aggaataaat	agaaaaatcaa	acaaaaacaaa	taatgagtaa	gttgattttaa	7930
aaacaaaataa	aatccactta	tcaaaaaaag	ccaaagcctgt	ttatcttctac	tgtcgaattc	7940
agcagacata	tataaaaaac	tggtagtatt	tttttttca	ctatgcataa	ataaaggatg	7950
atgatctattt	caaaaaacaa	tagatgttaac	atatacaaat	aacagataatc	acaaaactat	7960
aaggtctctcc	tcatagagact	actaaaaaca	tttgagaac	tttgacattt	cttactgata	7970
tccctcttcaa	acaaattagg	cagagcagag	ccagatgggt	gaataggaga	caaacacctat	7980
taaaatgaaa	acattatcag	atagcacctc	tgtaacacaga	aaaaaaaaaa	aacaccttca	7990
aaagaggcac	ctaaagagata	ggtcagacaa	atagtactatg	gtttttaactt	catatccctg	8000
ctccccacac	tbgagctgtg	gcoatgatgt	tcttgagctc	cttgacactat	cccttccccct	8010
gagcaacatg	caatttbtgag	gcaattgaaca	acagagcctt	gctttaggca	ctgagggagg	8020
gcccaaaccaa	actcagctaa	cccttctccca	aatgtctgtg	ctgttttagag	agaaaggaaa	8030
gtcaggttatt	gctgacccga	gggtgtctgaa	tggagggagt	attttaaacca	atgtgagcca	8040
gtcacctaac	atgtctttgtg	lctctaaaata	atcaagttcc	cacaaactctt	gccaccttagg	8050
tgcacacata	tgtgagctctt	agtgctgaac	aactagaagg	acagtctagg	acataaggagc	8060
ccagaatatt	tcagagacac	caactgcacc	taggctcaga	sactatggac	tggtgggaaga	8070
			agctgaggca	ccaaagagca	tgtctgcctc	8080

accacacccc	taaccccagg	cttcacattt	cacagctcca	aaagaaaccc	cttcctcttg	8460
cttgaggaga	ggagaggga	gaacggggaa	gaatttgtct	tacatcttgg	atatacagctc	8520
agacaaagca	ggataggcca	actgtcctaa	gaatgaggcc	cctgctttaa	gcccctagctc	8580
ccagatgaca	ttcttgaca	tacctgaac	caaaagggaa	cccaatgccc	tgaaggaaat	8640
gatgcagttc	tggcagcalt	caccagccct	aactgaagag	cccttggccc	tcaataaacct	8700
cgagtgtatc	ccagatacta	tgttgagggc	cttaggtgag	cccttgagac	tgtctggctt	8760
cagggtaccag	catgggcaca	ggggatagag	aaccacctgg	gcicccaggg	ccccagcttc	8820
ctggacttgc	gcatttttgg	gcatttttgg	acataccatg	gaccagatgg	ggccagcttc	8880
cccagaaggg	tgaatcctag	gctagccagg	attaccacca	aactgactta	ggagcaacta	8940
aaaccttaagg	gaacatcagc	agtgtgtctg	cagtaactct	catggcctgg	agggtgttta	9000
gaacctaggg	tgaggctctc	ctgacttttg	aaaggggagg	gaacagttag	gaggatttct	9060
ttttttattt	ataccttaag	gtttagggtg	catgtgcaca	acgtgaaggt	tagtltacct	9120
tgtatatact	tgccatgttg	tgtgtgtgaa	cccagtaact	cgctcahtaa	cattaggtat	9180
atctccaaat	gctatccctc	ccccctcccc	ccaccaccac	ccacaacatt	ttcaacttga	9240
atatgaactg	cagcccgagat	acagtaacct	ataacatcaa	gcagacatct	aaggtttttg	9300
aaactgggtc	ctctggaaac	accttggtcc	agggggccctc	atcactctga	atbctctcag	9360
atctgtgcca	agacactcaa	tagagtaccc	ccaggaagtc	gcaagaacca	ctgcatttgt	9420
gggattttga	ccacctgtaa	agaagtttaca	gcttaggtca	caacacccaa	atbctctcaa	9480
acatgtggaa	catcttgcca	agaaggatgg	ttacaattaa	gcccagacag	tgaagaaaaa	9540
taaaataatt	ttaactcttc	gtccccagac	acagaagaat	atctgtctag	atbaagccca	9600
tcacggaaaa	cccgacotca	ccaaatgaac	taacaaagc	accagggaac	aatcctagag	9660
aaacttgagtt	atgcaactct	tcaacaacag	aattcaaaat	agtttttggg	aaagaaactc	9720
agaacaaatca	agataacacaa	gagaaaggaat	tgtgaactct	atcagataaa	tgaacaaag	9780
agatttgaatt	aatttttaaa	aatcaagcac	agtttctgga	gcgaaaaact	ccaattgaca	9840
tactgaagaa	gatatctaac	gtgctattct	ttaatagcag	aatagatcaa	gcagaaagaa	9900
gaattgttga	gcttggaagc	aagctatgtg	aaaatacaga	tcagaaagag	acaaaanaat	9960
aaagaatttaa	aaaacaatga	gtatgcctac	aggatctaaa	aaataacctc	caaaaagcaa	10020
atctaaagat	attnacctta	aggaaggaat	agagacagag	ataggagtag	aaagtttatt	10080
caaatgggata	atccacaaga	acttccaaaa	actagagaa	gatcatctata	tcagggtata	10140
gaaggtttata	ggatgccaag	cagattttaac	ccaaagagaa	ctaccctcac	tcactttaat	10200
atcaaatatt	ctaaggtcaa	ggataaagag	actattctaa	aatcagtaag	acaacaaagaa	10260
taaaatacat	accaatggagc	accaatacat	ctggtagcag	gctttttaga	ggaattctcta	10320
caggagtgat	atgacagaaa	ctgacagaaa	ataaacgttt	atcctagagt	agaataactct	10380
gtgaaaaat	cccttaacaa	taaaagagaa	ataaagacat	tctcagataaa	gcaaaaggtg	10440
aggaattttta	ttatggcaga	cctgtcctac	aagaatatgct	aaagggaaata	tttcaatcaa	10500
aaaatttaatt	tcattgaacaa	taatcacctg	aagacacaaa	tctcactggg	aatagtaagt	10560
acatageaaa	atacagataa	ttaaaacact	gcaactgggt	tgtgtaagct	aatatctcaa	10620
ctgaaagagc	tcaataatga	actaatgaaa	cataataact	acagattttc	aagacatagt	10680
ctgatacaata	agataaaaat	agaaacaaca	aaaaagtgtg	acagcagaag	gaaatctaa	10740
gtggagagta	tttatagatt	ttctttggct	tgtttgttta	tgcacaaact	gttaagtgtg	10800
ttctcgttta	taagatagta	tttgcaatcc	ttatggcaag	ttgaaacaaa	gaattctaga	10860
atctggaaat	taagaatat	gccccgnaat	gcacagtggg	tcaatgaaga	aattaaaaat	10920
ttttgtgaaa	caaatgtata	tggaaacaca	aaactatgg	gatatagcag	tttttagtacc	10980
aagagaaaaa	tttatagctta	taagtgtacta	cataaaaaag	aaagggaaaa	cttcaaaaaa	11040
acaaatttgg	gattttatgt	aaagaaactg	aaagggaaag	gcaatccaaa	ttcaaaaatta	11100
ttagaagaaa	ataataataa	aatatcacag	cagataaaat	tgaatttgaa	atgaataaaa	11160
tcanaagatc	aatgaataac	aggttggatt	tttaaaata	laaacatgct	gactcaactct	11220
tatcagactc	aagagaaaaa	gagtgagaat	tcaataataa	aaaatcagaa	atgaaagaga	11280
aaacttccat	ctgatctctg	agaaattcaa	agaattctta	ttggccacta	tgtggaatga	11340
tattccataa	aattggaaaa	tctagaagaa	atggacaatat	tcctagacac	ataaaaacct	11400
ctaagattga	agcagaagaa	aatccaaaac	acacacagat	caattattta	tacaagctat	11460
gagatcaag	ccagataaaa	aagctccata	gtaaaagaaa	gctcaggaca	tattggcttc	11520
acttgttgat	ctctcctaac	atttaagaaa	gaactaglac	caattctcat	ctcaactctt	11580
tgaaaaaatg	agggggaggga	ggagcaaaata	cttccaatgt	gaggttaata	ttacccctgaa	11640
agaaaaatca	gacaaagaca	cattaaaaaa	agaatactac	aggtcaatat	ctctgacaaa	11700
tgttaattga	aaaaattctc	acaaaagaa	agcaaaccaa	tttaacagca	tactagaag	11760
atcatccaac	atgacccaal	gggatttttc	cttgagatgc	aaagtggct	caacataat	11820
aaactcaatc	atgtaataca	tcataccaac	acaaatgaag	atataaaca	catgattatt	11880
tcaattgatt	ccaaaaagga	atttgataaa	atccaaatct	cttcatgata	aaactctaaa	11940
gaaaaactga	gatagaagga	acacacccaa	acataaatca	agctcgattt	gacagacaca	12000
cagctactat	caaaactgaa	ggagaagaatc	tgaanaaatt	tcctcaaggl	actgggaact	12060
acataagcata	cccaactctac	cactgttatt	caacataata	ctgggaagtc	tctctacagc	12120

aggttagacaa	gagagggata	taaagggtatc	caaactgaaa	agaaagaagc	caaattatct	12180
tgttttgcag	atgggtataag	tlttttttoga	taaacgttaag	gtaatcacc	gaatcatatt	12240
agaacttgata	acccaatcca	gtaaaagggtc	aagatataat	ctcaacataa	aaaacagta	12300
gcatttgtat	atgttgacag	caacaalct	gaaaaaaatc	ctcaaggtaa	ccccattac	12360
agtaaccaca	gataaaaaba	aataattaga	tatlaaccaa	agaaagtcaa	gatctctata	12420
agaaaacag	taaaaacacta	aaaaatagaag	ctgaaggagga	cacaaaagata	aaaaaagata	12480
ttctcatgatc	atggacttga	aggatcaata	ltgtttataat	gtccalacta	ccccaggaca	12540
ctctacagatt	caagaaaatc	ctatgaaatc	accaggggaca	ttcttcacag	taattagagas	12600
aaacaatcct	aaaattttta	tggtaccaca	aaagctaaag	gtaccacaaa	tagctaagcg	12660
tatctcaagc	aataaaaaaca	aaactgaagg	aataacatta	cctgacttca	aattatacta	12720
cagagttgtga	gtaactaaaa	cagcatagta	ctgggcataaa	aaacagacata	cagtcctaag	12780
gaacagataa	gagacaacag	aaacaaattt	acacatctac	agtgaattga	tttttgacaa	12840
agggagctgt	tggaaaaagc	agtcctctca	attaacgggtt	ctaggaaaac	tggattttca	12900
tatgcagaa	aatgaaaacta	gacctctatg	tttcaccata	tccaaaatc	aaatcaaatg	12960
gataaagact	taagtctaag	acctcaaat	atgaaacttc	taccagaaaa	catgggggaa	13020
aatctcaagg	acttttgtct	gggcacaaat	ttcttcagca	ataactcaca	agcacaggca	13080
agcaaaagct	aaatggcaca	atgagatcac	atcaagttaa	aaatgttctg	cacagcaggca	13140
gcaccaatga	accaagttaa	gaataaacac	tgagtgggac	aaatatttgc	aaactaccac	13200
ctcgaacagg	gattaataac	cagataaatt	aaagagctca	aaacactcta	tcagaaatca	13260
ttcataaatc	agctcaaaaac	agggcacaag	stctgaatat	agatttctta	aaaggtatca	13320
ttcaaatgaa	aaacagacat	gtgaaaagat	gatcaacata	actgatcacc	agagaaatgc	13380
aaatcagaaa	tcacaglgaga	tatcatctca	ctccagtgaa	aatggcttat	ctcgaaaaga	13440
gagaaaaata	cagatgtctaa	tgaggatgtg	gagaaatagg	aaatcttcta	caactgttgc	13500
gggaagtgtaa	ctataataca	cnactatgga	gaacagtttg	gaggttttct	agaaaaactaa	13560
aaatttgagct	accttatgat	coagocattc	taagtctgtg	tatacaacag	cagtgtaacg	13620
aaatcagctg	atgggaagcg	tatctgcaca	ctcatgttgc	ttgcctcac	gtatcaaatc	13680
gctacagatt	ggaaagccacc	aaagtgtcca	tcaaacagtg	aatgaataaa	taaatgttgc	13740
ccacacataca	caatggagta	ctactttgcc	ataataaaga	atcattttgca	taactttgca	13800
acaaactgga	tggaactcga	ctacttttgc	ttaagtgaag	ttagcagcgc	acagaaatac	13860
aaactctcaca	tggtctccct	tatctgtggc	atctcaaaaat	gaactcttgc	gaactcttgc	13920
actatagaag	ltgaaggatg	gttactagag	actgtcaagg	gtggataggg	ctagaggggg	13980
agatggggat	ggctcaatgtg	taagaaaaaa	aatagaaaaa	ataataaagc	gcctactatt	14040
gcagccacaa	tcggttggtct	atagtcaatg	ataacttact	gttacatttt	aaaataaact	14100
atcacgtatt	attggatgtg	tggaactcaa	aggaagagata	cttgaggggca	tgtatacccc	14160
attcccagct	atgtgtccat	ttcacattgt	atgctctgat	caaaaacattc	taagtactcc	14220
atcaatcacat	acacactact	tacacctatg	atgtgcacag	gaaaatttaa	aaacatattg	14280
atagaagaaa	agtcacccaa	tacataaat	agcatatatg	acaaacccat	aggttaacttt	14340
tatatctccat	ggctgtccat	acaattgttt	atlggcatgt	accagagtag	aataaaaacc	14400
tactagatgat	tgaaagaagc	agaaaatacg	goccatattt	agaaagaaaa	gactctccaa	14460
taatgtctaaa	gcacaaacat	atagttaata	tagtaaaaaa	agcaaaaact	ctctccataa	14520
ttttaaataaa	ctgcacaaaa	taagacaaaa	atcttcaggga	aaatatatac	gttaattgtg	14580
acagagaggtg	gaatttccag	tgaataatga	caacttagcca	agtaataacg	gttactgaaa	14640
acattttcag	ttctaatgna	attttaactc	atctgttaag	agttttctga	aaaactttat	14700
aaaagcttgc	taattttttaa	aaactatgtt	agttatttta	agatgggtgt	ttttgaaatt	14760
ctataaaaaa	ataactcttt	tgaaaaat	tttatttttc	caaggtgtcc	aaacttttgc	14820
aaactctgtg	atttggtcga	aatatgggtg	ataataaact	ttaaaaatac	gcacaggggt	14880
tttccaaagt	tttttgtata	aaataataac	agaaattact	gaccaaggag	cttagtgaag	14940
acacccagga	atccactaat	attgttaagt	gtgctattaa	caaaaaaaga	ctcagccctc	15000
tcatttaatta	ctttttaaag	tatagcatag	caaaaaaccc	tgcatatcca	aaatgacaca	15060
cnaaagtaag	taggttctcc	agcggttatt	taggagttta	tatgacttta	tgtatttagt	15120
gatagattat	atattttttc	aatattccgt	gaatataaac	taaatatacc	aaactgaaac	15180
atgctctcata	cttttctctt	tttttacata	aaattttctc	tatggaataa	tttttagatt	15240
acataaaagt	tgtaaaaagt	atcagataaa	ggtcttttgt	aatctgaaaa	tcataaaaac	15300
aaagatttaga	tttattacat	gaattgtcaa	tgaacttatt	ttttgttaag	taagcatatt	15360
tacaaaaagac	atttagcttc	cttttctgta	cttagttaga	aaatgtatc	tattattatt	15420
aaatagaaata	tatttagctc	gcgaatttga	aatatataat	attatcaata	ctctagtcta	15480
tatttatlaag	tgtgaacacc	atgctgtgaa	atagatatga	actgagctac	cttcagcttc	15540
actgaaaatt	tatacccttt	gaccaacacc	taaatgttaa	tttcttagat	ttccatcttc	15600
tgttaaccac	cactctactc	tcacctttct	tgacttttga	ttagatagca	taattgtccc	15660
aatlaagatca	tgcaggattt	ttcttttgtg	gaacttttct	tttagattgt	gtaatgattc	15720
cagattctctc	ccagtttttcc	ctattgtaac	aatgttcttc	tttttagttt	ttttttattg	15780
ctactgtgtca	ttcataccac	atattctctt	ttttcaacaa	tttttattta		15840

gcaaaataaaa	ttgcaratat	ttattatgta	aaacatatatg	tgttgaanaa	tgtatatactt	15900
agatagtggc	taaaatcaag	taataaataat	atgctttccct	tcacataactt	ctccatttttg	15960
tgtgtgtgtgga	gaotgcttaa	aaotcaacact	aagttagtttt	caagaataaca	acatattattt	16020
gttaactaaaa	gtccacatata	tttacaacog	attgcatgta	taagtgcaact	catgtgtgttt	16080
tgtctgtctct	atccacacta	acttaatgtc	ctccctgttct	attctatgtt	ctctgaaattt	16140
cagggatttcc	ttttttcaaa	gotgaatagt	attacattgt	gtatatagtc	ccatttttct	16200
ttatctatat	actctgtaatg	galacttaag	ttgattccat	atttttgccca	ttataaataaa	16260
tgtctgtaatg	aagatgggaa	tgacagataac	tctttgacat	actgtattct	ttttctltgt	16320
acataatatto	agtagtagga	ttactggatt	gatfataatgt	tctgtcttttc	atbttttgaca	16380
aactctatag	tailltccat	aatggctata	ctaataatata	tttccatacaa	caatgtgcgaa	16440
gtgtgtctcct	ttctccacat	gtttgataaac	acttgatgtt	tttttgtatt	gttgataaata	16500
atactttgtgt	gcoatttggt	ogtcttcttt	tgagaaatgt	coattccaggt	acatttgccca	16560
tttttaaaatt	ggtttaattcc	tttttattag	ccattgagtt	gagttccctta	tatattttga	16620
atattaaocg	tttatcagat	atatgggtgt	caaatatttt	tgaaatctat	gagttgtctc	16680
ttccactctgg	gcatttgttta	ctttgtctgt	cagaagottt	ttagtttgat	gtaatacaaat	16740
gtgtgtatttt	ttctctttgt	tgcttatgct	tggggaagcca	atocaaagaaa	tcatagcccc	16800
gaocaaatgtc	atgttattttt	ttctctttta	tttctcctta	gcagttttat	agttttcaagc	16860
tttccactgtc	agttctacat	atattttgag	tagtttttag	tgtgtgtgaaa	catgtggtaaa	16920
atttacaattt	tctatgtgtg	aaatactcogat	tttcccagca	agatgttatgt	aagagactcat	16980
tattttccctt	atgttgagttc	tgtctatcttt	tattgaaatt	atattgaaatt	ctattctctgt	17040
ttattgttgtt	cttgtttttat	gccaatgtca	tgtctatogtg	octataaatag	catbatatoca	17100
taatttcaaaa	ttttagaagtg	taatgcctccc	agcttttgttc	tttttaatcca	aaattactctt	17160
gaoccttgggg	atoccttgttc	atttctataca	tatttttgaa	ctgtttttcca	tttttccgtg	17220
aaaaaatgaca	ttagatttttt	gatggggagct	gcattgaaot	ottacattctt	tttgtgttaat	17280
atgaacacttt	tatccabattt	aaacttttgca	gtccctgaac	atgggctatt	tttctgtttta	17340
tgctgtgtctt	ttccaatgtt	tttcatcaat	attgtattgt	ttbaaatata	tttctgtttt	17400
agatcctttgt	ttaaattttac	lccaaattttt	atbtttttgt	gttatocgaa	aaggaaataga	17460
ttctttaaaatt	tcttttttcag	acagtttttt	gttagtatat	aagaaagaaa	gatgaacaaa	17520
cttccagctga	agaacacaaag	tgaaattttaa	tatccacalc	latggattctg	gtaattaggggt	17580
gaaccagaga	taagaaaglat	tttaaatcatt	tttgaaattga	agattccacac	tcagagctaca	17640
ctatcttaggg	gcacaaataaa	cacaaagaaa	tttcatgaat	catgttagtag	tttaactact	17700
aatagcaaacg	tttccattaca	cttttgacat	atagttgaat	agaataaata	agacaaatga	17760
gagaagaaba	tatttaatga	gcataaaact	aaagttaatt	atbgacatt	agatctagta	17820
tttgaatgaca	caacagggtg	actatagtea	aaagtataaaa	tgctagagatt	ttaaaattcaag	17880
agggataaatt	ggatttgtttg	taacacaaag	gtatgctcgt	atcaaaaatat	gatgaattacc	17940
tcatttaccoc	tgatgtgatt	attacacctt	caaaaaatgaa	aacatgtata	tttatgtacc	18000
tcatacatcat	atagacgtac	catatactca	tgtaaaatcc	agtgagaaca	acaaactttt	18060
gtttttccacag	atgtattattt	aaatttgaat	acccaaaatc	octgaaaataa	atatactttt	18120
atttttttcat	tatatattcaa	agattttacc	atacttcatg	gttcttgtagt	bctaaaatttt	18180
caaagtatttg	gaactttocca	tctatttoca	ggaaaagtggt	atgatttttga	actgttgggca	18240
cttctgtctt	aaaaataaot	agcttttcta	tatgtctgaaa	aaaaaagaga	gaattactcca	18300
ggggaaaatat	aaagtgtaac	tagaaactgt	ggagcactga	tcagagata	tcagagtgtga	18360
gataaaaatta	gggcacatga	caaagcactga	acaaacacact	acaaacaaoca	aaaaactctt	18420
atgaatctaaa	atacacagact	atattatatt	caaaaactag	aagtaaatatt	ttgtgcoatt	18480
cttttttttca	aaaaagacat	aartgtaatca	atatttttca	tttctataaaa	gtatocatttg	18540
aaacttccatt	tttactgatt	cacgttatata	tatccaatat	ctacacttgt	ataaacatttt	18600
caaatacaaa	ttttattatt	gctaatacaaa	ttgttttga	attttcaaaa	ttatcatatt	18660
ataagtgttca	tcncaaacct	taagaactat	ctaggtctct	agaaaattatt	tgctctaaaa	18720
tattataaac	tatagctatc	atgcttttaca	ttctccactg	tgcaacccct	ggtaactata	18780
cttltgataat	octagctgaca	tctctctatt	gtttttttag	ttccaaatat	aaatgacatc	18840
cttctactctc	ccatctctat	gagctcaggt	acttcaacta	ottaatatct	gcatgtttta	18900
atgcagcatt	tgctctttgt	lgtctgtgttt	tcttttttaa	ggcagaattt	aatgtattcc	18960
actgttatat	tgccaccact	agatttgccct	caatcatctt	tgacagaaac	ataagttttg	19020
tcctataatca	agctattgtg	aaacatccctg	caaaaaacat	gagngtgcag	atattttctta	19080
gacataactga	tttgttttct	tttgtttata	caocccagaag	tggaatttgt	tgatattgcg	19140
atagttcttat	gtttaaactt	ttgaggaacc	ttctataagt	tttctacatt	ggctgtataca	19200
atctacattc	ccaccocata	tgtaacaagt	tttctttttt	ttccactctt	accocacact	19260
tgtcatgtgag	cttcagtgaa	attattgaaa	tttttatggg	gacacacccc	caaaaagaaat	19320
cagccatttta	gaacacagata	actcatttta	ggcagagttta	agacaaattt	aaagtgtgaag	19380
ccacacagcg	cagactagct	acactaaatt	gtgagaaaaa	ataaattttg	cttccatctgt	19440

gattaaagat	gactgatgac	taagagcaga	atcaatagtc	aacaccataa	ttagttcatc	19620
ttacaaatct	tgatgggaaa	atcaatgtta	tagcaaaatt	tcattccagt	gagaccocag	19680
acacatgcac	ccagatggag	gttagtagac	aagagaagag	tgttttgttt	ttgagactga	19740
gtctgggtcc	gttgcccgag	ctggagtgct	gtggggcaat	ctcagttcac	tggaagctcc	19800
gcctgccggg	ttcaggccat	ttctctgcct	cagcctcccc	agtagctggg	actacaggcg	19860
cccaccaccc	cgcccgacga	ttttttttta	tttttagtag	agacgggtgt	tcaccggtgt	19920
agccaggata	gtctcgatct	cctgacctcg	tgatcctcac	gcttcggcgt	cccaagtgct	19980
tgggattaca	ggcgtgagcc	acgycgcocg	gocagcaagg	gaatagtttt	taacggaaaag	20040
tgtattaaac	aagtgggaat	aegaaacctga	aacatttctt	caaagatttg	taacaaagagc	20100
tgaacacatg	gtttatcagt	atgatcctga	atacaaaaaca	taatacaaac	aatggccatc	20160
caagagtgga	agtgggtcca	tgaagacaas	agcaggccag	tcaggagaaa	acatccatggc	20220
aacagcttat	gagatggcca	agccatttta	ctagttgagt	ctcggaaaggc	caaaagagaaa	20280
catttggctt	ttaagagaat	gttttgagaa	sgttttccaa	gcttttagcag	aaaaatgcc	20340
agggaaaact	catacagagag	ttctcttcca	ccagaacaat	gtcctcgtct	atctcctcca	20400
acagacaaaa	acaattttgt	gagaattttt	atgggaaatc	tttgagcatt	ctcacatllaa	20460
agctcgtggt	tgctctctcc	tgacttcttt	cttttgctta	attttaaaaa	attottacaaa	20520
gggtaccctat	tgttttcagtt	aattatgtga	aaaagactgc	ttacatcgga	tattgttcca	20580
gaaccatctg	gtcttttagg	atggactaaa	tggtctgtat	ctaactgttt	aaaagttgtgt	20640
tgaactttat	ggagcttatgt	ttasgaaata	aagtgttagtt	ttaaaaattt	ctttattttaa	20700
ttcaattttgt	cattgaatatt	tgggaagtgc	tttatatatg	catgatttta	tttcggagct	20760
tttaattctg	tctatgtatc	ttttttgtat	caggactaaa	ctgtctctgal	tattatagat	20820
tgtagtgta	atttgaacc	agagagcatg	atagttgtct	gtctctctct	tttttgcctt	20880
ttggaactgc	tttagctatt	tggtgtctct	tggtctatat	caattttaga	attttttttc	20940
cattttctgcg	aaagagtggt	tttagaatct	gacaataatg	ctatggaatt	ggagtgttag	21000
gtaattgaaga	caatttttata	atattgattc	ttttgatcct	tgagacaagg	acatcttttc	21060
atttatattgt	gttttcttcca	atttcttcca	tcactatttc	tattttttgat	gctatgttaa	21120
ctctcatctc	cttgctttga	tttagttcca	agtatattta	tgattagtta	tgaanaatga	21180
atcagatggt	tggtttcma	ttcttatttc	aatagcttgc	tgattgttga	ttacatrrag	21240
actgctctgt	ctctgtagatc	ttgtacocgt	caacttttact	gaatgggtta	ctctgcgaaa	21300
caaagtcttg	tgaagtccct	gggttttcca	tgatatataa	ggagcatcgg	ggatttccag	21360
cagcagacaac	tggtttctttt	ttcaatttcc	gctctagcca	gccttagcca	ccattttccag	21420
catcatgttg	acacataagt	gtgagagcga	gcctcctctg	tttttttttt	ttttctgcgt	21480
atagacataac	atgttttcaac	ttttcactct	tgagtataat	gtasatgtg	agccctgtgat	21540
catgatgcct	tattgtcttg	gggtaatctc	ttttatggct	aattttgtga	gaactttttat	21600
ctgaaagagg	tgtttgatct	gttaaatgct	ttttctgtat	ctattggagt	gaatatacaa	21660
tttttgcctt	tcattctttt	aattcgggtg	ggaaacagtaa	ttgattgggtg	tatatatact	21720
atctttacat	cccagataata	cattactttt	cattatggcg	aatgatctct	ttaatgttgtt	21780
gtcttccact	tgggaagtatt	ttgttgagca	tttttgcctc	tatatctcat	aagaatatgt	21840
acctataact	gtttttttgta	gtgtcactgt	gtggcttttg	tttcagtagt	atttttgaac	21900
tcataataata	aaactgagag	ttcactotta	aatttttgac	agaatttgag	aaggattagt	21960
gttgattctt	taaatgtttg	tggagattcc	atccatcatg	agccatgag	ttttttttgt	22020
tttgttttgt	tttttttgat	agagactttt	tattactctg	tcatttttct	tactcatctac	22080
tgttcttgat	taatttttgta	ttcatttatg	tttcagtaat	cggttgaggt	gttagagtgt	22140
tatgaataata	ttcttttcca	ttaggttata	caacagttat	atgttggaat	ataactgttc	22200
atagcggctt	ctctcgttgt	tttgtatttc	tggtcctatca	gttacaagtgt	ttccctgttcc	22260
gttttolaatt	tttttttgct	ctctctctct	tttttagtca	gctaaagggt	tgctcaacttt	22320
atcttatattt	ttcaaaagcca	acttctagtt	ttgtggatcc	tcattatttt	ttccagctgt	22380
ttttattttat	ttctgttctg	taccttacta	ttttttttct	ttcagtagct	ttgggttaat	22440
ttttttctct	attttctagt	ttcctgagat	acaaagttaac	ttttttttat	aggatcttca	22500
tggagtcatt	catatctcta	aacatccctt	tatactgctt	ttgttgcaia	ccatatgttt	22560
ttttagaagt	tgcttttcca	tttttgtttt	ttctcaagata	tttttaattt	ttccctttgaa	22620
ttttctcaatt	gcccacttgg	ttgttccgga	tcattgttgt	taattttccat	gtatttttga	22680
attttctaac	atttctctcg	ctattgtttt	ctagatttcat	atgaacatgt	taaaaaaatt	22740
tattgataatt	caactctttt	aaattttttt	aagacttggt	ttgtggccoc	acatatgact	22800
tatatggag	attatccctt	gtgtgttga	gaagatttgt	tattccactg	ttgtccaatg	22860
gaatgttcta	ataggtctcg	atggttccat	ttgtgtcaat	atagagtcca	agttccaatgt	22920
ttttattgat	ttctgtatag	actgtctatc	cattgttgaa	tggtgggttat	tgaggtccoc	22980
tactattact	gcattttctg	ctatttcttc	ctttagatgt	ataatgctt	gctttataag	23040
tttctatgct	cccatgttga	gtgcatacat	atttgcaatt	gttataactc	attttgtgaat	23100
tgaactcctt	gtataaargac	cttctctgtt	tttttttaca	gttttagactt	aaaaattcaat	23160
ttttagtcaat	gttagtatag	ccccctgctt	ttcttttgtgt	ttccattttac	atggaaacta	23220
ttgtttatct	gctatgctgt	gctatgggtc	gcattagtagt	accccttcaa	aatatgtgtg	23280

ttaagtcctc	atcacatagg	tgatagatgc	aggaagtaag	gaactttttag	gtgattagg	23340
ctatgagatt	ccaccctaat	acattggatt	agtccttttt	caagaagag	ctatgggaact	23400
cccttgcccc	ttccacattg	taaggacata	gtagggaagg	acocatagcg	gaaggacaca	23460
aaacagggag	gaagccctta	caagacatca	aatcagttgg	tatctlaagc	tggaataatct	23520
cagcctctaa	aactgtatga	ataaattttc	tattttttat	aaactagcca	gtttatggta	23580
attctttata	gtggotcaaa	tgtactaaaa	caatttagga	ataaogtat	attcccaaat	23640
gttaacattt	ctatcaacat	aagttgtcaa	ttataaocaa	tgtcoctttag	atttttgaaa	23700
ctctgcttca	ctcnaactca	gcaattttat	taaaocagga	tcactaacaa	ggagacagcc	23760
tggagtata	agccacotga	ttttatcacg	taagaagtaa	taaggtatca	ttaaataata	23820
tttggtgtgt	attattgata	totttatttt	tcacataatg	gctlcacctc	ctttatgagt	23880
ttaaaattgt	ccataatcaa	aatgatltta	cctaactagt	gctgattaaa	aagaattgaat	23940
ataanaatta	caatttcagaa	ccttactatt	gaaatttcca	aaactctctc	actccaaaaa	24000
tactttaagag	gctatttgat	gttaagatca	ttactgtalga	aatctttatc	attctcaaca	24060
tctggcttct	tgtctgttag	acatcattat	tttaaaatna	atttgtcttt	tgtttccaaa	24120
gtgatatagt	ttaaaagtag	aaaaatcaga	ggataccgat	atatacaaaa	gaattaaacc	24180
ataactttta	ccctcagtat	ctctaaatac	acacacacac	acacgcacac	actcacatat	24240
ctatcacctc	atcacacac	acacacacac	acacacacac	ttctctatag	ttttgaattt	24300
actggccaat	ttttttctat	aaacattaaa	tcagggccaaa	agtatcatgt	ttctatgttl	24360
gcaagtggat	gcattgcgaat	gagcatgttta	taactgtatc	tgtgtttttt	tttttttgat	24420
gattattttg	taattatttat	ataccctatt	acgtttttaac	tcctctttat	gattagtgtg	24480
cttatatcag	tgtgtgatag	tgacatcttg	tagaagtatc	tacattttcat	taatttttgt	24540
gcattttatgt	attgatatac	cttttggctg	atttatgtat	tgataaatag	caactactta	24600
tactctctat	ccaacatgag	ttaaagacttg	acttgggttt	tacatctttg	taaagtgtata	24660
taatttttga	atcagagaca	atgatatgct	tgcacttttc	tgtaaaacag	tgagcctcag	24720
aagctgtgga	gaagctgttg	ggagatttaa	gagtgatgaa	cagaaataaa	gctctgaaaa	24780
tgtcgctcaa	ttctctgcca	caaacatttt	atgaaactga	cacaaacgtt	agttttccag	24840
ggtttacat	gggtgtttta	agaagagagc	cccggtcttc	agcttataat	taaatatttc	24900
caaatattatc	caaaattlla	cgtatgaata	aaaaaggagt	aaacaataca	tgattgtatc	25020
acttcagaac	tgtatttaata	ctaaagtctc	gaataaaagtt	gtgcacttta	tcgaacttga	25080
tactottttg	caacaagttg	atactccagt	ttccactccc	aaactgttgt	tcgcaalggt	25140
tgtgaagctg	atgaaaagagc	atatcccgct	ttcacacaca	attcaactgt	ttccacttgt	25200
ctcgaataaa	tttactgttt	ggctgtccac	cttaagtcta	tgtttataatt	ttccataatt	25260
tctcgggata	ttcacacagg	attctgaaaa	aaaaaaacag	aaacataaaa	caataagtag	25320
taatgcaaat	ttcatagact	ttcaggtttt	caagtagaat	gttatatgat	ggttcagga	25380
tattttctca	aaacactatc	caaaccaact	attgtagaac	atcatattga	tttgaataaa	25440
cttagaatgg	taatcgatgt	gaaaatgggg	ttcgaltttt	aatgtatgag	aattgggggt	25500
gtatltatca	tgtaltcatta	catttttagga	catttttagga	tccttgcgtt	ttagaactta	25560
ctattgtctg	ttttgtattaa	gatatttggtc	aaagagtaca	aactttcagc	tataatattga	25620
ataagaatac	ggaatcaaac	atagagatct	agtgataatt	agagcttaata	attatgtattt	25680
gtttactttga	aaattggttaa	gaaagcagat	tttaagtgtc	ctcacacaaa	acacacacac	25740
acatracctca	acaccgccct	acacccaatg	ctaaagcatag	gtgatgaaga	atgtgtctaat	25800
taattttgtg	taattctttgt	agcataaata	tatcaaaaaca	acatatgttc	aaacatcaaa	25860
ataatatcttt	atttgtcaac	taaatgcttt	aaaataaaaat	ataaatataa	agagaaaaaat	25920
tacttttttt	tgtgtttttt	ttgagacgga	gtctcgtctt	gtcacccagg	ctggagtgca	25980
gtggcgcgaa	ctggcgctcac	tgcaaccctc	gtctccgggg	ttcccgccat	tttccctgct	26040
cagatccccc	actagctggg	actacagggt	cccgctcacca	tgccgggtat	tatttattatt	26100
tttatttttt	agttagagagc	gggtttccac	gtgttagcva	ggatggtctc	taactctcgt	26160
acctcgtgat	ttgcgccctc	cagcctccca	aagtgtctgg	attacagggt	tgagccaccc	26220
caccagcccc	taagaagaaa	aatttctaaa	ctttactttt	tgacagaaat	atttggtagg	26280
caagaaattca	gogaatttgt	tgtttcaata	ctctgtgata	ttttgttcca	aacagtgaaa	26340
tactcagact	atccagagaa	tttttccaga	acgttgataa	ttaaagtaact	tacgttaagca	26400
ttttgtgtgt	tctgacactt	gtccattttc	acagtgtatt	cgctgtttac	cctcaggttg	26460
atacaagtc	tggaactggt	actcaactga	tgaaagttag	agacagggaa	acaaagctgga	26520
tgaagcaatg	tcctccattgt	caataggttg	agggggccca	cattttcccg	tagaattctaa	26580
aaaacatcat	ttcatccatt	gattttgtgt	gagagcaaat	caaaatacaa	gttccaaaaa	26640
ggcaaacgca	aaccagcac	tgtatataat	atcaacagtt	ttgtgatttc	tggtgaaaga	26700
aatgagctct	ggaagaaatt	ttaacctttt	aaactgaaag	taatatattt	aggttctttt	26760
ctccgtactt	aaagaaacaa	taaaacatta	acaaatctg	ctcgttatgt	tagacaggga	26820
tttaagaatg	ttcttccgaa	tgaatacatg	ctaaacatag	aaaactatga	caaaaggaat	26880
ttcttatctc	attattcgaaa	aattcccatag	gaattataaa	atggaaaagt	atgacaaaaa	26940
ttttttaaaa	acaactgaata	tacttaataa	tacatggggg	gctgcagacg	aaataaatcc	27000
atgacactga	acatacagca	atataaatta	cccaactctga	aaataaactg	aaaaaaaaaa	

actgaactga	gacattcaga	aaaatacaac	aacaantaat	gcogagtcgag	aaaaagagsg	27060
gaagagabat	tgggctlgaa	aaatgaataa	atanaatgat	gcotgaaaaac	tccccatttt	27120
gaccataaag	tataaaccta	tatttaagaa	gctgagtgaa	ctccaaagag	gataaaaaaa	27180
tgggaattta	taccaatata	cattaaaata	aaactaottt	ataaaaaagaa	gataaatacct	27240
tgaagaacac	tagacaaaaa	ctatgctttt	ctctcagggg	atcaacacatt	caaatgatgco	27300
tgaatttttt	acttataacc	atgtggcgag	gttttcaagt	gttcaaaagaa	ctgtcaactc	27360
caaatcttgat	atccagtgac	acgatctttt	acaagttaag	ggatcaatcac	agacattcttc	27420
agagaaaggg	ataccaaagg	aalttgctct	cagtagacct	atgcctaaag	ataacttaaa	27480
ggaaattcttc	aaattaaaaa	aaaacagata	aaagaaaagag	cttgagagctt	taggatcctg	27540
tcatatagctt	aaastagaat	ggataaacag	aggagtcact	ataacaggat	atctttttccc	27600
tcatatagctt	tttcaattat	gttogatatt	tgaagcaagt	gagtttaata	tggagctcaa	27660
tgtatgogaa	gaataatact	gtggcattta	tacttacaac	gtggagagtg	taaatgtgctc	27720
tsoatgaaag	taagggtttcc	atattccagt	tgtagatitaa	aatgtcagtg	ccagtagaca	27780
gtaatatatt	attacatata	tagtattagc	tagagcaaca	acttttlaaa	aggaggagaa	27840
aagctatata	aagggtaga	atggaaaaca	atacatatga	atcgaaatta	atctccclaa	27900
taatttccct	acagggaaatg	gaggaatagg	gaataggac	tgaaccaccg	aggaaacagg	27960
csagaacaaa	acaggacagag	agatttaagt	ccatatatct	aataattatt	taagtgtaa	28020
atggtccaaag	tgcacagatt	aacaggccat	gaagggatga	atggatatgt	aaactgaccc	28080
caactatagt	ctgctacaaa	aaactcactt	caataataaa	cataggtaga	gtctaaagtaa	28140
aaatgtgaaa	aaaaaaatca	agaaaaactc	taattitaaa	acstaagggt	gagtagagata	28200
taatttccct	ttttgggttc	cottatttcaa	tctctttata	ttagaatgac	ccaggagctat	28260
gtgctcggag	tctcttttaa	aaatcacagtc	agtcacacac	ctttaaatat	ataccatata	28320
ctgaagatgc	ccacatttat	atacagctct	atgatctctc	tccaactgoc	tattccatatt	28380
cttagaatgc	acatcaccta	tggctgtcaa	atgcacataa	tgatcttttt	atbacagcta	28440
tcccgagaa	ggaaactaagt	ctgttaatgc	ttaaaaagta	ttgtttttca	ggttccaaact	28500
ctcaatttgg	togaattctt	ctggaaaata	ataacaccta	ttaacttgrgt	ttctgtcaaa	28560
ggaaagaattg	aaatttaagc	accatcagtc	atatttatltg	catlttgaaa	atctatfaat	28620
aaaaattgact	tcatitttgt	taaatcaaca	tatttttaac	ctgtctatct	cccccacaaat	28680
gtcaaaagaa	atataaatct	ctacccttgc	atcgaggtgg	ttccgtccag	tttccattta	28740
acaacatcac	tctctcatcc	ccaaacatttt	catagaggct	ccclacatga	tacagtactc	28800
tctccacaga	tgggacattta	ctcatctgtc	tcgacacttt	ataagcattt	tgaactgtgg	28860
goggatctac	acaggaggtg	tctgaataga	aaaaaaagaa	gtgggtccac	ctagtgtttca	28920
ttttgagtag	caaatcaact	gataacagtt	acaaatatac	ttcaagacga	attttaaaata	28980
agttagacaat	ctcatcaaat	atltttgtga	tttttaataa	tttaaatgta	atatcgagga	29040
aaagacatga	actatatttt	tgtaaaggtac	aagcgttgat	gttttaaat	tcttctcoat	29100
ctttctgctag	aaactctgata	gacctttatt	tctcccttct	ggaagccagt	gtaaaagaaa	29160
gttttctcgg	atactctctc	ttgagtttga	gtaaaacaaat	attaccagtt	ctattttattt	29220
aacatttatc	tataaaatgc	aaaaagtcag	cataaaataga	ttaatgtgata	ccagatttttt	29280
gttctcaact	atctcgtcta	lacatttttag	ctcttlaaaa	ataaactcaa	attaggcattt	29340
tcttagcgaa	taagcaaaag	atataaaaca	catlttgaaa	ataaccacag	ttaaaaagggg	29400
gaagaatggt	taatacaagg	atccaaatgc	gagatgtgga	aaaaatttttt	taaaaagcctc	29460
ataatataat	aaataacotc	agataattta	attgccaatg	ataaaggata	ttatgtcgga	29520
caatgcacaaa	tccatcgagc	agtttcatat	ccatgtgtga	tgaatagact	atagcaatgc	29580
tctctactgc	gaagtgctaaa	tagaattccc	tggaggtgtt	ggtaaaaacag	tttccagggt	29640
ttactttgag	acttttgtat	ctggatgtct	agaatgagct	tacggaattt	tttttccatt	29700
tcaaaacatc	tccaaagaag	tgatgatgct	acgggtttag	cgacccacact	ttgagaacta	29760
tttagctaaag	attaatcctc	aaatactcag	ttccattctt	ttatttttag	ctgacagact	29820
actttgtcct	gcgcataaaa	cttaattttat	gtccatttta	atgatgttag	agacaattct	29880
ataatttttt	cccaaaacac	tctatataaa	taaatgtgac	tttatatttt	attattttca	29940
ggtttatttta	ttttttttag	acggaaatctc	actctgtcac	cctgggtlga	gtgcagtgcc	30000
ecgatcttgg	ccacactcaa	tcttcatctc	ctgggttctc	gcgattctgc	ctccctagtc	30060
tcccaagtag	ctgggaactc	agatgcatgt	caccatgccc	cactattttt	tgtatatttt	30120
agttagagacg	ggtttttacc	atgttgccca	ggctggtctc	gaactcttga	ctcgaagtga	30180
tccgcaccac	tgggctctcc	aaagtgtctg	gattacaggc	gccagccact	gggctggggc	30240
caacacattat	ataaaattat	tttgaaattt	caccaagata	ccctgcactg	ttggccttcc	30300
tgtccatctg	ctataatagc	atgtttacatt	actggctcca	tccattttgt	aatatgttgc	30360
acaagtgtaa	gtcatcttgt	caccogcctt	atacacatcc	ttctctctct	ccatggggtat	30420
ggcatlttca	aagctaggtta	aactgagaca	atctgtttct	gaaataggaa	aaatatgtat	30480
tgttctcgca	aatcttttaa	aataggttac	atacaatata	tglaattggat	tctaaatag	30540
cgtatatag	aatcaatgaa	tactgtacaa	catltttctc	ataactgctc	aaaatatatt	30600
agccattttg	tcttaatttat	atataattctt	tctaaattct	ttaaaaaatc	agatagataa	30660
tgtatagata	agactgaaga	aatatgtgta	gcgtgacaa	ttagagattac	acattttttt	30720

gttcacatta	tttttgtcca	tacttgcac	ctgatatgg	taggctttgt	gtcctcacc	30780
aaatctcacc	ttgaataata	atctccagg	gttgagagag	agacctgggt	ggagtgatt	30840
ggatcaatgg	ggcagtttcc	ccatcgctgt	ctctcagatg	gtgagtgagt	tctccagaaa	30900
tatgatgatt	taactaactgt	ttagsagttc	tctctccact	cactcctctc	tctcctgcc	30960
cccttgtgaag	aaggtgccc	cttccctctc	agcggttaatg	gtaagtttcca	tgcacacctcc	31020
tcatgcatga	ggaaactgtg	tcaattaaaa	ttttttcttt	tataaattctac	ccagctctcag	31080
gaaggtctctt	acagcagtg	gaaaaacggaa	taatacaccca	ccatatattgt	ggtgtgaatt	31140
ccaaatttttt	tgcttctatc	aaatgtgaaa	tacttataat	gatttttttaa	aaattttcag	31200
aaaaatgtact	tataggcaga	ttgttgataa	actgacagaa	gattgaaata	tgtggagatt	31260
gatgagtaga	ggcagctgtg	ccctaagAAC	agagatgaga	agctcgagaa	tatacatcag	31320
aggtatgctta	taacttcacac	aagatgatgt	gaaaatgaac	taattttggct	tataatgtca	31380
aatgttttttaa	tgtctacacg	tataatttcc	cacagcagtc	cagaatattc	aagaaaacct	31440
tatgaatttc	tagagtccct	gtttactttc	ttattgggtac	cacttacact	ttgaatgaag	31500
aatattttatc	atacatataa	taaaattcaa	tgccacatac	ttatgcatga	tgagggtgtga	31560
gacctatttt	ctcttaagca	ttttgcatt	gcaggcccat	caattccaaa	accttcaaaa	31620
cattttgtacg	taacttcttc	tccatactga	taactgtctg	actgtgagc	tacacacca	31680
tgagaaatct	caggttgagga	tttacaagg	aggcctaaaa	aaaaaagaa	gaattcaggt	31740
ctattctaact	ctaaatttta	attttatatg	ctgtttttaa	lattaaagt	ttttatttga	31800
aaataaaacaa	tacaggagct	actatgacat	cacagagaag	taacacaaat	gtttcctcaa	31860
actagcctctc	tggtgtctgt	ctgtctatcg	gactgtcacc	aactgaagaa	ggactgtgaa	31920
ctaaaaaatct	caatcacatt	cagaaagaga	tcatctatgc	ctggtaaaaa	atgcctctgt	31980
aaacttacta	gtgataataa	gatacacatt	gagagtttaac	gattccagg	aaacataaat	32040
attattgtagg	aaataaagag	gggcatttgtg	ggaagaatgt	aaagaaatct	tataaaacta	32100
gtgggcaagc	aaacatgaca	acttgacaga	caggttttag	lgtgtcccca	cccaactctc	32160
atcnggaatt	gcaattggcca	taactctcac	gtgtttgtga	tgggaacctg	tgggagaaaa	32220
ttgaaatcat	agggcgattt	ttcctctctc	gtgtctctca	tgatactcgc	tgagtctctc	32280
tgagatctga	tggtttttata	aggagctttt	ctgtctttgc	tttgcacttc	tcttctctgt	32340
catcatgtga	agaagagacat	gttctgttac	cttccacca	gggtttgtaa	tttccotgag	32400
ctctccagcc	atgtggaaatt	tgagtoaat	tacactctct	tctctttata	atlaagcag	32460
ctctggtagt	tctttatagc	agcatgataa	cagactaaat	cagtaaatgt	gtaactgaga	32520
gagtaggggtg	ctgtcttaaa	gataaccaaa	aatgtggaa	cagctcttga	aatgatgaac	32580
aggaagggggt	tagaacattt	tggaggggtc	agaagaagac	aggagaatgt	taaaaattgt	32640
agcaactctc	agggagtgtg	acggctcaga	agacagaagt	tgggaagtct	tggaactctc	32700
tagagggctg	ttgaaatggc	ttgacaaaa	tactcacagt	gatatggaca	atgaagtcca	32760
gtgaggggtg	gtcacagatg	aagatgaggt	gaggaaactg	tttgaaactg	gagttaaagct	32820
cactcctctg	atgcaaaag	actgttgga	tattgacctg	ccttagagat	ctgtggaact	32880
ttgaacttga	gagsgatgat	ttagggtatc	tggcagaata	aacttctaag	tggcagaagag	32940
ctcaaggagga	agcagagcat	aaaagtgttg	aaaatgtgca	gctttgtaat	gcaatagaaa	33000
ataaaactga	atttttctgt	ggagaatttc	aaagctctgt	cagaaatttg	aaacataaat	33060
aaggagagcaa	egtttaabac	caagaacaatg	gggaatatat	ctccggggcca	tgtcataggtc	33120
ctctcatgaca	ccccccacca	tcacaggccc	agaagcccaa	gagggaaaaa	tgggtttgatg	33180
cagcttgatc	aggtccctgc	tgctctatgc	agcctcagga	ctgtatccca	gtctgtctag	33240
ctccagctgc	ggcttaaaag	ggccaaacaaa	cagcttggtc	catgtctcca	aggggtgaaa	33300
ccccagagct	tgggtgatt	catgtagtct	tgggacctgt	gggtgcacaa	agtcagaagt	33360
tgaggttttg	gaactacaa	ctaggtttga	gaggtatat	gaaaatacct	ggatgtccag	33420
gcagaagtgt	gtctgcaggg	ggagcccaaa	tggagaacct	ctgtactgcc	atttagagaa	33480
ggaaatgtgg	ggcagagcc	ctcacataga	gtcccacag	gtctggagag	caggtggggg	33540
gtgagaacag	gacacaacat	attgaagccc	cagaatggta	gatccatcaa	tactgtgcc	33600
tatgttctgt	gaaaagccc	agacactcaa	tgcacgccc	tgaaagcaac	agagggggg	33660
actaagccac	atctgcacaa	ggctgtggga	gcccactctc	tgcatcagca	tgactcgaat	33720
gtgagcatc	ngtataaag	agataactct	ggaaatttaa	ggttaattga	tgccctatt	33780
aaatttcaga	cttccctcaa	gcabatagcc	actttgtttt	agccatttcc	tcccttttgg	33840
atttggaagca	tttcccaact	ccctgtacc	ccattgtgtc	taggaaataa	tcaactgtgc	33900
tttgattttta	caggtctata	agcagaggg	acttgacctg	tctcagatga	gaactttgat	33960
atgaactttt	gagtttaatg	tggaaatagt	taagattttg	aggactgttg	ggagagcatg	34020
atgtgttttt	gaattgttag	gacatagact	tgggatagct	catgtgtgaa	tgataggatt	34080
tgactgtatc	tccaaaccaa	taacaatttg	aattgtacc	ccataactct	catgtttttg	34140
tggaggggag	tcagtaggaa	gtagtgtgat	aatgggggca	gttaatccca	tgttctgtgt	34200
ctcaggatag	tgagtgtgtt	ttcatgagat	ctaatgtttt	lataagggcc	ttttccctct	34260
ggctcgaact	tctctctctc	gtctctatgc	gtttgctctt	ctccaccaa	tgaattgtaag	34320
tttcccaaga	ctctctcagc	catgcagaa	agtgagccaa	ttaaaccttt	tttgtatgt	34380
ataaactatc	cagttatggg	cagttcttta	tggagagaa	agaaataatc	atagagttgt	34440

aatttcaccta	gatattatttt	tttaatgcc	gaatcacaaag	tgactctctc	atgaacaaat	34500
aaatataaca	taaatagaa	agattcaalc	atgcacaaag	tttttaaatg	gtataactata	34550
taaatkatttt	tatatatgca	gtaatctcaa	ttattccccc	caotttgata	acaagagatt	34620
atttttatga	attctactat	aaacagaaat	tgagtattca	tattggccca	aootttcacac	34680
tgagggtggag	aactccattt	ccccatgtag	catgttcttt	catittctctc	agatatccctg	34740
aaacacccct	acacaagtata	actcaattta	gtcccaatgtg	caataactttc	ttgtggaagac	34800
ctggagatgac	taactgggtcc	gtgtttctatc	tgaggtgggt	gtgaacattgg	aattttttctc	34860
aaatgaagaa	tgaaatcaaa	agggttaaaa	acaaataaaa	tacttaataa	gaaatacaaa	34920
actaaatact	atttcggatt	ttaaagttag	tataatttga	acaaataaaa	ttattttaaa	34980
acaaaaacat	attagaaact	cgcaagata	tattccctca	ccatattctat	gtlaccatcc	35040
tctctgtccaa	taactctctt	cattcatgtc	ttgtttcatca	caaggattaa	aatatggatg	35100
aatggaaaatg	ttactctgca	tttacaata	attccaaaga	ttttggctgt	attttgttca	35160
aaaaactgaa	agagtgggtga	tgttataatg	tgcttaggtc	ctaatttatt	ttgtcaggat	35220
aaagttaatag	acacagagaa	agaaactctc	tcttgtttac	acgaagcaca	agagaattatt	35280
aacctctattt	gaagaataa	tgtaaaacaa	attatcacct	actgaaccaac	acagagtggt	35340
attgaactgcc	atttccatc	tttgcattga	atttctctc	cttccctgaat	tagataaatt	35400
tcttgggaaa	gaacagatac	tttttctcca	tcccgataat	tcagttgggt	tgctcatattg	35460
tgagaattgg	gaactctgagg	tgagggtggg	cataattgta	tttgtgccac	taaaaaatat	35520
tcaaaatata	tttaagtgtta	taataaaaaa	taaaaaata	aaatattaaa	atttgaattat	35580
tgtatgaaaa	ataattttata	tgattaaaaa	agaataaata	gaagatgtca	taactgtttc	35640
ataaattctc	acatatttaat	tatgatgttt	ttgtatgcaa	atattatact	tttcagctgt	35700
gttacaagtta	acttaaaaca	tagaactttt	ggcttgtatt	ctcatagact	tctctgtagt	35760
ttttctcatat	attcttttgt	taataaaatt	gctaatattt	tgtantaatg	attttaacta	35820
tttttagaact	tttagaattgt	tttaatggaa	tacacactct	taattacatg	catataaalaa	35880
aaattgacat	ctataactcaa	atgtatccagg	attggattaa	aacactcaaca	aattttctctc	35940
acttgggaac	tgtattagcaa	gaagttagaat	tatatgtagt	taataatacga	ttttgtractg	36000
acactttgacc	aatatagaaca	ttaaatatata	ccactagatga	tttatagtgt	gclttttaaa	36060
acttgaactc	ccccatgagc	ttttattttac	tagtcttaact	gtactgttla	gggatattta	36120
atttggatgtt	atgcacccag	tttaattgcat	tgccacagct	ggctttagtt	gtataaactc	36180
atataaagac	acctttgttaa	actcacagct	aagcttctgt	taaaactcgga	tacactcagaa	36240
atatctcaat	ttttctataat	atgaanaatga	agcatgtctc	gtttgactga	cgggggagtt	36300
tgtcaagcatc	tggggagcatt	ctataatccc	ttgtatttcc	tttctccat	catagtgtat	36360
gcctactctc	acctaaagct	ttatgttaatc	gtactatagc	aaatcatggc	aatgatattta	36420
agtgctctgac	atttttgttat	caacttcaggc	agacgtttcg	atgaacaaaa	cttcaattaaa	36480
ggtttatlgat	aatgtctgagt	tttctttttt	cgcttatgat	aaagtatttc	atattttatca	36540
aaagtatttt	gcttatttct	gtttttccat	attttgacat	gttlttaaca	ttctcatcaa	36600
ttttattttt	tttaagattaa	tggtcaacta	tttatgtctg	aatgattott	tccctctatt	36660
tttttgtgggt	gtacattctct	gtctaccttc	tagattgtag	tactctgttc	ttttattttt	36720
tttttgtttt	ttttctatgc	atgtttataa	gctaaaataca	tctctgtttc	agctgtatcc	36780
ctactgattt	aatgtgtctac	acaaicalta	ttattttaat	taaaagtattt	gotgatagta	36840
acaaatttaag	aaagagattta	tttaacattt	tgtagacatg	caataaaatt	tgtagaagaca	36900
tggtcccccag	tgagcgtcaa	ttctacattt	agtggttatg	catatttttt	ttttgtaaat	36960
gacacgtttg	caaggtagac	tatgtgctga	gcaattaaaa	aactgsgtgt	ttcaaaaatat	37020
tgaaattttc	ccagtattctc	ttcacaaag	aattaaatta	gaaaccagca	aaaactcactt	37080
actatagaaa	aaacaaatat	tttgaataa	aaacataaac	ttcatataaa	ttaactatca	37140
acnagaacaa	ccaaagacaa	atgagaaatc	atttcaaatc	aaataaaaaa	gaactctctc	37200
tctctgtctc	ccgacacata	gaacataaac	acacacacgt	gtgttaacat	ctgggacaca	37260
gctaaagagc	tgctttaaag	aatagagctt	taaaagttta	tatttttcaa	gtctgatagt	37320
tttcagacaa	gttttcaatt	ttccacctaa	galtgagaaa	agtgaaatta	aaactgaagt	37380
catcagaagg	agaagaacag	taaaatcagt	gaagaagaga	aaacggacaa	agaanaacag	37440
agagagggga	aaattgtgcaa	agctanaalc	agtaaaacat	atgaataact	aaataaacag	37500
agcaaatggga	gaaaattctaa	aggcaattaca	attgtttttt	gaaatattta	ataaaattga	37560
ggcaaaagta	aaaacaatga	tcaagattta	aaaaattgat	atgaagagg	atgaagagg	37620
cgagtgacat	cagcacagatg	ccagtatagg	agaccacac	tctccctctc	ccccacaggc	37680
acactgattc	aatgacgata	ctggaaacaa	ttccctttat	gagaaataca	gaaacaggat	37740
caaaagcctc	tgcaaccccc	taaaagtaaac	agagacattt	atattttgac	tgcttctctc	37800
tcagagaggga	aaagataaag	tgaactaaag	atctatcact	ctagcttttg	ggggagactc	37860
ctaaagtaca	ggtttctctc	tgtctgtgtg	agggacattc	atgtcatttg	gaaactatct	37920
agttttctctg	gggttaaaata	aagagctagg	cagggtatga	tgtcagcaaa	atggcagaa	37980
tggaagctcc	tgactctctc	tccacccaag	aatgtccata	aaacacatct	attcctaata	38040
gaaactctctc	tgaagaagaaa	tgaagaacaa	gtaaagggac	tctactctaa	cagggaacaa	38100
agacacacatt	ccacttganc	aagtaagaaa	agttgcacaa	caatggagca	tgagcccccag	38160

ccctgttccac	tgcaccacac	aattagaaaa	ggaatctcaa	aaacccagtt	tctcccttgt	38220
gagaaggtttt	tggatctcac	ataaagcacc	ctgtgttttg	goccttaatt	cactaatttt	38280
ggaagccagag	gagatataaac	acatgagagt	ctctctatgat	caacaggaaaa	atggttsgtat	38340
gtacacaggtg	ctgagaagct	tccagaacct	tcaattccctt	atagcagcttc	agagaaagggg	38400
ctgaaaaaac	agtcocccgt	tbtctocnag	aagtttttatg	atatatttttt	ccctgtgggtc	38460
ctctagaggtc	tgaattctaa	aaaactctgca	gtctggattc	taatgaaatt	gcatcaggca	38520
ctctctctagc	cggtttccgt	ggctcaccct	agtgatacat	ccaggtacat	taactcactct	38580
atgaacacac	tgttccacac	aaacttgagt	gocctaactt	ttacaacttt	cattcaggga	38640
ctgtatttcta	aagctctttag	tctctgggagt	agaggggcaca	aaatatatcc	agagttctatc	38700
tagaccactg	aaaaaagaaa	lygcgttttta	tatgggtgtg	taagcacttc	caggagcttc	38760
attgcccagg	agcagctgcag	agaaaagggtt	tttaaaatgc	agctccocctg	tttatctctca	38820
aaaagggtttg	tgtctatccat	caagtgctac	aaccttttaca	gttaacctcca	aaaaggactcc	38880
tctttaaact	cttaactgtc	acagcagata	ttagaaaaat	accagctctcc	atagatcgtca	38940
aagcaaatag	atbgttcttaa	aatgcttatgt	aaaaaactcca	ggcgctatgc	caaatgggag	39000
cagtgccagaa	aaggaaaagag	aaagttccaa	ttcctatttct	ctgtcgaaaag	ggcttagggc	39060
acatactctcc	actggctact	taatgaactg	gocctctatcg	agcttgcaca	gggtatctaa	39120
tgccgcacac	aaaaaataact	cttccocgag	ccaaagccaa	agtttggcac	ttcatgagtc	39180
tcgccccact	gataaattcca	gattttacca	ttcttctctg	accaagttta	gcatcgactt	39240
caagagttct	cacttcttata	gctccaactc	aagagatcgt	ctccttaaca	aactcactat	39300
ggagagttct	agagatctgc	attcctgaaa	ggocctacat	cacagaaattc	aaaaagctgy	39360
taatacaatg	gactcattct	aagcagatac	ctcttcaggga	tcagagcatg	cagctgaat	39420
attagtcacg	gtattagcca	cagatctctt	acttgggtga	atcacgagag	agagctgggag	39480
ataaacacgc	acacttcaact	tcaactatga	aatagaagta	agtaaataca	cagcccaagtc	39540
ttcctaatttt	tcagctacat	ctgagcctcc	tggctcctaa	ctbtttggct	ccaggtgcgtc	39600
aaaagatgtg	gcacattcta	acctccaggg	ggccacaaaa	aatagaagac	agcagctccgc	39660
acaagagctt	gagaggccaa	tgaaaactct	tggctggaaa	aattagtgcg	cttcttctcc	39720
cttatggaagc	gattctgata	agactgagaa	agggcattgt	cttatctatt	gcatagaaa	39780
actgtgagtt	aaagaaaata	aaagaaacag	atatcataac	ttcaaacaaa	gggtatctaa	39840
gagttctccag	aaatttgacct	gaggggaagt	gatataggtg	ttttactcaa	gaagaaatct	39900
aaataaatgg	ctcataaagat	acctcactgag	accagagagc	actatgaaa	acaaattaac	39960
tacttccaaca	aaagggttaga	aagttattttt	aaatcaccca	acaaaaatca	caaattttag	40020
ataactatata	ctgaacgggaa	aagtttttaa	gaggttatcca	tcagcagact	agatgaagga	40080
gagagaggaa	ttagtgaaact	tgaagtccaa	ttactgaaaa	tcacccaaatc	tgagaaccaa	40140
aataaacacaa	taaatataata	aaagtgaaga	tagcttaaga	tcacagatgga	atactacctt	40200
gtggaaataac	gtatgcatta	tcacctgttt	aaaaaacagaa	agaaacacaa	cgatcacagaa	40260
aatatatacca	aaaaaataat	gacagaaaac	ttttcaacaac	tgggaaagaaa	atagaacacc	40320
accocacagaa	atctccaaagg	aaatcaasta	agtttaatga	aagatagtcca	ctttaagaca	40380
taacacaaatc	aaattatcaa	aagttataga	ccaagtattg	aaaaaagcca	atgaaaagtct	40440
aatgggttaca	taaaattgaaa	tttccacaa	actatctagc	gtataactcaa	cagaaaacctt	40500
cgaggcccta	aggaagctgga	atgataact	caaaattctg	aaagaaaaca	actgcnaagc	40560
aaataattcta	gattccacta	ttctgtcttca	aaaacaaaag	agtgatanaac	gcttctctgag	40620
attgaaaaaa	agctgcagaga	gcataaggac	actttcctgc	cttacaagaa	atgtttaaag	40680
gagttctctga	aggttgaaaga	agaggatgct	atgaagatgc	taagtgataa	taagtgataa	40740
aaacttactag	taaaagctaa	cacaatatga	aattcaaaaca	ctctaatact	gtaattagcta	40800
tgggtaaatata	cagctagcat	aaaggttaaa	agggcaaaag	ggttaagaaca	ctgtgaagta	40860
caaaactttgt	taagagatca	gaattattga	aagatgcaca	gcattgtgac	aaatagaata	40920
ctcgggagga	gcagagctaaa	atttgatata	tttatatgta	atcaaaatcc	agtttccatc	40980
agcttaaaat	acctgttata	agatagtgtta	tgcagagctca	aggataacta	caacttcaaa	41040
tacotttttta	taaggatagc	tatgcagacc	taaggatgta	actacttaata	actacttaata	41100
gtatcccaaaa	agattataaag	aaaaaatctct	aagcatatgg	ctacagaaag	tcatacaaac	41160
algmataaag	caagcagaaga	agaaaacaaag	aaattttaaa	acaaccagaa	caacaattaac	41220
aaatbtaccac	taataaactct	taacctatcta	aaattacttt	aaatggaaat	ggaatatatt	41280
ctabatatcaa	aagggcataga	algactaaat	aatatacaaaa	tttaactcca	cttatataact	41340
gccttaccact	gacttacttc	actgtaacgt	aaattccacag	attgcagtgta	agggcatggaa	41400
aaatacacta	aaaaataaaa	actaaaagag	aacaggggta	gttatactca	ttctagacaa	41460
atagatagggg	ggaataattg	tataaaggta	caaagaaagt	tatttatata	tgatagtggg	41520
caataaagaa	ataatgaaac	caactatatt	aaactatatt	atgcacccaa	catcaagctca	41580
aagaaacatc	catatacaaca	actttaggaa	ctgaatggag	atgtggactg	caacacagta	41640
cagaaattgt	taataattgt	tttactttta	actttgagac	agatcatctga	gacagaaat	41700
		ttaataccaa	tttatccaaa	atagatttga	cagacatata	41760
		aaaaaacacat	attcttcttca	aatgycgaca	gaattatccc	41820
		gccaacaaaac	aagctttatct	aaattcaaga	agactgaaat	41880

catatcaagt	cacttttctg	acaacaaagg	tatgaaatga	gaatcaata	ataggaggaa	41940
ctatggaaaa	tttcaaatat	ggtgaaaatt	agacaatatg	ctctgaaaca	atcataaggg	42000
caaaacattt	taataaatat	taaaaatatt	tccagtaaa	gagaatggaa	aaacaaagg	42060
ctataatca	tgggatgcag	caaaagtgtg	tctaaagatg	atgttttttag	gaataaattgc	42120
agaaaacaa	aaagtggaaa	gaactcaaat	aaacagttcta	gtagtacacc	tcaaaagagc	42180
tcagagttaa	gaacaaaact	gtcaattcca	aaacttagtag	aaagatggaa	atcataaaga	42240
ttttttttta	agtaagttaa	atagagcccc	caaaagcagta	caaaatatca	atgaaaatag	42300
tacggcttaa	gtataastgag	aatbgacaaa	gottttaacca	gaataactca	aaagagagaga	42360
aaaaacaaaa	tggataaatt	gatcgaggat	gaaaaggggtg	atatatacaac	tgatatacaa	42420
ctagagaaaa	acagagtaat	tctagacaca	tagcaatttat	atgccacaac	atbggataac	42480
tcaaaagaaa	tccaagacct	catgaggcaa	cagctaatcga	cgattaatct	agagggaaat	42540
actaatacca	attcttctaa	gatgggtcca	cagatttaagt	cgtaataaaa	atgtttccca	42600
tcattctagt	ggcccaacat	aacgctccca	ttgctgaatt	atacaacat	tttagaaagg	42660
gaaaaactca	ggcaaaatcc	tactctggaa	aaaaattgat	gaggagatca	ttttctctaac	42720
cgaaaaaaat	tcttcacagca	cctgatgaac	ccaaaaccag	acaaggagcac	aacgcacaaaa	42780
gaagggagag	aaagtgtggt	cattaaaaag	atcattccat	atgatcaaat	gggttttaact	42840
aaacttctag	taacataggg	taacataggg	aaattagttaa	agggtgatgca	tcccattaac	42900
aaagggagag	taactaatat	gatcatttta	ataantctat	atagaatggc	taaaactata	43020
gaacttctag	aaaaaactgt	agaacatgta	cacttcaact	catatataata	ttakttgtct	43080
acttaaggag	ttataaacata	ttgaatgttt	gatagcagat	tagtttttgt	atgtgtgtgt	43140
aatgttgttt	ttctatccta	gactggcaga	cattggtaaa	aatatttgaa	cttagtgaggc	43200
aaggaacccc	ccaattggat	agcaaaatac	agatataaaa	ttatgagaaga	ctggaataaaa	43260
acctacacata	tccaagtggaa	actgtatgtg	tcaatttgca	taacttttca	agtagagtgta	43320
aaactaaatt	aatagataaaa	tagatagtta	ggtagatgaa	caggttagatg	aatagacaga	43380
gagatagatt	aaaataaatga	atcaacgaaa	atagatatag	atcatatcac	acatgcatac	43440
agacatatat	aaacagatac	atagtagtta	ttggcataga	cagaggtata	ggocacaggaa	43500
catcttgtga	caagaaagg	aatgagaagg	actggtctct	caacagtaat	gatgacatgt	43560
agtggtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	43620
attactaaagg	taactaatct	acagggcaca	gttcaataat	ggacacagtg	aaatagctgt	43680
ttctagttaa	tcagtgcatt	tcagtagcat	ttgtcaataa	taactttctg	ttctctagt	43740
agacacacat	acctattact	tttccaaatg	agaaatagaa	actttatctg	aaacacaaat	43800
aagagcttct	ttggagcagt	caactctcga	ttccatcttc	actttatgac	gaactgtgtgt	43860
atccatctct	cttttctctc	acatctgtac	cttatgttag	aattatgac	gaattctctc	43920
ttgttttttta	aatgttctct	aaagttaatt	aaatttgatg	atttgcaact	cttaagttta	43980
tctatttgtta	taaaataaat	atatttttat	gaaatctcaa	atgataggaa	tcaaaaccaac	44040
tttactatca	aaatagtctat	aaagttaata	gtattagcat	ggtaaaaata	tgaacttaact	44100
attataaaat	tcaccacaca	agttattctc	gactcacattg	catcaaaaatg	cttattatgtc	44160
aaaataaagg	ccctgtatct	tgctcgtcaa	atgtttagaga	ctactatcag	agacactttt	44220
atctcttggg	aaatacaaaa	tatcatttgg	tatttcaattg	gataaaaatag	tatgattgga	44280
catctggcag	cttagaattc	aggacccagg	aaaacttttag	gaaaaactct	agtttttagaa	44340
aaagtgaatg	aggggtcccca	agatctcccc	gggtatgctc	caaaaggcca	aaatgatttt	44400
aaagatctgta	catccccaag	cacaactgtaa	gtgaaatcacc	ttgcctctct	ctgtgatcaag	44460
acatgagatt	tcagatgtga	agtcctgcaa	tgagatttacc	gtcctgactc	agtcctcgac	44520
tacctcatgc	catccagcta	taccactgat	gtagagggac	tggtggccac	caacccctgca	44580
ggcactctac	ttattttggc	tgatattgaa	caaacctgaaa	aattatcact	tttggagaact	44640
tttaagagaa	aaagaattct	atggggagagt	agtaagtagg	tatttttgca	acttttgttct	44700
ttgtctctct	agtgctctaaa	aagggaatccc	atacaataao	aataaatttt	atattttata	44760
taaaactctgt	ataattttct	agtaattagt	actcatattt	ataatcatga	taattttttaa	44820
ataattttgt	tttttaagaa	aagagtctta	ctctgttgcc	cagggtggaa	tgcacaaatg	44880
agctactcag	aatctcgaat	ctctggcctt	aagcaactcat	tctctcagc	ctctcccaagt	44940
agctggattta	caggcatgca	ccacccacac	ttactaatat	acaaaatttt	tttatagag	45000
atgggtctttt	gctatattgt	ccacactagt	gtctactctc	tggtctcaag	caactctctt	45060
gcttggacct	cttgaagtgt	tgaggttata	ggctgtagca	accacccctg	ctctcatgga	45120
caatttttgt	aggtaaaaat	tgtctcaaca	cttttaataa	taaacactac	tgttatcaga	45180
cgagaaagaa	tctcataaat	tattactact	gotttatttt	ttctttctag	acacatattg	45240
aatltataagc	aatatgcasa	agattggctt	catattgaa	cttggaaagt	tttagggcta	45300
tcgtgaaatt	tcaaaaattt	agttgcaatt	attgttgtta	caataaaaaa	attaaacttt	45360
tgtaaatgtt	gatttaagaa	gggtatcttc	acccacacac	tggggagagt	gggtccatct	45420
lccatgaata	ccagtaattg	atctgtgtcc	aatcatctga	aatgattctg	agcaattgaa	45480
ttccactgaa	tctccatagt	aataggagag	ggagaaagag	tggttccacg	catgtttcaag	45540
ttcaggtata	tctccagtga	tactctcttc	cactatgtaa	attttacaaa	aaaagtttaag	45600

tgtgaaacaa	tgatgtatgt	gtttttagata	caaaatacaaa	aagttttgac	aagttttraaat	45560
atlaaatat	tatacattac	caatacacac	tggtaaagt	gtccactctc	caatacaacaa	45720
tgaatattta	ttaggtccct	tcattagaaaa	tctaggattg	caataaatat	ccaccacttc	45780
actgtgtcca	tattctctct	tcgttttlltc	cttaacattc	ccattgagaga	gttcaggagg	45840
gggacacac	gattgtacct	gcctctatagt	agaaatacta	tgttaataat	ggttaaatctg	45900
ctctgttttc	aatataaaaa	ttcagtaaaaa	tggaaagatt	ttctctcttt	attcagtgat	45960
tctctattat	gtaactttat	atagatctct	aaacaataca	gaatgggtgt	ctcagtgat	46020
tactttact	aaattgtcat	altgaaggta	tattaaaaat	ttaaaaatgt	ctcagacttc	46080
tagatatctt	aaagatgcac	gaaaaccacat	tagcaaatgt	ggttatgaaa	atcatgttaa	46140
tttttaccat	tcatggaaac	atlttatcat	aacattttgg	aaaaatatca	taactgaggc	46200
aagcatttga	tcaacataaa	gtttgactaa	tcatacaag	caactgaatt	gaactataagc	46260
tgcttcaata	tgttttagac	acacccgggt	aaacttaagt	tgacgcccac	actatataaa	46320
atgtccagaa	tggatgttga	catttcaagc	aaaaagaaaa	ttacaaagaa	aatccctcca	46380
ttgtctaccca	ctagtatggt	ttaaatgttt	gtcacctcca	acccatgttt	gaacttcat	46440
ccccagtggt	tcaggtgggg	tcataatggga	gatgttttga	tcattgggtat	ggatctctca	46500
tgaacagatg	aatgccccct	ctcagggtga	gtctctactc	tattagctcc	tggaaagctc	46560
ggttctctga	aagagcctgt	cactgcctct	ctctctctct	tgcttctctc	ctcatcatgt	46620
gttctcttga	cacagctggc	ctcttctctc	ttctaccagc	ttctaccagc	ttctactgaa	46680
tgcagatgccc	cgatcttgaa	ttttatagtc	atgagtatgt	tgagcccaat	aaacactttt	46740
tacaaatcat	cacagctccg	ttattccttt	atagaaacat	aaactcaaat	tagactaaga	46800
ccgacacacac	ctctgtgtgt	gggaataactt	ccagcacatc	gttcaagaaa	cagtgagat	46860
taactttaagt	gaactgaatc	caggtattcca	gtactcaata	ctgtctctca	ccaggcaaat	46920
alttgactta	atctcattga	ttacaggcaa	tgggagocaa	aaacaaaata	atcagaaaaa	46980
agttgggtat	caaaagtctca	atttcttatt	cagcaatgtc	aaagataagca	ttcaccttta	47040
catatctggga	ggtcaggaga	caatccaaag	tgttagcact	gaacgggaat	aggttccaat	47100
atgtgaaatc	ctggttttga	ggagaatttc	aacactcttc	caactttata	ctggtctttc	47160
tgtogtatcag	gaacttaagt	tacactatkt	ttagggaagt	cgaattctct	ttcttgaana	47220
aggtaaaaata	atttcctgag	aatatataat	baactcatgt	ccaaagttaat	ttacattatg	47280
ccacactataa	cttgggtgtga	ctattgggtca	tacagagggg	cattcagataa	atccttttcc	47340
ctgtgaaagaa	tgtctacatat	tatgttttat	atgtcttcta	aattgaaatg	gaactttat	47400
ataaatgttta	tgttattgaa	atatactgt	tctaaaaat	aatttgttaa	ttcaacttat	47460
tcaaatgaa	tctagtttta	atcactgaca	ttaatgaat	tttaatatc	ttttttact	47520
taaaaaactga	aettactctc	tcattattaaa	aaagaaaaat	gcatatagat	cagaattggg	47580
gcttttttga	aaacagatga	ctgactaagg	agttttggaca	caagtctccc	tcagaaaaaa	47640
gaaccaaaagt	tacaggttaa	tgatcataac	ttgaaaaata	tttaagagag	ggtgcaggag	47700
cgctcatagag	aaacacatgga	gagaagccaa	agcatggaaa	aagacagaga	caagagccctg	47760
acaaaaggctg	actaggacc	tgtgggacct	catagaaagt	tagggtcagga	gtctctctgg	47820
ctctctcgag	ctccccgtgt	ggatccaaag	catcagagag	ctctctctgt	ttctgtgaaca	47880
ccacacactgg	tgtgagtggga	gatttgggaa	ctctctgagg	gcattacac	aaactctagt	47940
ttgaatagagg	tcactctgct	tcoccttggg	cttgagctgc	cagctgtagg	ttcatcgtct	48000
cagtgctact	atgtggggac	tgtttctcact	ccaggaaact	agggcctctg	ttcccatcac	48060
ccacagagccg	caacaaatatt	ccctgtcacc	tgtcttgtag	tggcagtcac	ccatagctgg	48120
ctggaccacaa	aggagtttaca	gcattcccaa	tagttttaacc	agctggaggg	ctatctctaa	48180
gtgcaaaagt	aaacaaaggaa	caacccctgt	ggcaaaagaa	actgtagcat	ttcctttctc	48240
tgtgcacaaga	gcaacctgct	tgtgggctga	aaatgactac	gcgaacttcca	cgagacacgc	48300
agacccgggtg	tttggcctct	caaggggagg	gtatagatcc	atcccagag	cccaatggct	48360
ccagcgcttg	ggcacccgatg	tagagagggg	aaactgtccc	gtggatocaa	ttctgtgttc	48420
atagctctgg	tcactcgcac	aggagactgg	tgtagccaca	ccagaggagc	gacattgtat	48480
gaaagacaag	gggtgtgctac	aaactcactg	gtcaatgaagc	aggtctgcac	agagctgttc	48540
gtctgtcttc	ctacgggatat	ctccccaggg	tcttccctgt	acacccctgt	cagggtcggt	48600
gtctccccagc	atctctggag	catccaaagg	tgagcttagt	gttacagatc	tatcccgctc	48660
gagagctctcc	tcttcagagc	actgtacctt	tcacagatca	gtccattctc	tggggcaaca	48720
tactgtctgc	cataaaacgt	gacaagcata	ggctcatctg	ctctctgtgc	gttcgtctct	48780
gcacactaggg	tgccaacctac	tgtctcgtaa	gttgaaactgc	acagcccgat	gcaaaatgct	48840
tcaggaggcca	gtaagctctg	aaacagggtta	gtttctctgc	tagtctctca	tccagccctc	48900
aaagccctcca	tacaaaagt	atcttcaacc	agttactca	tactacaacc	agcaatttaag	48960
aaagaccocag	aacctcaaac	aaatagccct	atacacaata	aaagagctct	ttaccactga	49020
aggggaaaaaa	aaaatctctg	ctgttggaaa	ctygacttaa	catcgtatgc	atatctccaa	49080
tttggatgag	aagaaaccac	tgaacacatt	ctggaaatga	aatataaag	ggaatgttca	49140
aacactcgcca	aaggatcaca	ctaactcttc	agcaataagt	ccataccaaa	agcgtatttc	49200
tgaacttcca	aagaatttaa	aatatttatt	ttaaagttagc	taaatggggt	ccagagaaaa	49260

gttgaaagac	aacacaaaga	aattagaaaa	aaaactcagg	atatgaatga	aaaatgtact	49380
aaaaatat	tttaaaaaac	aaatagaact	tatggaaat	aaaaattco	tgaagatca	49440
caaaatat	ttgaaagatt	taattacaga	ttaactcaag	cagaaaaact	tgctctcaga	49500
gcttgaagac	aggctcttcc	aattaccctt	gtcagacaaa	aataaagagc	aaataaacatt	49560
ttttaatgag	naaaggtttt	gagaaaaaat	acgttctcaa	aaatgagana	actbaagagt	49620
tatagatat	cttgaggagg	aagaaaaagc	taaaaaaacc	tttttgagg	aaatttatct	49680
ctctctgcoc	tcttgctaga	gacatagaaa	tctttatata	agaggctcag	ataaccaccg	49740
gaagatgcat	tgcgagatga	acttctacaa	acataatagt	actcaggctat	ctaaagctca	49800
tgtgaacggg	aaaaattata	aaatcagcaa	gagaaaaagc	tctaactcaac	tataacggaa	49860
atctcgtaag	actacaagtg	gacttctcag	cagaaaaclgt	acaagccaga	agatatgtgt	49920
gtctattttt	cagggttctt	aaagaaagat	tagttcatat	ttattgaaaa	aacatatatt	49980
agagatatat	tttctatttt	gctaaactaa	acttcataaa	tgaagaatat	ataaagttct	50040
tcccaacaaa	gctaatacta	aggaaagtca	taccactag	aaatccactt	taggaaattca	50100
ccccacaaga	aatgatccag	ggagtctctga	acatggaaat	agatgggtcaa	tactcaatat	50160
cataaagaca	tgcaaaagta	caaaaactcac	aggctcttat	aaaaaattac	acagttggga	50220
ctacaaacca	gctaggtaac	aactaacata	atgacagaaa	caaaacctca	catgacataa	50280
ttacttttta	actataaagt	attaatgttt	ccacttaaaa	gatataagtt	tgtggaccaa	50340
actatgaaa	cagaaaccaa	ccactgtctg	ctcaaaagaa	acccaactca	ctlagagaaa	50400
ccctatacaa	ctcatggttaa	aggtatggag	acagatattt	tgaacacagc	aaacaaaagc	50460
actttgggtt	agtttatatt	atataaaaa	aaagatttca	actcaacagc	aaaaaaaaga	50520
caagaagtct	attacacaa	gataaaggaa	gcagaagat	atacaatttc	taaatatata	50580
tgcactcaaa	actccagcac	tongattcat	aaatgaaatg	ctactagagc	taagttagaa	50640
galtaaacag	aatataatga	gggcaagcaa	ctctccacc	cccactgact	atctatagaca	50700
gatttgcggg	acaaaaaaat	aaacaaagaa	actcaatgaa	tgtagaacaa	tgtagaacaa	50760
atggacctaa	cagacatttt	acgcgacttc	caaccaacaa	cctcaganaa	tatgttttct	50820
ttacctgtgc	atggaaactt	ctccaaaaat	gaacctatgc	cttgctacag	ctcagaagca	50880
atcttccaaa	attttaagg	ttgaaaataa	tccaataact	cttatcgaaa	cttggtgaaa	50940
tacaactata	aaatcaatat	ataaagaatt	tcaaaaacta	tccattacag	tgacaattaa	51000
atgacgtgct	tctgggtgat	tgtgatttaa	actaaaaatt	ttcttccagc	caaaggaatt	51060
aataaacaga	gtaaacagac	aaactcagaa	tgaagaaaa	tatttgcaaa	ctatgaaatt	51120
gaaaaaaggc	taatatccag	gaactgaac	aaacacaaac	aaacacaaac	gaaaaaaaa	51180
taataatccc	atgaaaaagt	ggacaaagga	tatgaagaga	tatttgcgaa	agaagacat	51240
gaaaatgacc	aagaatatgc	aaataaaaa	tcaatatacg	taattccagc	agaaatcgga	51300
atataaaaa	tgagttatca	totttaacta	gaacacgtgg	ccactgtcaa	atagcacaaa	51360
aataataaat	tgtggtgaca	gtgaggagaa	agaagaaatg	ttatacgtgt	ttgttgggaa	51420
tgtaaatatt	tacaactctt	atggaaaaca	gaatggacat	ttcccaagaa	actaaaaaca	51480
gaactaccat	ttcaccagc	aatccactca	ctgtgtatct	acccaagaga	aaatcaattat	51540
catatcaaaa	tgataccagc	actcatatgt	ttatagcttc	actactacca	gtagcaataa	51600
tatggaatca	aactaatctg	ccaccaacag	atgattggat	aaagaaatgt	tggttatagat	51660
atattccata	gaattactct	cagccaaacc	aaaaaatcaa	aagaaaaaaa	agaataaaaa	51720
ctatgccttc	aggaagcaaa	tgtataaaac	taaaaggcca	tattttagg	aaaaatattc	51780
agattcagaa	agtaaaactc	cacatatatg	actttatcag	tgagagctaa	ataatcgcta	51840
catatgggca	gagagtgctg	agtaaacagac	atgtggagct	gcaggaatagc	gcaggaatagc	51900
agaggggtga	ggataaacga	attacctaat	gggtgcaatg	ttcagtattt	gggtgatgaa	51960
tacataaaaa	gtcacagact	caccactatg	caatatatcc	aaatacaaaa	actgcatttg	52020
gacctactaa	acatataaaa	catagaaatt	aaaattttta	aaatanaaga	acacatatct	52080
naaacocag	gaatatctct	agaaggttaa	atttataata	gaactccgga	gtgcccag	52140
aaatgatgat	gtataataat	tgtcattgca	gagtcaatga	taacttttat	taactgaaac	52200
taaaacaact	caaatgattt	ctggtctcat	catgttttat	attctttagt	atgtcacatat	52260
acatcagaaa	anggttaatt	ccatccaaag	atttatagtg	gaagatatat	gcactaagaa	52320
attaattaaa	attggtattt	ttgttttaag	taatacagga	aaagaacccc	aaatagcat	52380
tttaataata	tttttaagta	aaaaaaatat	aaaaaacaca	taattaatat	attacaataa	52440
agaaaaacaa	accagataaa	attttcaagt	taacatggaa	aygcaaatct	tggtattctt	52500
gaatatattat	gttaacatat	aaacaatttt	gttatgtgta	ctattttat	caatgtttta	52560
taaatttgat	aaattatctg	attcagatana	gaattgtgta	aaattatctc	ttacatgttt	52620
aaaattttta	aaaatcagca	acattactaa	attattacca	aaatattatt	tttcttattc	52680
agaattctct	ttcttgyta	acttagaaaa	gtcacagttc	gaattcaata	attagaaatca	52740
tactaaaaag	aaaaattaat	acatcataac	ctocattgta	aaaaatacaat	tacaaaataa	52800
gcttttaaaa	tattctcaaa	agtaaatgtc	caaaaataa	actcaaaaaa	tttgcctttg	52860
tgtttggttt	aatgagtttt	cgagattatt	tgagaaaaat	acacttgaa	gagaatcact	52920
gggattctct	tctcaaaagt	ctataccaat	ctctacataa	gcaattcttt	tttttlylat	52980
tgtggtctgt	caogtatttt	gtgcnaattt	tatatcaatt	ctgtctgtgt	taatatgtgt	53040

aaaagcatta	tcttaaaaag	gaaggttaag	atcttgatta	tgggttatta	ttcaaatgct	53100
gtatttatat	aggggtaata	acttcaaaaa	cgtgatttag	agaagaatgt	gaatggacac	53150
tccatggaatt	agaaatattt	tcttctcatct	aaaactcaaa	acctaaaglc	cttagactag	53200
atattgtgaaa	tgtaaatatt	aatlittlaac	tctgagatac	atactcccta	tttagctctaa	53280
gtgtgccata	atacaaatct	tgtggaaacc	tcttccacaaa	gaagagacct	ccataggacac	53340
ttaattatata	ctcagatgtc	tgctaatcca	catgcagttt	tctgttaaat	ggctgagaga	53400
agataatttt	aaagaataac	taagctggta	littcttcgtt	taagctttgg	aggcctgtac	53460
tactatagca	aattcctagt	tatgtgttca	aatgatctca	agtctttgta	caatttgcac	53520
tagaagacac	ttttctacat	cagctcttcac	tgtctatgtc	gccactccaa	ctttctctcc	53580
tactatagca	catttcatgt	ctggtagtg	gaagactcac	tgaaacaata	tattcacaa	53640
tttgtgttct	ttttttgaaga	agcccccaca	aaattgttaa	agctctctggc	ttcatataaac	53700
ctaaattctac	ctcatcatcac	agaaaagaaa	tttatgagtc	tctttaaata	agcctccccc	53760
tctcaattag	agcaaaactc	aacctcttta	tgtatcatgc	ctactcttcc	aatgttatca	53820
aatgtctctc	tcttccacta	aatccaggat	tcagatttta	tgtatcttga	attttattaa	53880
aaaggtcaag	ttcttctgtc	ctccagctgt	tgcacatacc	cttctcacta	taacaaatgg	53940
ctttcaacca	tcttttgcac	cgatgacttc	ctatgtaaaa	cagatctcca	gttctctccc	54000
tcttattttc	tatctcaatt	attggatttt	ctatttctct	gtacacagtg	atacatataa	54060
tctatttttaa	atattttttat	tactttggata	tttgggttat	ctctttttat	tttctccact	54120
tcttatattta	gaataaaaatc	tctggatga	ttagcctgtg	cttgggtttt	caccattttc	54180
tctgtctcta	tgtatgtgtg	ttacaacagc	aggaatgagt	caaattttaa	tgagcctttg	54240
acactgcctt	tcatctcaaa	tgtactcaat	ctctttctca	gctgtgacta	tttcaaaact	54300
tttctattct	acattagtaact	cttccctctc	cttccgcacac	acactattca	atctcagatg	54360
acactattct	atacttcaaa	acagaatcca	tcagcttcta	ccattttcca	agcttactgc	54420
ctattttctc	tcccatcttc	tgtcccaaa	ttgtaagcac	ttctgtttgc	acctgtacaa	54480
aggtttgtag	cagtcctgtt	gcccccacaa	ccaaataact	ccacagtagc	tgtgtgcttc	54540
tcttctctgc	atcttctcag	ggcaactatg	tgcaactatg	gttcagctct	tcagcgtctc	54600
ttcttctgt	atctgtctgt	tgtcttctca	tctttttct	tttaattatc	cttccagctc	54660
acactcttc	tcagcaata	tctgtatct	ctatagat	tcnaagccag	aalcttgaaa	54720
gagttatgtc	tacagctctg	attgaaatgc	tagctcata	tttttttgg	cagattctat	54780
tgagggtctg	tcttctctac	tctattaaaa	ttcaattttg	tttactttg	ctattgagatt	54840
tacttatcct	aatccatcac	aatlittgaa	ccgaatata	taactaaact	agaaatattt	54900
gactatttga	taagtataat	aaggtaatta	aattacaact	ttcttggact	tattatata	54960
ggcactatgt	caataaata	ttataaata	tttatctgc	taactaaac	aalcttttga	55020
ataattagaa	ctgtttgtaa	atatgtgaca	ttttaccac	aagaaagagt	caacaaagct	55080
lcaaatagac	tgtctgtgtt	ggccaaagat	acatgcccag	caagcagtag	atttagaatt	55140
cagacaggat	gacttatcaa	gcaactctgt	acactaact	ttcattaata	atttctctat	55200
ttttatgtct	atggcaacat	tctagatttt	tctctgtgt	tctctgggtc	ctctcttttt	55260
ccccatttct	tttactatct	attgctcttc	tgtcttatat	ataaatgtgg	taattgtttca	55320
gggctctcat	tgtagctctt	tgtctcttct	attctgtatt	cttactcaat	tagtgctctc	55380
catlittatg	atgatattcc	gaaatgcata	tctctctct	agatgcata	ccaactccac	55440
acttccata	tcaggtttgt	attttccatt	gggacactca	lcaataatgt	tcacagtcaa	55500
aagttgcaaa	gccctctcaa	aatgctcttc	atocagtcag	taoatattga	caaaatgggt	55560
attgacctt	actacataac	tttgtgaaaa	acaattgaaa	acaaacatgt	gagtcctcta	55620
atgctactct	ttttccacac	caactattag	taacatcacc	tgtacttttc	atccactaaa	55680
tgtttttcaa	atnagccttc	tgtcttgca	ctccctcat	atcactctat	ccaggtctccc	55740
acactttctc	acocctacctg	gactcatggt	gtgcctctt	gcttcaaaaa	agtaacagat	55800
ccaggaatac	aatccaacaa	aactagaat	caaatataac	atctcttttt	cttaaaactc	55860
ttttattggg	tttactgtgt	catataatga	atocaaatga	tatgatgct	ttagctgact	55920
tggaataatt	tttctgtgoc	tcccatctag	ctccagcagg	atagactctg	ctttaccac	55980
ctgcaatata	ttgttttgtt	tttaccagct	tgcacatatt	tttctttgcc	tgggaacact	56040
ttgtcatata	ttgttttccc	acagagcoca	tcttcttct	acaactgaaa	aatagatggc	56100
tgtattgana	agctaaatga	gattcatgta	atgttcttca	gaacttttca	taatttagaaa	56160
ataaagacac	acctcagza	agtacagaaa	ttacacacaa	agatagaaga	tgttaagatg	56220
aaattaaaaa	acaaatltag	ctgaggaagt	tgtaaacccc	tataattttg	gtaatgaagt	56280
ctaggttcta	ataaatttga	aagcttttat	aggggttaac	taattattat	cttattatgt	56340
acaaaatctg	gaagtgaggt	tttccaggt	aagtattaat	ttaatgcaat	acttttagaa	56400
tatttttcaa	actcccttct	ctctatata	attcacaatt	ctaaatltgg	aaacacagat	56460
atacaacttc	cttaaacact	attcttgaa	aaccagtact	tacactaaca	tatgggtaaa	56520
tatttttcatt	ttgaaaatga	acacactatg	gaacagctgg	tgtctccagt	cttggttttca	56580
tcagagccaac	catgtgaacc	gtccaatgtg	tcattcagct	taaacatgt	gaagtcattt	56640
taacatcatc	ggcattcata	tactgggata	tcacaagatt	ctagtgcata	aaaattttag	56700
ttagtctctg	catctcataa					56760

aatgtcattt	ctaatgtcat	ctaataaaca	atctgagtat	tcccatctt	aagaagaaaa	56820
agctttatbt	attagatcta	ctaataaata	ggtagcgtac	aaaataatct	tatgacgggt	56880
gagaatttgt	tgtcgtaaaa	tagttgtcaa	aagtgaaagt	atatottctt	acacaacatt	56940
ttttttcttt	gcttaagccc	caaaatatat	tttaaaaaaa	ttttttctta	ttcatttata	57000
ctaaagcatt	tatgacaatg	ctagtaataa	aacaggccat	tacaggtata	cattattttt	57060
taaaagaaaat	cataacagaa	tttlytaaat	taagagtcct	actaatctcg	tagtttgagac	57120
atattgtaaaa	agggagaaaa	gactgaaaat	ataaatctct	atgttataca	agacattcttc	57180
cttttaataa	taagaaaatc	ttaaaagaat	aatataaata	aatllagtat	aaaatttagct	57240
tttttatgag	gactaacatt	ttttgtaaac	tagacctcat	attaagcaca	gacattaaaa	57300
aatgaaaaca	gtatacatga	ataccttatt	cacttcactt	aacatgagta	tattaaatat	57360
ctcttcaaat	atattactga	gaggcaggag	gatcatttga	gatttaagagt	tcgagaccag	57420
ccttgctaac	atggcacaac	cctgtctcta	ttaaaaatat	gaaaatttag	caggcatcgt	57480
ggaggggtgcc	tgtaatccca	gctattcagg	aggctgaggt	aggagaaattg	cttgaaaaag	57540
gaaaatggag	gttgcagtga	gccaaagatca	tgccactgca	ctccagcctg	gcgcagcaca	57600
gagcaagact	ccatctctct	ctctctctct	ctctctctct	ctctctctct	ctctctctct	57660
ctctatatat	atataatat	atataatat	atatacatat	atatacgtat	acacacacac	57720
acacacacac	acacatatata	ctgagtgggt	ttgcaaaaaa	taagacaaat	tgaacccaatt	57780
gttccccagaa	atttttctata	aatactctga	tagtgtggta	gggaaattctt	catanaattat	57840
tagtatattgt	ggtaggggaa	tcatcaacaa	gagcagaaat	tggtaccatc	taggnaattat	57900
ttttctctct	actacctctaa	tatttatgaa	aaatttctaa	gagggaagat	attcagattat	57960
agacattatct	tacagtgtca	aattctacaaa	ttatagagtt	taaattatttt	tgatttgatg	58020
catcaggcatt	ccatctctct	aataaaaaaa	ttgcttttgt	atctaggagt	aaagaattttg	58080
atgtaaaaagt	ctaatctctat	aaaaacagata	tataattaaca	gtcataaagg	ttctcagctaa	58140
agcaaaaatna	gttttaaaaa	gaatacacat	aaagctccct	aacttgtttc	tgtaacagct	58200
aattgctttag	agtgagaaaa	gctctgaattg	aaagacagag	taatatctga	gtaatlaagt	58260
caaatggag	aaaaaaattga	tgtctgtcttt	gttctctcag	gttttttttt	ttatctctttt	58320
ctggataatc	tatatctggc	cccacaaaaa	gactaaaagt	agtaaaatttt	tggtctatcat	58380
tccattttct	aatacaaaa	taataaatta	cttactaatg	cagctgggtt	gagctgacca	58440
tttgcattct	ccacatgtaa	ttgatctgta	tgtttcacca	tctgctgtta	catatctcgt	58500
cccatctctca	tatttctgctt	ttcttttttaa	ggcatatgta	tactgagatt	cagaaaataaa	58560
aaagcaacag	atctctatct	ttgatttgga	ctgattgttt	aaaagggaag	agaaataagaa	58620
aataatcgagt	catctgttaac	taactctttaa	taagaatttta	agtaaatatg	aataataaaa	58680
aaggaaaata	agctcagagt	tgccaaagac	gataaccata	agcaatcaaa	tacttaagct	58740
aacaaggctc	tatttaagac	acttaacaatt	attcaatcaa	gaactctcat	cacttttttaa	58800
tctaatcggt	ttggaattct	acagcatgtc	atcttcaaga	aattatttga	aatctgtttt	58860
taggactttt	taactctgct	tattgtagat	agaaactcaat	agacaaatgag	tattattttg	58920
attggagtat	cttgagattct	gtgatgatct	cttctggcaa	ttccaaatct	catttagcca	58980
cttttggctc	aaagatttga	aatgtcatct	tagaanaatc	gccaanaata	ttttctatgc	59040
tgagagtctca	aggaagcagag	gaacagttaac	ttattgtgtg	cttcaaaagt	aattggacatg	59100
tgattctctca	aattatgtag	aactlaactt	agatttattt	tttgtgaaag	gccaanaata	59160
tgatgataga	aattactctc	gggtacatgc	gaaagagtg	aaagtactgt	ttctgttaaac	59220
atagcaaaatg	cttggaacca	acccaaatg	acatgtatgt	ttaattggcg	attattcana	59280
tgggcacatct	acacacatga	atactatgca	tcaacaatga	tgatgggat	taagaaaatg	59340
gtgagggcat	ggatgaaatt	ggaaabctct	gccaataaaa	atgaggagta	catgtcccttt	59400
acaaacaccc	acatgtctctc	actcatagat	attctcaaga	aactatcgca	aggaagaaaa	59460
aggaagggga	acatacacat	gtggggagct	gggggggggg	caatgagaac	acgtggacac	59520
catbagggata	tatcgttaat	gctaataatg	ctgtgggggt	gtgcagcaca	ccagcatggc	59580
taataatgata	atttgttaact	aaactgcaca	ttgtgcacat	gtaccctaaa	acttaagata	59640
ttccocagaa	ctcagctctat	ataaccctaa	aaaagaaatt	actgtogttt	actaggttgc	59700
aaacttaaat	atttttgatt	gaatgataat	ctcattgata	aggaagaaat	cagaagagga	59760
gacwtctcaa	caatcctcag	agggaaattt	aaaaacatat	taaattaaac	ttgggtgagat	59820
aaaactgaaa	ataaaattatt	attttataata	aattataaca	aagaacccag	acaaaattcca	59880
gcgtcagata	aaatttttga	acaaatccaa	atatgagaag	aaacccaata	gaaaacaaatc	59940
atgacagaca	tttaaaaaag	gtaaaagacc	agggcaagaa	aatcaagtaa	acacagagtc	60000
ttgcccaacca	taaggaaatg	gacaaaata	gatgaaaata	acattttcag	acatttgaaa	60060
gcaggaagaa	cotaattcca	gagaaaaagt	gacaatgaga	tgagttccat	catcaaatgt	60120
actttatgct	gyyagaattt	ttccaaaacag	cagcatggag	agggagaatt	cagcaggaag	60180
tgccacactt	gctgagtaga	agaaaacaaa	ctcagtgctc	ccaaagagaa	tgagttctact	60240
agaaatctga	ggaaacagag	tgagaaaaga	agaaactatg	gagtgaaaag	gctctacaaa	60300
tttccacagc	aactccctag	attatttggc	tgaatttga	cactctggag	agtagagcaa	60360

aactccccaa	gaatggacaa	aggatacccta	tcagatgaag	aacactacca	gagaacaaaa	60540
aggtaaagga	ttccacagagc	acacacacaa	cacaggggaga	catttaaatca	gnaatcaatca	60600
gagtagaagc	actcgttttga	acatctaggt	cacgtagtag	agacatcaga	agcagctctaa	60660
tattctgaac	aaaactatctc	tggggttttt	taagcttttt	aaaagctctaa	aaaatagacct	60720
tgaagaagct	aagtttgaccnc	aaaaacaaacc	taaaacttaaa	aaaaaatttaa	aaaacagttaa	60780
ccctggggctc	tcacagatgt	acagactctga	gaagttccaa	agctcgtctca	cttagccaaa	60840
atacagatgc	gagtttaaaa	aaaaaccaca	tttttgtaat	aatcacccctc	tcacacccctc	60900
ctccaaaat	ccacgttaaat	cttttatgga	atactcaccc	taactccagcc	aaacacgtgat	60960
tgataacta	tatatcaaaa	gttgaggaa	ggcactagag	cagtatgaaa	taaaattgggt	61020
tcactaaata	ctgggataag	aaaatgacgg	tggtccactt	caataacctt	agccctctacc	61080
attagatata	agttaaaagta	gaaaaaatta	atctcacaagt	agcgagaaga	aataactcaaa	61140
taagatcag	agatgaaata	atcaagaagt	aaaatgtgat	ataaaccaagg	aaacccaaga	61200
cttglttatt	tagatctcta	taattgagaa	nocttttagac	agactaaatc	agaaaaataa	61260
acacaatttg	cttataacag	caatgacaga	aatgacatca	ttatggtttt	tacatatatt	61320
aaaagaaaaa	taaaaatat	tcgtataaat	gccatgtcaa	taaatccaag	aacttgtagtg	61380
aatttaaaaa	ttactgaagc	cacaaactat	catgggtctc	tcagaagga	ttagtgtagca	61440
tttaataaatt	ctgtctatga	acaaatatta	atttttcgtt	gatggatgaa	atacaaaaaa	61500
tttagtttata	taacttagtaa	aatcavaggat	ctgtatgctt	aaaaataaaaa	aaactcagggc	61560
aagacttgat	ctcttacta	aatcaaaagga	tataataat	tcactggattg	aaaaatttaa	61620
tactataata	tactcagttct	ccccagattc	atctgtgaak	gtgtcccgat	cttagtgaat	61680
aaccagacac	aatgttttgc	acatacgaac	atgctgattc	taaaagtata	tggaagagta	61740
aaagggctga	aacagctaaa	caattcttcca	aaagataaga	gaagttgaaa	aaactcacatt	61800
accaaatatt	aaagcttaaa	aaaagctaca	gtgagtaaa	gatctcatga	tactgggttaa	61860
aggcaaaaaa	cglgggaagaa	tagaagagaa	aaocgtgtcc	agaaaatagca	tcactacatt	61920
ggatcgatcc	tataaaatagc	ttctatttcta	ttttgttata	agactatcag	gttccacatg	61980
ccactgttta	gcaatagacc	aatacgtctga	gacagtgggg	tttgacagaa	agaaaggctt	62040
taactcaaac	aaagggcaca	aaacaggaat	tgggaggatt	ctcaagcccc	agatctgttc	62100
tgagaagaggg	ctactgtgaa	gagaccttaa	ggggatcatg	gaggggtgacg	gctgagaaaa	62160
tttgggttgt	caattgggtca	gggttaagggg	gtgaagatca	ccaggaatgtg	gaacctgcac	62220
tattttcctga	gtcagcttttt	tgctggggctc	tttagaccag	ctgagtgtgtg	tgctgtgtgtg	62280
ctgtgtgtgtg	tatgttttgtg	tggtgtgtgtg	tggttttgtt	tttagacaga	tgactcttgt	62340
ctgtgtgccc	ctctggatttc	agtaggtgtga	tcacagctca	ctgcaacttc	gctccctcag	62400
gctcaagttg	tcctccaccac	tcagatctcc	tgagcagctg	gtactacaga	ctgtgtgcac	62460
aatgcccggc	taattttttta	atcttttgtg	aaaaatgaggt	tttgccttgt	tgaccagatt	62520
gttgctaggt	ttttttttcca	tatgcagaac	ctaaaaggaga	aaactcatga	gaagagattat	62580
catctccaaa	tgctcttagat	tttatctata	gaaaagggaaa	ggaccaaaaa	gtctctgtgac	62640
gaagccctct	ttatctcagg	gtagtataca	atgaccacgt	acagagaagt	tggaacaaatg	62700
gaaagctgat	ttatgttata	ctgtgtgatt	tcctgaaatc	atagtgtgaat	ttttccccctt	62760
tatacctaatt	tataataact	tccttagggac	agtttcaagt	ccctccgggc	ttgtatccctt	62820
ctcctaattct	aggggtataaa	gctaataatgg	tatgaatcgg	gcaatggcca	ttcttagcttt	62880
ttttctgtga	ccagggggcac	agagagagag	tcaggattag	aggaatgaaa	cngcttttga	62940
acaaactgcga	agctcgttata	ccagacttag	gggtcgtgat	gaacatgtta	gtacttcaagt	63000
ctatggtttt	attgttaatat	ttaattgaa	catgttaaat	ataatcccta	taaacagagat	63060
gtgtgagcttg	aactccaaga	gtccttgaaa	aatggactgga	aaaacatgga	gtatgtcaggg	63120
ggaaagctca	aaaaaactatt	cagacatagg	gtctctggtg	gagacatag	gtctccagagc	63180
agactcgtga	aatattttctt	ctagttttgt	ttttttttta	ccagaagcat	tgataaagt	63240
acaaacagctc	galttagtca	ctgtacagac	tcctctctct	aaagccaaga	gaaaatacaag	63300
tgtagttccg	ttgtccaagaa	ctatctgggc	aaagtaaat	gaagagtttt	cccagccctca	63360
agttctcttg	cagcctctttt	tgcaattatt	ctctgtgtgt	ccaataagtt	ctgatatcag	63420
tcocagtgag	gtatatctcc	atagccagga	ctcgtgatgc	ctagaaggct	ctgcocaccag	63480
atatatttat	atagtccctg	cagtcctctt	tggagtcggt	gggaaaatgg	cgagaataatt	63540
ttgtacttag	gatgatctga	gaagtatctc	agtaagtgtg	agcccttaat	atacaggtta	63600
tttagacac	agtggggttg	ccctaacaga	ggaggggtctg	atcctatgoc	acaaataaac	63660
atgtaccagg	ggggcacaoca	ggtanaagccc	tcaaggggtgc	atttatgtat	ggatttttttc	63720
atggggagaa	tagacaaaagt	gaattgaact	agggatcttt	ttttacaggc	tcocccagaa	63780
ttgtgtgata	ttcccactct	taaatatttt	tggcatagta	agggagaact	tttagtttta	63840
tttccctct	ccatagctggc	tttgtctccc	cagtatgcga	tgggcatgtg	agggcctatg	63900
taatggaaatg	acatttccatt	tatgataggg	agagagagat	tgacaacatgg	gggtgtgtgatt	63960
ttttgtgtga	ctattacttg	gacctggaaa	gtagccatgg	taagaaagctg	gtgcagatag	64020
gtagtcatat	ttggacacatc	cagaaaagtca	gtgacacagta	tgactaacag	aaaattgctta	64080
tttgtgaatg	tttggggggg	ttaactgacag	atcccatcat	ctgtgaagtt	ttctccaggt	64140
gcaataactct	gaaacagttg	aactcagtg	ttgctatggc	ctgttaggca	ctgtagttaa	64200

aggagaggta	taattagaag	ttttaaaaaa	agagtgacca	tttctaasatt	ttagaattgct	64260
cacataaatga	gtggcatbag	actatgtttag	catgggaatag	aattgtctaga	aaactctataa	64320
gtcttaacaaat	tgtattgacac	aaggcaaat	tgaagtaaatg	tctataaggg	tgaacgaattg	64380
aattatactag	gcaattataa	tgaccaagta	aataatattggc	ttaaagcatct	agtaaggagac	64440
ggaatagaca	ggaaggatct	tcaccttttt	atataaaata	attataataaa	caaacacttcc	64500
tgttatgctct	aaagtaacta	ttgtagtgtg	caagaagaca	taigtltttgt	ctaatttctac	64560
taaaagttaact	tatctgatat	ttttcctcaa	aagatatttg	agggcccatct	aagattttact	64620
taicctcatca	atagaggttg	agacagctctc	tgaagtgtga	gtggccctctc	tacattttctt	64680
gatagggacaa	gaatctggcg	ggcggggttt	tatatggctg	tggtgaatcc	aggggtctaaag	64740
tccttaaacg	tgaacagagg	aatgggtcac	cagtcattgct	ttgcatggcc	tcctttcaactg	64800
tgttttaagt	gggtccccagg	atgtcgacatt	ttcctggctc	tgagcagaaac	ccaggtctctcg	64860
gggtggatgg	gatgaagag	aatgtcagtt	ggataccaca	atctgctgga	accacaacctc	64920
cgtgaatagt	agttaaagta	caacctaaag	atgtgttatg	tttgataata	tctaatttat	64980
tttatgtctat	gttatgtgca	ttccttagtc	tgagaaggta	acggagaat	gatctcccat	65040
gtasaaatctt	taaagggctt	aatttaagcc	caacttttagg	gaccaccctt	actctgagca	65100
gggcaattgga	cagaatgtta	ttccaggttg	ttagtttctt	ggcaaatatt	agctaataatt	65160
tgttttgttt	tatatagtat	gatttatctt	ttgagttttt	tcagtagact	tcagtctgca	65220
ggcttatatga	agattccaga	ttatgctgag	ggcctggaaat	atagtgtctc	ctagcgataca	65280
gaaatttgcc	tatggttcca	ctggatggag	acaggccacc	taaacctgag	ggtaattcttc	65340
tctacccaag	ctctcatctg	ctcagcaatt	ctcttggtct	tgacgggaa	tgtatttttgt	65400
tatcttgaaa	atgatctcaa	aaatacaagc	aagtatttaa	aatttctctg	tacccctggc	65460
atacagggtaa	actcaatttg	ccagtcctct	aatagccctg	caacctcttg	ttgaaactct	65520
gggtactgggg	gtggaggacn	agctttaaga	ttgtttctggg	caaccaagtac	gtatttttaa	65580
attatcttttt	ggatagttct	ctttaagtgt	gtcccaaaaga	catagctctg	gatcaatttga	65640
aggggtggcat	gcctggcata	ctgtgtggta	ctcatgtatg	tcttgatgat	atctgcatac	65700
agataacttgg	gcaacagagac	ctttctctcc	tgctgcatac	ttcactcat	ttgagttctt	65760
tgtatggagt	caaatgtctca	atcgaaattc	ctctttacat	ctcttccat	taggtaggga	65820
ctttaggctg	aagttttatt	cagggaattaa	tggaactagg	aaggctttgg	gcattttttt	65880
ctctgtctac	ctcttttagtg	gcctgctctg	ctcagttatg	ttttttttct	tgctaccocaa	65940
ttgtccatcc	actgatgtcc	atggtagtgt	attataagta	ttttctttggg	taccagagact	66000
ctcttttagt	agggctaagat	ttctttagca	tgcttaattg	ttttcttttgg	ctaactcatc	66060
aagggttaaga	gcccgctttc	ttcccaaacg	gcccacttag	catygaacac	ataaaaaaca	66120
tacccgtgaat	cagagttaac	ggtgactcag	gagtcctttac	ctagtgtgga	tgccctgatt	66180
aggactctaa	gttctgcctt	ctgtgcgat	gaacccagag	ggagtgtctc	tgcatcttagy	66240
atctgtcaca	gggtttacaat	agcatactca	gccttctgtt	gtccgttggtg	cataaagctg	66300
ctttctctcag	tgaatatttt	taagtccagg	ttttttaaagg	gaattttggg	catgtctcgt	66360
tgaatagaaac	acactgtctc	agtaatttat	atgcaatcat	tctatgggtt	atttagcagg	66420
attttaaagca	gaaacagctc	tcaaagttaac	actaggatla	tccaggaggga	tgaactgata	66480
cttattcagt	cttcttaggg	taagtacgta	gtccactctc	tgttccaaca	aatagcatac	66540
acagtatggg	gtgtgtacag	tgctagggtta	accocaaagtg	aactctctctg	ctctctggag	66600
aagatgcacaa	gtgggtgcac	tggtccagag	ataagaagtc	caacccatctc	taaacattgtc	66660
catcgtgttt	gaaagagtagg	ctacaggcct	catgatattc	cccaagttctt	gggttactac	66720
ttctaaaccc	ttctctcttc	tctcatgtat	gaacaaatca	aatggctctt	ttagtccagg	66780
gggtctcagt	agccagatct	attagtaatt	tttacttaat	ggttagaagag	gcccttttga	66840
cttctcttg	catcttagaa	gtcaagtgtc	tggtcttagg	ggtctaatga	gcatattttgc	66900
tataagccca	aaataagaaa	atgaaatag	gccatcacta	gccatcacta	aaaacccctc	66960
acagctgctg	ccaatgtccg	agctcggcca	ccctyacaag	agctctctct	cagtcocgaa	67020
cgagatattt	ctgctcctga	gaaatttcaa	acctaaaata	tataatttag	tttttcaata	67080
tttgtgattc	ttttcttgga	tactttggat	ccccactcag	acaaaaaaaa	aatgtgaagc	67140
cagtaataata	ttctgtctcaa	tttgccatag	tttgtgtggc	ttctaatatg	ccgtccaact	67200
actaaagcaa	agtklcatctt	tcaattggga	ggltccaaaa	ctcttagatc	tgtattttcc	67260
cggagcgggt	agtgagtttt	tgaagccttg	atggagcatc	atccaggcaat	actatcattt	67320
aggttttaggt	ctcaggtctt	ccatttcaaa	ggcaaaacact	tcagtggga	ctggactcag	67380
gggaatcacg	atgaggcat	ctcttcagatt	caagactgaa	caccagttaca	actcactgtg	67440
taagtctatg	taataatgat	aagcatcagt	tatcacccga	taattggctt	tgaaaaattg	67500
ccatagctg	ctcaaaactc	gtacaaaacca	ataaactctc	gttccatgtt	tttgtctctg	67560
cgagcaggtt	atgtttacatg	agaaaacagg	aattcttctc	gtattctcag	aaggccatla	67620
cgagaggcta	aatgcattgc	tgtgcctttt	ctctccaaag	gggtctctg	agatttggca	67680
ggcgcactcc	tgcacaaaac	ttgacttgta	ctyagatgc	agtttttgtt	ttccctggcc	67740
ttctcatctc	ccatgtttcc	ggactaacct	tttgagatg	ctcttcagg	gtgcaggcac	67800
ttccaaagat	ctccagttgt	ataaatatgg	actgcagagc	acatgtctgg	tctgaggcca	67860
ctcgaatgct	caatcatctc	agagaaaaag	taattcttagc	atttagtttg	gttaagagta	67920

ctgcccataac	aggacgggag	cagtggtctca	cacctgtaac	cccagctccc	agcactttgg	67980
gaggcccaag	agggcagalt	acotcatgtc	aggagtttaa	gacgagccag	gcaaacatgg	68040
tgaaccacgt	tctctactaa	aaatataaaa	atagctgtgc	tgtgtgtggca	cagcgtctga	68100
atcccagctg	ctcggggagg	tgacagagga	aaattgtcti	agctcgttga	tgtggaggttg	68160
cagtgagcca	gaggtltgac	tgagccacaa	ctcgtgccac	acagtcacag	ctggggggata	68220
gggcagagct	ctgtctcnaa	acaaaaacaa	acaaaaacaa	ascaaaaaag	gaagacttcc	68280
cccaacaaag	ggataggaca	ttracaggatg	latagaaaaa	ctctgtctct	tttttttttt	68340
ttttttctgg	gacagagct	tgctctgtcc	ccagcgtgg	agtgagctgg	catgtctctg	68400
gctcacttgc	aagctctgcc	tcccogattc	acgcggtctc	tctgcctcag	cctccogagt	68460
agctgggact	acagggtgcc	accacccatgc	cogactaatt	ttttgtattt	ttagcagaga	68520
cggggtltca	ctgtgtltag	caggatggto	togatctcct	gaoccttgta	tctgcctcct	68580
tcagcctctc	aaggtgctgg	cattacagga	gtgagccacc	gcgcccagca	aaaaactctg	68640
ctttaaatag	tcttactcta	gctgacaaac	caaaaatttg	aggaatgatc	tcacagcat	68700
ttttttctgg	atctcagta	ccttcattat	ttctgagaaa	agtttagacc	accagatatt	68760
taacacccaa	tagatggcac	catgtctact	agaaagtcca	gaagctgatt	tctcaccctc	68820
atcagggatc	caagcccat	gtgggaataa	tggagggtgt	tgctgtgggt	aggaggaagc	68880
ctcgggtgct	acattttctg	gtctttttct	tttagatctc	tctcaagctc	ccagcgtctc	68940
ccagcgtatt	gtggggcaga	aggctgactg	tttaacatac	ggcttltgtag	ggcattgaga	69000
attttccact	cagtgctccc	ccclgtgcag	taagcacact	ggttgggacc	tgcaatggga	69060
tgctcggttt	taattggctt	tgggggccca	gggtgttcta	ccatagatgt	agtcctctga	69120
gaocggccctt	gtgtgtggcc	agggactact	aggltcagag	ccacagataa	caagtcagct	69180
tgccattttc	atctattcct	gtgttttatt	ttccactctc	ttaactttgt	atcagtaaat	69240
acataaaaaa	caactctcac	taattggagac	aaaaaacatg	coaatggctc	agctacgttt	69300
tgttaacttc	tctgaatatc	tgggggcactt	gtttggalaa	acatcatgtt	agctactatc	69360
aaattctctg	gggtctctgg	gctcaatctc	atcttattct	tgaaaagctc	aaagactctg	69420
tctaagaatt	ccaaagcaac	ccctcattag	ctctcgtctg	acatcctcgg	ctcttactga	69480
gaotcctbgy	cltggggcact	cccttgoga	gtctgtatct	ccctccag	gtcagaggtg	69540
caaggtttaga	tctacttcca	gtgtttatat	gagagtcagt	gtgaataaga	tcagcctttt	69600
tctgagcagc	tgccctctac	ggattactgg	tctctgaagt	caacaaaaa	ttgagacaaa	69660
ccttagcttt	tcttcaaaa	atctctttgt	tggaataatc	agggagaagt	atgtactctc	69720
tggtgggtgct	tgctccagta	gggtctctgt	aaactcgttc	cttccataaa	cttttaagatc	69780
tatgtcttgg	atgttttttt	tttttttttc	tttaagttagt	ctgaagtgga	gaacagagaa	69840
tctcaataaa	taggcataat	attttltcaa	gtggcagcaa	caactcctgt	aagcagttgt	69900
taaaacaaag	taaatctcat	aggtcggcct	gactccccgg	ctaaattggag	ttccctgttg	69960
tctggggaaa	tgctcctcca	gactcaatgg	agtcctcctg	tgggttataa	gaagtagaga	70020
tcatacctgt	tgccccggat	ttgtgaactt	tggtgtgggt	ggactctbga	gagcgccag	70080
tgtgctgtct	gcagctcccc	cataaagtgg	aggggggtga	gctcatagtt	ctcttaactg	70140
aaocatcata	gcactcatct	ttctctgtaa	atcagctcaa	agctcttcta	atttcttact	70200
ttatcatgat	lttactctttt	tctcatatgt	tgtaactttc	caaagcaaca	taaaacatta	70260
tacatagagt	atttctatcc	atctctcttc	ctcttcaaaa	acaaaactca	ctctcagagt	70320
cgactcttaa	gcactgagaa	catcgactgg	ccactgttct	cogaaatcca	tgtgggtata	70380
aggttaagcc	atgttataaaa	gtaagataat	ctttttttgt	ctgtgtgaa	gatagacaaa	70440
ggcctttcaa	tttttggaag	tgacgcccat	cagggttgca	ttgtgggtta	ctcttgaggga	70500
actaaaggag	agcccttagt	tcaltgagac	taagttaagc	gttagggttt	gtctctgggt	70560
ctgtccoggt	ggaaaagggg	cactaggcag	tgaatcaatt	ccctcaaaag	gagtgaacct	70620
gacctgtgct	gccacaataa	gttacagagt	tgtaagattt	gtatgcctgc	tgacacagaa	70680
cagacacata	caactgagca	gtgggggttg	cagcagagaa	agagttttaa	aatctcaag	70740
ccagacagcc	ctattgggtg	ctgggagag	ctgaatttag	atttccact	ctgtctggaa	70800
taatacacac	ataacaaaac	agatactagt	caccatctc	aggacccaag	tattgacctg	70860
gcaagactca	aaacttggtt	catttggcct	tgctcatctt	gatccactca	agctggagag	70920
ggatgacctt	cgatcagag	ttcagagggt	aaagcctggg	aaagattgaa	gagcagatga	70980
taccctgtgag	ttaggcttgc	tgagattcca	ctagcaactc	cttcaggact	aactgaatgt	71040
gactgaccaa	ccacaaaact	aaatacatat	ttcccttgagt	ttccactagt	aattcttcca	71100
gggatccccct	ctcagactcc	aaatcccaag	aaacaaactc	ttccactagt	aattcttcca	71160
catataaagt	ttoagactcc	tctcctccaa	acacaaactc	ttccactagt	aaagcacttt	71220
tttttccatc	tgaaggagga	caagaacctc	ctcacttgag	cctctcttgc	gagcagaaag	71280
acaaagccaa	aaagaggcca	ctgagaacac	tgaaagtoga	cactgcccgt	ccaacacaga	71340
gaactggggg	gcacagctgt	ggttgtgtgc	aaactaagcag	cttcttgagc	ttctctctgg	71400
gggttctctg	ctgacagaaa	aggttgcact	tgtaggttaa	tgactgcaag	gagagtggct	71460
agggcccccag	taaggccctt	ggcactggac				71520
gtcagcccca	gtggcactgg					71580
						71640

tgccatgaat	ttttttttct	tttctlllll	tttttttttg	agacgggaatc	tcaatctgtc	71700
tccacggatg	gagtgacgtg	gcacgctctt	ggctcactgc	aacctctgcg	tccacggatc	71760
aagtgattct	ccagcctcag	cctcccaagt	aacgggattc	acagggatgt	gccacatgc	71820
ctgggcaact	tttgtatttc	tagtagagac	aggggtttcc	catgttgagc	agcctsgtct	71880
cgagctcctg	acctcaagta	atctgcccct	cttgccctcc	taaaagtgtc	ggatctacagg	71940
tgtgagccat	catgtctggg	tgcttggcat	gaatttttat	aagatctgtaa	ggcttgatgt	72000
cttgcgtgtg	agcaacagaa	tataccaaga	gaatggagtt	tgcaacagag	agttctaccaa	72060
tctgaaggtc	accaacacaa	gacatgagaa	caattctcaa	gcctcaaaac	cattctcactg	72120
aagctttctg	ggcaagaatc	tttgaaaggg	gagtggtctg	aaaaattgag	tcatcaattg	72180
attcgggtta	gggggctgaa	atcatcagga	tatggaaagt	acattctccc	caagtctgag	72240
ttctctgtca	agcctttcag	aatgggtggc	atcagtagtt	ttgttagtat	gcagaaaccta	72300
aaggagaaac	tcaaatggaa	agtttgtcat	ctcatattgt	cttaaaattt	aactcaaaag	72360
cagaaaaaga	acaaagattc	tagtgacaaa	gattatgtta	tctctggacta	gtaatcagtg	72420
accagctata	aggaagtggg	tcaatggaaa	gcagcctcaa	tgattaccat	tgaattgtctt	72480
caacgacctg	tgaattttta	ctttttctct	ctlaactggt	tttaaaaatt	ttttgaggat	72540
gttttcaatt	taaaaaagga	gcaaaaggcaa	ttcaataaag	aaaaacatagt	ctttttaaaca	72600
agtgatattg	gaacagtaac	gcattccaaat	gcaaaataat	aacctctctac	attctctctca	72660
tacctctcat	aaaaattaac	tcatataact	asgtglaaaa	tgtttaacct	tagaagctga	72720
tatggctctt	glltagggcaa	ggaattttta	gatgacacaa	agagcgtgat	ctataaatga	72780
aaaattgtgat	aacatcaaaa	ttacatactt	ttgctcatga	aaagagacta	ttagagagaa	72840
aaatgaagct	acagatgcga	gaaaaatttt	tgcaaaatat	ttaactcagtg	aagggtctgtg	72900
agccacatac	tatcatgtag	tctcaaaatt	cogtaatgga	agaaaccaact	caatggaaaag	72960
tgggcaaaat	ttagacsgtg	ttccaccaaag	gaggtagacat	gatggtaaat	aagtacaaag	73020
aagatgctaa	gcagcatatg	tcacltaggga	atgcaatacc	atcacacaca	tatttagaaag	73080
gataattttaa	tggaaaaaaa	nacacattat	ctcaaaagct	ggcaaggttg	cgaaaccaact	73140
ggatctccaca	taacattagt	atgtgaaggt	acaaatgtat	atcgctcagg	aaaacagttt	73200
gtctattttct	tataaaaagt	aacacatact	tgatgatgata	tttgctatgg	gtttttaaaa	73260
aatagctctt	ataaatttga	gatattgttc	atcaataact	agttttatga	gtttttttac	73320
ctcgaagggg	tgtgaaattt	tattgaaggg	ctttttctgca	tctatttgatg	taatttatgtg	73380
tttttttgtca	ttcaatttat	tgaatttgat	atgttgaac	agcctctgcat	ccacagagata	73440
atgggagact	gctcatgggt	ataaagcttt	atcagggata	ttgagctgtg	ctttgcagag	73500
attttattga	ggatttttgc	atgtgatctc	aggaatgatc	ttgctccala	aaatgagtta	73560
ctctgttgtg	ctctgcaggg	tttttggtatc	aatagtttcc	aaaggaaagg	taccaactcc	73620
aggagggagc	ctcttttttc	tatttgtttga	aatccatctg	gtcctgggct	attttttgggt	73680
tcttagtagaa	tctggtagaa	tttggctgta	gaactgtgtg	ttggcctatt	aggggtcttg	73740
ggcaggctag	taatttactac	cacaattttca	gtgtatgtgt	ccaggaaatt	atccattctct	73800
acctctttct	ctctgctttag	tgttggggagc	tggttagaggg	tggttatagtg	gggtgattgtg	73860
ccacagattt	ctacttttat	tgatcagctct	ttatctgtct	ttgttttaact	ttttctaaaaa	73920
attctctctgg	gacagtlggt	gataccctct	gtatgtgtact	ttcttatctc	caggtctgtct	73980
ctctgctctt	ctctctttatt	agtatggcta	gglllctcatg	ttgttttgcct	ttgtctctct	74040
ccagctctctg	gggtgoattga	ttttttgaag	gcttttaggg	acatgtgcaac	taagtgaggg	74100
ctgatctctag	ttattttctg	tctctctgcta	gggtgtgtgc	accatttaac	tcttctattta	74160
atactttcttt	ttattttatt	tataaccttaa	gcttttaggg	cccccccccc	aacagggccc	74220
ttagtttaoat	atgtataact	gtgccatggt	gggtgtgtgc	acccatttaac	tcttctattta	74280
acatttagctt	tatctctcaa	tgtataccct	ccccctcccc	cccccccccc	aacagggccc	74340
gggtgtgtgat	gttccoccttc	ctgtgtccat	gtgttctcat	tgttcaatttc	ccacctatga	74400
gtgagagcat	gcgatgcttg	gtttttttgc	attggcatag	tgttctgaga	atgatgtgtg	74460
ccagctctcat	ccatgtctct	acaaaggaca	tgaactctct	tttttttatgg	ctgcatatga	74520
ttctatgtgtg	tatattgtgc	acattttctt	aatccagttc	atcattgttg	gacattttggg	74580
ttgggttccaa	gtctttgtcta	tttgttaatag	tgccgcaata	aacatacgtg	tacatgtgtc	74640
tttatagcag	catgatattat	aatcctttgt	gtalatacc	agtaaatggga	tggtcaggtc	74700
aaatggttat	tctagtataa	gatccctgag	gatctagaca	atgaacttcca	caatggttga	74760
actagtttat	agttccacaa	acagtgtaaa	agtggtccta	tttctccaca	tctctctcgg	74820
caacctgtgt	tctctgactt	tttaaatgac	gcatctctaa	ctgggtgtgag	atgttatctc	74880
atttgtgggtt	tgtatttgcat	tctctaatgt	accagtgatg	ctgagcattt	tttcatgtgt	74940
ctttttggctg	cataaagtct	ttcttttgag	aagtgtctgt	tcatatccct	caccacacttt	75000
ttgatggggg	tgttttgttt	ttctcttgaa	atgttgttga	gattctggat	gattctggat	75060
attagccctt	tgtcagatga	tttgtctgtg	aaatattctt	ccccatttgt	aggttgtcgtg	75120
ttcaocctga	tggttagtttc	tgccatttgt	tttgtatttt	tagatttcat	tagatccocat	75180
tttgtcagtt	tggttgtgtg	attgctcagg	ttttttttta	tagacatgaa	gctcctggcc	75240
ctgcoccatg	ctgaaatggt	ccatcttgaa	tttaatttga	gggtttttat	gggttttagat	75300
ctaacattta	agttcttaalt	ccatcttgaa	tataaggggt	aacgaaggga		75360

tccagtttca	gctttctaca	tatggctagc	ctgttttccc	agccaccatt	attaaataag	75426
gaatcccttt	cccatctctt	gtttttctca	ggtttgtcaa	agatcagatg	gttgtggata	75480
tgtagcatga	ttctctgaag	ctctgttctg	ttccatttgg	ctgcattctc	gttttgttac	75540
cagtaacatg	ctatttttgg	tactgtgggc	tttgtgtata	gtttgaagct	aggttagcatg	75600
atgcctccag	ctttgttctt	tttgtcttag	attgactctg	caatgcgggc	tctttctctg	75660
ttccatataa	ctttttnaag	agttttttcc	aatctgttaa	agaaagtcat	gtgtagctgt	75720
atggggatcg	catgctgcga	aaggtaattt	atagattcca	tgcacatccc	atccagctct	75780
atttctttta	attgtagctg	taggggtgtca	agtttagatc	tttcccactt	cttgatgtgg	75840
gcatttagtg	cgataaattt	tcctctaaag	actgccttlaa	ctgtgttccca	gatattctgg	75900
tacatttgtgt	ctgtctcttc	attggtttca	aggaacttat	ttactttctg	cttactttca	75960
tattttactc	agtagtoatt	cagtagcagg	ttgtttcagtt	tccatgtagt	tgtagtattt	76020
tgaatgagtt	tctttaatct	gatttctaatt	ttgattttcac	tggtgtctga	gagactgttt	76080
gttgtgtgtt	ttgttctttt	gogtttgtct	gggagtgttt	tacttccaat	tatatgtctg	76140
atottagaat	aagtgtctatg	tagtgccaa	aagaacactc	gacttctggt	ggagagtctt	76200
gtagatgtct	attaggtcca	gttggtccag	agtttgagttc	aaattgggaa	tatcttttgt	76260
aattttctgt	ctcgttgtatc	tgtctaggat	ggacatagta	ttgggagttt	tgcacacagc	76320
aatcaggcaa	gagaaagaaa	taaggagtat	tcaaatagga	agagaggaa	tcaaatgttc	76380
tcctttttgca	gagacataga	tggtatatatt	agaaaaacct	actgtcttca	cccgaaactc	76440
ctcttaagct	ataagttaact	tcaggaaagt	ctcaggatgc	aaatcaata	tgcacaaactc	76500
acccagcttc	ctatcatcca	gtaatgagca	gaaagccaaa	tcattgagtta	aaataaatag	76560
acaaattgcc	caagaataat	aaaatacgta	gaaatacaac	ttacaaggcc	tgccgaaggaa	76620
ctcttcagg	agaaactcaa	accactgtct	aggggaataa	gagaggccca	aaataaatag	76680
aaaaaatattc	catctctatg	gatagggaaga	atcaatatca	tgaanaatggc	catattgtccc	76740
aaagttagtt	atcacatcaa	tgctattccc	acttagctat	catattcttt	ctttcacagaa	76800
ctaaagaaat	tgctttaaat	ttcatatgna	accaaaaaaa	ggctccactc	agccacagaca	76860
actctcaact	aaaaagcaca	agctgtatga	tcacgtctac	tgatttcaaa	ctataactaca	76920
agactacagt	aaccacaaa	acttggtact	tgtaccagaa	ccatttatata	ggccaaattga	76980
gcagaaacag	ggcctcagaa	ataaacacc	acatctcaaa	ccattgtgct	ttcaacaaac	77040
ctgcacaaaa	caagcaaatg	ggaaaagatt	ccctattgaa	taaatgtgtg	agggaaaaatt	77100
ggctagcctat	atgcagaaaa	ctgaaaactg	acccttccct	tacacctaat	ataaaaaatta	77160
acccatgatg	tattaaaagg	ttaaatgtaa	gacctaaaa	catataaaac	atagaaaaaaa	77220
actatggcag	taggtttatc	aggacatagg	catggggaaa	gactttatga	ctaaaaaaccc	77280
aaatgcgaat	gcacacaaag	ccnaaatgta	caaatgggaa	ctaatcaca	taaaagagctt	77340
ctgcacagca	aaagaaacta	tcactagagt	aaatcaaga	tctacagaa	gggagaaatt	77400
ttttgcnatc	tatccactct	acagaggtct	aatctcaaga	atctacaagg	aacttaacaa	77460
attttataag	aaagaacaaa	acaaacctat	caaaaagtng	gtgaaggata	tgaacagaca	77520
cttctcaaaa	gaagacattt	atgcagctag	caaatcatgt	aaaacaaagt	taattgtcact	77580
ggctcatbaga	gaattgcaaa	tcaaaaccac	aatgagaaac	caattcaocg	cagttagaatt	77640
gcgcgatcatt	aaaacatctg	gaacacacag	gtgctggagg	ggatggaggag	aaataggaaa	77700
gtttttactct	gttggtggga	gtgtaaatta	gttcaaccat	agtgggaagc	agtggtggcaa	77760
ctctccaaag	atcaagaacc	agagatacca	tttgcagccat	caatccactg	actcgggtata	77820
ttccccaagg	aatataaatc	attctactat	aaeggcacat	gcacacatat	gtttttacaca	77880
gaccatcttg	cagtagccaa	gatttgggac	caaccacaa	ggccatcaat	gatagacttg	77940
ataaagaaaa	tgtgggcact	atacaccatg	gaataactatg	cagccataaa	tgaattagtt	78000
tcgtgtctct	tgcaggagaca	tggacgaagc	tggaaaccat	catcttccag	aaactaacac	78060
aggaacagaa	acccaacac	cacatattct	cactcataag	tgagagltga	tcaattgagaa	78120
catcagtgaa	tagggggggg	aacatcacac	acogggggctt	gttgggggtg	gcggggaaaag	78180
gggagagaga	gootcaggag	aaagagctaa	ttcatgcgaag	gcttacaacc	tagatgcagg	78240
gttgatcttg	gcagcaaac	accatgggac	acgtataact	atgtanacaa	ctcgcagagtt	78300
ctgcacatat	attccaggaac	ttaaagtata	ataaataata	aacacacaca	caacacacaca	78360
caacacacaa	caacacacat	ttatctasca	aaocccagct	tagatatact	ttccatgagg	78420
ataaatttgt	gtttatataa	aaactgcaga	tgaattattt	ttttaacagc	atgatttcaa	78480
aatgccaaaa	acaaatgcana	tgoccttcaa	ccatgaaag	ccatgacaga	ccgtgatata	78540
tgtatataatg	gaataaactc	tagcaataaa	aaaaggtgtt	ctgggttagtg	tgtatgaatt	78600
ctatgcactt	cagcccaatt	ctcccagag	ctgnaactc	ttcttgtcta	gtgcatccac	78660
agtttgaact	actcgtctgt	tactcaactc	gtagtctttt	atgaaatcct	atgcattcca	78720
gctccatccc	gccagagaca	tgaactctcc	ctctgtctag	tgatgcagc	acccctgttag	78780
tcacttagta	gtattccaa	ttactcaggt	gaaaaacata	gtctacttgg	gtttttactat	78840
ataatcattt	tcgggcattt	actggggagc	ctgggaactc	ttccacatga	ataagaggga	78900
ctagtgcagc	ttttttctct	caacaggtta	tcagagactc	tcgtctctac	ttcagagagga	78960
tcatttcagat	ggcactagta	attcaagttt	tacaagtcaa	gagaaattga	tactctgtga	79020
ttatctctgc	aaatttttta	tttaaatgac	tattttaagc	gaaactacac	ccagtttga	79080

ttcataaagg	atcacactcca	atatatatct	actgtactcca	ctcaagtatg	tttaattttt	79140
tctgcataatt	ctcacacacat	gggttatgagg	aatcttagatt	tattataatt	gaaaaaacat	79200
gtgatctcact	gacaaattgac	tgtacatgaa	aatataaactg	tgtatatctca	atctcgaaagt	79260
gaagctcagga	cttggttaatt	atatgacaac	cgttaaagtag	claaataaact	tgcctaaaggt	79320
acagggtctca	gcaltgaagag	taaaaatagta	acattctctaa	gaataaacttg	agccagacaa	79380
actcttgggcca	aeagggaaaga	aggaagggag	gaagggaagg	aggaagggagg	ggagggggagg	79440
agggagggagg	ggaggttgaca	gagggggagg	gggaagggag	ggaggggaagg	aagaaagaaa	79500
aagggaagaa	gaaaggaagaa	aagaaagaaa	gaaagaaaga	aagaaagaaa	gaaagaaaga	79560
aagaaagaaa	gaaagaaaga	aagaaagaaa	aagggaaggga	aaggaagaaa	aagaaagaaa	79520
gaaagaaaga	ggaggggaaa	gaggaagaaa	gaaagagaaa	aagagaaagag	aaggagaaac	79580
gtagacagaa	aaaggaagaa	agaaaaaaga	atgaaagaaa	gaaaaagaaa	gaaggggaag	79740
aagggaagaa	agaaagaaa	agaaagaaa	aagaaagaaa	gaaagagaaa	aagaaagaaa	79800
gaaagagaaa	ggaaggaagg	aaagaaagag	aaaaaatag	tagttgatgc	tacaatcagc	79860
tccaaaatcca	aaccaagagg	catataacgtt	gattgagttg	tttgaratca	ggagaaattg	79920
catatcttaat	caaggcatat	tattagctctc	aattaactctg	tgaagaaaaa	ataaaaagta	79980
atgggatcat	ctgcacatga	atgatgagac	aaaaagaga	ctgatgaagc	aaaaagattt	80040
gggtgnaagg	tcattgatctg	gggtgaaagt	catatccata	cttatataaa	acctataata	80100
ataaaattctc	agggagtgga	ggttgcagcg	agggcagatc	gggcatttgc	actccagcct	80160
gggtgacagca	gtggagttctc	atctcaaat	aaataaataa	aaataaactt	aatagagggg	80220
tactgcgaatg	cttggttaaaa	aattgtttac	taatagtgca	gaatactcag	agtaaatagtt	80280
attgtgtgtg	tgtatacaca	cacaattgtac	aaaatataca	ataaaaaata	tactgtttga	80340
gaaaggtatc	ataaaattgt	ttagggaaat	gttgagtitta	ccatatttca	tttaaacatg	80400
aaatcacagcc	attatcatga	atnaaatcaa	cacaaaatat	ttttaaataa	tgaagaaagaa	80460
aggttaactta	taacttttta	gaataaagaa	tagtatatgt	ggcctatgtt	tttgaagttt	80520
actcttaaat	agaaaacaaga	aacatctac	atgaaaaagg	attgactatt	atgtagttaga	80580
atlgagcaact	tatgttcata	atgcagaaaa	aaggaaagaa	aaatactgac	cacaaagaga	80640
atcacatttgc	attacgtata	ataaaaagg	atttatattt	cagaatttgt	aagatgattc	80700
caactaatcaa	taccaaaact	ctcaaaaagg	taaaataaga	aatctaaact	cagtttagtgg	80760
agatataagag	catataaact	caattaaact	gggaatatat	attctaaacc	cgattttgtaa	80820
tanaagaagt	gocaaactac	actataatgt	tataaatctt	tatagccatt	tggtgatata	80880
ataataaact	gtgacatcac	caatcatcaa	catgtaaaag	tagaatatgc	acaaagcttc	80940
aatgtatgtt	ggaataaata	ctgtaggaaa	ccttctagag	tagaatatgc	tgaaaaaatg	81000
agaataacoc	ttgtactcta	catatactag	agaaagctca	atagctttac	ttataattta	81060
tcataatcact	gcttgaaat	atgaattatt	gggtatcatc	gtatttactt	tcatttttaa	81120
acctataattg	tataaattatt	ttgagtcaaa	tgatttgatc	caatgtacat	attataattg	81180
ataaggagt	tgagaaaaaa	ttgttttaggc	agataatcag	ggtcacagag	tccttgataa	81240
ggttttctct	ttbaattgana	ggcagccccc	aaatcctttt	cttttctaac	aagaggaggcc	81300
tgtaaaatctg	aactgcacac	atagacaagc	aagctggag	cttgcaagggt	gaatgcacag	81360
agttgtgcga	atggggaaaag	gctacctggg	actaggcatg	ttcatatgtt	aggtgtactc	81420
ctctttctct	ttgttcagcca	cgtgtacagt	aaggagaaa	caacatctgg	ctggccagag	81480
aaagatccca	ttcgattcaat	aagattaggg	tggggggggc	agcttctctg	catattatgt	81540
aaatgtcaca	cctgattttaa	ccaatctttg	ggccctatgt	aaatcagaca	ctgcttctct	81600
agaagccctgc	ataaaatcta	gtgcactcca	ccaggggcag	ggattcactt	ctcaggtgccg	81660
ctctctctcca	caaagagagga	agctgttctc	ctttctcttt	cttttgctta	ttaaaacctgt	81720
gctctctcaac	ctctctctgt	ttgtgtctca	cgctcttaat	cgattctcatt	tgagataaag	81780
aaactccagat	tttataccag	acaattgatgc	cgcttcaata	ccattctcatt	taaacacaaa	81840
gtaltgtgtgt	caaatctctt	tactgttatc	ttgactaatg	ccattctcatt	ggagacttta	81900
tttttaactat	tacttatcaa	gaaatttgta	tattcattta	tacacagtgt	aaaaaacaaa	81960
actcaaatag	tccatttggt	aaaacaaagg	gacataaaca	ttttgcaca	attaatatag	82020
atgagtcttta	gaatgtctat	tatgtttactt	agaaagacat	gaacatgcta	ggattttcaga	82080
gtagtgtact	tactgaacag	gatgcactgt	ggagttaggg	accagccatt	ctccataact	82140
gtaacctgtg	tctgcgtttt	tggagagagc	tagccaggat	ggcagggaac	gttatagatg	82200
tctccctgtta	caaaactttct	tcaatgattc	tgatttatatc	cattttccaa	atggagaaaa	82260
tancatttttc	ctcaggacca	taacaatgat	aaataaataa	agtaaatgag	aaactataat	82320
tttgtccaaa	tgtataactg	caatttatitt	tacaattatt	aaataagatt	gcntaaacat	82380
ccaaaataaa	tgataaactg	aagaagaaact	aaagtattata	acaaaggttt	gcacaaaag	82440
aaatatcaat	attcaaatatt	acttatcttt	agtttttata	ataatagat	gtataaata	82500
tatagataatt	ctcataaagt	ccctatatatt	atttctctgt	tgattttcaa	gaagaaaacc	82560
tctaataga	aaagatctat	tttgtctact	tgtcgtgaac	aaactctttc	ttggccctat	82620
tcttggtaca	taagacaggt	gtaatcactt	atgtgcctct	ctttctctga	tctttggaag	82680
ttttatcatat	atatatagca	gttcagagggt	ttactactgt	agggcagyla	ctgctggcga	82740
cttaccactc	ttgtgtaagt	gaatgtgact	ccagtaactt	cctgagggag	ttcacaagt	82800

ttoatcacag	taataggagt	aatatttttc	tacagctact	ggaaagtatg	gtctacagcat	82660
tatctcatga	tatagacctc	catgtttaat	gtctggataa	tcacaaaggt	tcacttcgaa	82920
taaaaaatft	aaaaaaagta	taaaagaaat	tactgttaat	aaacactcat	atlagagata	82980
aattttatct	actgaattat	attctctctc	tagtataa	acacatlcca	ttagggttctc	83040
taggttcaaaa	caaatlgatag	aactcagatg	actgagatat	gtacaaagaa	gggtcttctgt	83100
actgaagatg	aaatttatgt	ttgtggatca	catgatcggt	aaatttgat	gaaggtctctc	83160
cagaaagaaa	aaatgcacga	cttatftaat	alatftccct	taaatacaca	taccotatcc	83220
ctggttaaat	aaataagctt	ttcgggtgag	aaatatgcoc	attttacocg	ttagctcatg	83280
tattttcttct	ttctttctct	tctttttttt	ctattctcat	cagtaaacaa	gagccctgca	83340
ttttcttctc	agaacaatct	aatgtaagga	agtagtattt	tgagggtatt	aaggttttla	83400
tttgttttag	attgaattca	tggtgtgggt	gcagtggcto	acgcctgtaa	tcccgagcat	83460
ttggaaaggt	gagacaggca	gataactcgt	aaggagtctg	agaccagctg	ggccaaatcg	83520
gtgatactcc	gtctctacta	aaaaacaaaa	aaaaatttag	cgggctctgt	gggtgcgccc	83580
tgtaattcca	gctacttaga	aagcagaggg	aggagaatcg	cttgaaccga	ggaggcagag	83640
gttgacgtga	attgagattg	tgcttttgca	ctccagcatg	ggltacacag	tgagactcca	83700
tctcgaaaaa	tataastaag	taataataata	aattaggcto	tttctatttt	attgcagaca	83760
actgtaaaat	atagagaata	acaaaatatt	ttctttgatg	atcccgcgca	gaaaaataac	83820
tctgttaatt	gactcctcaa	acsaattoatt	aagccaaagtl	ctccagctcg	tatttaaccac	83880
gagaaacaga	ctagaataat	ttcttcttat	ccaaatagtt	aagattttga	ttacactttt	83940
tgttttattc	taatttttaab	tgagagaaaa	aatataattg	atgtcataaa	atataatttaa	84000
gtaaggatca	atataaattac	attttactga	gttattatat	attaaatttg	acaaatatac	84060
ttgactgcta	ttctgtttlat	tatatataca	ggtttatata	tttttcagaa	aatttgctct	84120
tttctatgga	tattttgtbag	attatctagt	actttcaata	acaaaatggg	attaagtgtt	84180
tcactgaata	atgtttcttat	ttcaataaac	cttatgcacat	aggtttaaaaa	gaatttcaat	84240
acacacacac	acacacacac	atataaatat	ttttttacat	ctccatcttt	cttaaatctt	84300
gggattttatt	ttcttttgta	tttgattaga	gaaattttca	tgagtgttt	actattttta	84360
tgttgattat	aaactgaata	attgatatct	ttaaatgtat	ttctcttaata	aagactagtg	84420
aatgatacttt	cttttcagtat	agttttctgg	ctccacatct	atatacttta	taattgtatg	84480
attttttttc	ctatttttat	gaagctccca	gtgttgaaat	taaaaacatt	acttagtctt	84540
attttttttt	agtaaacatt	tacatttttc	ctccaccatt	tttaaaagat	tggaaatatt	84600
tttattttac	attggatttt	acaaaattca	ctcatgattg	tttagacatt	tattatttaa	84660
ccataattct	attggatggaa	agcttgagtc	ttggatttgt	gggagctgtg	ctttaaaagg	84720
ctcaabtga	ttctacatta	aalgggtagag	tagagatttc	aaagctcttg	gttgatttca	84780
aagcaagtat	gagtatccat	cttattatgg	tatttccag	aaggctcata	ataaaaaatt	84840
tcaccacaga	tttttttcca	aaaggaaata	aaaggaggca	taattaaaaa	catataaacct	84900
tcaccacagg	tcogactatt	tagctatctt	ctaattttgt	cacattttaca	tctgtttttta	84960
tcactttttac	aaatttgatt	cttgaagcaca	atatttagtat	ccacagagag	ttctcatcgc	85020
gttgagaata	gaaggagcttc	aaatagcttc	attctacttg	ttacactctt	acaaatttag	85080
ttttttgttt	ccacagcattt	atgggttttc	catcataaeg	ttgggtccaa	cagactcttaa	85140
aatgtataata	aatatctcaat	aattttttata	actgctgcta	atatattctat	actgttaattt	85200
atttgaccaca	agtcocaggat	cttagagcca	acatltgtta	atttcaactt	attagatltca	85260
gotttagacaa	taagagctct	tttgaatgct	gaactgcctt	aatgacagatt	ccottattatc	85320
actctctgta	tcattccaat	tgtgaattgt	tactgcactt	ccctcaaatc	atlaaacctgt	85380
tcactgacac	aagtgagtaa	tgaagcaggc	ctgagaataa	agtcactgct	ctgatataata	85440
gattgtggtta	tttaactgaa	ttaaaactgt	ataaacata	actatcatca	actctctctat	85500
cttggctcatg	agaactccag	atggttcatt	gtcaaaacatt	aataattgaa	atccaaatatt	85560
agttgttcct	cagttgtgtt	agctacattt	gggtgtgaac	acattgtcat	gggccaacca	85620
taaaaactcat	aaatattttc	ctcataactt	ttatgcacac	tgaatgttt	catactagata	85680
atagctctct	ctcttagggga	ttgggaattat	gccagggaat	aaagttgaag	taacttaata	85740
actattgtga	tcatattttt	tttctatgga	atatattagt	taagttgtagt	actctctgtc	85800
tatgtactta	tatgatagaa	gaaaagaaat	ttgatgtgtg	agatagaaaa	aacatttaaaa	85860
aggggttaag	gagcatccca	gaataaaat	actctattga	cttgagtggt	attttgtcat	85920
attgtatgat	ttttggaatt	taactccaaac	actaggaat	gactaaagct	tggagctcct	85980
caacactctc	cctcccaaat	agtggtgcct	aattttctct	cccttggtata	tatgtctggac	86040
ttagtgtctc	aacttogaag	aatagatagt	gtcgaagtgt	acagtgtgtg	agtgaatgat	86100
tgaatgggtt	tggtctctgt	tcctccaccca	catctcatgt	tgaattgttaa	ttcccactgt	86160
tgagggagggt	gtatggatca	tagagggtga	ttctcccctt	gtgttttcca	tgatagttag	86220
tgagtctctca	gagacactcg	ttgtttaaaa	gtgtgttagca	ctttcccctt	tgctctctgt	86280
ctctctctct	ctgcacatgg	aagatgtgct	tgctcccctt	tcacctccca	cccatgtgtg	86340
aagtlttctca	aggtcctcca	gccatgctct	tgctacaggg	ttgtggaactg	tgagtcaatt	86400
taacactcttt	ttctctataaa	ttatccagtc	tcaggtagtt	cttctctagta	gtgtgagaa	86460
acactaaac	atgggtattgt	ggcttctctc	attctcagat	tagcagtgct	ggagaaagct	86520

gcacatttate	aactcatgga	aaggccatag	tggtaaggac	ctgaggccctc	ctgacacagac	86580
ccatgtgtgt	cagtaabtgt	agaagcagat	ctcccttccc	agccaaagcct	tctgatcact	86640
gtagcctggg	ccatgatcct	gattgcaaca	cagaagacga	gtctgatctca	caactactcta	86700
tataagccat	tttgagat.ta	ctgaccgata	gaactctgaa	gataataaag	cttagtgtgt	86760
taagtaaat	atgttttttg	ggatatttgt	tacaatgcaa	taataaacta	atctagtctg	86820
tgttagatga	cattattttt	atctagtgtt	ttaatlcaga	ttttgggaag	attataaat	86880
tagggaacaa	tacatttcta	aacacacata	cacatttaat	tttgagtatg	aaaaaaactg	86940
agttttggcca	acttcogaaa	actaagaatg	cttccaaacg	ctctactttg	tateracaat	87000
aagacaaata	tttgggttta	tttagtccct	alttttttat	tgtttaaaag	aaatttcaga	87060
atnagaat	gggtcgaagat	atgaatggaa	cttaccggta	catctcggag	caggatccca	87120
gcagtaactt	gtgcattttg	ctgtatttcc	ccgggttgca	ggataaaaac	catlttcaca	87180
ctgttcactg	atttcacttc	cagttctgtg	tttaactcct	aaaggttgat	agtcacactt	87240
tgggaataaa	ggattatcac	atgatttttc	tgaanaagaa	aaggatataat	ggataatgca	87300
gaaataagta	tcogttaaaa	ttaatcattt	atataaacat	ttaaaagtgg	gtgttattta	87360
tttgcctcta	gcataataca	aaatggcatt	aaatgaaca	catcatagta	tcctttctcg	87420
tatatcactt	atltttccct	tcactatatt	ctcatctgac	atatttgcac	ctccctggct	87480
cttaactcct	tcttctccaa	agtcattccca	tacttcatga	ttttccataa	ctgggcaagt	87540
tctcatcaca	tataactaca	attcttactt	tcactttcct	tctatttctt	ggtttctcgt	87600
gttctcataa	ggatttgttta	caaatattca	gtgttttctt	ctctcggaca	atltgataag	87660
ctggccaaac	ctctcctctt	gaagtaactg	tggccactgtg	attgcgtagg	agactataat	87720
aaagtgtgaa	ctaatattct	ccactttaga	gagaagtctt	aaaagccatt	gtgtgaattt	87780
ttatgtctct	ttttccaaag	atcccgcat	taaggaagga	catgaaaaaa	aatgatgttt	87840
ctgtcaactg	atbcttaaaa	ttaatcaaat	gagtaaaagt	cctctcgtac	tacattgaca	87900
gtgaactgga	atgaanaaat	acttcagttc	taatatotta	acatttgaga	tactcgtaca	87960
ctttttctct	actataatag	gataanaatg	cagaggggtt	ggaaaaacct	ttccgttaag	88020
ggccagabaa	aatgtctctg	ctgcaaacac	tcaactctgc	catatatagta	caaaagtaat	88080
gaataaacat	taataaacaa	atgaacttgg	ctgtgtttca	ataaaaactt	gtttcacaaa	88140
agggggccag	ttgtatttta	ctcgagcct	atagtttgcc	acotttggcc	ccagttgtac	88200
ttaatctata	agggcaacttc	tcactccttt	ccattaaact	tgtctatatc	caatatggga	88260
tcactttgca	aaatttcgtt	taagataaaa	tactatgatt	tttaagtatt	tggaaaaaac	88320
tatatgaaca	cttctctatg	agtoaatatt	tttttggac	taaaagctg	tggcaaacat	88380
tcagacttgc	ttctctatgg	tttatatacc	cccaatctct	ttactatttg	atlttcccatg	88440
gtaaatgalc	catagtctcc	tctcttttct	caagcoactc	gaacaaagt	ctctctctac	88500
aacagataat	angtctccat	tcacacaaaa	caattggagc	cagcagtagt	yagtttctca	88560
tacttctctc	cagcactcct	caacattatc	tglatctata	ctgattttag	cttttagttt	88620
agtccttcagt	ggtaaatgtg	tgttttcaaa	ttcagggttag	ctttaattct	tcacttttcc	88680
ctgtcatttt	aaacocattgt	ttattccttc	ctctcttctt	accttatcaa	ccacacitct	88740
aaattgatata	ggaagctttt	ccaatcttca	tgctccttcc	tcaacctctt	gtctcaagtt	88800
agctaatgta	ctacattttct	ctcccccctc	aaaaaccaaa	tcaataaaat	accattttat	88860
aatgtctgtc	tcocattttcc	cgctccacat	ttattcttta	actcagactc	acctgaattc	88920
tgactctctat	tttgtgtgca	ttgtctcgat	aaaagctcac	actgaagctc	actgtccaat	88980
tcagaaatgc	tttgcatttc	acatatccca	gtcactggta	catattatgg	actcctttaa	89040
tatttatatga	actgaacaga	taaaaactctg	taaatattga	ctctgttgat	tacataactt	89100
tttgggtgtct	ccattacact	atahattttat	gttctcctgc	ttctccttgt	ctttgtctaa	89160
tgtatgtctt	tccttttatat	ctattatttt	tcctttactt	ctctctctct	gtctctctcc	89220
tttgcctctta	cttaattttt	taattttttg	gcctcgata	cttgcacact	ctcatctcct	89280
ggcatttttc	tactctctct	ctatactacc	accatttctt	cttcataact	tgtaattatg	89340
tcacacataa	aaattttata	agtttttaatt	attcattata	tatttctcct	ttctaatacc	89400
ataactccac	tgtgtccatt	cagctcctaa	ttttataact	gttctcgaca	gaataagctt	89460
taatatctct	ctatagctaa	caggataata	tatttagatt	agcaataaatt	atatgagaaa	89520
ataatgttat	gtcacttaat	atcacaagtt	taaaagctta	ctattttaaa	attttactat	89580
tttatgtctta	aaatgtctct	cagtggtttga	tgttgacaat	aacttcaaat	aagtctctaa	89640
cttatgtctct	ttttcttttt	lletgtcact	tcatttctct	ctatctatct	ttcatatacc	89700
catlaaagtt	cagtttttgt	atctccaatt	atttttccct	atgatatagc	tcaattttaa	89760
accaaatttt	gaagtcaaaa	gotatgagat	gcacaaaaca	agagtttaac	taagaaatca	89820
ataaaataat	atggacaacat	tttgttaatt	agaataagaa	agactctcgt	tgattatgct	89880
caagcagtag	acataaaatc	tgtgataaac	aacctctgac	agacatttga	atctttttaa	89940
aaatacatca	tgtttattaaa	acattgcccg	caaccttgaa	tttatccaaa	acaaatactg	90000
agactatcca	tatttttcta	ctattggaaa	caactatggg	ttcatttgaa	ttagataact	90060
aattcaaggt	tagcactcta	tgttttgaac	caatagaaa	tccaatctgt	acagggaaag	90120
gatagattcg	gatcaaaagt	agctttccct	lagicagttt	tcgtaccttt	gtgtttttct	90180
ataaataact	ttctgttaca	gattgtccct	atggacaaa	gagacaaaag	tttttgacaat	90240

tcaccccttaa	atcagctctc	tgcacatggt	gtgccataga	ccagattgaa	gaaaaattaa	90309
gtatttaaaaa	tttaagtaga	ttatttcact	ttaatattat	cttattatttt	aattcccaac	90360
ttctttataga	tttagaagca	acaaagagag	tttgaagtta	ccgtgatttca	gagaaaatga	90420
tggtgtataga	ttttgaattc	atcttatatc	agcaagtaga	tccttgctttt	gtaccaagaa	90480
aatagtcata	tttatgctat	attagtttggc	atccaaagag	tggaattcttt	ttactaagaa	90540
agactctctct	atatctaatc	agcgtaaagt	atatttcaat	aaaaataaac	gtggtgagag	90600
agtggtatgct	taactaattt	gggataaact	ctcctttatt	tatatcgatt	attagtgaaac	90660
tgctctcttga	aaaggagtag	ccaatccacg	tgctcttctt	tggtatctct	tttctctaaag	90720
aaagcaggac	ctgcaagcat	agratctgaat	attcagggttt	tacttgtact	tgtagctgag	90780
aaatggaaaa	aaattataaa	agaaaaatgt	tttataaatg	tgaggtcttt	gaggggtgtg	90840
tggtgtgtgtg	tggtgtgtgtg	tgatcaaat	agtggtcaag	agaagcaaga	atagaaatgc	90900
agtaatacat	ttgggaaaaa	cagatggatc	tctcattgtg	aaaaacaata	tggtgtaagg	90960
aaagattttta	agttaggtatc	aaagtgaaga	agtaaaagag	acgaaaaaat	cagatgacta	91020
caatgaggta	gtaatgctac	agagtcacat	attcaaataa	aactaaattc	ccagagtctt	91080
attttgtaatt	cattgaaagc	tggaaatgat	gtltatttga	atgtttattct	tcaatacaca	91140
gcaaggtctct	gatgtaaaat	aegtgtgttta	taagttacat	tttgattact	gcattggataa	91200
attcactata	gatttgagag	gggtctctgga	aataatatac	ttcaggtaga	agttaatgcc	91260
aaaaggctctc	tgactgtcact	tcctttgtct	aggaactacg	aattgcccat	gtacaaaatag	91320
ttgggacccca	caaccactta	gccaaacatg	gatctgatgt	gggttattac	tgctctcatgt	91380
tcattaatttt	ctttctaaaa	tattctctta	acagtgctca	aaagtagaga	tcaacgaatt	91440
gtgagagaaaa	atctgttttc	caaggagaca	cttgtgggct	caaaacaaaa	tttttttagt	91500
gtataaaatt	aaccacaaat	taactattct	tttgtaaaag	aggatttacta	aagcacagtt	91560
taaaacatgta	tgattgaatc	atgggatttta	aaagtccagag	ggctcttaag	agttcacttc	91620
ttctcttctct	ccagtatagg	cagtatcaac	cttttagatt	tttggttaac	atttggttaac	91680
actgttctort	gtttcactaa	ttgcagcaga	ctctatcaaa	agcaaaccca	ctttattttat	91740
aaagtgtttga	aaatatctca	aaactgttat	caacacacta	tagctgtagc	ttcttactgt	91800
acgtcttatgt	caactaattt	ttaaaaagtc	acaactgtcc	aatattctctc	ttcttggcca	91860
tgatagtttg	aaactttccc	gtttaaaatg	aagttaggtta	atagagaacac	ttctttccag	91920
tatatattttt	tggtgggaaa	agagcacagt	tgagaggaac	tcctttggctc	tgtagtaaat	91980
ccctccatata	tgaaagttag	agaggtttttt	tttttttttt	tggttaatttt	acaggacaaat	92040
ctacacogtt	gagtcactac	gggctgtgtg	tttaaaaaaa	tttcaacttc	ctccaaactta	92100
attcctatgtt	cagttgagag	ttctctcacc	tggtatttaat	acgaagtact	tttaaggtat	92160
tttaaaatcat	tcattataat	taaaataaatt	ctgggcataa	tgaggagcaat	ctactgtgtt	92220
gagaatttgta	tgttactgag	aattagggaag	tcattattag	tcctcaactg	gatccagaca	92280
tggttttttga	tgatagacca	atgacttaat	aagctactga	actttttctg	ccctgtttat	92340
gtctgtttttc	agagtgtgtg	tatctgaoga	agtgtaacta	aaatgaacct	tgaaacacaga	92400
aaatgctata	tgtttttttat	aatagtttat	ttacataaat	tagcactctta	cttttgatta	92460
aaataagttg	attttattaa	agaatttaatt	aaaatatgtt	ataaaatttt	aaagatccag	92520
aaaataaagg	taacattacc	ttcacatgaa	ggcaacggcg	gcatccoaag	tcagtgcaat	92580
acagcatctc	ctctttctact	gtattcatata	cccatgtttac	atttatattg	aaatcgctta	92640
ttctctcttat	aaataaactt	ctgagatata	ggagatccat	ttataaacat	tggggatttg	92700
ctcgaattatt	ctaaataaaa	gggattaaat	tcocaaatgt	ttattgcaaa	ttaaaggact	92760
gtgacccggga	cataactata	tgaaaacaga	aatgtgtgtt	ccatcaggtta	aatcagctaa	92820
ccaaacaaaa	gtttctgttt	gaattgacog	cttaataaat	gatttatctg	agaaagatta	92880
taaaattctgat	taaaaattatg	ctctgtgatt	tatttagttt	catttgattg	taagctctct	92940
gaaattataa	gtgacacgta	acattcatca	acgtataaaa	taaaatttgat	cataaataata	93000
gtttttattgt	gatgttttca	ctgaatgac	tgocaaaaat	aaacacattct	ctagtatttg	93060
ataagacag	aattataaac	aggaacttttt	gtcacaagaca	ttgatttaac	tcattgtcat	93120
tcacatctctg	aaagtaact	gacctgtttt	tggtctatca	ctatttagcc	agaatttctc	93180
cagaaaaaaa	aaaaatggcc	atcatctttt	atacctttta	tacccacttc	tctcaaacat	93240
ttttaccttg	gattgtgcna	atcataagta	gtttcccaaa	ctctgttctc	ccaactttct	93300
atccattttt	cttgtgtata	gcttaaatgac	ctctcaggta	gacacattctg	acactccaatt	93360
gaaactcttc	attgatccc	aaatcaactt	gaataaaaga	cgcgtctctc	agcactgtgc	93420
atgcagcacc	tcagacactat	gtattggccc	acctcttat	tatcactgac	tgcttcccta	93480
cttgcatctc	agactaaggt	gctaggaac	aatgggcaag	aatcagltgt	gcttcattgt	93540
ccctaaagct	ctactggct	tcacacttccc	tttccctgaa	ctctggtatg	cttttgctct	93600
cattttcatc	tacaaaaact	cgtttttttt	ctttaagact	taatcgtagg	ctatcgcaat	93660
tcacaggaagt	tttccactac	ccacaggaatc	tagttgtgaag	gatgtaaatt	ccatccatgt	93720
acttctaaag	tcacataaat	ttgtctatgct	gaataaaaa	attagatttta	acataaagaa	93780
ctattgttgt	tacaaagtgt	tcttaaggaag	agaaattctt	ttatctgtat	ctaaagtata	93840
acagacttta	atagtaaaaa	taatttagat	attttagata	atattaaata	ataaatatgo	93900
cagaaacttc	tgccaaaaaa	ttattgggttaa	aatgaacttg	aactatggta	ctactaaaaa	93960

aatcaaccac	gatgtttatc	acagaagcca	aaatctttga	ttggctcatga	tgcaacaggtt	94020
ggcagtgatta	tgactaaaaa	aatcctgggt	tacagtttac	tataaaacct	tttttaagag	94080
gcacacaatt	atttagtgga	ttctgttcaa	ctagaacaca	tttatagtaa	acttgagta	94140
caaatattaa	ataggctcgc	ttcctaaaag	tgltattcaa	aaacgaatgt	catcttaagt	94200
tatctcttgca	aatcacataa	gaatcttttg	cttccaanaa	aaaaacaaat	gtctattcca	94260
gaggctctac	agcttcagag	agaaataact	agcattctct	ttcaacctaa	gagacaacta	94320
caatggagtt	atgggttaag	catggactct	gggtgcagat	aaactacatt	taaatcctaa	94380
cttgactctt	atgcctatga	taatccaggg	catggtgatt	aaactctctg	caccagttctc	94440
ttcacttata	aaatgaaagt	gatgagtaag	taaatcoatgg	agtttttttga	aagttaaaat	94500
gaaatgatgo	atgcacaagaa	cttagctcaa	ttacaggcag	atagtaagtg	ctcaataaac	94560
attagctatt	gttaatatgt	ctgatattcc	ttagaatgaa	cgatgtttta	aatgtatat	94620
tacacttaaa	agctctaaaa	tactaaaaaa	gtaagtgtat	cttaccacca	caacttgggt	94680
ctctcttact	ccaaaaacca	tcgtctgaac	aatgcatttc	ttctctctct	tcaatctgtg	94740
agcctgagtt	acatacaaac	cgtaactgct	gtccaaaaatg	gtattccoga	tctgggtcca	94800
ttgcoactact	gacaattttt	ccattctctg	gtgctgtcac	tggttaaacac	ttcacaactg	94860
aagaaaaatac	atgtaatgtt	ttctaattgga	attttaaaag	tttactgtga	aaaatatgtg	94920
tatgtataaaa	atcatcctca	ggataagatt	ggaggaaatt	acttaaatat	tttttagaag	94980
caatttgatat	acctgtttgc	tagagatact	ttcctctaat	aaacagacaa	atggaaatgt	95040
tatccttgat	tottttctat	gggagtgga	aatgaaaatt	actactttca	acgtgagctt	95100
gtatttttgt	agtaacaaac	tagtattttt	aaataattaa	gaaatataaa	ctctggatga	95160
ataaataata	tttccattta	tgccctagaa	taataataca	ctgtgttctc	aaaagatgta	95220
aaagaaacat	ttatgacatt	aacttcaata	gagaaatcat	cgtaaatctt	ccctctctct	95280
cgaaacaaagt	gttttaaaata	atttgagtag	ttcttttgat	tctacttaat	attttccaat	95340
tctctcaaaag	ttgtgggtcaa	actttattgt	actatagaat	gactcaggat	gctgtgttaa	95400
acaaaaatttt	taggggtctac	ttcctgcact	ctcaccccaa	agataactgat	taagttaggtc	95460
atbtttttagt	aacccaagat	tttagttttt	aaacagctac	ccagggtgatt	tcaatgtaga	95520
tgctctccatg	acocatattc	ttctctctcc	aahtttcata	gatgaaaaaa	ttcttccaata	95580
ttttctgttag	ttgacagttt	ttgaatgatt	atocagtttc	ttctgtatct	ctctccaact	95640
gccactcact	gtggaaattag	gaaaatactac	ttcgtgttat	ttcttttatt	ttccaataga	95700
ctagagatttt	ggattattag	ctcaaaaact	gaaaaacagaa	tctacatttt	ctcaattttca	95760
ctggtttgctt	tacagagctag	tgagaaataaa	ccctagctgc	ccctagttta	ttctcttttt	95820
cagtaaaaggt	aagtccacag	gcaaacctccc	ttagtgggag	gtctcaactca	cgtttctccc	95880
ttccagctgtt	accatgagtc	ctgcagtttg	gggtggttact	gggtgagttc	ttcttccatta	95940
ataaaggcaa	aattctgggtc	tttatttagc	taatgatgct	tatatgggct	ttcagtcatt	96000
agaaatccaaa	aggaataataa	aatcagtttt	agattctcta	atgtcttaata	ctcaatttat	96060
tatatccagat	caggctgcac	tcgttttttg	cttttgaac	accagaagat	tagtaataaaa	96120
aagantagat	tcocactctc	catgttatga	gaaaaaaaaa	cttaataata	aaatatattaa	96180
tagagacttt	aagatatattt	aatgtaagac	tttttttaaa	tcttagatata	ttatttccat	96240
atacttgttaa	atacattttt	tgctacattt	cacataatgg	actcatcttg	gtccatccat	96300
ctgtgtccaca	ttcccggttaa	ttaatctcac	cagcaaatgt	atacctgaaa	accaaaaaat	96360
aaacagacgt	tgacatctgt	tggttttaca	tgacagttta	aactcgtatg	ctctgtgagt	96420
gtccagaaaac	ttccatatcaa	ggaaaatgaa	cagcatatgc	tttcttttgt	ttcttggttc	96480
tgtttttgttt	ttctctctcc	cttctctccc	ttcttcaact	atgtcttagt	ttcttaagct	96540
tctcttagaac	tttaattcttc	ttctctaat	ttctatagat	gaaaaaatctc	ttcaactctc	96600
ttctctcttta	ctttttctctc	ctttttggtg	catgggaotga	aaaaaatcat	aaactcttgt	96660
ttcacgacaaa	ttcattatttg	ttctatcaaa	agttattctta	tttttctatg	aattatctaa	96720
tttagctctaa	tcaataaata	agtaagctcc	atgaactaat	cccaaaaaca	actgaataaaa	96780
ttccatagta	accaacgact	aaccttatgt	ttcctctccc	tccagtctta	gaocgtattt	96840
ctgctctctga	tgactctgat	attttctgaa	caactttagg	tttctacata	ataaagatag	96900
ttccagccaaa	aagtttgttat	tggtgtgatt	actttcagca	tttgcctcca	ttcttccatc	96960
tctactgttag	agatttttttc	ctgagaaatc	ccagtgagto	aaatctgtct	atccagacca	97020
tctaattgttg	aacttaangta	atttttagtaa	cccatcaagg	ctgcctcttg	aatctaaaaa	97080
atgctctact	tgaaatagag	ttcctctgga	catgtgcaaa	atgtccaatc	attgtcagag	97140
tgctcagatc	tatacatltt	tatctcttca	gccaaagcaa	gtgctgaact	taaaagagag	97200
acacaaagctc	gtgataaag	aaatatttca	gaggtgagga	aggtagcaaa	ttaaaaaatt	97260
cgcccccaag	atatttaaac	ctatttgggt	atgtgtgata	agatcagcag	taatgattga	97320
agggctcaaaa	atgtatttga	aaaaacctccc	tcaggtagta	gaataaggaga	gaataaactc	97380
ataagaaatt	atacttatlt	ggatctcact	atatctcaag	gtctcttcca	agggctcag	97440
atgtgtgtct	tattttatttt	tctgtccaat	ccatgatgca	caataaaatg	ctctgttttg	97500
taggagagga	aatggtagtg	agagagalata	tttttaaat	ccataaaatg	tttaagtggt	97560
gagttttgaa	agggcaggtt	actccagtgta	ctaaagttta	aactattata	tttttatgtt	97620
tcgaatttaag	gaaaaaatgg	ggaaataata	agtttatccc	atttgttaata	tttgtgtaca	97680

tttatatttta	tgaagtatac	gattatagty	alcataactc	ggttttccca	tacataaatt	97740
ttttcccaaaa	ataaatttttc	atctagcaga	gaataaagggg	gataaaaataa	cactgaggat	97800
atcacagtgat	gatttttggca	atgaaacccc	agtagtttgg	tagaagggaac	agagttcaatg	97860
attcttgaaag	agtagtattt	tttaatccatg	tggtaagaat	aatttgcaac	ctcggggacat	97920
tttagtaacct	tagttgttaag	taaaacttat	nagcaggtgga	aagttcttgc	ttcctttaaat	97980
ttatataaaat	ctgtccaaaac	agttacccata	caatataaatt	lgyttacaaat	tcttacttgtt	98040
ccgtgacacat	tgaactccca	tgatactctg	cacaaaatag	aatgtctgta	agactttgtgt	98100
gatttatataa	tatatattctg	ctactctgtt	tccacttctt	ccataattat	actctatlcag	98160
agaagtattata	cttcattttaa	atctttccaat	gttaagggaga	taatatvgta	tccagatttta	98220
attattttcca	tcatagtttaa	actttccaggt	actctgtgtat	tactttttta	aatgtctcata	98280
gaaaaataata	ataaccttaa	aaatatataa	agtagtagag	ttcctattta	ctatcttcaat	98340
tataaaccttc	gactacatac	ccctcattac	atgtatcacac	atgtatcacac	agctttttaca	98400
ccatattttcaa	acacattttcc	lccgttaagg	gtaaaagtac	caaaaaggagt	atctccagga	98460
tgctccacagg	gocctttctaa	aacgaaaaaa	aaagtttatga	attagttatgt	aaatagcaagg	98520
ataatattttt	atgttaggagt	gggggaaaca	glatatlllga	tattatataa	gaagacagat	98580
ttatatataaa	taaatatttaa	catagcaaaag	ccattatbto	ataattgaac	ltaaacctaca	98640
ttctgttgttt	tttaattttt	gagggacgac	accccttttt	gaaaatgatg	atgtatttggc	98700
tgggctcaggt	ggctccagcc	tgtaattccca	gcactttggg	aggctgaggt	gggtggatca	98760
cgaggccaggg	agttctagac	cagcctgccc	agccttggtg	aaaccccatc	tctactaaaa	98820
atacaaaaatt	tagccggggg	tggtggcagc	tgccctatgt	ccagctctct	cgggagattg	98880
aggcagggaag	atrgcttgaa	ccaggggagc	agaggttgca	gtgagccgaa	atagccgcac	98940
tgcactccagc	ccagggcgata	gagggagact	ccatctcaaa	attgcgccac	tgccatggag	99000
ctcagggtgac	agagccagac	tccattccaa	aacaaaaaaa	aaagattatg	tattattttgt	99060
tatttggctgt	gcaatagtga	tataattcga	gcataattga	tacaattatta	aatcttaagt	99120
attttttacac	ctagttttta	taaaattccac	aaatgtatta	agtaacttact	ctgacatttca	99180
cttaattggat	taagagcaac	ccattctccc	tctctgcata	ccattattac	attttccaaga	99240
gactatatac	caggggcgga	tttatagata	gcctgggtgc	cttctggata	tgttttggtca	99300
cgccagggaac	ctgtccagat	ttctgtattt	cttcttgtag	gaagtctcat	gcaactctaca	99360
aaacattcaaa	caaaaataag	tgcaataaagt	gtctatttcaa	atgtacagta	tatttagtta	99420
attgttgtctt	tataaaaatgc	ctagacagtc	acaggtctat	atgtacagta	tatttagtta	99480
ctctctctccc	taaccccatca	tctatggagt	catattttta	ctatatttact	ctctctctct	99540
atacattttca	ccattataaaa	tttgtatcta	atcatatttt	laagaattgt	tagttgaaat	99600
aaacaccttaa	aaaactcttgc	ccacttaatt	ttgggaaatat	ctatttgagca	cttaatttgc	99660
ggagagcatt	aaacaatgca	agaaacaacac	tatctgttct	caaaagattt	ccattctatt	99720
ttataaagaa	gttattaaat	aatcaaaag	atgtataata	tgcaattacag	gtgaaaaaat	99780
atgaaatagg	aaaatttagca	tgataagttta	atcacaggaat	atacagggaac	tcccaataag	99840
atgaaatagg	atggaaaaaga	acaatgtttc	tactccaatt	tggaacaaca	acaaatttgc	99900
tggtcagtag	tatgttccaaa	ggtaaagttt	gggagcaaaag	aggaactaaat	gaacaaaaac	100020
caagtaggaa	ggacctgttt	caagttaata	tagggctctc	ggccattttt	taccttggtta	100080
tttttgtcag	ctctggatag	ggattgaaag	tcaggccctct	atttagtctg	aatgagagaa	100140
tggttaatgag	gtaaagaaaga	accaaacata	aggaggctat	acttagcctg	agaagattctg	100200
aaactttgcc	aaatcagggt	gctttgtctag	agttctaggta	gcttcaacag	ggagagactga	100260
ctttccogtt	gtctcataga	aaaaaagtct	caataagaaa	atggatctga	ctcaaatca	100320
caactagtat	ctctcatcaa	acatgccata	tttgaaagtc	actctggagt	attatttaaga	100380
ggcagatgat	aaacagcaga	aaaagctgtat	acatatatat	attattttata	tataataaaa	100440
gtctcttctca	atatgttccac	ttttctgtctg	tttctagcat	atatgagcat	ttaagatttat	100500
atataatata	gaacagagtc	aaaacagcag	aaaagcaaac	atatatatata	arggtttttta	100560
tatatatatat	atatatttgt	cacatacata	atatatatat	gttggcttct	tctatctcaa	100620
aagtcttaata	tatgtacacaa	catatalagt	atatatatat	acacatattt	attattttatgt	100680
atatatatgt	gtatatagat	atactctgtg	tggtgtgtgtg	cttggtgtgtg	tggtgtgtgtg	100740
tggtgtattag	tctttttgaga	tagaaagaaac	caaccagagt	cttgactttta	aaaacccaag	100800
aggggttttaac	cttttgagact	agaaaaccaga	aatgggactg	actcaaacct	aaagtgtttac	100860
ccagggtccct	ctgagtttaa	tttttgagtg	gctcaagaaa	gagcaaacac	tcttgtttgat	100920
gagagtaggt	tatatataact	tttgtcatca	cargtttttt	tliaaaaata	cgatttttgaa	100980
taaaaatttaa	agaatcacaca	aaaangcaaa	aaacactgtg	aacaaaagga	gaaaataaat	101040
atcagtagga	acagacacat	cagattcaga	tggtagaatt	agttgttaggt	ctttataaca	101100
gctatttttag	gaactatata	ggaaactatag	aaatatatga	aatgaaatct	tanaaaagat	101160
atatacaaat	aaattgactc	ataaactatg	tgctatctga	aaattgagca	aaaactttat	101220
aatatacaact	tgtagatggg	ttttaagaat	caaatgggaa	cagcaacata	caaaactttat	101280
aacctttagag	gaagtttaat	gtaaaaataa	ccaaaaggaa	atataagaag	acaaaagtg	101340
ataaacacaga	acaaacaaaa	cagagtataa	aaaaattgtg	gggtgtagag	caagttataa	101400

aacatgttta	attggaattc	taacaataga	gaagaaaatg	aacataggca	atatttgaag	101460
aaacaatago	tcaagggttc	ccaaatttga	tgaagaataa	cagctcacaa	aatcaaaatt	101520
tctaaaaaac	cccaaatgct	tgtataccaa	gaaaacctat	cctgatacct	tgctgaaaac	101580
caaaagtaaa	ggcaaaatct	tanaagcaga	tgtatttagt	acatttttgc	acagctatga	101640
agaatacttc	aagactgggt	aatttatase	gnaaagagat	ataattgact	caaatctcca	101700
catgtgttgc	gagggctcag	gaaagttaca	gtcatggctg	aaggggaagg	aaagacctct	101760
tcactatgat	gcaagagaga	agtgcaaaac	ggggaaatgc	cagatgctta	taaaacacct	101820
gaaaactatc	agaactcatt	cactatcaag	agaatagcat	aggagaacat	gcccactgat	101880
ccaagocagt	cccactgggt	ccttccctca	acacacaggg	attatgggtg	ttacaattta	101940
agatgagatt	tgggttaggg	cacagagcct	aacctatatta	ttctgccccct	tgctttcccc	102000
aaatctcatg	tcttccactt	tcaaaacata	atcatgcoctt	cccaacagtc	cccccaagtc	102060
tttaactcat	acagcattaa	ccttaagtc	catgtccaaa	gtctcatctg	agacaaggca	102120
agtcctcttc	acatatgagc	tgttaaatc	aaaagaaaaa	tagtcatttt	caagatacaa	102180
tgggaataca	ggcattgggt	aaatgctccc	atcccaaatg	ggatgaattg	gctaaaaaaa	102240
agggaccaaa	ggctccatga	aagtcagaaa	tcccaatagg	aagtcattaa	aactcaaatg	102300
tccaaaacag	tcccctttga	ttccatgtct	cacattccag	tcacactgat	gcaagagggtg	102360
agctccccca	cacttggggca	gaactgcccc	aatgggtttg	caaggtagtg	ccccctgccc	102420
tggctacttt	tcctcttggt	attgagtctc	tgtggcbltt	ccaggccaaa	gggtcaacct	102480
tgcaagtgaat	ctacccattct	gggactctga	ggatctgtgg	ccctctttct	acagctccat	102540
tggcttagtgc	cccactggga	cctctgtgtg	ggggctccaa	tctactattt	cccttgctca	102600
ttgcctagat	agagggttct	catgaggggt	cctcccttgc	agcacacctc	tgcttgagca	102660
tccagcauct	latatacatt	ttctgaattc	aggtggagggt	ttgtattctt	tggtaccacc	102720
aggaccaaca	ccatgtggaa	gctgccaagg	cttagggcctt	tcattatctg	aagcaattgc	102780
ccaaagctga	tgttggccct	ttttagacat	ggctgcagct	ggtgcagctg	gggtgcagag	102840
cccaactcct	atggacttga	tacagcagtg	gggcccaggc	ctgcaaaacc	atttttccct	102900
ccgagggcaac	caggccctgt	atgggagagg	ctgccttaaa	gatcactaac	attccctgca	102960
gaactttttc	ccttgcctag	gtgataaaca	tttggctcct	catctcttac	acagatttct	103020
ccagtgggctt	tgcatttttc	ccaaagaaat	togggtttta	ttctattgct	acagataggc	103080
tgcgaatttt	ccaaaatttt	atgctctgct	ctgggtttta	acataagctc	caatttcaga	103140
ccaaactttct	caaagtccaa	agttccocag	atctctaggg	aaggggcaaa	attgttgcga	103200
tctctttgct	aaaaacacag	tagagtgtatc	tttgtactgg	ctcaactaac	gtctctgtct	103260
cccatctcag	accaacctcag	cctggaacttc	atattccaga	caactcttcc	atttttgggt	103320
taaaagcttc	aacnagcttc	taggaagttc	caagctttcc	cattaccnag	tgcttctctt	103380
tgagactccc	aaactgtttc	aaactctgoc	cattaccnag	acncttggat	tattagttcc	103440
tttgagggtat	cttttaataa	gtgocctact	acncttggat	ctgggttagt	gaagttttaa	103500
ctttgctcagt	cttttaacaga	ttacctgtaga	cttcaggaaa	cttcaggaaa	cttacaatca	103560
tgtattcata	cctttcaacag	gttggggagg	gtacagggag	gtacagggag	agagaagtgc	103620
taaggaagaa	gagaggatct	tcttcatatg	taagaactca	ctcacactca	aggttggggg	103680
tgctccagat	gctttaaaca	ttaaactctca	ctcccccact	agttctctcc	tgcagacatg	103740
atgggcaaaa	caacccccat	gatccagatca	atcttgggtg	ggacacagag	ctgaacatg	103800
atgattattgc	agattataat	tttaagttag	gagaaatagta	taactaaagt	ctgaanaatg	103860
ctccagcagag	agggaaacct	ttttttccag	gtcttagcatg	caaaaatgaa	agcnaataga	103920
gggaagtaac	actggaagtct	gaatatatat	aaatataact	taactaaagt	ctgaanaatg	103980
aaagtccagca	gagaacctct	taaatgttga	gaattcaaca	taanaataaa	gcnaaagaat	104040
aaacacattct	taagcacaaca	aaagcagaaa	gaactcagac	taaaataaaa	caagctatag	104100
aaataactaa	aaaagtctct	tgggctgaag	taactagaag	aaagataaaa	cttgactgtg	104160
acaaaaagaa	ataagcagaa	ctgaagaaaa	taactagaag	aaagataaaa	caagctatag	104220
aaacatgcta	aacctctatg	tatgtatat	tttaataaatt	caagagtata	cttgactgtg	104280
taactcaata	gacocatgtt	aatagtgttt	gaaaataaaa	gtgttgtgat	atttgaaaaca	104340
atagtgaata	aagttgtcagg	aaaaggttaa	gataaattgt	taataatttta	gcttttcccca	104400
tagtcttgat	tgtgttaaaa	tatttaattta	ataatattga	gatacataaa	ataacatagaa	104460
tgtgttaattg	ctcaagttagc	caotaaaccca	ttgattaaaa	gaactataaa	acaggaatag	104520
tacatgatgt	aatgaggtga	tcaagactat	caatagtcta	gaactataaa	gaactgtatc	104580
agagagaaaa	attgaggctaa	aagtaagtag	caccatacta	aaacatacaa	aggtgtatctg	104640
agtaaatctca	tcaaatataa	aaactcaaat	atatgatgat	tacttttaat	aaanattgtac	104700
ctggatcaaaa	gcataaaaaga	ataaaaccca	atatgtatga	aaagtatcaa	ccaaagttag	104760
atacaaatgt	agagttaagt	ataaaaccca	tgataaattt	agttagaaga	tattatttaga	104820
aatgtattata	atgtatttaat	atcnagcagaa	aggtcacttt	aaagcaaga	tgtataaatt	104880
taaaaaagaga	gtcattttcat	attaaataaaa	ctggctcata	ctgactcata	ggagccaatt	104940
gcnaatgtgt	ctgaacaaat	tttgcctggag	tgtatgacac	ttggttaact	gaaattgacc	105000
atcacacatct	tttgtcataa	caatgtctcc	gcaaaattta	caaaactaga	ttgtttccctt	105060
atatttgtgag	aattttcaccc	atgaactcca				105120

tcctttttaa	aaatagttgg	ttgtttttaca	tttaccagca	tgcctctttg	cataaaacta	105180
ttcaatcatc	ttcaaaatat	aacagaaata	aaagaagtaa	gcaatccacc	atcatagttt	105240
gagattttaa	cacactgttt	ccaatatoca	atagaaesga	taclagaaaa	taaggetaba	105300
gcagatataa	gcacatttat	laaccaaatt	aagtgttttt	taclataataa	acactgtcct	105360
caacaattgc	aagatgcata	ttaatctcaa	gcaaatctct	accaaactcca	aaaaattcaa	105420
gcacatctga	gtatactccc	tgaccaatag	acattgtcta	cagaaaaata	gtggaaaaat	105480
cacaaaatttt	ttgaagttaa	gcaaccccttt	tttttttttt	ttttttttga	gagaggagct	105540
cgctctgtcc	cccatgcctg	agtgcccaat	ctcagctcac	caacaactcc	actctctggg	105600
tcacgccatt	ctcctgcctc	agccatctga	gtagctggaa	ctacagggtg	ccgccaccat	105660
gcccgggtat	tttttgggtt	tttttttctt	gtatttttag	tagaaaaagg	gtttcacogt	105720
gttagccagg	atggtctctaa	ttctctgaac	tcggcctccc	aaaagtgtac	cgccccacct	105780
ggctctccaa	agtgctgaga	ttacaggcgt	gagccacccg	acttggcaag	caacacttat	105840
ataaactoca	tgagttaaag	aaaaataata	tataaatgag	aatatgtatt	gaataataca	105900
aaatctgaaa	tatatgttaa	aatttgtggg	ctgatgctga	agcactgatt	agagagaaaa	105960
aaataaact	ogaatgaatt	agaataaaaa	aactgttga	aatcaattat	ccaaatttct	106020
aattcaagaa	actagtaaaa	cattaaatga	aatctaaga	aaatagaaaa	cagcaataaa	106080
tagtgatgat	cacatnaact	accctccaag	ttcaagggtga	caactasaat	attttaacta	106140
aggtacacca	attctgttgt	tacccggcat	ggatgtgacc	tatactggca	ctaacattta	106200
tcctttcatca	gcacaaattct	ctctgtgggg	gttaagatat	tagaagctga	gttttcagtgc	106260
ctgaaatctc	ctcagacgtg	ttcttgtgca	tactgccttt	atccttattc	tgtattttcc	106320
ttcaagccaa	gtaaccttgy	caatgggttaa	gtctatcgta	ctgtgttaac	ttggactacc	106380
tcnaattgaa	actcaactct	gcaggcttgc	aaataaaaac	ccctggggcg	gggtgcgggtg	106440
gtctacgctc	atattccocag	caacttggga	ggctgagatg	gggtgatcac	ctggagctcag	106500
gagttcagaa	ctagcccgac	aaacatgtcg	aaaccccgto	ttactaaaaa	atacaaaatt	106560
agccaactgt	tggtggcacat	gcctgttaac	ccagctacgt	ggggcgctga	ggcaggagaa	106620
tcctctgaac	ctgagaggcg	gagattgcag	taaccocaga	tcacgccatt	gcactccagc	106680
ctgggcaaca	agagcgaagc	tcgtgtctcaa	aaaaataata	taataataaa	taaaaaataa	106740
aaocccatcg	aaatgcaatg	ggataaattt	gaactcctaa	cttatctgca	ccagcaatgc	106800
caocaaatcg	ccaggtagagc	taaaagattt	ggtttaaaac	aattttaaat	aaatacatat	106860
atgtttcaatt	cttttataact	ttttttaaata	tcctgtatat	atgtatgtat	gtcaattttaa	106920
ctctactatta	ctcttagtgc	atctatctat	aaattatatt	attttataaa	tatatattat	106980
aaaaagtatg	ataaaatatt	aaaaaaggaa	ggcttaalgt	ataagcaat	ttgcaaacag	107040
acaatataca	catlaaaact	ttgttaatta	aaaaatttat	tttgtaaaaa	atcatatata	107100
caaaatctgg	agaaaaatct	actgaaaaat	tattcttaac	acaaacactt	cttgacgtaa	107160
caaaagtcag	aaacactcta	taagaaaaaa	tgltagagta	ggatagatca	tttaacttaag	107220
aacaggcatt	aacgtgacca	ttaccaataa	ttaaaagaga	taaaaaataa	aggaataata	107280
ttctttgacc	aatttttaaca	caaaactgta	aaggagatga	taactcaatt	tgctggaaaa	107340
ttaggttaata	taaaacttat	tatttaataa	aactgaaatt	taaatgacta	ttacttcaact	107400
aaaaagcaac	ttagcaataa	agaaactctaa	acgtaaactc	acgtaaagtgt	acaaaataatt	107460
tcattttttt	aaaagtaaca	aaataaattt	aaagattttg	tgaataatttt	aggtcagagg	107520
tgatttatct	agcattttta	ataatggata	taatttagaal	atkttagaa	tttgtcaaat	107580
tatgtctaac	ccatctgaat	taaaaattgt	gggtttgggt	atattttaat	atgtgcataa	107640
aattttataat	agtaagaagg	aaagtccagta	tatatattgt	gttatagtga	gatacatatg	107700
gtcaggggcc	agaaaaactaa	ccctgtggcc	aaatccaatc	gctgcttgtt	ttgttaataa	107760
aattttttaga	gaacacagat	atgctcatat	agtttatatt	tgtcttatgac	tcotttttatg	107820
ttcaaataga	agagctgagt	agcgagacat	tatggtctac	gaagtctaaa	atattttatg	107880
trtggtctatt	tcacaaaaaa	tttgagtgcc	ttgggattca	ttatttcaga	taactcttat	107940
cttttaggac	acctctacaa	taaaaccagg	tgccagccca	tggtggctca	caactgtaat	108000
cccaactatt	tgggaggctg	aggtgggaga	atccccttga	gcccaggagt	cttgagacac	108060
ctgtggcaat	atagcaagat	cccatctcta	caaaaaataa	aagaaaacaa	ttagttaacc	108120
atgtgtgagc	caactctgtg	ttccagctat	gtgagaggct	gggacaggag	ggtcttttga	108180
gcccaggagt	tttaaggatgc	agtgagctat	gatcatgtca	ccgcactcca	gcogagagac	108240
aggttgagac	ctctgtacaaa	aaggggaaaa	aaacaggaaa	acatatgttt	tgaataataat	108300
actttttcat	agggactttag	aaagctgacg	agacagttaa	gaattaccat	acacattatt	108360
ggataataca	gaaccocagg	aggaasaacg	gcagccaatt	ttttttctga	ctgtggggat	108420
tcaccatttg	gggaagacac	aagcttggct	tttgatagcc	ttattaggct	aaagcaacaa	108480
aattcaaaagt	tggaacaccta	aatgaattca	ccacaggat	aaggagataa	tggaagttaa	108540
cccaactcct	cttaaccggaa	cccagctttg	aattgtctag	agcaccagag	aatbtttaag	108600
acaaaatttg	gcttaaggta	gtctccacact	gaaagtctct	ctagccaccc	agaaaagata	108660
atattgttaac	ttaatatgag	gaagattttt	tttttagaag	ccaaatttat	attcaaaagt	108720
ttcaagacat	tatacggggg	aaaaagcccc	ragttaccat	aaacttcat	aggaacaaaa	108780
tagatatattg	atattggaa	aaatatatac	agactataat	caacacact	attctgtgtg	108840

tttaaatgta	agagaaaagt	ttgactaatg	atatctgagg	aaagaaatta	taacaaagta	108900
gtgacagatt	ttaaaaaagt	ccaaatataa	tttctaaaaa	tgaaaaaacc	cattttaatc	108950
atcaatggac	agcttaaatag	cagataaacac	agtttgtataa	agaaatctcgt	gcagaggagg	109020
cagggtcaaa	gaaatataac	aggatgcacac	acggagagac	acatgltgtgg	aaaaacacaa	109080
agatgagcta	agagtgcaatg	aggatagaaaa	agccagagca	atgttgggaag	agaaatttaa	109140
aaaaaggaat	gaacataacca	attaatatat	ccagaataa	aaaaattcca	agcagttaaaa	109200
aaacacaccc	atatgcataca	taaggaaatat	gcgagaaaac	aaagagaaaa	tatcttaacc	109260
ttgttagaga	aaaaatttaa	tttaaaagca	gtaatgggta	gatttbcaaa	gactctccaa	109320
lagcaaatagc	agaogccacc	aggatattaat	cacttccatt	ttcagggaaga	aataactatc	109380
tatatagaaat	tctatataca	gaaataaatt	tttgagaata	aagttttgat	tcataaaaatt	109440
tatttttatt	taittttttga	caagatctct	attgccccagg	ctggagtgcga	gtgggtgtgt	109500
tttagctctgc	tgcgacccctg	acccctctggg	ctcaagtgggt	ccctgcctcc	agcccccocaa	109560
gtagctgtgta	ctacagctcac	aaactacctc	tctcagctaa	tttttgtatt	ttttgtagag	109620
acgaggttttt	gcgcgttttgc	ccaggctgggt	ctcaaacctc	tgggctcaag	caatccactc	109680
accttagcctt	cccaaaatgc	tgggatttgca	ggagtgaacc	acgtgcctccg	ggctgattaa	109740
taaaaatttga	gagaatttgc	cactataaat	acacattaag	gagagaaaaa	agatatattt	109800
cagaaaaactg	aaactgatcc	taaatataag	gtcttaggag	gaagagaaga	atgaaaaaca	109860
aagaaaatttg	taaatgttctn	agtaaatata	aatgaatact	gactataaatt	taataaaaaat	109920
attgaccttao	atggtttttaa	atcaaaacat	gtatgtgtat	acacccattt	acataaaaaac	109980
ctgcacaaat	tgtagtaaac	tgtgagaagg	attaaataaa	taaatgtctt	taagtctctt	100040
cacagtgttcc	glgaaaaaacg	aaaggttatta	atgagctgtg	acagttttct	taataagtcac	100100
tttgtctttaa	ctgcagactc	ccagttattgt	agtcacaaact	atcfaaatgt	tggtgtggaaa	100160
atagtgttgc	agatcacactc	ccaaacagtt	gactttaaac	aaagctgacac	tcttaggttaa	100220
cttagatagg	ccagatcaaaa	tcatttgaaa	ggctctgaac	atagggctga	ggctcctctg	100280
aaaaagagag	ggaaatttgt	ggaaagcagc	tctcttctct	gtgagtccca	tctgtctgtgt	100340
aaatcttccct	tctcagactac	ctgcctctgt	gatttcagac	tgtcttatct	catgtccaca	100400
tttctcttgag	gcaattttat	taaaaaacaa	aaacaaaaca	aaacaaaaca	acaaacacctc	100460
tttttaagta	ggtagatagg	agatttggtat	gtcaatcaat	taattgactg	atagatagg	100520
aatcttctcat	tctctattaa	gcttcccgca	ttgaaatctg	atgactataat	tattattaga	100580
cttttagtaag	taagaagaag	atattgctatg	ctctgaatac	atgcaacctc	cccacaaccc	100640
ccaaatttata	tgttttaacc	taattaccaa	tgttagagta	ttaggaagtg	gggaacactgg	100700
gaagtgaltta	ggctcgtgaag	gtggagctgt	catgatttgg	gatgtgtgtcc	tttatagaag	100760
agggccaccca	gagctgtcctt	gtccctttca	tcatttggag	acacagccaa	aaggctacgt	100820
cttagaaccca	gagagcagac	ctcaccaaac	actgaactct	ctggtagact	cttgtgtcta	100880
gactttcttag	cattccgaag	tgttaagaaat	acattctgtg	tgtttataag	ctaggcgatt	100940
ataaatatttt	tgtttgtaga	gccaaagaaa	aaaagtittta	gaagtgcoca	ttcaacttgg	101000
ggaaacaaatc	catatgaaaa	cattttgcac	tatttcataa	gaagaaaaac	accatataaa	101060
atctatatttt	acaaaaataat	gtgaaaagtt	ttatttggaac	taattttccc	ttgacactttt	101120
tgcataatttt	tattagtgaac	ctcatataat	atgtgattcc	actatgcact	atttctgatgt	101180
tataaatttta	agtnaaacata	tctactocac	ctagatgggt	ctaatactct	atcatacaaa	101240
ccataccccc	ggccccccttc	gcacaaaaag	aaaaactgatt	aatatacaag	tgatattgtt	101300
gttttttaact	tccaaaattt	agatccattt	gatgatgttc	aggttatattg	aaanaacaaa	101360
taagttaaagt	aatccacttas	ccacaaaaaaa	gttttagccg	ctcaactctc	agtgagaagt	101420
aaatgcttttc	ccttctgggtt	attattatat	ttccaggtga	tacgttttgt	cccctaattc	101480
tatttttccca	aatatagattc	attgtctttaa	acaaccagat	tgagaaaaac	aggaacacac	101540
tcttcccacaa	aatcttcccta	ccaactctct	actctgtgaat	ctctgtgaat	atgtttacta	101600
tataaanga	attatcatat	tgattacctt	ttctttocaa	atagtaacta	aaattctgggt	101660
gcttttttcca	tcagtgattaa	atggcactct	ttgatctctg	ttgtaagaaa	aaagattgac	101720
cgcccttggtt	ctattttccc	tgtcctccac	tacactttgt	taoactctag	tccagatcat	101780
catctgtcac	tttgtgtatg	aaacttgpcct	gctaactagc	ctccagttctt	ctactctctc	101840
gtgactctcag	tctattccaa	gagtgacaag	tgattcttgc	aaaltctgtg	atgtcattcc	101900
tgtgattaaaa	attcttctat	gacttcaact	tttactttat	cagacttctg	aaactcttct	101960
cttggttttgg	gaaccocctta	tctggctcttt	gcactttctc	gcactttctc	catgttaaat	102020
ctcccatgtta	tctactgtgc	aaagtcaagc	lgattttatt	gtttattatt	gttgtagcat	102080
ttcaaaactta	tcttcttctct	agatcccttta	ccaggggttat	tctctctctc	tgaataaatt	102140
ttcagacaga	tctctgtatga	ctggctttgt	ctactcttcc	agggctctac	tcaaagtctc	102200
tgtcctccaaa	gtgatccact	catlctagtc	cccaagacca	agccactcct	atgtctctac	102260
atctaccat	cccatctctc	atttctctct	agggcctaat	tctatctccc	cacaaatttt	102320
ttcacaaatgc	tataactatt	tttgttcaatt	aggtttctta	tctatctccc	cacatacaaa	102380
tgtaaagtctc	ccacaaattga	agaaacaaatg	ttttactagt	tctgtggaaga	atttttcaatt	102440
agtgctcaggt	cttctcactt	cagataacact	tctctgtctg	ctttgtttct	aaacatttatt	102500
gatttgagta	ctttcagat	aggagatggg	acttggacac	tggacaaaat	taggatttat	102560

ccaaaaacag	ttctgagtgg	agccctccc	tgtaagacac	acagaccagt	gtgctatgac	112620
agttttacat	taccatggca	acaccagaa	gttacaggcc	ctttccacag	caatgaccac	112680
acaaacggaa	gttacaatcc	tcctcctggc	aatttcagca	ttacataact	cttaatttcc	112740
atataaatta	aagtgcatai	aaalatgagt	gcagncactg	ctctgagctg	ctaactgtggg	112800
cacactgcct	atgggtagcc	ctgcttagca	aggagaggtg	cccttgaggg	tgctatcacac	112860
tgccacttca	acaaaatttg	ctgtttaaca	ccacaggctc	accttgaat	ttcttactgg	112920
acaaaaccaa	gaactctccc	aggctaaagc	ccaatttggg	ggcttgcgtg	ctcacatcat	112980
tatcaactca	tgccatagca	aaagtatbta	aggtaatgat	tcactgcact	gagttctaat	113040
aataaattag	tatatcttgt	gacataaact	ttatttgect	gaattgacta	acaaatcgaat	113100
gttcaagctc	agttgaacca	ccttcaagta	gacaaacaac	ggttattttg	gocaaagtag	113160
ctaaactctc	agcatgtatg	tacaaagggo	ttatttaata	ggatgcatac	aaattgaag	113220
gcacagaaac	atttttttga	gatgtgattt	atcttlaaac	taaaagaaat	agccactctca	113280
ttttttctcat	tctagattaa	tgagttagact	aagccatcat	atctaagtat	ttgagtttaa	113340
acaatgaata	cttcatctta	cgtttacaag	tcatttaatt	gocagttaat	ttgtgtttaca	113400
aaacactaca	tttggtgaagc	tttaattcat	tlggctttat	tttacaattt	aaaattagtt	113460
ttagtcttga	tgccagtggg	catgcttata	atccagcac	tttgacatgc	caagtcaaga	113520
ggatcaatag	acccaggagg	ttccagacca	cctggggcaa	cgttggtgaaa	ccctgtctct	113580
acaaaaaatt	ttaaaaatta	cctgagcagg	ccggggcggg	tggtctcatgc	ctgtaatccc	113640
agccatttgg	gagggccaagg	ccggcgagatc	accagatcac	gaggtcaggga	gataccagacc	113700
atctcactca	acctaacaac	ggtagaaactc	cgtctctact	acaaatacga	aaaaatagcc	113760
gggcttgggt	gtgggtggct	gtagtcccag	ctactcggga	ggctgaggca	ggagaatggc	113820
gtgaanccgg	gagggcgagc	ttgcagtggg	cogagatagc	gcactgcac	cccatctctg	113880
gcgcagagag	agagactctat	ctcaaaaaaa	aaaaaaaaaa	aaaaattacc	tgagcaagggt	113940
ggctgttaac	cctcctactt	gggatgctta	gggtgggagga	cgtcttgagc	ccaggaggtc	114000
ggggctggcg	tgagccatga	ttgcaccagt	acgtcgcagc	ctgggtgcaga	aagtgatctc	114060
ctgtctcaaa	aaagtagaag	taataactaa	cnaaatcaag	ttttttttaa	ggccatgaat	114120
taagagtgtg	aaatcgttta	actacttgta	aagggtagga	attgtttttac	tataaatttga	114180
ggaaaattagt	tatatataatt	ttggtcaaa	taaaaactca	tattacttaata	tatttttaata	114240
atcttaattt	acctaatttt	ttcactttca	aahttttagg	gggcatattg	gacatacaaa	114300
caccaaagcta	atctactatt	attgacatc	aaacatagaa	ctaatacttt	tttttcaagt	114360
tcaaatatct	ttttaactgt	tagttgaaaa	gtgtttttat	tc aaatgaaa	taaatcatga	114420
taaaaattata	tttttgggaa	atccttaact	aaatttgggc	tagattgtgt	tggtagactga	114480
aagtttgtct	ctttgttcaa	ttattctatt	ttttcaaaat	tatttttgct	acaaaaaaca	114540
gtagatatta	tttttttaat	agcctacttc	taaaacttagt	aggtatcaga	atatattata	114600
aagcaaaagtt	acaaaatcaa	tttggaaaaa	aataaagcaa	atgaacaaaa	cagaatagtc	114660
aaaaataggt	atbtctgcat	aaatttcttt	cttatctctc	cactgatcta	tagtaatact	114720
atttatctca	taactccttg	gctttgggtat	acacaggggga	tatatattcc	aggactccca	114780
ccaggggcaa	aatctgcaca	tacttaaat	ctacatttgg	ctctctggaa	accogtatga	114840
cgaaaaagtca	gtttttccta	tgcttaagtt	tgcaaaccca	ccaataccgt	atbtttgacc	114900
cagggtttagt	tgaaacaat	tcacatagta	agcagacccc	tgaagtctca	gacatatttg	114960
gtccaagggtc	aattctatct	gcatctatc	gatatgatct	aaattagcttt	tcacaaatag	115020
aatatttcaa	atcattttat	aaataacatg	agataaagaa	tcatttccaga	agtaaacat	115080
atacctttgt	aacagagcta	agaatttgtt	taaaagaaaca	aaactcagag	acaaagagca	115140
atagagatta	tgctacactt	aataggcatt	tgagaaagaa	aaagaaagaa	gaagaaagaa	115200
aaattttagct	aggtgtggga	ggctgaggca	ggaggagttg	ttgagcccaag	gtgttggaag	115260
ctgcagtcaa	ctatgatcgc	accactgcac	tcacgcgtgg	gcactccagc	ctcaggccaac	115320
saagcagagt	ccgtgtctcaa	acacaaacaa	caacacacaa	acacacttca	cgtgaaagag	115380
agcaggaaga	aaattccaga	accataaaaa	ccagatagga	gaatagacga	tagtcaactg	115440
agcttgyata	gaattacaag	tatgtcataa	ttagagatas	aacaaagata	tatcagaaca	115500
tggtgttgaaa	ttccacacaa	tctcttgaat	gtgtatttga	atagcttaatt	tctaatgcca	115560
gttaltgttc	cagtcacaaa	aaaacgaactc	agocacaaag	acacagctca	attaggaccc	115620
tgaanaataga	gaaaaaaaaa	aaaaaacgca	acacacattg	taccaagtat	tactaatagtag	115680
tgactgtfsga	agtttaangt	atggaaaaat	gaatgagcga	aaagacagat	gagtaaacat	115740
gaaactactct	ggagcgcttt	ccattatata	tgtagattat	ggagacagct	tggaaaaaag	115800
gtagttagaca	gtagtgaata	gaaaatataa	ggagaagcaa	ggtgataact	gttttagtga	115860
cttaaaactc	tggttcaaga	accocaggaaa	ctctaacatt	tgtaattcca	ttgtacatct	115920
gaactatggt	tcttaagctt	aaatttatgt	tacagttcag	gagtttctga	agaattatgt	115980
cttttctctt	ctcttctctt	ctcttctctt	tttttttttt	ttcttttttg	agatggaaat	116040
tcctctctgt	gcccaagctg	aaagggcaatg	geatgatctc	agctcaactg	acagggcacc	116100
tcctctgattc	aagcaattct	ctcgcctcag	ctcctgagtt	agctgagtt	acagggcacc	116160
gcaccacgcg	ctggtctaatt	tttgtatttt	tagtagaaga	gggggttcaat	caatttgggt	116220
aggtcgtctct	cgaactcctg	acatgggtgat	ccaccacact	gggcctccca	aagtgctggg	116280

attcacagggt	tgagccacca	tgccccgcct	ggaagataaa	tcacttttct	atctattaca	116340
ttccacagtta	acaagggttta	tgaaaaactt	ggctaagtta	aaatgtcaga	agaaataaaa	116400
gtgtgtgtgtg	aaatgtgtttt	tcttttccct	ttatgtgttct	atttttgtat	gttcagttac	116460
tttatttttct	cttagcttatc	tttttatgac	tctttataat	tttaagctaa	aatgcaatac	116520
ttttttgtcoa	attacatcat	cccccttcca	tgtaactagg	tttttgtgaag	aaatgggttad	116580
agttacagctt	agtttaactga	gcacgggata	gattgggtgg	cagaactcca	aaagccctagg	116640
caggtgggggg	atggtgtgtg	tgggggaggag	gagaaggcat	saactgggaag	aatgaaaaagt	116700
ggcaaaaggt	tgacagataa	acaactcgag	attaaagcaa	tataactggg	tcaatgtaga	116760
ctggctcaga	tcttagaaca	caaaaggccac	acatgaagaa	cattttaccaa	tctgtcttctg	116820
aacttatatt	tggaactcta	cttctaccta	agaataaatt	tagttagcaa	taacttagata	116880
ttctattttt	agtttaaaatt	atatgtaggc	aaaagagtag	catatgcatt	cccgagatata	116940
gctcaaaatt	aaaaaagca	aagcttgccct	tgccagacgt	ctcaggctcg	tgccattttct	117000
gtgggcattt	tctctaccoc	ttctcttata	gaoctcacta	tagcactcoa	accagcagat	117060
ctgtctcacc	tgggaaaacc	coactctcca	gaatcacttt	gttctatctc	tatctctatc	117120
aaacatccatt	tctacctccc	cccccccaact	gaattgtttt	cagggaagtt	gtccagatgat	117180
aaataatccaa	agtaaatttat	gaataatact	aaattttaact	atcctaaaat	atgtartcoag	117240
tgtattttgt	atcccatgta	aatgacagat	tgggtgaaat	tatagtaata	ttaatatcaa	117300
cacgttaagct	attttagggag	gagatgagat	attggaagcca	attgggocact	cgcaacaatt	117360
aaatcacccc	atattagataa	atacacatac	tactatctct	gaaaatatgg	gggtttgggg	117420
gagcaaaaggg	gaatttcttat	ttatcacact	gaaattctaaa	catacaattt	aggatttttag	117480
accactattc	tctttttctct	gactgtaatg	gaatccatca	atctctgtatc	tataaagttc	117540
ctctgggaagc	gaataaactg	ttctgcactc	taaatctcca	ggattaaaaa	acatgtctcc	117600
csacacaaac	agccagattat	tacttgaaaca	tgthtcagta	gagttttaat	tttactcatc	117660
tatacatctt	ggaatttctg	ggctgtggcc	baatttcata	tagtcacaaa	tttgttagacc	117720
ctaaatctaaa	aaatctcgct	tggtctaatat	atattcaaaa	ccttggttat	actatatttc	117780
aaaaaggtga	aattaggtgg	tacgtattgag	aaactgttat	tttaaaactt	gtctctgtaa	117840
ctcgacccaa	ttctttagtag	cctgcagtag	ccccctgaga	cagactgtta	aaacagggag	117900
ggcaattaacg	tctctacaca	attggaatg	ttatgttagc	caatataatt	catagagaag	117960
gtcttatgtg	gtacccaata	tattaaaaaa	agaaaaacaa	tagaagagctg	aaattacaaa	118020
ttattctcgt	tggtataaat	ttctttctag	taatgaatag	tggttttttt	gaagaaagtt	118080
cactcttaaac	agagcagaag	tactgtctaa	atgttatgtct	gttgaataaa	cgagatgtgt	118140
atagattacca	aaactatcttc	taatttttgt	atctcagatt	caatgtggaa	aaataataaa	118200
gaagcaaatata	tgtaaatata	tgtagtatatt	ttctgatctc	aaagctactc	tgtaagttaa	118260
aaatttttcta	gatatggtag	attaatagaa	ctgaaggaca	tctcgaaacta	gtttagtctc	118320
agagagtagtt	tgggaaaaca	ggaaataaatt	aggagctctga	tatccactga	aaattcatgt	118380
atttttctctc	cattggcctt	tgcattacat	gtgcttttat	gaaaaattatg	aggctggccc	118440
agcattttctc	ttaaaatacaa	agttgtgott	tatcttttag	gaataatac	gatttatatc	118500
attttcacca	tacatataat	agtgccgatg	ttcaattcac	cagttagaac	tgatacacca	118560
ttttaaaccaca	catctgagtaa	aaataaaaata	aaagtgcaaa	taatacgtaa	ttatcaattta	118620
tgtaaatatag	atgttttaaat	cactatbtgt	taattatocct	atatactttg	atgtactctta	118680
ttttaaataat	atftt.aaatt	caacttttta	ataactttaa	ctgtttttta	actgttgcctt	118740
tgattctctga	tttt.aaagat	tagaanaataa	acaaatctct	cttaattgac	aaatggatata	118800
tatgttaaac	tggaagcaac	agtatgtagg	tatgnaacct	tagaacaact	cccatataatt	118860
tagtaagaaa	agacagaat	atttacacaa	agaaacagaa	aaagatgtct	tttcaaatag	118920
gataatttga	cattgttctg	gaactgtttg	taaatacaaa	aaagtttcat	ttt.aaataac	118980
taatttataat	attttatgtt	acaaggaaat	aatgttttct	ttcattttaa	aaagtggctac	119040
atacaagttt	tacaagccaa	agaaacagca	ataacatttg	ataacataac	tgaaataaat	119100
tcaactcttcc	aaaagggtatt	aaacatattt	gaattttttt	taaaatacna	aaagtgtatcaa	119160
atataagaat	atattcgtct	ttatttttcta	gatttgaaaga	ctgaacacga	tatttgatatt	119220
attttgtaatt	atcttctcagt	tcttagaggg	tatgttaatg	tcactcaact	aaaattttctt	119280
taoctagatga	aaagattttta	gaatttatga	ataatargta	actcatttcag	ttt.aaaaatg	119340
ttttacaaat	atctatcaca	taactgggtta	ccatcagaaa	actaggaaag	caaaactctct	119400
ccaagataaa	gcttttt.ata	ctatcaagaa	gcagtgatatt	aatttaattt	tatttatgatt	119460
ccagaaatgt	tcttactgaq	gtcagaaaaa	aactcctaca	ttcatattca	ctacttccaaa	119520
agactctctct	tcaagagat	atgttatata	caactacagg	aaaaaatctg	ctatttcacaa	119580
tactaactgt	tacaataatc	glatatttcaa	tggggtttica	aatttatata	atattttttat	119640
ctctgataata	caagtaatac	tgctctacaa	gaatttctaag	gtctatgacaa	tatcagttgt	119700
aaatgatataa	tgaatttttta	tttaggaaga	gttaaaatoca	tatttgaaat	aaatctaatc	119760
tattatgattt	galggctttt	attgactatg	tatatctoca	tcctttcttaa	gtctttcaca	119820
taatacaatt	tggtttatact	cctaagcnaa	aaagttaatt	acsttttaag	ataatttcaaa	119880
gggaatatgat	tattccagat	calagttttt	cagaaatgtt	tattaaaacc	ttttatttota	119940
tttttatatta	aatataattta	tgatgaatt	ttagatatac	catttcaata	aggtttcttac	120000

attttttaaa	ctcaacaatg	tcaaaagcca	ctcaattgtc	aagttacaga	atacttaaga	120060
acattttcta	aatcaaat	ttattactoc	tgtgaaaagc	atcattagca	aatgtttcat	120120
aaatacagtt	tcagaaaaga	gtctctttta	atctlaectt	ctgctacaa	aaatgcccat	120180
aaactagggc	aaataatctt	tgctagaagt	ctcaattttt	ggatctttta	agaggacatt	120240
taccagctaa	ctctgttcac	aacgtccagt	tctctctctc	caagaaattgt	gattagtgta	120300
ggaagaacct	tgctgcacaa	ggaagtggaa	actagatgct	ccgctaatct	gaaccttttg	120360
caatagtaat	aaaaaatcaa	ccacaagcca	caagcccgca	aatgccagaa	gttcaaaccca	120420
attctcaact	cactcccact	aaatgttaat	gctgtgacgc	gctcttgga	tttttcttat	120480
taagctaggg	aaattctcgc	tgggaaaatg	tctatgtctc	tggtatgtgc	aaatcagcag	120540
ctgggtgat	ctctcggatt	tcataaaccc	tccaattatt	caaacctcat	togggtctat	120600
tgttgtataa	cctcagaaca	ggaataaaga	gaaactttaa	agaaactcac	atacaaaact	120660
ttggttttag	caatgttttc	acaatcagca	ccagacaaat	gtgtacaaac	ttgtccaaaga	120720
atcgagtgct	tgatgaattt	gggggtctgc	ttttctagca	atttatgaaa	ttagtcttct	120780
aaatactttt	tgtatagtgc	latgaagcaa	ctggctcact	ctcatttgac	tgaataagg	120840
tttaataacc	aaaaatcaac	aaattgaaat	gctgattttt	aaaactttgt	atgtagtgtg	120900
aatatgata	agaaaaacet	aaatcatatg	ctggatattg	agaaagttaa	gatacctgtg	120960
aaacccacac	caaggctcaa	scactgaaca	ttattacatc	ccagaaaacc	ccagctactcc	121020
ttttcagcta	atacgcctct	caecctctct	ccacaccccc	ccacacagca	ccagcagatt	121080
ctgatcttca	agaacatgga	atatatttgt	ctggcttttg	tacttttgtat	aatgaaaaag	121140
aaacagctta	ttcttatgtt	tagagttttt	caccaaaat	tggttttgga	ccattcaaac	121200
acattgtttc	atgtagttaac	agatagtcca	ttcttatgtc	gatttaatac	tcocattttt	121260
gaatagttca	ctattttatt	atctgtgtgc	ctgttagtga	gcatttgagc	agatttttag	121320
tggagctggg	tatgaatagg	gctgctatgg	gccttatatt	atgaggtttt	tggtaaacac	121380
aaatccactt	cttggttaagt	gcatacttgg	tagtgaaaca	gttgagacata	attttatgtt	121440
aggtgttaab	gataaaatta	gacaattttc	caaatggatt	ataacacttg	acatcacttt	121500
acatttctat	cagactgtgc	caagttgtgc	cataccctca	gagatacttg	gtaattttta	121560
tccttgtaat	ttaggttktt	ctggttaaac	aaagcaataa	ttctccgttg	ttataaatgt	121620
aatcttctcg	atgactaaat	gaaattgtgag	agatccctga	ttcccttgga	agggacatgca	121680
acnggtgtgc	ggcttgocag	ttagggtgcgc	ctgcaagtca	aaacccctac	gggggggggg	121740
agcacacaga	tgcacccggg	cgggaaacgg	agttagcgctg	ggggggctat	ggcctcacag	121800
cgacatctag	gggtgggtgt	ctgcgatttc	cgaagcccaa	gtggggctat	gttaccgtgt	121860
ctctccttag	cttttgcac	tgcacaaagt	ttatgtgtta	atcagctcaa	caaacccctc	121920
tgcttatctc	atgggttagtg	ggacagtgaa	atagccctct	ataccccag	ctgttgccca	121980
gtgtcccaaa	agantcggat	cacacggggg	ctcgagggat	gagggcaact	ttttattgag	122040
tggttgcagg	ggctgtcagc	aagatggagt	gggaagtgta	ccttcgcoca	gtgtcaggcc	122100
tcccagtggc	cagactcttc	tccacccgtc	cctgggcocaa	ctccctcogg	agtcacagatg	122160
tcctcctctc	ctttctctgc	tgtgtcatte	tgccatcgca	ggcctgtttg	ctggcttgcc	122220
tcctcgtctc	ctccacttgta	ggctctctct	ggagcttgga	gtttgggatt	tatatggggg	122280
tacgacagcy	gggcacaggg	ggcccaaaag	caactttttg	gggtgtaaac	ctgaaattgc	122340
ctctcctatt	tcgggcacaa	ggctctcagg	cttgagggtg	ggggccttgc	ttggggacac	122400
cctcctctcta	ccagactatt	ccctgtctcc	tgcccttaac	atgaagttga	gaaactttcc	122460
tgtgtgcaact	ggctcatttag	ataccctctt	tggtaaaagt	ttatattcaa	tcctttgcatt	122520
attttttctt	tatttaggttg	tttgtctttg	acttatttga	gtgtaggaaac	tgtttatata	122580
taattactta	tatatcttag	atatgaaat	aatcttatta	atatgtatta	taaatatcct	122640
cttccagact	gtgggttttc	ttcttattoa	gtattacatg	ttttttataa	taataaaaag	122700
aatctctcaa	tttttaaaat	gagcaaaatt	tcaatttttt	tctatgacta	gtgcactatg	122760
tgtctctatt	tactgaaagct	tgccatgctc	tagaaacacaa	tgcttttctt	ctaaaaagaat	122820
taattttatct	ttccacttta	agaccttttag	aacaacttgta	attgtctttt	gtgtatagca	122880
tactaaaaag	ctccagatga	atttttaaaa	tagagatata	caattgttat	agcatattct	122940
aacggaagta	tcattctctc	ctctgtactg	acatgctttc	acottttgtca	taagtcaagg	123000
gctgatatg	gtggggcttc	tatcaccaag	ctcttcttae	ttctttttaa	ttttttttaa	123060
actttttctaa	agtgcaaaatt	tctgggaact	ttggctttct	agttatcctt	taaatgtgatt	123120
tcttttttaa	ttctcatact	taaaataatta	cactgtttta	aaatttgatg	agtcctttctt	123180
latggcccat	tatatgtcaaa	attctacata	tgctagtagg	tcaagtttgt	aattttgttaa	123240
aatcttttgt	attttttatta	ttgtttttgc	tgaattttcc	atcagatctt	gaaaggggtgt	123300
attacacttc	ccattataaaa	tgtggatttg	tgtattttcc	tggttaatgc	tgctgaattct	123360
tatatatttt	agggctatga	tgaatgctgc	ccacccctaa	ctcctaattt	gcttccaatg	123420
ttgtcattgt	cattttccca	tattaaatgg	tatttttgt	taaaaaaata	taaggaataa	123480
tgaattttac	attttttatt	alittttattt	aataaagaaat	aaaaatgcat	ggatataatga	123540
gagtttgact	tagtcatctg	ttctgagaaa	cattctgaag	tttaagttaa	tttaactgag	123600
ataatcaaga	aaatcgaat	ctcgaactat	aactctctct	ttattctctc	cttagtttta	123660
aacacatag	ttgaactact	agactattta				123720

tctgttttgag	tatgaatcca	aacattttac	ctgggggcta	aatttccaat	agtgggtttc	123780
attctaatag	caatattabc	acttggagag	tattccagaa	acttactaag	attaatatta	123840
tgagtgctta	attatatacc	aggcacagat	ctaaagacat	ttattcaata	cttaactgca	123900
cacactgaaa	tgaggagacta	ttactctttc	aaaggtatag	atgactgaac	tgaaccacag	123960
aaactttttg	caactccctc	aaggctacaaa	gacattgctg	gagccaggta	tcaaatccag	124020
tggtctgtgt	ttaaaataat	tgtttaaaaa	tatgtataaa	tattcacata	tgtacctgat	124080
tgtagctgtc	acattttatt	attttacaat	tatgcatata	ctgtaaaagt	attgaaggta	124140
cacacaccca	tatatattgt	tgtaggaat	ttaaagtaca	tacagggaat	attttgctat	124200
acaaactctc	acctaatatt	caattgttga	atgtaaaagt	ccaactctact	atccaaagta	124260
gaataactct	cttgaattaa	tttcaacaaa	talctttcag	atgtattatt	tttactattt	124320
tttcttttct	ctaccttttt	tcaaaagctg	atgggttaacg	tcaattgagt	gttttttggt	124380
cccttttttt	atcaataact	ttcaaaaacta	caaaaagtcta	ttataaagaa	attcagaaga	124440
taagaaaatt	agcaacatat	tatgctctaa	actcataaaa	ttattatgta	gtatttgatt	124500
acconttagaa	agaccagata	gtaaatagtt	aactattaat	actaagatta	aacatgaat	124560
ggatccaat	tatttttcaat	attcatgttg	gcacattctc	agcaaalaca	tactatgtat	124620
atttggacat	taaaaattta	gaagagtaag	gatataaatt	tgtatttagag	aaaaatccat	124680
attttaaanaa	ttagaataag	ttaatatcta	tgctaaagtaa	caaatgactg	ttatgattaa	124740
aattttcgaa	ggagttttac	aagaaagaga	aattactgaa	cactggtttt	ctagagggat	124800
gatttttaaga	acaacttggat	attacactgt	agttttaaagg	aagagtcaca	ctggaactgt	124860
tggaagtatg	aaagtgtggg	gaactaatcta	gaatttaatga	gaagactcac	atttggagcag	124920
tggtttttgca	caaggaaatt	gtggaaagag	taaaaggagc	ttlaaatgag	gaattgttttg	124980
aattccagat	caaaaaactg	caaaattatt	tacaggcaat	aaagaaatct	tgtagagctc	125040
gaattttggaa	gaatatgaa	tcatgcatta	tttaagttaat	gggtcgttttg	cggttgtatt	125100
aaataggatg	gaggaaaaag	gactcagaga	aatgcagaat	aaagctcaatt	actbgaacga	125160
ttcataactac	aaactatlaa	cagcatctca	atgtaaaaga	aaagggttaa	aaactaatatt	125220
tataacagag	cttggttttt	ctatgaagct	aattgaagctc	agcctcaatt	gcctcaattt	125280
tgaacagaca	ccatcaagga	ccatgagctgg	cccttaataaa	cgttcttcgca	tggtcatcta	125340
tttttgttaa	aaattgaaga	gaattaatct	cttaaatgca	agagaatgaa	cggtcgtccc	125400
tctatttcta	tgctgatttc	cccttcattg	catttccaat	gattccagttg	acattacagb	125460
ctggggcatt	tgaaggatgc	aaagaaaaagt	tacacataga	atgcttatgt	tttgagattt	125520
attgtgttata	ttttcacagt	tcaattaaat	ataatttgat	aaactgatgt	ccctcaagtg	125580
taagaaatggo	tccagggaat	actctaccca	ccctctggcc	aaactcaatt	gcactataac	125640
acaaaactct	agtggtctgaa	ganagcacat	atgaaatgc	cgacacacag	aagtcotatgt	125700
gtagtgaagg	agaaacaaag	ttaaaagata	taaaagctat	gaccagctgt	gtaaaaattt	125760
actgtggatga	tccattctct	attgatctct	accatagtaa	aaatgaaaaa	ttgtctcaagt	125820
catccacaa	atatttggcat	caataacaat	accataaaat	ttaacaacgca	cccttgaagt	125880
gaagacatbt	aggctcaaac	agtttccaat	gtttccaatt	aaagaacatc	taatatfaat	125940
tatatcatta	gaactctttt	aatgtcootga	aaacttggag	cttatctatg	cggggaaact	126000
tgacaggatt	ttttccgaaa	tttgatgaca	tttttaaaaa	gttttagaca	taagtgtgtga	126060
acttgaattg	acttccaaata	tttccacata	acaaagaaaca	aaatttaaatc	aaaactacta	126120
aaagaagaac	tgaattattt	ttctctattt	attgacactg	aaatatatct	aaaactgtgt	126180
catctgaagg	aaaagctcaaa	aaagatttca	acaaaaacgt	agaaattcmaa	ggtaacaaag	126240
actttactac	acaactgacta	tactactact	atttttgttt	ttctatgatat	ttcatgttgg	126300
tttttaatttg	catttcccta	atagtatttg	atgttgagta	ttttttctct	gaacctgcata	126360
gtttatttga	tgttttttct	tgagaagtgt	ctgactcaatt	cttttgccca	ttttttaaatt	126420
atgtlatttg	ttttcttgct	attgagttgt	ttagagttcc	ttcatatttt	tggaacttaa	126480
ctctctatca	agtgtagtgt	ttacaaaagt	ttctctccat	tcataggct	ttctctctaat	126540
tctgttattt	ttgttccatag	ctgtacagaa	gtcttttagt	ttgatgaaat	ccctatttgc	126600
tatttctaact	ttgttgtcct	gtgctttcag	agacactaaa	aaaaataaaa	taaaaataaa	126660
aatccatttt	gtggagattt	taactcaatt	cttctagtaa	tttiacagtt	ttttgtcttt	126720
gcataacagat	gggttgahtr	ttgtatctag	tgtaagataa	agacccaatt	taactctctc	126780
tggtttctct	accacaaatt	cccaatacaaa	tttgttgatg	agtcgtgctc	ttctctcatg	126840
gtttctctat	gcactcttat	tgaaaatacaa	ttgcccagta	atgactgggt	ttatttttgg	126900
gatttacaata	gtttttctgt	gataaataat	tttgtttota	tgccagcacc	agttgttttt	126960
ttttctctat	aaactctgtt	aaattttgaa	atcaaggagt	atgagccctc	caactttatt	127020
tggtgtgtgc	ataatctggt	cttattattg	ggaaactttat	tgttttccata	tgaatttaact	127080
tggaatttttt	atcatgaaa	gatatttgat	ttgttcagat	ttctctcata	cttagtcgggt	127140
gatgatcact	tggtttttgt	cccttcattct	gttatattgg	tatatatccg	tatttatatga	127200
gcatttgctgt	caacatctct	gcactccaga	gataaaactg	acttgatcat	gggtgatgat	127260
tctttccatg	tggttttgaa	tccagtttgc	taatacatgt	ttgaggtttt	tggtgctcat	127320
gtgatgagag	atactggcct	gtaattttca	ttctctrag	tgctcttggc	tggttttggt	127440

atcaaaataa	tattgacttc	atagaatgat	gttagaagta	cttctccac	ttcaactctt	127500
ttaaaaaggt	taagaaagat	cgatattagt	tctctctaaa	agtttggtag	aatttagctg	127560
taaaacccata	cagcttttgg	cttttcttgg	acaggaaact	tttttlgat	caatcatctt	127620
atttggctatt	gatctatcca	gatttctatt	atttlaatgat	tcaggcttgg	tagatgtgat	127680
atgtctagg	tgcabtgga	tgtgtcttga	tatgttglat	gtgtagcat	gtagaattat	127740
atacaattct	tctaggttga	ccaaattatt	ggtgtatgat	tctctaatgt	tgtctacaaa	127800
ctttttattct	ctgtgtgtac	aatltgttagy	tctctctctt	catttatgat	ttttatttct	127860
tcattctctct	tttttaattct	agctaaaatct	tattatcttt	tcaaaaatcc	aactctttta	127920
ttgattttttt	ctgactattt	tattttctctg	ctctgttctt	tgttatttcc	ttctctttgc	127980
taggttttgaa	ctttgttctt	ctctcagttc	cttgaatttt	acatagttca	tttgagatct	128040
tttttttaata	tagacatttt	tgtttatata	ttttctatga	agaactttcc	acttataaat	128100
ttttttcgtct	catcccgtag	gttttgcaat	gtagtttttt	cattttttatc	ctgtattttt	128160
tattttctatt	tgtatttctt	ctctgacaca	ttgttgaaaga	gcattgggtat	taattctccac	128220
ataatttgtaa	atttttcatg	atttctcttg	ttattgattt	ctagtttcat	tgttactgtga	128280
tgggaaaaga	tgtgtatgat	ttcaattccc	ttaaaaccta	acttatttca	tggcctaacc	128340
tacgatctat	ctctggagga	gttcttctag	tgtttgaaaa	gaattgtgat	tctgtttctg	128400
tgtggttagaa	ttttttggat	atatctgttg	ggctattttt	gtctaaagtg	taattcnaag	128460
ccatttttttt	tttttttgat	tttctgtcta	gatgattlgt	tcaattgttga	taattggggtt	128520
tgtgaagctct	tgtgtatgtt	tatgtttcat	tctatctttc	cottcagatt	gcttagccat	128580
tctctctgtt	gacccaaaga	tactagctgg	tggcatttgt	gactgcagca	tttcaacctaa	128640
gatgaattttt	cattgaaata	tcttgggtgt	actatttatt	tttactattgt	ctagtatatc	128700
aaacttttgaa	acaaagagcg	tcattctatt	tatagcaatt	tgacttttag	agtgatattt	128760
tgtgtttcaaa	aaatatggtaa	tccttgatca	ctgaaaatgt	caaatcctag	aaaacgttag	128820
attctctacat	gttactgttaa	ctactgtctc	gaacagatgc	tggctgaaga	tctcatttgt	128880
gaactctgatt	gttctcaaat	agatgattct	gatgtccatt	ctgttttagaa	ataactccaa	128940
gaaactcttca	tattttattt	tcacattgaa	aactcagtc	atttgtctca	acctcaaaag	129000
ctttgttttat	gttaaaatcaa	gtgaatgttg	gcagcaagct	ttaactttgt	ttccraaagt	129060
ggaaaagagt	tataaactcgt	tttatataatt	taggtgtctc	ttaggttgtat	gcataataat	129120
ttacaattgt	tatatattct	tgatgaatt	accactttat	cattacacag	tgaactctct	129180
tgtttctttt	tacactttac	tacttaaaagt	ctatttttgt	tgtataccag	cagttctctg	129240
ctgtctctct	tgtgatttcca	ttttgcgtgg	agtatctctt	tctatcccg	ttgtttclgt	129300
gtgtctcttaa	aggttgaatt	agttttctgt	taacatagta	tactllggatc	ttgtttclgt	129360
ttttaaaaaa	tattctctct	gcactcttg	atctttgaat	tcagaaaglt	aattcaattta	129420
cattttaaaggt	aattattgat	aagtagggac	ttgtctctg	tactttgtaa	tttgtttttt	129480
ggctctctct	ttctgcctct	ctctcttgtct	gtctttatbt	gtgttttgtat	aattttctct	129540
ggtgtgtatc	tttttaattct	ttcttttttg	ttcttttgca	tcacttatag	gtttctgcct	129600
tgtgtgttagt	taccatgagg	aatacataaa	acactttaaa	cattttaaact	aatttaacat	129660
ttttaaatcac	ttccacagtc	tcactagtca	catttcaaat	actcaaatagc	cacatatagg	129720
taatggctat	tacagagcat	tttcatcact	atagaatttt	actaaagata	gtgtcaagtg	129780
atagtgttagt	ccaaatcagg	tgccacttat	gctcagaaaa	aggtatggaa	ggaaatagat	129840
attttccata	tgtgtatctt	gatataatat	caaaaagagca	gggatattaaa	catcatgaat	129900
tatttaataat	aaaactacta	gttacctctg	attgtgtaac	caatttcaatt	tttttttttt	129960
aagacagagct	ctcgtctctg	caccacagct	ggagtgtagt	gagtttcaatt	tggctcactg	130020
caactctctgc	ctcccgagtt	ccagtgattc	tccgtgcctct	gcctcccagc	tagctggggt	130080
caccaggcgca	caccaccact	tcgggctgat	tttttttgtat	ttttttggtag	agaacggggt	130140
tcactgtgtt	gcccagaagct	gtctcaaat	ctctagctca	agaaatccac	ctgcctccagc	130200
ctcccaaat	gctgggagta	caggcatgag	ccactgcacc	ccactgaatt	tttttttaata	130260
atcacaaaata	taagtgttat	aattccacatg	tgaagattca	gtcatcaatt	acrcagctct	130320
tgtttttttt	ttttctagtg	tcattgtgttg	ggctttcttg	tttgtacctc	cacacaccca	130380
ccagcaattt	gaagatgatag	ctagtacaaa	ttaaagcaca	acacaaatta	aagtatacaa	130440
aaagaagaga	attlgtcgaa	gtccattgtc	ctttctclaa	tttaactcaa	catgatctag	130500
cttgtctatt	tgtttcactt	ttctctgatt	gaaatcaaat	tttctctccc	ttaactgact	130560
agcatatacat	ttctctctct	ttctctccaa	aaaagagttt	taaaatccct	aaaagtgtcc	130620
ttgttatatt	ttctctctct	ttctctccaa	aaaatattgc	cccaatccct	ttatgttgtt	130680
atatgccttg	ccctaagata	aggtctacct	tatgatttat	tttagaacat	ttttctatgt	130740
catgaagaa	ccctaaactt	caaaagttcc	tttccactat	agtagattta	cttttttcta	130800
aaaggacact	gctagccaaa	ttcaaaattt	ttgaacaaag	gtgctctaat	tttatattat	130860
ttttgttttaa	tttttagttgt	aagggaagtga	ctgatagatt	aaagctctct	aaataattaa	130920
tgcacttatt	tatttagtggt	catttatlaaa	atactcttgg	caactctctc	agttactctaa	131040
ccctctgaag	gtaaaggaaa	aaaaaatacc	gagaaaattc	atttctctcc	cttactacta	131100
aactgcctgc	aaactctttt	aaaactctcc	aggttccagc	gcattttatcc	cagggtacaa	131160
ccagctgcct	cttttaattgt	tctctttccc				

cacacacacac	aactgcaaat	ttotgtctt	taaatggcat	attgagaatc	tgtgagcaaa	131220
gtcaactttt	tgccccagca	ctggccacgc	atcaacttcc	caagctctac	tgactcaatt	131280
ttaaattgtca	tgtaattgat	aatttatatg	tgctcagglg	tgatataaat	gacttatcta	131340
attttaattca	ctcaaaaact	ttataatata	cttttatcat	tgccgtttat	tgccatagga	131400
attctgaattc	cagagaggtt	aaaatgactt	gcttaagtta	gtagtgaaat	tgagatttga	131460
tccctgcgtcg	tctgtgtctc	caattgagca	tgtagacacat	agtcctcgct	ctttcttgac	131520
tccaagtgta	ttttattctc	aagcttttgt	alcaaatttg	gtttttggaca	gaggggaaact	131580
ttagagctga	tattctccag	ctctcaatga	agatttoatg	agacataaag	taattcngltg	131640
tgtaattgatc	atacttaagt	agagtgtatt	tgctttctgt	aagtttaatt	tccaaagata	131700
ctaacaacatt	argtactgct	acatatcaga	tagaagtaat	catttctctg	gaaaaataaa	131760
accagtcctta	octatgatgt	ataatttaga	aargactgaa	agtagatggg	taattgtctat	131820
ttattgtattc	taagttaata	atttataacc	cagttaatat	aactaattag	attagcttat	131880
acatatcattt	taaatgaatl	tcaaatccaa	aatgatgcct	gaggaattcat	atatgtttac	131940
attttgatgat	ttattatgct	atctctatcc	cccccacaga	aaaaatctat	tccttaaccc	132000
taatttaattt	ttaaatcaac	agcaaaaaaa	aaaatgtaaa	aattaatctg	ggtagatgac	132060
caacttttag	tagaattgat	aaaatatttt	attgatatat	cagaaaaaaa	cataattact	132120
gctagtttcca	ttgttaagtt	tttaattctaa	taagaaatcc	tatttatata	tccttaaaaa	132180
ttacattacat	ataaatattc	atatttaagt	taactcaaaa	attcaacaaa	cagactttga	132240
ttgttaaaaga	gaactttttt	tccatttagat	attccagggg	aataaagttc	cactcacaaa	132300
gtattctctca	anaagtattt	taaaagtaac	tttaaggtaa	tcccaaatcc	tcaatagcac	132360
staaagaaact	gcatttttca	aaagtatcca	ataaacccaa	aaagatgaag	taaacattta	132420
atttccclggg	agattttctta	atggttataca	agtggtttat	tttctcttat	atgaaaacct	132480
ttagaataaaa	atttgaatgc	caagggtgat	agatttctct	ttgtattcat	atgaaaacct	132540
tcttttaaaaa	ttactcacng	atanaaatlt	tcacttctcc	atggtttctag	tgcacagggt	132600
tatatatacaa	aaatgggttaa	actgttaaat	aaaatatgca	attctagggtg	tccttattgt	132660
aatcccttagt	ccgtgtctcag	cagttgttcca	aggtcaggct	aattgttatg	tcactttctg	132720
tagaagaaata	tggtaaggaa	gacttttgtt	tggttgttgt	taagatggag	ctctctctgc	132780
tcacccaggc	tggagtgtag	tggtgtgcat	tcagctctcc	ggaacctctg	ctccctggcg	132840
tcaaaaacttt	ctccctgtctc	agccctccga	gtagctggaa	ttcacaggcat	gcgccacac	132900
agccctgtcta	acttttgtat	tttcagttag	gaacgggtgt	taacatgttt	acnagctttg	132960
tctcaaaactt	ctgacctcaa	gtgatccacc	gactattttt	ccccaagggt	ctgggattac	133020
agggcataaag	caactgtgccc	agctgagggt	tagtgtgaaa	ataattggcc	cttaaaaatg	133080
ttaaaactatt	taaaattlaaa	aggtcattaa	ctcttcttgt	tatttccact	gaagttaatt	133140
ccactttctac	agtgagattt	gtaatagatg	catacatcaa	tataaatgatt	gnlgtgata	133200
cattaaatatt	gtacagtttt	atgtgttaat	ggaataaatg	gtagtgaata	tgaaaacaaa	133260
tgttcaaaagt	cagttgaaac	ctattcttaa	caacacaata	tgggcttcag	gtgttgttaa	133320
accocgtact	accagtatct	aactaatagc	tgttatttta	agattgaaat	ggctagttgg	133380
agccagatag	aagcattctc	ctggcccttg	attctttgca	catagaaact	acatattgac	133440
cttcataaaca	tggnaatgaaa	tgttatccctg	attctttgca	catagaaact	gctgcaaaag	133500
aaagtctgagt	tagattacac	agcagggaaa	taaaagaaaag	agaaaaagta	ctcttctactt	133560
ctatttgtaat	gtacactgtga	aaatggstgt	atgttaaatat	ggctaataata	cgcttaggna	133620
gggaattttct	aaaaatgaaa	tacatttgca	aaagccacaga	tgttatgaa	ttttatgrrt	133680
caagacattta	caaatgtgttg	tccaagaatg	tatctctaat	tcocaaactc	ccaatgtcac	133740
ataaaggcag	gtatttttcc	acagccttgc	aaaattgctt	aataataaac	ttattacgtta	133800
ctgtttaagt	aagtgaaaaa	gcataatata	ttctgttttt	gtacacttca	gacatttttg	133860
ggaagatggt	ttatgnotat	gatatttaatt	tatttaattac	tcacataact	ctcagctact	133920
tgatatttga	tttgtctctc	actgtttttc	taaaactatt	attctgacac	atccocctgt	133980
cagcttctcta	atcatttagt	ctttttcttt	tottttttatt	ttctttcttt	ctttctttct	134040
tttttttttt	tttttttttt	tttttttttt	tttgacacgg	tttngclctt	gtgtccacgg	134100
ttggagtgag	gtggcagtag	cttggctcat	tacaacctct	gctccocggg	ttcagatgat	134160
ttccclcgct	cagctccocg	agtagctagg	attacaggca	tgacaccaca	cgccnagcta	134220
attttgtatt	ttttatagag	acaggggttc	tccatgttgg	ttaggctggt	ctgaaactcc	134280
cgactccagg	tgatcaaccc	actctggcag	cccaaaagtgg	tggtgattaca	agogttagacc	134340
actgtgcocg	goccatgtcc	ttttcaacgt	attagtttcc	cagggtctgt	atcacaattt	134400
accactaact	gggtggtttaa	aaatacatatt	taatcatttc	tggaggttag	aaatatttag	134460
taaggtgtgtg	ctgtcaattc	ttgttaattcc	agagatgcca	ggagaagatc	cttctagcat	134520
gcattctctca	tcacatagac	tttttctattg	tggtctctcc	gttgcataac	tcataatct	134580
ctctctctctt	ctcataaaat	caccaaatca	gtatgaacctg	tgcttctctg	tgtaaatctc	134640
gnaaagactc	tatttccaaa	taagtccaat	tcataacttg	tgggggttag	ggtagtcagc	134700
acatattggc	aaccacatat	atttatgttt	gggtgggcat	gatttgttgg	agaaaagtta	134760
agttataatca	tcagcttaga	gaacttaag	tagaacaaga	agggcacatat	aaatatgcca	134820

ataagtgcag	aactgagtc	aaaagaaata	caggtaatgg	aaggagaaag	ccgtcaagct	134940
agagaagaca	ctcaaacctg	attttgataa	aattagtaag	tgttcgacag	gccagctgtt	135000
tgaattttctg	ctctgcgtatt	ttttctcttg	gtgggaaggt	tttaactcatg	aagtgttatt	135060
ctttaataaga	tataaaaat	tcatatttta	atttctgttt	gtgttaacot	tttaataaac	135120
ttttttatttt	agtatagttt	tcaatttata	gaactgttga	aaatagaata	cacagattcc	135180
tgaatacctc	atatagaact	tcccccata	ttaatatctt	atattactat	gggtacattt	135240
tcacaaacaa	tgaagcaata	tggccacatt	ataattcatt	aaaattccatg	gttttcaact	135300
atttctctat	ttttaccaaa	atcttoggte	tcttgacaaga	tccatttggg	gatataccct	135360
attttagtoat	catgtctcct	gtggctcctc	tagaactgaca	gtttcttaca	cttaccctgt	135420
ttccttgaaa	aatlttgagg	gaactgggta	ggtatttgaa	ataaactctc	tcagttggag	135480
ttgggtctgaa	gttttctcct	tgatttaata	aggggttatgg	gtttttgggg	gaagcttccat	135540
ccacatgaagt	gtcattttca	ttacatccca	tcaaggggtac	atgataccaa	catcacatcc	135600
tgattatgttt	aacctggaat	acttggctgg	agtagtgttt	gtcagggttta	tacagtgttt	135660
attttaaacta	tttccctatt	tcacatccgt	gtttatttgg	aagagcatta	ctaaagcaac	135720
cttatatttca	aggggtaggga	cattaaagct	ccctctcttg	aaaaggggaat	actacatata	135780
ttctttgttaa	ttcttttagtg	ctggaaactt	gtttctctcc	tccatttaat	ttatgtcatt	135840
aatcattttat	gtatatataat	atggactcct	ggatgttttg	tttcaatttt	gggtttgat	135900
ccaaaaactat	attatttatt	ttgtctttca	gattaggcca	tgtggagac	ttgggtgag	135960
tttcagatttg	actcttgyat	gottttgaca	tgaccccatc	attttatttt	tttccagtgt	136020
tccttatttt	tgacactaca	ggataactca	gtttcatctt	gtatatctcc	tgctcagtc	136080
ctagaatccg	ccctttctgc	aagtacaacg	ccctttctgc	ttgtttccgt	ctattggagg	136140
atagttcttag	aacccaagat	ctgggtgtgt	agtggttttg	ttgctttgtc	gtgactgagg	136200
tgttattttct	cataggtctc	ctcagcaaat	aatagagcta	ggaaahgtac	ctatgtatcc	136260
tatatctatct	atgcaatata	ttataataat	ttccatttgt	acctatccat	tattagagct	136320
agactaggtt	cagactagtg	ttctctgact	taaccacagt	ctacaggggt	tattctagat	136380
ttccctctgtt	ttgagttaac	ctccctctcc	aacagtgaga	actcggctcc	ttggagtgaa	136440
catctcattga	cttttgttta	atccagctac	acatgtatag	aaatttgaga	atbtatcact	136500
ccaccccaca	tgagacataaa	ctttggcag	tagaaaagta	taactgtact	ngataagcaa	136560
ctttcagact	tacagttttcc	aataatcctc	aaagttactt	aatagagtta	tttggataca	136620
ctttctttaag	tgaggttgata	acatacatct	tatttttaaa	ttgttgaaag	gtaatgtccc	136680
accnagagat	ccactctgtc	ccactctgtc	ttgttgaaag	agagtggat	aatctacaaat	136740
ctcttttgtgc	tatgaagttt	tataaaattt	agagtggat	tctccaaact	tatttttact	136800
ctaaagttaac	atatggtaact	gccagcttat	atctttttct	cttgaaataa	aagagaataa	136860
gaatatatttc	ctttactctc	attttttctt	cttgaaataa	tatttttact	atgtaggtcc	136920
asgttttctga	cttgatcact	cttctctctg	taattttctc	ttcatttttg	taggataaatt	136980
ggctctactgg	tgatgaatttc	cttctgtttt	taattttctc	taactctgtg	gcattttact	137040
ttctgtgata	tageatttcta	tgctgataga	tgtaacttct	atccttgatt	ctctaatggg	137100
ccactctgttt	cttctgtttg	taattttctg	gattttcttc	ttgtttcttc	tttgggtttc	137160
taaggtgtttt	ttttctcttg	gattttcttc	tttctcttc	tttctctgtt	gggttgttgt	137220
ttaaaatttga	ataaaatatt	aggagtactt	tttctcttc	tttctctgtt	ttgttgtttg	137280
aatctctctga	gaactgtggg	ttgggtctgt	cgtaattttt	tttctctgtt	ttgttgtttg	137340
taattcacaat	ttttctctgc	ttccctctct	gtttttttct	cttctctaat	tcaaatatta	137400
ccaggtcact	ccaggtgaaat	ttttctcaga	gttctctaat	gttctctgact	gaggtttttt	137460
tgcttttcttc	tactttataat	ttttctctct	aaatttaagt	ttggaaagtt	cttatgtaac	137520
ctctacagag	ccagtgatg	cttctctgag	ctctactgag	tctactgatg	agcttactca	137580
aagtaatactc	cggttctgtt	acagtgtttt	tggtttctag	caatttcttt	atatttcttc	137640
tcocaaatttc	tatttctgtc	tacattatcc	atctgtttct	ctgattgtgc	tattttttcc	137700
actgagaccc	ttaacatatt	aatatagttt	atttttaaat	attctgtctc	ataagtcocaa	137760
gaactgtgtc	atataagtg	ggtaagtggt	gttctgtatc	tttgtttctc	cttctcaact	137820
gtctttttttg	tttctctttg	gttgtaactg	laattttttg	tcaaacaccca	aacatgttat	137880
atcagatctg	aggaactgag	gttaactgag	ttctactgtg	aagatttatg	ttctgattag	137940
aaactgaaat	ttatttaagt	cttgorgcag	ctatggatac	caaagaattc	atattctctc	138000
agtgctccttg	actttctctc	cttgacitllg	ggcatctcca	agattatttt	ttctcaagag	138060
gtgtgtctctg	cagttctctc	atctgttaac	aaacaagctc	ctgtgttggt	gatggtaagg	138120
tggttagggga	gggggtgttt	gttaaactatt	caattaaact	taattgtggg	gtgggggggt	138180
ctctgtatttg	ctctgtatct	tccaaggtgt	tttttctcat	attttttttg	ttttgtttttg	138240
ttttttaaata	ttcttcccaa	gggtgagacg	gtgtaagta	atgggtctga	gtgacaaaga	138300
ttacccctctc	catggctctc	ggacaatgct	ctgtaagta	ttctctctgg	agagtgtggg	138360
tttgtttatgg	gaaggtttct	tggtcatattt	tttcttaatt	ttctctccaa	ttctccatgc	138420
cagaaagagg	tggtttctgg	actgaatttt	gtgggtctct	gtgttaagct	tggaagtaaa	138480
gcatacaaaa	gtgtgtgtat	ttcccaactt	agttctctaga	aatlttgtaa	ttgatccatt	138540
atattctctat	ttctattcta					138600

taattottat	tagtttatgg	cttcagctac	ttttgcttga	aalaagcaga	cctgggctgt	136660
gactctctga	atttacttct	ccagatttca	gggtgggtgt	ttgctcgcaa	aatcaattct	138720
ttgttggggt	ccagaaaagt	cactgatctc	taattttatc	accttttcc	tggtglaaga	138780
ataggatgct	ctgcttctta	gattttgaca	fatgagagct	gaagteoct	tatatattgt	138840
acatgaatgt	ctcagtlgct	caaatgcgat	ggtatctcta	ttgggttata	gtcatcatga	138900
tcttttgcct	tggcatctaa	aaaagctaga	ggaagggcat	acagaaatgt	ccaaacctaa	138960
batgtctctc	tagcttgcaac	aatggaagca	atgtttcaga	ccaggagaag	aaatagtgtt	139020
tgggtctctc	acagaagctt	taatalaagt	aggggctcta	tcccgagttt	gtcttcaagt	139080
taacagctct	gacaaagacag	tataagccac	tgaagactac	agaggycttag	ataagaaggg	139140
gtcatgttct	caaacctgaca	tagaaatgac	aaaatgtgyc	cctggtatgt	gtcttcaaac	139200
atttgcaagt	ctttttaaaa	ataacccctc	aaaagaaaac	caagtcatgc	taactagtcta	139260
atgcaacaat	atcagctgag	ttattgacaa	atcatcaata	aatctcagga	caactattgtc	139320
aaatttattg	gcaaatcatc	ataaatttct	agaacaatat	aaactcttga	tgcattgtcta	139380
gattcttghta	caatgatgat	ttttgataat	ggcttctact	gagaaaaact	cctatgtatc	139440
acattgcat	ccatcttagc	acaactgaca	aaaacaggct	gactttgaat	atagccaaaa	139500
tcccaaggcat	catccaaggt	acctgttgg	gaactatttg	gacctaat	caaagaaatt	139560
gtaaagctgt	tgctgttgatt	catcagccat	taagtacaaa	aaaggagcct	caacactgtga	139620
ctgatattgt	ggcatattgc	agatagcaca	taccacaatt	aaaaatlgta	ctacagcctc	139680
tagaactaat	aaacagacta	ccagcttaat	atctcacagt	catgctcttg	aaactcaagc	139740
aaatattgt	actccaagc	ctgaagctca	tatctccttc	gaactccatg	acactacaag	139800
gtttcttagc	cacagggttg	attgaaacct	atggcacaag	acctgagta	ctccctagcc	139860
tctaggattc	gactctcaag	actttctcct	gctacagaga	astgtctcta	ccattttctc	139920
agaaagctaga	actgtgctct	ccctcaaaaa	tgctgttatt	cottagcaga	gcccccaaat	139980
tacagatllta	tgctctataaa	gagacttag	ccaggctacc	aatccacact	ttacacaaag	140040
cagccttcca	acataataat	agatgtccaa	tacagagana	acaaaactag	tgcagaagaag	140100
gagttgcaca	tcaaatgggtg	ttcctagaca	tcccaabatt	ogtggatgt	ttctcggaat	140160
gactctctggg	ccaacactaa	tagcctgaaa	ctacactgat	ccaggactgt	cgtttgtgtga	140220
ctcatagga	aacacctggc	ccactaggaa	tgctctgagc	ttggagctgg	gaatgaataa	140280
atbttagaga	ggacacagat	ccctcccttc	ttttataaac	agtatgtata	aaatatgtg	140340
ccatctctct	tttctttttt	tttgtgctta	ccatgacctc	tgaagatact	tagaattttt	140400
tagatgcttt	ttttaaacttc	aatatgtgaa	aggaagaatt	atatgtgtca	acgtlaagga	140460
asttgagcag	acatgaaact	ggacattgac	tttgtctcaa	gtggctttac	acaccccctg	140520
ttctgtcccc	atggactgct	catgaaaata	atctggtgac	ttgtttccct	gtgaaaactca	140580
ccatcctgga	gaaagaacat	tcagtctgtc	tcagtcccaa	gaggggaatg	aaacttttgtat	140640
tggtttgggtg	taaaactacc	aactctgaga	gatggatggy	agggtagaga	ctcataaata	140700
attttgttgt	ttgtctattac	acatatgtaa	aaataacctg	aaatactctt	tacaaaattct	140760
tttggggcaat	ctcttttgat	ataaatccgt	tacaaaattg	gatatgttac	atccactctg	140820
atccagagctg	tggtttctca	ctgatgtctc	attctcagaa	ataactgtgt	ttccctctct	140880
actccagac	alaactgtgaa	cccactatg	agtttgtgtc	aatcagagct	aaattacttta	140940
ctcttaatga	gtgcccacag	gggatgagag	aaaattatga	atggtttgga	ggctcatttc	141000
cttccctctc	tttttttttt	tttttttttt	tttttttttt	tggtagtata	gcaagagatct	141060
ggccagcgtt	gggcaaatct	ggggaganaac	aaggtctttg	gtgcaatca	gcaattttgt	141120
ccctcaaaat	ctttccaagt	gcaacttaact	tgcagacctt	ggctgtgaat	atgctatgct	141180
ccgtgtattg	ctcctgagat	tccttgaaac	attttttatt	aatbaaata	tgcactctca	141240
ttttatctct	aagctaaact	aaatatttgt	naaagaaga	taggaactat	tctctttttt	141300
gatgatctct	acttccaact	ccatctgtga	caggttaggt	tttgctgagt	ggaatatttg	141360
taatggtcca	catagaaact	caatgttttg	cctgtactgt	gaatgagtg	ttcagggatg	141420
ttcttggaat	caggttttaa	gttttaactg	aagacgcaat	gtcttttaga	gttgcttgac	141480
tctttcatct	tcttatttct	cttttaacta	gtttttctaa	cttttaattt	tcttgaanaa	141540
ttgtctatct	catatgcatt	ttcaaatata	ttggcatlta	tttgtctata	attgtctctat	141600
tgtttttaato	tbaaktattat	ttaatcttgt	ctgtctctct	tttagttctc	cttaacttta	141660
actcttatct	aggttttaact	attttattag	taatttcaaa	aaaactcaat	cttgagcttg	141720
ttagttaact	aggttttttca	attttattat	ttttttcttt	attattttcc	ttccctcaat	141780
cttgtttgat	tctatcatct	gttatattt	taattctcat	agatagctgt	ttagctcatg	141840
gatlttcaaca	ctattttttt	cttaagttag	atagtattta	tatccattta	tctctatatt	141900
ttttttttaa	ttcaaacctc	attatgatcc	gtgatccaag	agtttatctc	tttttccaaa	141960
tttttcccaa	tttctctagt	gttttttct	ttttgtatt	attcttlaat	ttttttctgt	142020
attttacaagt	tttgttttat	tctagtcata	tgaaaatttt	aaaactcaac	tggtgtcatc	142080
tctcatgaag	ttactgttgt	agcaactatt	tatgtgcta	aaaatgcata	ttgtgactt	142140
ggcacactat	caactttcat	aaatattota	actttaggtt	tagtaatggt	tttttgaatt	142200
ctcatgtgac	actatttgat	atatatttat			gttgtaaaa	142260

ttctctaaat	tgtttctgtt	ttataaaaa	ttattttatc	tactaacac	taagagaggt	142380
atgataaaat	aacacagaa	gttgatagat	ttgtcaaat	ctcttctgt	atgctgtgat	142440
tatttcaact	tcttttcttc	ctctctcttt	tctttgtctc	tctctccctc	ctctttctct	142500
ttctccctcc	ctctgtcttc	taigtcttta	gatagataaa	attgtataaac	gtgtacagat	142560
tgagaaaggg	acatttttaac	attatgcact	gatctctctt	aattttaataa	catcttgtta	142620
tctagtggat	tttttttagt	taatttgaca	attttatctt	ttcactgcag	agttctagccc	142680
aattagtcca	attgtgattt	tcaattgttt	taactatttt	ctctgtcatct	tacaattact	142740
tctcttttta	ctttttttac	ttttctcttt	taagcatctt	ttttttatcy	ttctcatctc	142800
atttttcoatt	tttattttta	ttgttttaaat	catctcttta	aaatgcactt	aattgtataa	142860
aataaaatcca	tatttcaatg	accttccaac	caataagaaa	ttataatact	tgctctgttta	142920
tgactttccc	aattttacatg	atctttatttc	ctcgtatctt	aatccctgcc	ttctttttta	142980
cacctctcag	caaaaattat	gattatttaat	ttttaaggaa	ataattattta	cttaattttta	143040
ctcctcaaat	gtctctttga	ctatccctct	gttgctcatt	atgaagacac	aaactctaga	143100
agctctcttc	ttctttttct	ctttcttttt	ttttttatat	gggtttctgt	ctctgtcacc	143160
caggctggcca	tgoagtgcca	tgataatggc	tgactcaaat	ctcaaatctt	tggggtccagg	143220
gtgttggaac	tgttttgtcc	ccagtgtctc	aaagaaatag	cattogaaca	taaacctaat	143280
tcctctcagca	agggcagttt	tactttctgc	agaaaggggtg	ctctctgcag	atatacaagg	143340
ggactctgga	ccctagtcct	ccctagtagc	tggaacttca	ggcattctgc	atcacacttg	143400
gctaattttt	ttcttttttt	tgtagatgog	gcactctcat	atgttaactca	ggctagtctt	143460
gaattctctgg	ctccaaagca	tctctctctt	tcactctccc	aaagtctctga	gatttaaggct	143520
atgagccctgc	acacccctgt	aaaagctttt	ttacaaaggt	ctgtgttttaa	taatttatag	143580
ctttttctta	caaaattttt	cttcaaaag	agttttctgt	agtaactcat	tggaagctga	143640
tttttttttt	ctcttgacaa	tgbaagagaa	ctatttcaact	atctcatagc	ttccatctgt	143700
gottaaaagg	ctgtttccag	tgtagcagtc	tttgttttgt	tggtgagctt	tttttttttt	143760
ctgtctctct	taggactctc	ttcttgtctt	tagtgttctt	caattttact	aatgtatgct	143820
taggtatgca	ttctgtttta	cttgtttaca	accttctgtt	actcaattgt	ttctatctat	143880
ttttttattg	ttctgtttta	ttctgtgaca	tgactctctc	aaatgttttc	tttttttttt	143940
tatatattct	ttctgtggga	ctcagaggta	tacgataccc	togcttatag	ctctgtgctt	144000
ttttctatgt	gtttttatct	gtttttatct	tggggctatg	tcttcagatt	tatatatttt	144060
tttttatatt	tggtgctgat	aaattttacta	cttaattgtt	gtgtcattgt	aaattttttg	144120
gtctcatctt	ttctgactcc	caactcttgaa	gacaaaggtc	ttgtgtgtgt	cagtgatctg	144180
tgttttgtcaa	ttcacatttt	cttctcatgt	gggaacatct	gaacataatga	gggctaatca	144240
ttttttcata	gaaagaggaa	attttcatct	gggtctgcca	ggttccagaa	gtccagcagtg	144300
agccatgcac	catcttcagat	agctccasgc	atcccatcaa	ctaaagtgga	agtaataaaa	144360
acactcagaa	tctcagtggt	tttaaatgag	tttttttttg	ttttttatat	taaaaacaca	144420
aacgcataaa	atataataat	atacaaaata	ttgcattttg	ttgttatat	atacaacata	144480
ttgtgtttgt	atgtacataa	tccaaaaata	caataaattt	taaacagatt	ttgggttaga	144540
catatttttt	tagaacaact	tttaatatct	gttttatctc	ttttctcatc	atgctgtgtg	144600
cttttaagggt	ccccccatgg	actgacagta	catgtttttc	tcacctgcag	atccaatatga	144660
gaictccagto	tgagatctag	gctactgtgaa	cgctatcagc	cacgaagaga	aaggaaagaa	144720
tcgggtaaat	tgtaactgtt	ttcttaaaag	ttctgatllag	agatcatata	aaactaatca	144780
acctctattt	aatgtctctc	agagggttcc	atgggtgtat	tttctatcaa	aaactatgaag	144840
tacagtctta	ctgttagctt	caaatactct	caattctattg	ttctcatatt	ttgttaggtt	144900
taacatttat	tctgattgtt	caaccttaca	ttcaatttca	cttaataatt	ttccaatttt	144960
ttccaactct	agttttgttt	ctaagtgat	ttattttttg	cogcgaaat	ttccaagtgt	145020
ggctctctgt	ttatttgagt	cttaattttg	attcatcttt	ttttctctgt	tatttcatca	145080
tcaaattttt	aggtataagc	gtgttgagac	tctattctct	gatttctcgt	acatctcata	145140
attttttctt	tttatactaa	aatgtccaact	tgactaaata	taaaaagtat	tgagtcacac	145200
ttcttttttc	taaggacttt	ataaatatta	ttgcactcat	tttttagctg	tgattctcgt	145260
cttaagctcat	tcagattttt	ctctttctct	tgactttctc	tgaataactca	tgagtgactt	145320
tttaactttt	aaacaaattt	aatttaattt	cttttcatct	gttaaaaatga	caaaataaga	145380
tataactgtt	taccagtgca	ggttaaacccg	agatatagaa	agaaaaatat	cagtagtatt	145440
tataaccctc	ctctttaagc	tagtttttcc	cttttttaaa	tataaatatt	tattgtctac	145500
aacacagtta	gagaaatgt	gnaaatcgta	tgctcaggat	gaattactat	tttcaattga	145560
aatcacacaac	tgtaaagtac	atgcagatta	agaaaacata	caagattagc	agcaactccag	145620
aggttctcgc	atgccccttt	ccattagctt	gagtaaccgt	taacttgact	actcaacagc	145680
aaaatragtt	tgcttatctt	ttttttgaat	aaaaaaacaa	gaagtttttt	cgaaaatttta	145740
aatcacacaa	gtcagaata	taaatgggat	ataatattgt	ttatattttg	tattatacga	145800
agcatttgat	acagatagtg	tagcatcaca	caaaaagggtc	tggttatatt	cttaataata	145860
atatttgat	taaaattttg	gagctatgtg	aaaggagggc	aaatttttat	atctgcaggt	145920
atcaacgggt	gtacttatgt	gaaatcgttg	gcatlgagaa	agatttgagg	aaacacagaa	145980
tttgtatat	tgctaatgaa	aacgaacctt	ggtcaaatat	ctttaaagaa	ctctgtagcg	146040

gaatctacca	aatttggaaa	tatccacatg	tgcagctctg	tcagttctct	tcctaggtat	146100
atacttataa	aatttataga	catgttccac	gacagacatg	atatgtatta	aaatttccaat	146160
atctctctacg	atggagattgg	tgccttttcta	agaagagatc	caaaagagtc	tcttctctct	146220
caatctctct	ctctcccccct	ttctctttct	ctctctctct	cactctttcc	ccaccacatg	146280
aggetatttac	agagagagacg	ccatctgtga	acctaaaga	aggcactcac	caaaacccag	146340
accattcttga	cttacttgatc	ttagacttca	aaccttcaga	actgtgagaa	ttaaatgttt	146400
gtttattctaa	ccacacaatt	tttggatctc	tatttttagca	gcccaaatgt	tcaggagaaa	146460
taataataata	aaactacact	gcattattac	catccaccca	caagaataaa	aaaaagctca	146520
aaatgaaaaa	aatcacatca	taagggtctc	agccccaggc	ccatgacctc	atcacctccc	146580
aaaggccccc	tgtgtctaaag	taattccatt	gcagggttagg	ctttcaacat	gaatttctgt	146640
ggacacaaatc	atcacagtcca	tagcaccttat	ttaacagttt	tatatctctc	tacagctttt	146700
cttctctgtt	catatataaaa	gatatacaga	tgattttttt	ctactttatc	ctctattgtt	146760
attttaaactt	taactcatgca	aaataattatt	tataacatgt	ataaggacct	actgtaaaaa	146820
aaacctacact	ctgtcttaaga	aatgggaatgt	tatcttttga	gaattcttga	tctatctttg	146880
aaattccaata	ttttccaaaag	aatgtttttt	tgtcttttatt	taacctatcat	ttttaaattta	146940
ttattaatttt	tctattaatt	cggtccaga	agcagtgagt	tgagataatc	atactcttta	147000
cttctaaaagc	acotttagtgg	tttcatttta	tttccatctc	ctctctttalc	gccactccct	147060
gtctgtatttt	tttcttctcc	lactaaactgc	caaacacatt	aaatatatttg	atgcatataac	147120
atttctgttgc	atgtttcttcc	aaaaacataatg	tttcaotttt	tcatagaaatt	tattttttct	147180
acacacactta	tactaggctt	tsaatttttt	attctgtatt	ataattttaa	taactatcgt	147240
gttttatatat	acatatttgt	gcatagtttt	catatgtac	accaatcaca	gatgactttt	147300
cttatccctcc	agtgacagctc	actttaactg	ctccaactcc	ttcttatccc	accaataaag	147360
caatgcactcc	gtgtgtacat	gtgtctttat	gggtgattgt	gaagacactc	cggtggtatag	147420
tttttggagct	gtatttctttt	tccaaaagt	ttatgtatcc	taaatatcat	ttgtatccaa	147480
ctaatctgtct	cttggaaatgt	ctacatcagt	ctatatattca	atnagttata	caagggtctc	147540
tatatctctta	tattctcaact	ttgtttttaa	atttgtatat	ctctagttac	ttgtatagca	147600
aaactttttct	tctttaaactt	cgatgggtta	ttagctttta	tttcttttct	gtaaaactcc	147660
tactctatct	cttttctatg	agaagccata	cttttaatt	attgatataa	ttgtatagca	147720
ttctctatct	atataatttt	tactattctt	caactaaccc	ctaattgtatt	tttatatttg	147780
ttaaaagtcag	atltttcccaa	cttgtcattg	gtttgttttg	tttaacttaa	cagttgtttt	147840
tttcttcaga	aaaggccatg	tttttgttaag	cttctgttg	atccagcaat	ctttatgcac	147900
tctatgcact	cttttttttt	ttttttctgtg	ctctgcctcc	gccctatcac	caggctggag	147960
tgagtgagc	agatctccgc	taactgcaac	gggtgtccac	accatgccca	cgattttctt	148020
gccttagcct	ccctgtagtc	tgggatttga	gttggccagg	atggctcacta	gcattttttt	148080
gtattttttg	tagacacggg	gttccacct	gtctggcagg	accagcgtga	gccactacac	148140
tcgtgatccg	cccgccctgg	cttcccaag	gtctgggatt	caatgaattc	gcgtctcca	148200
ctggccctca	tgccctcttt	tattattgtt	aatagtttgt	aatcaaatat	gcgtctttaa	148260
gtgtttttct	tagttttttt	gttctagatt	gtttctttag	tttgaattt	tataaaacta	148320
ccctataaata	aaggattctc	ttcagaaaaa	aacagataaat	ttctaatct	taaacacat	148380
ttttcttatta	tcatattatg	attacataat	tgttttttcc	ttcatctcag	taaacagcat	148440
tttctgtata	ttgtatttgt	cttttatatc	tataaataga	tctctaactc	gctttattta	148500
ttttttttta	gaattccatg	ttgattctct	caagttttct	tttcatgtcc	taaaatagat	148560
caacaggata	aatgtgtgtg	tgtgtgtgag	tgtgtlcatg	tgtgggggtt	atgtatgtgt	148620
atatgcacac	aatgtgtcta	atgtgtctt	tattctgtga	tttgttttgt	ttctctcttt	148680
tatcttttct	tgagctctgt	gaacttaact	ttcaattctg	gtctataaat	tggtttattgt	148740
tttcttttaag	tccttttgac	tcagaagat	trgattagaa	actatatttt	gggttttgtt	148800
aatgtttctca	gtgttatltt	taacctcttt	ttattctcta	tattgtcttt	ttcttaacta	148860
ttttaaatttt	aatctcaagc	tatgtcatcc	atgtcttgtt	ctttctgtatt	cttactattt	148920
ttgaattggga	tgccacatct	tagttttaat	atctgtcgaa	aaaaaattaa	aggtgagaga	148980
tgtgagcttaa	agcagtgcaac	acttaggaca	tatctctatc	atcttttgtt	tgtcatctcc	149040
tttgattataa	ttctccactgt	ttatttaacct	tctgtagcag	ctgtgagcag	aaaaactttt	149100
gagtttttoat	ttccacagta	aagtctatg	ctccagggtg	ctgtgacact	tttagaatct	149160
atttaatttat	tttctgtctg	ctttgattag	gtgtatgtgg	ctgtatgtat	catgtgtgac	149220
tctctactttg	actgattctct	gaaaagatgg	catatatatg	tggcttctta	ttcagccctt	149280
ctcacctctct	caactcttgt	ttataaacac	tgatttgtat	tcacatcttc	catgttaagat	149340
actcttggatc	ctttcagagc	tgtgtctaat	attttgaaga	acctctgcac	tattttaaatt	149400
ttctcttaagt	gtttgcactt	actcttgaca	ttttttccca	tttlygtccc	ataaaatttt	149460
tctttttatt	tgaggtttgt	gattttaaatt	gtgtttgtct	cctgttccca	atgatgacac	149520
agcagttccat	atlttttttta	lacttgggtgg	tttcttcagt	tggaataaca	gaaggagatg	149580
aaataaaattg	caaaagtgaa	gaatgtctaa	ttcatgcagt	taaaaatgat	gtaaaagttaa	149640
tattattaaaa	tatggtaaaa	tatttgggtaa	aatrtttttt	ctttgttcaa	aacagagctc	149700
cacctctgtg	ctcagctnng	agtgcaatgg	tgtgacttca	gttcaactgca	acctctgact	149760

55/64

```

cctgggttca agcattctc ctacctcagc cccctagtag ctgagattac aggcattgca 149820
caccacatty gctaattttt gtattcttag cagagacaag ttttcacat gbtgggcagg 149880
atgggtctcaa actcctgacc tcaagcgatc caccaacttc ggctcccaa agtgctggga 149940
ttacaggcat gagccaccgt tccagcctgg ttaaaatatt ttaattgct tatctttgaa 150000
agtctgctat tatgtgaaa ttgatttttc tatgggactga gatggactga tgctttgtgg 150060
tgggtgtgta atcactgcag aagaaaattt ggggaactgaa cctggaatgt tagtccatgc 150120
caattatttt aaaaattaga tccaaaaagc aataaaattt gttgagaaaa attgaaagt 150180
attacactac ctagtttttc taggaaaaaga ttctggcatt gggccaatga tgactgataa 150240
ttatccatag cactattgaa gagattgatg tattttacta ggaatttttc aggtgtgagt 150300
gatcgaaatt cagctctctt aagcaaaaag ataacttatt gattcctatg actgggtact 150360
ctaggagtgg tgcttgcttt agtcatagcc agatccagaa gattaaaaat aaactctgtg 150420
ttgctgcaaa gtttagggtat tttcggacca ttcccaatat ggacagacat agcccctagt 150480
tagaaatcta gcagacacaa aatttttgtc tctgtatct catacatgaa atattccttg 150540
tcaccattgc cctactctct tgaaccacat tagattatat gcccattgaa gtatatagaa 150600
aggggtagta gaatgccacc atgatac 150626

```

<210> 10

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward promoter primer for CFH gene

<400> 10

agaatcgtgg tctctgtgtg tgg 23

<210> 11

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse promoter primer for CFH gene

<400> 11

agcagctgggt gatatcctct gg 22

<210> 12

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward promoter primer for CFH gene

<400> 12

tcaaatgaga gtgagccagt tgc 23

<210> 13

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse promoter primer for CFH gene

<400> 13

ctgttcacaa cgtccagttc tcc 23

56/64

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 1 primer for CFH gene

<400> 14
gtgggagtg agtgagaatt gg 22

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 1 primer for CFH gene

<400> 15
aactcaacaa tgtcaaaagc c 21

<210> 16
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 2 primer for CFH gene

<400> 16
gatagacctg tgactgtcta ggc 23

<210> 17
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 2 primer for CFH gene

<400> 17
ggcaatagtg atataattca ggc 23

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 3 primer for CFH gene

<400> 18
acctcagcct cccaaagtgc 20

<210> 19
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 3 primer for CFH gene

57/64

<400> 19
tgcatactgt tttccaccac tcc 23

<210> 20
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 4 primer for CFH gene

<400> 20
aaggaggagg agaaggagga agg 23

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 4 primer for CFH gene

<400> 21
caggctgcat tcgtttttgg 20

<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 5 primer for CFH gene

<400> 22
ccactcccat agaaaagaat cagg 24

<210> 23
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 5 primer for CFH gene

<400> 23
acttctttgc accagtctct tcc 23

<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 6 primer for CFH gene

<400> 24
gataaatcat ttattaagcg g 21

<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence

58/64

<220>
<223> Reverse exon 6 primer for CFH gene

<400> 25
gaaccttgaa cacagaaaat gc 22

<210> 26
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 7 primer for CFH gene

<400> 26
ggatgacttt ggagaagaag g 21

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 7 primer for CFH gene

<400> 27
tatgagtttc ggcaacttcg 20

<210> 28
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 8 primer for CFH gene

<400> 28
tcattctcat taacaaagac c 21

<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 8 primer for CFH gene

<400> 29
agatctattt tggtoacttt gc 22

<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 9 primer for CFH gene

<400> 30
ctttgtagt aactttagtt cg 22

<210> 31

59/64

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 9 primer for CFH gene

<400> 31
ttatacacag ttgaaaaacc 20

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 10 primer for CFH gene

<400> 32
ggcaactctg agcttatttt cc 22

<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 10 primer for CFH gene

<400> 33
agagtaggaa aagcctgaat gg 22

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 11 primer for CFH gene

<400> 34
catagattat tttgtacgg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 11 primer for CFH gene

<400> 35
caaaactccc ttcttttccc 20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 12 primer for CFH gene

60/64

<400> 36
 atctggtgccc cctctgtatg acc 23

 <210> 37
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Reverse exon 12 primer for CFH gene

 <400> 37
 attcagtagt caatacatgt cc 22

 <210> 38
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Forward exon 13 primer for CFH gene

 <400> 38
 caccattctt gattgttttag g 21

 <210> 39
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Reverse exon 13 primer for CFH gene

 <400> 39
 gaatctccat agtaataagg 20

 <210> 40
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Forward exon 14 primer for CFH gene

 <400> 40
 caatgtgttg atggagagtg g 21

 <210> 41
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Reverse exon 14 primer for CFH gene

 <400> 41
 attgaattat aagcaatatg c 21

 <210> 42
 <211> 22
 <212> DNA
 <213> Artificial Sequence

61/64

<220>
<223> Forward exon 15 primer for CFH gene

<400> 42
catttcagcg acagaataca gg 22

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 15 primer for CFH gene

<400> 43
gtgtgtgtgt gtgtgtgtgc 20

<210> 44
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward intron 15 primer for CFH gene

<400> 44
aaggcaggaa agtgtcctta tgc 23

<210> 45
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse intron 15 primer for CFH gene

<400> 45
gtcaaattac tgasaatcac c 21

<210> 46
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 16 primer for CFH gene

<400> 46
aactgttaca cagctgaaaa g 21

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 16 primer for CFH gene

<400> 47
gtggtgattg attaatgtgc 20

<210> 48

52/64

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 17 primer for CFH gene

<400> 48
ggtggaggaa tatatctttg c 21

<210> 49
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 17 primer for CFH gene

<400> 49
atagaataga ttcaatcatg c 21

<210> 50
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 18 primer for CFH gene

<400> 50
cgatagacag acagacacca gaagg 25

<210> 51
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 18 primer for CFH gene

<400> 51
cagctataat ttcccacagc agtcc 25

<210> 52
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 19 primer for CFH gene

<400> 52
gtgtaatctc aattgctacg gctacc 26

<210> 53
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 19 primer for CFH gene

63/64

<400> 53
 caagtagctg ggacttcaga tgc 23

 <210> 54
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Forward exon 20 primer for CFH gene

 <400> 54
 tagtttcatg tcttttcttc 20

 <210> 55
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Reverse exon 20 primer for CFH gene

 <400> 55
 gaattttaag caccatcagt c 21

 <210> 56
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Forward exon 21 primer for CFH gene

 <400> 56
 ccaggactca tttcttttcac c 21

 <210> 57
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Reverse exon 21 primer for CFH gene

 <400> 57
 ctttctgaca gaaatatttg g 21

 <210> 58
 tgaatgtttct acatagtgtg 20

 <210> 59
 <211> 25
 <212> DNA
 <213> Artificial Sequence

64/64

<220>

<223> Reverse exon 22 primer for CFH gene

<400> 59

ggagtaaac aatacataaa aaatg

25